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Background: Patients with malignant pleural disease (MPD) have advanced cancer and 
high symptom burden. Goals of patient care are to optimise health-related quality-of-life 
(HR-QoL) and participation in daily physical activities. Supportive care interventions such 
as nutrition and exercise could offer benefit to patients. However, there is a lack of 
information on the prevalence of low muscle mass (i.e., pre-sarcopenia), malnutrition, 
inactivity and poor physical functioning in patients with MPD. Additionally, little is known 
about the factors associated with development of pre-sarcopenia and malnutrition or their 
associations with patient outcomes. 
Purpose: The objectives were to: 1) characterise physical activity levels and their 
relationship with patient outcomes; 2) compare methodology used to classify pre-
sarcopenia; 3) determine the prevalence of pre-sarcopenia and malnutrition and investigate 
their relationship with activity behaviours and HR-QoL; 3) determine the prevalence of 
poor physical functioning and nutritional outcomes throughout the two years post-
diagnosis; 5) describe body composition changes and investigate their relationship with 
physical activity and dietary intake; and 6) examine the effects of nutritional status and 
dietary intake on outcomes of an exercise intervention.  
Methods: Three studies in patients with MPD were conducted: a cross-sectional study, a 
prospective observational study, and an exercise intervention study. Participants in the 
cross-sectional study (n=46) underwent assessment of physical activity levels 
(accelerometer). Participants in the observational (n=36) and exercise intervention (n=33) 
studies underwent assessment of nutritional status (Patient-Generated Subjective Global 
Assessment), body composition (computed tomography [CT], dual-energy x-ray 
absorptiometry [DXA]), physical activity levels (accelerometer), physical functioning 
(Timed Up-and-Go), HR-QoL (Short-Form 36; Functional Assessment of Cancer Therapy 
[FACT]-General), appetite (FACT-Anorexia Cachexia Scale) and fatigue (FACT-
Fatigue). Participants in the intervention study underwent additional tests of physical 
functioning (Six-Minute Walk Test, chair rise) and muscular strength (1-repetition 
maximum leg press). 
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Results: In the cross-sectional study, 89% of participants did not meet physical activity 
guidelines. There was moderate agreement between CT and DXA for the classification of 
pre-sarcopenia (ĸ=0.424; p=0.006). Fifty-four percent of participants were pre-sarcopenic, 
and 38% were malnourished. Compared to participants with normal muscle mass, pre-
sarcopenic participants were more sedentary (p=0.001) and participated in less light 
activity (p=0.008). Compared to participants who were well-nourished, malnourished 
participants had poorer HR-QoL (p<0.001). Throughout the two years post-diagnosis, the 
prevalence of poor physical functioning and low appetite was ≥50%. Participants with 
muscle loss (56%) became more sedentary (p=0.008), however energy and protein intake 
did not change (p>0.05). In the exercise intervention, participants with adequate dietary 
intake (40%) had a significant increase in muscle mass (p=0.004), while participants with 
inadequate dietary intake (60%) maintained muscle mass (p=0.737). There were no 
differences between well-nourished and malnourished participants with respect to 
completion, adherence or tolerance of the intervention (p>0.05).  
Conclusion: Overall, there were high rates of pre-sarcopenia, malnutrition, inactivity, 
and poor physical functioning among participants with MPD. Pre-sarcopenia and 
malnutrition were associated with negative patient outcomes. Muscle loss was associated 
with decline in physical activity. The results indicate dietary intake could influence the 
effects of exercise. Interventions that target both physical activity and dietary intake could 
be most impactful. 
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Glossary of Terms 
Aerobic exercise Exercise in which the body’s large muscles move in a rhythmic 
manner for sustained periods.1 
Cancer cachexia A multifactorial syndrome that is defined by an ongoing loss of 




A condition that results from the activation of systemic 
inflammation by an underlying disease such as cancer.3 
Computed 
tomography 
A method of measuring body composition based on the density 
of pixels in an image of a person’s body tissues.4 
Dual energy x-ray 
absorptiometry 
A method of measuring body composition based on the amount 
of energy absorbed when photons pass through a person’s body 
tissues.4  
Exercise Bodily movement that is planned, structured and repetitive and 




The collective term given to cancers that involve the pleurae.6 
Malignant pleural 
effusion 




A primary pleural cancer primarily attributed to asbestos 
exposure.7 
Malnutrition A state resulting from lack of intake or uptake of nutrition that 
leads to altered body composition and body cell mass leading to 
diminished physical and mental function and impaired clinical 
outcome from disease.3 
Muscle strength The amount of force a muscle can produce with a single 
maximal effort.8  
Physical activity Any bodily movement produced by skeletal muscles that results 
in energy expenditure above resting levels.5 
Physical function The capacity of an individual to carry out the physical activities 
of daily living.1 
Physical performance An objectively measured whole body function related with 
mobility.8 
Glossary of Terms 
xxiv 
Pre-sarcopenia A term given to the presence of low skeletal muscle mass in the 
absence of low muscle strength and function.9 
Resistance exercise Exercise that causes muscles to work or hold against an applied 
force or weight.1 
Sarcopenia A progressive and generalised skeletal muscle disorder that is 
associated with an increased likelihood of adverse outcomes 
including falls, fractures, physical disability and mortality.10 
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1.1 Background 
Malignant pleural disease (MPD) is the collective term given to cancers that involve 
the pleurae.1 MPD currently affects more than 8000 people within Australia and 1 million 
people across the world each year.2 MPD includes primary pleural cancers such as 
malignant pleural mesothelioma (MPM) and secondary pleural cancers or metastatic 
disease.1 Globally, 90% of cases of MPD are comprised of patients with metastatic disease, 
with cancers of the lung and breast most likely to metastasise to the pleurae.3 In Western 
Australia approximately 40% of cases of MPD are comprised of patients with MPM.4 
MPM is a unique cancer in that its aetiology is primarily attributed to asbestos 
exposure.5 Asbestos is a group of naturally occurring hydrated mineral silicate fibres6 that 
were extensively used in Australia in the manufacturing and construction industries.7 
Historically, people working in mining, manufacturing and construction occupations were 
more likely to be exposed to asbestos.8 As these occupations were made up of a 
predominantly male workforce, there is a higher incidence of MPM among men.9 Notably, 
there is a long latency period (mean 44 years)10 between exposure to asbestos and the 
development of MPM, therefore the mean age of patients at the time of diagnosis is 
approximately 70 years.10 
MPD represents incurable cancer and the 1-year survival rate is less than 25%.11 
However, the median survival of patients with MPD varies considerably depending on the 
tumour type. Patients with primary lung cancer have the shortest median survival of less 
than 3 months while patients with MPM have the longest median survival of 12 months.4 
Other factors associated with poorer survival include poor performance status and high 
inflammatory markers.4, 11 While patients with MPM have the longest median survival, 
additional factors associated with poorer survival include the non-epithelioid subtype of 
disease12-15, elevated platelet count12-14 and weight loss.14, 16 
Patients with MPD typically have a high symptom burden.17 The majority of patients 
present with a pleural effusion, which is the excessive accumulation of fluid in the pleural 
cavity.1 Fluid in the pleural cavity, which is in excess of 1 litre for most patients with MPM,18 
can cause breathlessness and chest pain.1 Research in patients with lung cancer indicates that 
breathlessness is negatively associated with activity levels and quality of life.19 Therefore, 
the management of patients with MPD is mainly focused on controlling symptoms in order 
to optimise physical activity levels and quality of life. While there is substantial data 
regarding quality of life,20, 21 there is a notable lack of data measuring physical activity in 
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this population. Information on the physical activity of patients with MPD is currently 
limited to self-report of physical functioning as part of quality of life assessment.22 
Standard management of malignant pleural effusions has changed substantially over 
time with an increasing focus toward least invasive interventions that will alleviate 
symptoms, ideally without need for a hospital admission.23 Current practice for 
symptomatic patients typically involves insertion of an indwelling pleural catheter to allow 
for ambulatory drainage of pleural fluid.23 For patients with MPM, first-line treatment of 
the disease with cisplatin and pemetrexed chemotherapy can improve symptoms22 and 
offers a modest survival benefit.24  
Malnutrition is defined by a low body weight, weight loss or low muscle mass in 
combination with reduced dietary intake or inflammation.25 The potential relationship 
between malnutrition and patient survival in MPM has been raised in previous research 
studies.14, 26 However, an accurate description of the nutritional status of patients with MPM 
is not available as the amount and timing of weight loss has been poorly described,13, 27 and 
there has been no measurement of muscle mass, appetite or dietary intake using validated 
tools. An existing challenge in the measurement of muscle mass is that there is no consensus 
on the optimal technique or cut-points for the classification of low muscle mass. There is 
also evidence that the techniques are not comparable.28 Therefore, further investigation into 
the comparability of methods used for the measurement of muscle mass is relevant. 
In advanced cancer populations, low muscle mass and weight loss are associated with 
poorer quality of life29-36 but no study in this population has examined the association with 
activity levels. Further, no study in MPM has investigated the relationship between body 
composition, nutritional status, and quality of life and activity levels. While anecdotally 
clinicians and patients are concerned about malnutrition and low muscle mass,37 there is a 
lack of evidence available to empirically inform development of interventions to address 
these concerns. 
There are multiple factors which contribute to the development of malnutrition and 
low muscle mass in the cancer context.38 As MPD indicates advanced cancer, it is plausible 
that the cancer may indirectly contribute to reduced dietary intake, physical activity and 
altered metabolism which could lead to the development of malnutrition and low muscle 
mass.39 This condition is commonly known as cancer cachexia and it is thought to be at 
least partly reversible in its early stages.39 An understanding of the factors associated with 
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the development of malnutrition and low muscle mass in MPD could lead to more targeted 
interventions to address these conditions.  
Exercise is regarded as a potential strategy to reverse the effects of cancer cachexia.39 
Resistance exercise training is defined as exercise in which muscles work against a force 
60% or higher of maximum.40, 41 Resistance exercise training is well established as 
promoting gains in muscle mass,42 and is effective for improving muscle mass in patients 
with early stage prostate cancer43 and breast cancer.44, 45 However, patients with advanced 
cancer are a distinctly different population. The high symptom burden46 and high rates of 
malnutrition47 among patients with advanced cancer could negatively impact on adherence 
and tolerance to the intervention. Furthermore, reduced dietary intake could limit muscle 
gains as amino acids mobilised from muscle are used as an energy source.48 There is 
limited body composition data available from resistance exercise intervention studies in 
advanced cancer populations. Furthermore, no studies have reported on the impact of 
nutritional factors on exercise outcomes.49 
1.2 Significance of the research 
Patients with MPD face debilitating symptoms and a disease that has no cure. Research 
aimed at improving daily physical activity and quality of life is imperative for improving 
clinical care. Results from this study will provide information about the nutritional status 
and body composition of patients with MPD and their relationship with patient-centred 
outcomes, which will serve as a rationale for future supportive care interventions. 
Effective supportive care interventions are both feasible and target the underlying causes 
of the problem. Reduced dietary intake, physical activity and altered metabolism have all 
been implicated in the overall body weight and muscle loss associated with cancer.39 
Therefore, Fearon et al39 in their review of mechanisms and treatment options for cancer 
cachexia have recommended the use of multi-modal interventions inclusive of dietary 
counselling and nutrition support, resistance exercise training and pharmacological agents.39 
A potential problem is that few studies have reported on the feasibility of resistance exercise 
training in patients with malnutrition. This is a particularly important factor to consider as 
malnutrition is associated with high symptom burden which could negatively affect 
adherence to exercise.50 Additionally, there is no data available on the dietary intake of 
patients with MPD or the relationship between dietary intake, biochemical markers and 
nutritional status and body composition. There is paucity of data available to inform the 
design of supportive care interventions in patients with MPD. Results from this work will 
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provide information on the feasibility of resistance exercise training in patients with 
malnutrition and the relationship between changes in body composition and dietary intake 
and physical activity to guide the development of future supportive care interventions. 
1.3 Research purpose 
The overall purpose of this research was to describe the physical activity, physical 
functioning, nutritional status and body composition of patients with MPD. Further, this 
research sought to evaluate the physical activity and body composition methodology that 
underpins the research. The objectives were to determine if there was a relationship 
between physical activity, nutritional status and body composition, and important patient 
outcomes; describe body composition changes over time and investigate the relationship 
with physical activity and dietary intake; and examine the effects of nutritional status and 
dietary intake on outcomes of an exercise intervention. 
1.4 Overview of thesis content 
Chapter One is an introduction to the thesis. This chapter provides background to the 
research along with an overview of thesis content. The significance and purpose of the 
research are also stated. 
Chapter Two is a critical review of existing literature related to the measurement of 
body composition, physical activity and functional status; the prevalence of malnutrition, 
pre-sarcopenia, physical inactivity and functional impairment in advanced cancer 
populations; the aetiology and consequences of malnutrition and pre-sarcopenia in 
advanced cancer populations; the effects of exercise in advanced cancer populations; and 
the impact of dietary intake on the effects of exercise. 
In Chapter Three the results of a cross-sectional study (Study 1) conducted with 46 
patients with MPD are presented (Figure 1.1). This chapter provides information on  
adherence to an accelerometer wear protocol, describes objectively measured physical 
activity and sedentary behaviour and compares these results to physical performance 
measures used in clinical practice (Manuscript published).51 
In Chapters Four and Five, data from the baseline assessment of a longitudinal 
observational study (Study 2) and exercise intervention study (Study 3) conducted in 
patients with MPM are presented (Figure 1.1). In Chapter Four, the measurement of 
skeletal muscle mass and rates of pre-sarcopenia measured with Dual-Energy X-Ray 
Chapter One.  Introduction 
6 
Absorptiometry and Computed Tomography is compared. In Chapter Five the rates of 
malnutrition and pre-sarcopenia are reported and the relationship between nutritional 
status, body composition and dietary intake, biochemical markers, quality of life and 
activity levels are reported (Manuscript published).52 
In Chapters Six and Seven, results from a longitudinal observational study (Study 2) 
conducted in 36 patients with MPM are presented (Figure 1.1). In Chapter Six, the rates 
of nutritional impairment (high need for nutrition support and poor appetite) and 
functional impairment (self-reported physical functioning and Timed Up and Go) at 
different points in the disease course are reported. In Chapter Seven, changes in body 
composition over time are described and the relationships between energy and protein 
intake, and physical activity and sedentary behaviour are assessed. 
In Chapter Eight, results from an exercise intervention study (Study 3) conducted in 
33 patients with MPD are reported (Figure 1.1). Adherence to and tolerance of the 
intervention were compared between malnourished participants and well-nourished 
participants. Additionally, the relationships between energy and protein intake and 
outcomes from resistance exercise training, namely body composition and objectively 
measured physical functioning were assessed. 
Chapter Nine is an overall discussion of major findings and conclusions of the 
collective work with recommendations for future research. 
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2.1 Malignant pleural disease 
Malignant pleural disease (MPD) is the collective term for cancers that involve the 
pleurae, which are two serous membranes that attach to the chest wall and lungs.1 The 
small amount of fluid secreted by the pleurae acts as a lubricant to enable the membranes 
to slide against each other during breathing.1 MPD comprises both primary pleural cancers 
and secondary pleural cancers.2 Primary pleural cancers include malignant pleural 
mesothelioma (MPM), localised fibrous tumour and pleural liposarcoma.2 Secondary 
pleural cancers include metastatic disease, thymoma and lymphoma2 
2.1.1 Clinical presentation and symptom burden 
Most patients with MPD present with a pleural effusion,2 which is the excessive 
accumulation of fluid in the pleural cavity.2 A malignant pleural effusion is a unique fluid 
that is rich in protein (4 g/100 mL) and tumour secretions such as cytokines.3 The 
accumulation of pleural fluid occurs when the volume of fluid that enters the pleural space 
exceeds the capacity of the lymphatic system to remove the fluid.2 Approximately 60% of 
patients with MPD have at least 1 litre of fluid in the pleural space at the time of 
presentation.4 A high proportion of patients with a malignant pleural effusion present with 
symptoms;5 half of patients report breathlessness, while one-quarter of patients report 
chest pain at presentation.2  
2.1.2 Aetiology of malignant pleural effusions 
The imbalance between the volume of fluid that enters and is removed from the 
pleural space occurs when a tumour increases the permeability of the pleural surface; 
involves the lymphatic system; causes an obstruction which decreases pleural pressure; or 
involves the pericardium.2 
2.1.3 Prevalence 
Approximately half of all patients with cancer will develop a pleural effusion over the 
disease course.6 Currently, 8000 people in Australia and 1 million people worldwide are 
affected by a malignant pleural effusion each year.7 The majority of patients with a 
malignant pleural effusion (90%) have metastatic cancer.8 Patients with lung and breast 
cancer represent approximately 55% of all cases of a malignant pleural effusion.5 
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2.1.4 Prognosis 
MPD represents advanced cancer, however the median survival of patients with MPD 
varies according to tumour, biochemical and functional factors.9 Patients with lung and 
gastrointestinal cancers have the shortest median survival of less than 3 months while 
patients with MPM have the longest median survival of approximately 12 months.10 High 
pleural lactate dehydrogenase levels, which is indicative of localised inflammation within 
the pleural cavity,9 and a high neutrophil to lymphocyte ratio, which is indicative of 
systemic inflammation, are associated with poorer survival.9, 11 Poorer performance status 
is also associated with poorer survival.9 
2.1.5 Treatment 
The management of malignant pleural effusions has changed substantially over time. 
Early clinical trials for the management of malignant pleural effusions were focused on 
preventing the reaccumulation of pleural fluid using surgical techniques and sclerosing 
agents.12 However, the key goals of patient management have evolved over time to a more 
patient-centred approach to alleviate symptoms, with the least invasive means and without 
need for a hospitaladmission.12 Consequently, recent clinical trials have focused on 
improving patient-reported outcome measures including breathlessness,13, 14 chest pain,14 
and quality of life,13, 14 and reducing the amount of time spent in hospital.15 Due to the high 
failure rate of talc pleurodesis (~30%) and the subsequent need for reintervention, many 
centres now use an indwelling pleural catheter12 for the management of malignant pleural 
effusions, which enables ambulatory drainage of pleural fluid and reduces the need for 
reintervention and time spent in hospital.15 Existing guidelines on pleural fluid 
management state that symptoms may also be managed with medication.16 Where patients 
are asymptomatic, observation is the recommended approach.5 
2.2 Malignant pleural mesothelioma 
MPM represents 90% of primary pleural cancers8 and develops from the mesothelial 
surfaces of the pleurae.17 There are four histological subtypes of MPM: epithelioid, 
sarcomatoid, desmoplastic and biphasic, which contains both epithelioid and sarcomatoid 
components.17 The most common of the histological subtypes is epithelioid, which is 
present in 60% of cases.18 
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2.2.1 Aetiology 
Most cases of malignant pleural mesothelioma (MPM) can be attributed to asbestos 
exposure.19 The association between MPM and asbestos was first described in 1960.20 
Asbestos is defined as a group of naturally occurring hydrated mineral silicate fibres.17 The 
proposed mechanisms for development of MPM from asbestos exposure include pleural 
irritation, interference with mitosis, generation of toxic oxygen radicals and persistent 
kinase-mediated signalling.19 People exposed to brown and blue asbestos are more likely 
than those exposed to white asbestos to develop MPM although the reason is unknown.21 
2.2.2 Patient characteristics 
In Australia, asbestos was mined, manufactured into building products and used in 
construction from the 1950s. A total ban on the use of any type of asbestos was not 
introduced in Australia until 2003.22 Historically, people working in mining, 
manufacturing and construction occupations were more likely to be exposed to asbestos.23 
As these occupations were made up of a predominantly male workforce there is a higher 
incidence of MPM among men.24 While concerns around MPM originally centred on those 
workers who were responsible for mining asbestos and manufacturing asbestos products, 
the ‘new wave’ of MPM could be attributable to those who have had short term or low-
level exposure to asbestos through home maintenance or renovation.22 
Data from New South Wales indicates there is typically a long latency period between 
exposure to asbestos and development of MPM19 with a mean latency period of 44 years,25 
and a mean age at diagnosis of 70 years.25 
2.2.3 Clinical presentation and symptom burden 
Patients with MPM often have a high symptom burden. Between 60-80% of patients 
with MPM have breathlessness and chest pain at presentation.19, 26 Breathlessness in MPM 
is related to the presence of a malignant pleural effusion or the restriction of lung 
movement by the tumour.27 Chest pain is usually a consequence of the invasion of tumour 
to the chest wall or rib involvement and is therefore more prevalent amongst those with 
advanced stage disease.27 Other commonly reported symptoms at diagnosis are the 
constitutional symptoms of fatigue and weight loss.19 Between 20-50% of patients with 
MPM report weight loss at the time of diagnosis, although the amount, composition 
(muscle vs. fat loss), and timing of weight loss has been poorly described.28, 29 
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2.2.4 Prevalence 
Australia has the highest incidence of MPM per capita in the world with 30 cases per 
million people and rates of disease are expected to peak between 2014 and 2021.17, 30 These 
high rates of MPM are reflected in studies of patients with MPD. Patients with MPM are 
usually less than 10% of an MPD cohort, however in Western Australia patients with 
MPM comprise almost 40% of an MPD cohort.9 
2.2.5 Prognosis 
MPM is a universally incurable cancer.19 Unlike other advanced cancers, MPM is 
predominantly a localised disease and the reason for death remains largely unknown.31 In 
the largest post-mortem study published, including 318 patients from Western Australia, 
a precise cause of death could be determined in only 20% of cases. Notably, patients with 
an unknown cause of death had significantly lower body mass index (BMI) than those 
with an identified cause of death (18.8 ± 4.3 vs. 21.0 ± 4.7; p=0.034), and the authors 
proposed that nutritional status or body composition could be associated with the cause of 
death in patients with MPM.31 
Patients diagnosed with MPM have a median survival of 12 months32 with the one-
year survival rate reported as 41% and the three year survival as 12%.33 In the largest 
prospective study investigating prognostic factors in MPM (n=8740) the presence of non-
epithelioid histological sub-type of the disease and poor performance status were 
associated with poorer survival.33 
The most recent prognostic model for MPM was published in 2016.32 The study, 
which included patients with newly diagnosed MPM (n=482) identified individual 
clinical characteristics associated with survival and defined four risk groups based on a 
combination of clinical characteristics.32 The individual clinical characteristics associated 
with poorer survival were non-epithelioid histological subtype, weight loss, performance 
status ≥2 and altered blood parameters (haemoglobin ≤121 g/L and albumin ≤43 g/L).32 
Regarding the risk groups, those with a combination of no weight loss and haemoglobin 
≥153 g/L and albumin ≥43 g/L had the longest median survival (34.0 [IQR 22.9 – 47.0] 
months),32 while those with a combination of weight loss, performance status 0-1 and the 
sarcomatoid histological sub-type of MPM had the shortest median survival (7.5 [IQR 
3.3 – 10.9] months).32 
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2.2.6 Treatment options 
Treatments are usually provided to MPM patients with palliative intent. 
Chemotherapy, with pemetrexed and cisplatin is the only first-line treatment available.34 In 
a phase III randomised study of patients with MPM (n=456), patients who received 
pemetrexed and cisplatin in combination had a greater median survival time compared with 
those who received cisplatin alone (12.1 vs. 9.3 months; p=0.020);35 and greater response 
rates to treatment compared with the single agent (41.3% vs. 16.7%; p<0.001).35 
Radical surgical resection, which involves en bloc resection of the parietal pleura, 
pericardium, diaphragm, lung and visceral pleura has been shown to be detrimental to 
patients with MPM.36 In a randomised controlled trial (n=50) the reported hazard ratio for 
overall survival was 2.75 (1.21 – 6.26; p=0.016) between those who underwent surgery 
and those who did not.36 Median survival for the surgery group was 14.4 (5.3 – 18.7) 
months vs 19.4 (13.4 to time not yet reached) months in the non-surgery group. 
Research trials are currently investigating the effects of immunotherapy in patients 
with MPM. While there are some promising results from phase I and phase II trials, results 
of phase III trials are needed to determine if and how immunotherapy should be integrated 
into standard care for patients with MPM.37   
There are several treatment options available for symptom management. 
Radiotherapy for localised pain can improve pain temporarily in approximately half of 
patients.16 Pleural fluid management should be considered to manage breathlessness in 
patients with a pleural effusion.  
2.3 Measurement of physical function, physical performance and 
physical activity 
2.3.1 Physical function 
Physical function is defined as a person’s ability to complete the physical activities 
of daily living and is a reflection of a person’s physical fitness and their usual physical 
activity level.38 In clinical practice, performance status measures are commonly used to 
describe a person’s level of physical function. 
The most commonly used performance status measures in cancer are the Eastern 
Cooperative Oncology Group (ECOG) performance status39 and the Karnofsky 
Performance Status (KPS).40 The ECOG performance status scale consist of six levels 
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from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 
(dead) (Table 2.1).39 The Karnofsky performance status scale consists of eleven levels, 
which decrease by ten points at each level, from 100 (normal no complaints; no evidence 
of disease) to 0 (dead).40 
Table 2.1 Eastern Cooperative Oncology Group Performance Status Scale39 
Grade Performance Status 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature 
2 Ambulatory and capable of all self-care but unable to carry out any work 
activities; up to and about more than 50% of waking hours 
3 Capable of only limited self-care; confined to bed or chair more than 50% of 
waking hours 
4 Completely disabled; cannot carry on any self-care; total confined to bed or chair 
5 Dead 
Assessment of performance status is an important part of clinical care in cancer 
patients, including those with MPD. There is a strong relationship between performance 
status and prognosis in patients with advanced cancer41 and MPD,34 therefore performance 
status ratings are used to determine a person’s suitability for treatment and predict 
treatment tolerability.34 
Although performance status scales are simple to administer,42 assessment is 
subjective and could inaccurately assess a person’s actual functioning.42 This is 
highlighted in research that has compared patient and physician ratings of performance 
status;41 patients rated their performance status worse than physicians, which suggests that 
patient and physician ratings of performance status differ. Additionally, performance 
status categories are broad, and where a response to an intervention is expected to be small, 
performance status scales may not detect this small, but meaningful change in a person’s 
activity. Therefore alternative measures are required provide a more accurate and objective 
assessment of physical function. 
2.3.2 Physical performance tests 
Physical performance tests objectively measure a person’s functional capacity. 
Suboptimal physical performance may be present before a person’s usual daily activities 
are affected,43 and could predict a decline in activities of daily living.44 As these tests 
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assess the integrative capacity of skeletal muscle in a functional setting they have greater 
clinical utility than muscle function tests, such as handgrip strength, that measure only 
strength and power of individual muscles.43  
Several studies have reported on the relationship between physical performance and 
patient outcomes. In a recent systematic review, the authors concluded that poorer physical 
performance was associated with reduced survival in patients with cancer.45 Physical 
performance tests can predict patient outcomes better than performance status.46 In a study 
of 62 patients with non-small cell lung cancer, better physical performance test results 
were associated with an increased likelihood of completing more cycles of chemotherapy 
and decreased adverse effects of treatment.46 Notably, no relationship was observed 
between ECOG performance status and treatment outcomes.46 These result indicate that 
physical performance tests are associated with important patient outcomes. 
Commonly used physical performance tests are described in Table 2.2. Physical 
performance tests are typically low-cost and easy to administer. Currently, there is no 
information on the physical performance of patients with MPD. 
Table 2.2 Commonly used physical performance tests43 




test (i.e., 4 m walk) 
Measures gait speed The time taken to walk the required 




tests (i.e., 400 m 
walk) 
Measures gait speed The time taken to walk the required 
distance is recorded with a stop 
watch 
15 min 
Chair rise test Measures lower body 
power, balance and 
endurance 
The time taken to stand from a chair 
and sit down five times. 
1-2 min 
Timed Up and Go test Measures gait and 
dynamic balance 
The time taken to rise from an 
armed chair, walk 8-feet, turn and 
walk back to the same chair and sit 





balance, gait speed 
and lower body 
strength 
Includes three physical performance 
tests: standing balance, a short-
distance walk test and chair rise 
test.  
10 min 
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2.3.3 Physical activity questionnaires 
Caspersen et al47 defined physical activity as movement of the body that is generated 
by skeletal muscles and leads to an increase in energy expenditure. Physical activity is 
most commonly assessed with a self-report physical activity questionnaire. Questionnaires 
are inexpensive and relatively low burden, which is often advantageous, particularly for 
large population based studies. The Godin Shepherd Leisure-Time Physical Activity 
Questionnaire (GSLTPAQ) is frequently used in cancer research to assess physical 
activity.48 Participants completing the GSLTPAQ are asked to recall how many times in a 
week they participate in mild, moderate and strenuous physical activity for 15 minutes or 
more.49 The International Physical Activity (IPAQ) and Global Physical Activity (GPAQ) 
questionnaires have also been used in cancer research.50  
Self-report physical activity questionnaires can appropriately classify patients as 
sufficiently active or inactive relative to physical activity guidelines.50, 51 However, 
participants tend to overestimate the time spent in moderate and vigorous physical activity 
(MVPA), for example brisk walking, vacuuming, running, swimming, and underestimate 
their time spent as sedentary such as sitting or lying down.50, 52, 53 Factors that affect the 
level of accuracy include education level, sex, and age52 as well as activity level.54 
Therefore, physical activity monitors may offer more accurate information about a 
person’s individual activity levels. 
2.3.4 Physical activity monitors 
Physical activity monitors objectively measure a person’s activity levels. Physical 
activity monitors are small and portable to facilitate continuous monitoring of activity 
behaviours. The current available physical activity monitors are pedometers, 
accelerometers and multi-sensor systems.55 Pedometers only measure step counts. 
Accelerometers assess and quantify a range of movements associated with activity 
including sedentary time, light activity, such as shopping or walking around the home, and 
MVPA.56 Multi-sensor systems measure the amount and intensity of physical activity 
alongside a physiological measure such as heart rate or body temperature. Therefore, 
accelerometers and multi-sensor systems provide more comprehensive information about 
activity behaviours compared with pedometers.  
Accelerometers are reliable and valid when compared with the doubly-labelled water 
method of determining energy expenditure.55, 57 Despite their validity, there are several 
factors that need to be considered in research using accelerometers. Accelerometers collect 
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continuous data and convert physical activity behaviours into a digital signal. Data are 
compressed, filtered and analysed using algorithms to generate physical activity outputs. 
These activity end points include measures of the amount of activity, for example time 
spent in light activity, and total number of steps, and patterns of activity such as bouts of 
light activity, and breaks in sedentary time). 
Decisions made regarding accelerometry measurement and processing can affect 
accelerometry outcomes. Accelerometers can differ in their placement on the body and 
how they collect data.56 Additionally researchers can choose how to process data by 
making choices around physical activity cut-points and non-wear time.56 These factors can 
impact on reproducibility and comparability of the physical activity outputs produced.56 
2.4 Physical activity levels in cancer populations 
In recent years there has been a growth in research examining physical activity in 
cancer populations.56 Existing research indicates patients with lung cancer are less 
physically active than healthy adults.58, 59 Several studies have evaluated activity levels in 
lung cancer patients with early stage disease. In a study of patients following curative 
intent treatment for early stage non-small cell lung cancer, participants with non-small cell 
lung cancer (n=20), compared with healthy controls, spent a greater proportion of their 
waking hours in prolonged bouts (≥30 min) of sedentary behaviour (42 [30-58]% vs. 49 
[42-65]%; p=0.048) and lesser proportion of waking hours light intensity physical activity 
(26 ± 8% vs. 21 ± 9%; p=0.04).58 In another study of patients with stage I-IIIB non-small 
cell lung cancer (n=50), the participants with lung cancer, compared with age and gender 
matched controls, took significantly fewer steps per day (8483 ± 558 vs. 6120 ± 579; 
p<0.01);59 and fewer participants with lung cancer met recommendations of 150 minutes 
of MVPA per week (71% vs. 40%; p=0.01).59 Therefore, even in lung cancer patients with 
early stage disease, the majority were inactive. 
Few studies have reported on the activity levels of patients with advanced cancer, and 
no study has included patients with MPD. In one study of patients with advanced lung cancer 
(n=84), participants took, on average, 4246 ± 2983 steps per day and spent 19.7 ± 2.1 of all 
hours per day as sitting or lying down.60 Similarly in another study that included patients 
with early and advanced stage lung cancer (n=124),61 participants completed on average, 
4596 ± 2106 steps per day and spent 9.8 ± 1.6 of their waking hours per day as sedentary; 
only 23% of participants met recommendations of 150 minutes MVPA per week.61 In a 
study of patients with brain metastases (n=31), the average step count was lower, at 2784 ± 
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2278 steps per day.62 By comparison in Australia, an average healthy adult accumulates 
7400 steps per day.63 These data indicate that patients with advanced cancer have 
particularly low activity levels. However, research is needed to understand the physical 
activity levels of patients with MPD, and how this relates to important clinical outcomes. 
2.5 Physical performance and muscle strength in cancer populations 
Research indicates that patients with lung cancer have poorer physical performance 
and muscle strength compared with healthy adults.59, 64 In a study of patients with early 
stage lung cancer (n=50) the average Six-Minute Walk Distance was 84% of the predicted 
value for healthy adults,59 and handgrip strength and quadriceps strength were lower 
among participants with lung cancer.59 In another study of patients with lung cancer 
(n=39), including a high proportion with advanced stage disease, the average Six-Minute 
Walk Distance was 76% of the predicted value for healthy adults;64 and the majority of 
participants had upper and lower extremity strength that was 20% below the healthy 
reference population.64 
A number of studies have also reported on the physical performance and strength of 
older adults with cancer.44, 65-67 In a study of breast cancer survivors aged >65 years (n=40), 
the average chair stand time, handgrip strength and Short Performance Physical Battery 
score were lower than for healthy controls,65 while in another study of patients with early 
stage breast cancer aged >65 years (n=123), 20% of participants had a slow 4-m walk 
speed, 31% had a suboptimal Short Performance Physical Battery score and 57% had a 
low handgrip strength. In two larger studies of older adults with cancer (n=389 and 
n=354),66, 67 with approximately half who had advanced stage disease, a suboptimal Short 
Performance Physical Battery score was recorded for 71% and 78% of participants, 
respectively. Overall, these findings suggest that physical performance and strength are 
commonly impaired in people with cancer. Two of these studies65, 67 also reported a higher 
symptom burden was associated with poorer physical performance. While the high 
symptom burden associated with MPD indicates patients could be vulnerable to physical 
performance limitations, research is needed to understand the extent of the issue of 
functional impairment in MPD. 
2.6 Measurement of body composition 
Body composition refers to the relative amounts of muscle, fat and bone within the 
body.68 The evaluation of muscle and fat, in particular, is integral for the diagnosis of a 
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range of conditions relevant to cancer populations. There are multiple methods available 
for assessing body composition and knowledge of how these techniques measure body 
composition is essential for understanding their potential research application. 
2.6.1 Levels of body composition 
The science that underpins current body composition assessment methodology has 
been explained in a five-level model of human body composition published in 1992.69 
The model depicts human body composition as atomic, molecular, cellular tissue and 
whole body levels (Figure 2.1).69 
The atomic level, describes the elements which are the building blocks of human body 
composition.69 Ninety-eight percent of the human body is made up of six atomic 
elements.69 Oxygen is the most abundant element in the human body, followed by carbon, 
hydrogen, nitrogen, calcium and phosphorous.69  
The molecular level divides body composition into six compartments; water, lipids, 
protein, carbohydrates, bone minerals and soft tissue minerals.69 Water is the most 
predominant molecule, comprising 60% of the human body.69 Fats, the term given to the 
body’s triglyceride stores, are the largest source of lipid in the body.69 Non-fat lipids, for 
example phospholipids, which play an important structural role in the body are present in 
much smaller proportion.69 Protein includes the nitrogen containing compounds found in 
the body.69 Carbohydrates, mainly stored as glycogen, minimally contribute to body 
composition.69 The predominant minerals found in the body are calcium and phosphorous, 
which make up bone.69 
The cellular level, divides body composition into cell mass, extracellular fluids and 
extracellular solids.69 Cell mass refers to the components found within a cell, including 
water, protein and minerals.69 Extracellular fluid is predominantly water referred to as 
plasma (intravascular space) or interstitial fluid (extravascular space).69 Bone minerals, 
collagen and elastic fibres make up the majority of extracellular solids.69 
The tissue level is comprised of skeletal muscle, adipose tissue, bone, visceral organs, 
the heart and brain.69 At this level, the measurement of tissues, for example, adipose tissue, 
includes both the fat (triacylglycerol) as well as the protein, minerals and water that make 
up the tissue.69 Analysis of adipose tissue at this level can be further categorised as 
subcutaneous, visceral or interstitial.69  
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Figure 2.1 The five levels of human body composition. Source: Wang et al. 1992 
2.6.2 Methods for body composition assessment 
Methods for body composition assessment can be combined into five categories. 
These categories are anthropometry, total body water, major body elements, impedance 
and imaging.70 Imaging is considered to be the most valid method for body composition 
assessment.71 Imaging methods are comprised of computed tomography (CT), magnetic 
resonance imaging (MRI), dual-energy x-ray absorptiometry (DXA) and ultrasound.70 CT 
and DXA are the most commonly used methods for body composition assessment and 
therefore, are described in more detail in the following sections. 
Computed Tomography 
CT evaluates body composition at the tissue level and identifies bone, skeletal muscle, 
visceral organs and adipose tissue (Figure 2.2).70 Participants undergoing CT are exposed 
to x-rays. The x-ray attenuation through tissues is detected by a computer software 
program and cross-sectional images are reconstructed.72 The pixels that make up the image 
have a known attenuation relative to air and water and this is signalled by the Hounsfield 
Units allocated to it.72 The body tissues have their own specific Hounsfield Unit ranges 
and these are used for body composition analysis.72 The total number of pixels in the given 
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CT is a valid and reliable method for whole-body and regional measurement of body 
composition.72 An advantage of CT is its capability to measure body composition at the 
tissue level, meaning it can examine individual muscle groups and intramuscular adipose 
tissue.70 However, the precision of the CT method may be affected by the phase of the CT 
scan and the use of contrast during the scan.73, 74 Whole-body CT imaging is associated 
with a high radiation dose and cost.70 
CT scans that are typically used for patient care can be re-purposed to examine body 
composition.75 This has the potential to reduce radiation exposure, research costs and 
participant burden. When re-purposed CT scans are used in research, skeletal muscle and 
adipose tissue are measured from a single cross-sectional image at the third lumbar 
vertebrae.76 Abdominal skeletal muscle is strongly correlated with whole body skeletal 
muscle in healthy adults77 and in patients with lung and gastrointestinal cancer.76 
Although, prediction equations used to provide an estimate of whole-body skeletal muscle 
mass may be inaccurate.78  
Dual Energy X-Ray Absorptiometry 
DXA evaluates body composition at the molecular level and therefore measures bone 
mineral mass, lean soft tissue and fat mass (Figure 2.2).70 Participants that undergo a DXA 
scan are exposed to low-dose x-rays. All DXA machines have an x-ray source and a 
detector. The x-ray beams have two different photon-energy levels (low and high).79 When 
the photons pass through an absorber (i.e., a person’s body tissues; person), the amount of 
energy absorbed (i.e., how much the photons are scattered; attenuated) can be measured 
by a detector.79 The overall attenuation is expressed as a ratio (R) of the absorption 
(attenuation) for the lower energy photon to absorption of the higher energy photon.79 
Each atomic element in the body has a characteristic R value/ratio, and the R values of 
molecules (calculated from elemental composition) and various body composition 
components (i.e., bone mineral, protein) have been calculated.79 
DXA assumes that humans consist of three components that are distinguishable by 
their x-ray attenuation properties: fat, bone mineral and lean soft tissue.79 Bone is 
separated out from fat and lean soft tissue because bone has a much higher R value.79 
Tissues are quantified from the assumed component R values, image processing methods 
and soft tissue distribution models.79 
DXA is considered to be a valid and reliable method for body composition 
assessment.72 Additionally, DXA involves a relatively low radiation dose and is quick to 
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complete.70 Although, the precision of the DXA method may be affected by differences in 
machine software or the machine itself, patient positioning and hydration.80 An additional 
limitation of DXA is that measured lean soft tissue includes skeletal muscle, organs, fibrous 
and connective tissue and there is no way to assess whole-body skeletal muscle separately.81 
DXA has the capacity for regional body composition analysis. This means the arms 
and legs can be segmented from the trunk, enabling measurement of appendicular lean 
soft tissue, which is predominantly skeletal muscle.70 Existing research indicates that 
appendicular lean soft tissue is highly correlated with whole-body skeletal muscle.82, 83  
Therefore, DXA can be used for research where skeletal muscle is an outcome of interest. 
Figure 2.2 Components of body composition measured by dual energy x-ray 
absorptiometry and magnetic resonance imaging or computed 
tomography. Source: Prado et al. 2014. 
2.7 Malnutrition 
Malnutrition is a term used to describe weight loss and the associated reduction in 
muscle and fat mass.84 Malnutrition can result from inadequate nutrient intake, impaired 
nutrient absorption, impaired nutrient utilisation, or a combination of these factors.84 The 
development of malnutrition and subsequent loss of skeletal muscle is of concern due to 
its important role within the body. Skeletal muscle is primarily known for its role in 
physical movement therefore, the loss of skeletal muscle mass could negatively impact on 
locomotion and activities of daily living.85 Skeletal muscle also has an important role in 
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organs for the synthesis of new body proteins.86 Consequently, reduced skeletal muscle 
mass could impact on the body’s ability to prevent and respond to illness. 
2.7.1 Diagnosis of malnutrition 
Multiple diagnostic criteria have been developed for malnutrition.87-89 In 2012, an 
expert group from the European Society for Parenteral and Enteral Nutrition (ESPEN) 
convened to produce a consensus statement on diagnostic criteria for malnutrition.87 The 
recommendations from the ESPEN expert group were that malnutrition could be defined 
by either 1) BMI of <18.5 kg/m2 or 2) unintentional weight loss of >10% over any time 
period; or unintentional weight loss of >5% over a 3 month time period in combination 
with several factors including: a BMI <20 kg/m2 if aged <70 years; or a BMI <22 kg/m2 
if aged ≥70 years; or muscle mass of <17 kg for men and <15 kg for women.87 Therefore, 
earlier diagnostic criteria for malnutrition focused on the physical characteristics 
associated with the condition.  
The clinical nutrition community has recommended that the aetiology of malnutrition 
is identified within the diagnosis.90 In 2017, an ESPEN working group published a list of 
clinical nutrition terminology that recognised aetiology-based diagnosis of malnutrition. The 
ESPEN working group recommended the use of ‘disease-related malnutrition’ to describe 
situations where underlying disease has caused a reduction in nutrient intake, absorption or 
utilisation84 and the use of ‘disease-related malnutrition with inflammation’ is used where 
malnutrition exists in the context of a disease that results in underlying inflammation.84  
Updated diagnostic criteria for malnutrition were required to reflect the aetiology-
based diagnosis. In 2016, members of the Global Leadership Initiative on Malnutrition 
(GLIM) convened to produce an updated consensus on the diagnostic criteria for 
malnutrition.88 The recommendations were that malnutrition should be defined by both the 
physical characteristics, known as phenotypic factors, and aetiologic factors associated 
with the condition.88 According to the GLIM criteria, a diagnosis of malnutrition requires 
the presence of either low BMI, weight loss or reduced muscle mass plus evidence of 
reduced nutrient intake, absorption or utilisation or the presence of inflammation.88  
Of several nutrition assessment tools which include the phenotypic and aetiologic 
factors of malnutrition,88 the Patient-Generated Subjective Global Assessment (PG-SGA) 
has been validated for use in patients with cancer.91 The PG-SGA includes a patient-
generated component where weight history, food intake, symptoms and function are 
assessed, and involves a professional component where muscle and fat stores are visually 
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inspected and disease and metabolic factors are assessed.92 Completion of the PG-SGA 
results in a score as well as a global rating of nutritional status.92  
While existing research indicates that weight loss is common in patients with MPD 
at diagnosis,28, 29 the amount and timing of weight loss is seldom described and there has 
been no assessment of associated changes in muscle mass, dietary intake or inflammation 
using validated tools. Therefore, a more comprehensive evaluation of nutritional status and 
body composition is needed to determine the extent of malnutrition over the disease course 
in patients with MPD.   
2.8 Cancer cachexia 
Cancer cachexia is an example of ‘disease-related malnutrition with inflammation’ 
and is characterised by the preferential loss of muscle mass but can be accompanied by fat 
loss.93 Three stages of cancer cachexia have been defined.94 Pre-cachexia is the term given 
to the first stage of the syndrome, while cachexia is the second stage and refractory 
cachexia is the final stage.94 Pre-cachexia is characterised by weight loss of ≤5% in 
combination with a poor appetite and metabolic changes.94 Cachexia is defined as weight 
loss of >5% in 6 months; or weight loss >2% in 6 months in combination with a BMI of 
<20 kg/m2 or clinically low levels of muscle mass.94 These physical characteristics of 
cancer cachexia are often accompanied by reduced dietary intake and systemic 
inflammation.94 Refractory cachexia is characterised by weight loss in the context of a 
poor performance status and expected survival of less than 3 months.94 
2.8.1 Mechanisms of cancer cachexia 
In healthy adults, there is a balance between muscle protein synthesis and degradation 
which helps to preserve muscle mass.86 For muscle loss to occur, there must be a decrease 
in muscle protein synthesis, an increase in muscle protein degradation or a combination of 
both.95 Muscle protein synthesis is affected by dietary protein intake, especially the 
essential amino acid leucine, as well as exercise and anabolic hormones.96 Muscle protein 
degradation can be affected by inflammation.86 Although the mechanisms are unclear, 
cancer cachexia is influenced by a combination of both reduced dietary intake and altered 
metabolism.93 
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Reduced dietary intake 
Studies in patients with advanced cancer have reported that individual dietary intake 
varies substantially97 and a proportion of patients do not meet energy and protein 
requirements.97, 98 In a study of patients with advanced lung or gastrointestinal cancer 
(n=51), energy intake ranged from 14 – 55 kcal/kg/day and protein intake from 0.6 – 2.2 
g/kg/day,97 and 27% of participants did not achieve an energy intake of ≥25 kcal/kg/day, 
while 43% did not achieve a protein intake of ≥1.0 g/kg/day.97 In another study of patients 
with advanced lung or gastrointestinal cancer (n=84), 27% of participants did not achieve 
an energy intake of ≥30 kcal/kg/day, 1% did not achieve a protein intake of ≥1.0 g/kg/day 
and 33% did not achieve an energy intake of ≥30 kcal/kg/day or protein intake of ≥1.0 
g/kg/day.98 These results indicate that inadequate energy intake, in particular, is common 
in patients with advanced cancer. 
A number of factors are thought to be responsible for the reduced dietary intake 
frequently observed in patients with advanced cancer. In particular, pro-inflammatory 
cytokines and hormonal changes are thought to result in a lack of appetite. A recent review 
article on the pathophysiology of cancer cachexia suggests inflammatory cytokines can 
mimic the hormone leptin, which is responsible for reducing appetite.95 At the same time, 
hormones that stimulate appetite such as ghrelin and neuropeptide Y are suppressed.95 The 
resultant lack of appetite can lead to a reduction in dietary intake. 
There are no data to confirm a causal relationship between lack of appetite and 
reduced dietary intake, however, there is a reported association between appetite and 
energy intake. In a study of patients with breast cancer who underwent chemotherapy 
(n=114), each point decrease in appetite was associated with a 26.5 kcal (95% CI 14.4 – 
38.5) decrease in energy intake.99 Research in patients with advanced cancer (n=143) 
found that those self-reporting a lack of appetite had significantly lower energy intake 
compared to those reporting a normal appetite (1515 ± 544 vs. 1149 ± 580 kcal/day; 
p<0.001).100 These results indicate that a poor appetite is associated with lower energy 
intake, which if unresolved could lead to the development of cancer cachexia. 
Beyond lack of appetite, cancer and its treatment can cause additional symptoms that 
negatively impact on dietary intake. For example, in the study of patients with breast 
cancer who underwent chemotherapy, compared to healthy controls participants with 
breast cancer reported poorer taste when measured with the Appetite, Hunger feelings and 
Sensory Perception questionnaire (30.9 ± 0.71 vs. 22 ± 0.57; p<0.05). Additionally, each 
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point decrease in taste was associated with a 16.4 kcal (95% CI 7.0 – 25.8) decrease in 
energy intake.99 In a study of patients with advanced pancreatic cancer (n=39) who were 
followed prospectively every 4 weeks until the end of life,101 moderate to severe pain at 
rest (≥4 on Edmonton Symptom Assessment Scale) was associated with significantly 
lower energy intake compared with low pain at rest at study inclusion and at three, monthly 
follow up assessments. Other symptoms including oral dryness, nausea and fatigue were 
also associated with a lower energy intake.101 
The difference in energy intake between weight losing and weight stable patients with 
cancer has been investigated in several studies. In a large study of patients with mixed 
cancer diagnoses (n=297), where weight loss was defined as >5% body weight, there were 
no significant differences in energy intake between weight stable and weight losing 
participants.102 Weight losing participants consumed 28 ± 12 kcal/kg/day compared with 
weight stable patients who consumed 24 ± 8 kcal/kg/day (p=0.052). A similar result was 
observed in a study of patients with advanced pancreatic cancer (n=20) where cachexia was 
defined as >5% weight loss within 6 months or >2% weight loss in those with a BMI <20 
kg/m2.103 Participants with cachexia consumed 22.1 [14.3 – 33.9] kcal/kg/day compared 
with participants who were non-cachectic who consumed 28.9 [8.6 – 79.7] kcal/kg/day 
(p=0.09).103 These results indicate that energy intake is not significantly different between 
those with and without weight loss. These findings may be attributable to variable energy 
requirements between individuals related to differences in age, sex and lean mass.104 
However, these result could also indicate that factors beyond reduced food intake are likely 
to be involved in the development of cancer cachexia. 
Altered metabolism 
Pro-inflammatory cytokines and hormones could play a key role in the altered 
metabolism of cancer cachexia. There are multiple components to the altered metabolism 
seen in cancer cachexia including hypercatabolism, hypermetabolism and hypoanabolism. 
Regarding hypercatabolism, tumour necrosis factor α (TNFα) and interleukin-6 (IL-6) 
promote insulin resistance that decreases protein synthesis and stimulate the ubiquitin-
proteasome pathway that leads to protein catabolism.105 Adipose tissue is lost as a result of 
increased lipolysis which occurs due to the tumour-induced lipid mobilising factor. 105 
Several studies have evaluated differences in cytokines or biomarkers between weight 
losing and weight stable patients with cancer. Although findings are inconsisent106-108 IL-
6 is the most commonly studied of the cytokines, with the most consistent results.109-111 
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Several studies have reported that serum IL-6 concentrations are higher in weight losing 
compared with weight stable patients.109-111 Additionally, albumin concentrations are 
lower and C-reactive protein (CRP) concentrations are higher in cancer patients with 
weight loss and low muscle mass.112-116 
Low concentrations of anabolic hormones such as testosterone could contribute to the 
loss of skeletal muscle in patients with cancer. Testosterone concentrations can be lowered 
by increasing age, cancer treatment,117 inflammation,117 and opioid medications used to 
treat pain.117 Consequently, low testosterone concentrations are common among patients 
with cancer, affecting between 40 and 90% of patients.117 Two studies in patients with 
advanced cancer have previously examined the relationship between testosterone levels 
and weight loss,118, 119 and both studies reported that there was an inverse correlation 
between testosterone concentrations and weight loss.118, 119 
Hypermetabolism, which is an increase in resting energy expenditure, could also play 
a role in the onset and progression of cancer cachexia. When energy expenditure is 
increased, amino acids are released from skeletal muscle for energy production resulting in 
an overall loss of skeletal muscle.85 The tumour, hepatomegaly and liver metastases, and 
activation of brown adipose tissue may contribute to an increase in resting energy 
expenditure.120 Conversely, some patients with cancer may have a lower total energy 
expenditure due to low physical activity levels and reduced food intake.120 Hypermetabolism 
affects approximately 40% of patients with advanced lung cancer.121, 122 Despite the 
theoretical relationship between hypermetabolism and weight loss, research indicates that 
weight loss does not differ between hyper- and normo-metabolic patients.102 Overall, these 
results highlight that more research is needed to fully understand the relationship between 
metabolism and weight loss in patients with cancer, including those with MPD.  
2.8.2 Treatment of cancer cachexia 
Cancer cachexia could also be partly reversed by addressing inadequate dietary intake 
before the refractory stage of cachexia is reached.93 Where weight loss is present, the 
American Society of Clinical Oncology (ASCO) guidelines for the management of cancer 
cachexia recommend referral to a dietitian for dietary counselling on a high-energy, high-
protein diet.123 Energy and protein intakes of 25 – 30 kcal/kg/day and 1.0 – 1.5 g/kg/day 
are considered appropriate targets.124  
Exercise has been proposed as another potential treatment for cancer cachexia. As 
resistance exercise training is associated with muscle hypertrophy,125 this type of 
Chapter Two.  Literature Review 
33 
intervention could help to negate muscle loss associated with cancer cachexia. There are 
currently a lack of exercise interventions in patients with cancer cachexia,123 therefore 
there is insufficient evidence to make a recommendation of the role of exercise in the 
management of cancer cachexia.123  
Cancer cachexia cannot be fully reversed without also addressing the underlying 
metabolic alterations.94 Early clinical trials suggest that ghrelin analogues, selective 
androgen receptor modulators, anti-inflammatory agents and cannabinoids are promising 
pharmacological treatments for cancer cachexia.126 However, there is insufficient evidence 
to recommend any of the studied pharmacological treatments for cancer cachexia, and no 
treatments are clinically available.123  
Multi-modal interventions that include a combination of nutrition support, exercise 
training and pharmacologic agents could have an important role in the management of 
cancer cachexia. Fearon et al93 has proposed that multi-modal interventions may be more 
effective than single interventions as they address the multiple factors that contribute to 
cancer cachexia. However, information on the relationship between nutritional status, 
body composition and dietary intake, physical activity and inflammation are needed to 
establish the potential for multi-modal interventions in patients with MPD.  
2.9 Prevalence of malnutrition in cancer populations 
Approximately one-quarter of patients with cancer have malnutrition.127 However, 
the prevalence varies according to the cancer population, stage of disease and type of 
cancer treatment received.127 Research from Australia indicates that upper gastrointestinal, 
head and neck and lung cancer populations have the highest prevalence of malnutrition.127 
Additionally, those who have metastatic disease or are receiving chemotherapy or 
combined chemo-radiation are more likely to have malnutrition.127  
There is a lack of information on the prevalence of malnutrition in patients with MPM, 
as patients with MPM have historically been included in studies of patients with lung 
cancer.128 Several studies have evaluated the prevalence of malnutrition in advanced lung 
cancer populations.107, 129-137 The studies range in size from 25 – 1219 participants and the 
majority of studies assessed nutritional status using the PG-SGA130, 132-134 or SGA,129, 131, 
138 although other studies used the Mini-Nutritional Assessment (MNA),107 Malnutrition 
Universal Screening Tool,135 or GLIM criteria.137 Notably, there was a large range in the 
prevalence of malnutrition of between 24 – 100% of participants (Table 2.3).  This large 
range in the prevalence of malnutrition is likely related to the different criteria used to 
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assess nutritional status. The lowest prevalence of malnutrition was observed where the 
MNA or GLIM criteria were used, while the highest prevalence of malnutrition were 
observed where a PG-SGA score of 2-8 was considered indicative of moderate 
malnutrition. A PG-SGA score of two can be reached if a person is older than 65 years 
and has a diagnosis of cancer, therefore this cut-point can result in a false positive 
diagnosis of malnutrition. Regardless of these differences in assessment methods, these 
results highlight that malnutrition is common in patients with advanced lung cancer. 
However, as advanced lung cancer is distinctly different from MPM, research is needed 
on the prevalence of malnutrition specifically in patients with MPM. 
Several studies have also evaluated weight changes over time in patients with advanced 
cancer. In a study of patients with unresectable pancreatic cancer (n=20), participants were 
assessed for a median duration of 27 weeks.139 The median BMI at diagnosis was 20.7 kg/m2 
and BMI just before death was lower at 17.7 kg/m2, which represented a median weight loss 
of 5 kg over the course of the disease.139 This result indicated that weight loss could be 
progressive over the disease course in patients with advanced cancer. 
Further studies have indicated that weight loss occurs only in a proportion of patients 
during any given time period. In a large prospective observational study of patients with 
incurable cancer (n=544) patient-reported weight loss was graded from 0 to 4 based on 
percentage weight loss and BMI.140 While the majority of participants did not change weight 
loss grade in 3 months, between 19 and 39% of patients progressed to a more advanced 
grade within 3 months140 and between 4 and 13% improved weight loss grade.140 A similar 
result was reported from a multi-institutional prospective, observational study in patients 
with non-small cell lung cancer (n=406) where the incidence rate of ≥5% weight loss was 
reported at four time points over the disease course.141 At 3, 6, 9 and 12 months the incidence 
rate of ≥5% weight loss ranged between 0.248 and 0.288. Therefore, within any 3-month 
period approximately 30% of participants experienced greater than 5% weight loss.141 These 
results indicate that in some advanced cancer populations there is a risk of weight loss 
across the disease course. However, research is needed to understand the extent of the 
issue of malnutrition across the disease course specifically in patients with MPM.
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Table 2.3 Prevalence of malnutrition in advanced cancer populations 





(age, % men) 
Timing of 
observation Assessment criteria 
Prevalence of 
malnutrition 





>5% weight loss or
>10% weight loss
49% with >5% weight 
loss 
26% with >10% weight 
loss 
Araujo dos Santos, 
2015143 
All cancer groups (27% 
prostate, 22% breast, 9% 









PG-SGA global rating 
of B or C 
44% malnourished 









SGA global rating of B 
or C 




Barata, 2017130 Advanced lung cancer Cross-sectional, 
n=37 






PG-SGA global rating 
of B or C 




Bozzetti, 2009144 All cancer types (42% 
colorectal, 18% head and 
neck, 16% stomach, 12% 











NRS score ≥3 and 
weight loss >10% 
40% malnourished 







SGA global rating of B 
or C 
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(age, % men) 
Timing of 
observation Assessment criteria 
Prevalence of 
malnutrition 









MNA score ≤11 23% malnourished 





PG-SGA score 2-8 is 
moderate 
malnutrition; and ≥9 
is severe malnutrition 




Ge, 2019133 Advanced lung cancer Prospective, 
n=495 





PG-SGA score ≥9 




25% with need for 
symptom management 
and/or nutrition support 
Gioulbasanis, 2011107 Metastatic lung cancer Cross-sectional, 
n=115 








MNA score ≤11 25% malnourished 




Median age 67 
years, 64% 
men 
First or second 
week of 
radiotherapy 
PG-SGA global rating 
of B or C 
15% malnourished (15% 
mildly to moderately 
malnourished, 0% 
severely malnourished) 
Koom, 2012147 Head and neck, lung and 
gastrointestinal cancer 
(lung 27%); included 
palliative treatment intent 
Prospective, 
n=1,000 
Mean age 59 








SGA global rating of B 
or C 
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(age, % men) 
Timing of 
observation  Assessment criteria 
Prevalence of 
malnutrition 
Li, 2018148  All cancer sites (lung 20%); 
45% metastatic cancer 
Cross-sectional, 
n=1138 





>5% weight loss in 6 
months or BMI <20 
and >2% weight loss  
41% malnourished 
 
Lin, 2019134 Advanced lung cancer Prospective, 
n=465 





PG-SGA global rating 
of B or C 




Mohan, 2017135 Advanced non-small cell 
lung cancer  
Prospective, 
n=148 
Mean age 57 
years, 87% 
men 
Not specified MUST score ≥2 




64.9% with a score ≥2 
 
Montoya, 2010149 All cancer groups receiving 
chemotherapy (lung cancer 









SGA global rating of B 
or C 




Muscaritoli, 2017150 All cancer groups  lung 










MNA score ≤11 9% malnourished  
Percival, 2013151 Thoracic cancer (0.4% 
mesothelioma); 74% 
palliative treatment intent 
Prospective, 
n=243  





BMI <18.5 kg/m2, 
>10% weight loss, or 
BMI <20 kg/m2 and 
>5% weight loss 
35% malnourished (20% 
of patients with 
mesothelioma 
malnourished) 
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(age, % men) 
Timing of 
observation Assessment criteria 
Prevalence of 
malnutrition 
Platek, 2011152 All cancer groups (lung 
cancer 39%); 40% 
metastatic disease  
Retrospective 
study, n=227 










BMI of <18.5 kg/m2 
9% malnourished using 
ICD-9 codes 
26% malnourished using 
dietitian assessment 
9% malnourished using 
BMI 











SGA global rating of B 
or C 




Segura, 2005153 All cancer groups (lung 
cancer 23%); 56% locally 











PG-SGA global rating 
of B or C 
52% malnourished (40.4% 
moderately 
malnourished, 11.8%  
severely malnourished) 
Wie, 2010154 All cancer groups (lung 
cancer 20%); 60.5% stage 









BMI <18.5 kg/m2, 
albumin <2.8 g/dL, 
total lymphocyte 
count <1200 
cells/mm3 and nothing 
per oral intake 
61% malnourished (36.5% 
high risk of malnutrition, 
24.8% at moderate risk 
of malnutrition). 
Yin, 2020137 Lung cancer, 40% with 
stage IV disease 
Prospective, 
n=1219 









strength to assess 
reduced muscle mass 
24% malnourished 
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2.10 Relationship between malnutrition and patient-related 
health outcomes 
2.10.1 Quality of life 
The relationship between malnutrition, defined by percent weight loss, and quality of 
life in cancer populations has been reported in multiple studies.155 No data are available 
on the relationship between malnutrition and quality of life in patients with MPM, however 
some data is available from patients with lung cancer.136, 156 One large study in patients 
with non-small cell lung cancer (n=531) with predominantly advanced stage disease, 
compared the relationship between the different stages of cachexia, and quality of life 
using the European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC QLQ-C30).157 The study reported that the functional, role and 
social domains of quality of life decreased with advancing cachexia stage.157 Additionally, 
in a cross-sectional study of patients with newly diagnosed advanced lung cancer (n=119), 
participants with malnutrition had significantly lower physical functioning and role 
functioning scores on the EORTC QLQ-C30 compared with well-nourished 
participants.136 In another cross-sectional study which included patients with all stages of 
lung cancer (n=180), global quality of life on the EORTC QLQ-C30 as well as all of the 
questionnaire domains, including physical, role, emotional, cognitive and social, were 
significantly lower in patients with malnutrition compared to well-nourished 
participants.156 These results highlight a relationship between malnutrition and poorer 
quality of life, particularly for domains related to physical and functional aspects of life, 
however it is not known if this relationship exists in patients with MPM. 
2.10.2 Physical activity, physical functioning and muscle strength 
There is little information available in cancer populations on the relationship between 
malnutrition and physical activity. However, one study in patients with non-small cell lung 
cancer (n=531) with predominantly advanced stage disease, compared the relationship 
between the different stages of cachexia, and self-reported physical activity.157 The study 
reported that physical activity decreased with advancing cachexia stage, such that 
participants who were well nourished participated in a median of 2712 metabolic 
equivalent minutes of activity per week and participants who were cachexic participated 
in only 495 metabolic equivalent minutes of activity per week.157 
Several studies have reported on the relationship between malnutrition and physical 
functioning and muscle strength. One study of patients with unresectable lung cancer 
(n=37) assessed nutritional status with the PG-SGA prior to treatment and reported that 
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those who were malnourished were more likely to have a handgrip strength in a lower 
percentile compared with those who were not malnourished (p=0.026). Additionally, in a 
study of patients with colorectal cancer (n=67)158 where nutritional status was assessed 
prior to surgery, those who were malnourished, defined as weight loss >10%, had 
significantly lower handgrip strength compared to those who were well-nourished, defined 
as weight loss <10% (19.4 vs. 27.3 kg; p=0.013). Regarding measures of physical 
functioning, a cross-sectional study conducted amongst older adults with cancer (n=185) 
reported that compared to participants without weight loss, participants with unintentional 
weight loss (weight loss >3 kg) had significantly lower handgrip strength (p=0.040) but 
there was no difference in walking speed (p=0.172).159 The available data indicates that 
malnutrition could be associated with poorer physical activity and muscle strength. In 
patients with MPM one of the goals of care is to improve daily physical activities so an 
understanding of the factors that could impact on daily physical activities will help to 
inform future research and could impact on clinical practice. 
2.11 Sarcopenia 
The term sarcopenia was first defined in 1988,160 and is used to describe the presence 
of low skeletal muscle mass and the resulting impairment of physical function.161 More 
recently, sarcopenia has been defined as a skeletal muscle disorder that is progressive and 
generalised in nature and is associated with a range of negative outcomes.162 Sarcopenia 
was originally used to describe the age-related loss of skeletal muscle mass, however it is 
now accepted that loss of skeletal muscle mass can be a consequence of inactivity, 
inadequate dietary intake, disease or a combination of these factors.161  
2.11.1 Diagnosis of sarcopenia 
The first consensus statement on the diagnosis of sarcopenia was published by the 
European Working Group on Sarcopenia in Older People (EWGSOP) in 2010.161 The 
working group identified three stages of sarcopenia: pre-sarcopenia, sarcopenia and severe 
sarcopenia.161 Pre-sarcopenia was defined as the presence of low skeletal muscle mass, 
while sarcopenia was defined as the presence of low skeletal muscle mass with either low 
muscle strength or function and severe sarcopenia was defined as low skeletal muscle mass 
with both low strength and function.161 
An updated consensus statement on the diagnosis of sarcopenia was published by 
EWGSOP in 2019.162 The updated statement does not refer to pre-sarcopenia and rather 
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provides an alternative algorithm to facilitate the diagnosis of sarcopenia in clinical 
practice.162 The working group recommended that assessment of sarcopenia begins with 
an evaluation of muscle strength, and only if this measurement is low, is evaluation of 
muscle mass or muscle quality performed.162 Although the EWGSOP criteria are 
commonly used to define sarcopenia, it is acknowledged that multiple definitions of 
sarcopenia exist, and there remains no international consensus on diagnostic criteria for 
sarcopenia in older adults. 
There is currently no consensus on the optimal body composition assessment method 
for the measurement of muscle in patients with cancer. CT and DXA are both considered 
appropriate for the measurement of muscle,162 although each has limitations as outlined in 
section 2.6.2. To determine if muscle mass is indicative of low or normal muscle mass a 
cut-point is applied. Multiple cut-points are available for both CT and DXA (Table 2.4). 
CT cut-points have been established from values that were associated with mortality,163, 
164 however it is not known if these values correspond with other clinical outcomes such 
as physical function. DXA cut-points have been established from values that were more 
than 2 standard deviations below a reference population of healthy young adults165, 166 or 
the lowest 20% of values of a population of older adults,167, 168 and are associated with 
functional impairment in older adults.169 There is limited information on the comparability 
of CT and DXA cut-points, however results from one study in advanced lung and 
gastrointestinal cancer indicate only moderate agreement between methods for the 
classification of low muscle mass.78 Further comparison of CT and DXA and their cut-
points are needed to investigate the impact of methodological decisions on research 
findings. 
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Table 2.4 Published cut-points for the classification of low muscle mass 
Study n/sex/age 
Reference 
population Cut-point method Cut-point value 
Computed tomography 
Prado et al. 
2008163 
250; 54% men; 
35-88 years 









<52.4 cm2/m2 for 
men 
<38.5 cm2/m2 for 
women 
Martin et al. 
2013164 
1473; 56% 
men; 64.7 ± 
11.2 years for 
men, and 64.8 
± 11.5 years 
for women  









<43 cm2/m2 for 
men with BMI 
≤24.9 kg/m2;  




<41 cm2/m2 for 
women 
Dual energy x-ray absorptiometry 
Baumgartner et 
al. 1998165 
808; 53% men; 
73.6 ± 5.8 
years for men 
and 73.7 ± 




2 SD below mean 
of healthy young 
adults 
<7.26 kg/m2 for 
men 
<5.45 kg/m2 for 
women 





Older adults Sex-specific lowest 
20% of the 
distribution index 
<7.23 kg/m2 for 
men 
<5.67 kg/m2 for 
women 





Older adults Sex-specific lowest 
20% of the 
distribution index 
<7.25 kg/m2 for 
men 
<5.67 kg/m2 for 
women 







2 SD below mean 
of healthy young 
adults 
<6.94 kg/m2 for 
men 
<5.30 kg/m2 for 
women 
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2.11.2 Aetiology of low muscle mass 
Age 
As people age, and particularly from the fifth decade of life, muscle mass declines.170 
In a review which included five longitudinal studies ranging in duration from 5 – 12 
years, the authors reported that median yearly muscle loss in participants with a mean age 
of 75 years ranged from -0.024% to 1.3%,171 the decline in strength was disproportionate 
to muscle mass; and that strength deteriorated at a greater rate than muscle mass. Notably, 
changes in muscle mass and strength differed according to the sex of participants. 
Compared to women, men experienced a greater decline in muscle mass (0.64 – 0.70% 
vs. 0.8 – 0.98%) and strength (2.5-3.0% vs. 3.0 – 4.0%).171 These findings indicate that 
while muscle loss and functional decline occur in both men and women, men are more 
severely impacted.  
As a result of this gradual decline in muscle mass, the prevalence of low muscle mass 
increases with older age. In the New Mexico Elder Health Survey study of older adults 
(n=426), the authors reported the prevalence of sarcopenia in Caucasian adults of different 
age brackets, where sarcopenia was defined as muscle mass >2 standard deviations below 
healthy adults.165 Sarcopenia was present in 13.5% of Caucasian men aged <70 years and 
23.1% of women aged <70 years; and in 52.6% of men aged ≥80 years and 43.2% of 
women aged ≥80 years.165 In another study, the authors reported the prevalence of 
sarcopenia in healthy older adults (n=4504), where class II sarcopenia was defined as 
muscle mass >2 standard deviations below healthy adults. The prevalence of sarcopenia 
was low and remained consistent across age brackets.169 Class II sarcopenia was present 
in only 6% of men aged and 9% of women aged 60-69 years; and in 7% of men and 11% 
of women aged 70-79 years and ≥80 years.169 These results indicate that the prevalence of 
low muscle mass increases with advancing age, although rates of low muscle mass vary 
by gender and between populations.  
The mechanisms responsible for the decline in muscle mass and function are 
unknown, although several physiological changes that occur with older age could be 
involved. These include an increase in the proportion of muscle fibres to a single motor 
unit, fatty infiltration of the muscle, neural changes and hormonal changes such as 
anabolic resistance, and inflammatory changes.172  
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Physical activity 
Individuals with higher physical activity levels are reported to have a lower risk of 
developing low muscle mass. Steffl et al173 conducted a systematic review and meta-
analysis173 of observational studies to evaluate the risk of low skeletal muscle mass among 
adults aged older than 40 years (n=4605) according to their physical activity level and 
reported that the odds ratio was 0.45 (95% CI 0.37 – 0.55) for those with the highest 
physical activity level. This finding indicates that adequate physical activity could be 
protective against the development of low skeletal muscle mass in older adults. However, 
there is little information on the relationship between physical activity and changes in 
skeletal muscle in patients with cancer. This information could be used to guide the 
development of supportive care interventions aimed at preserving skeletal muscle mass. 
Dietary intake 
Higher protein intakes are associated with greater skeletal muscle mass and less loss 
of skeletal muscle mass over time. In a cohort study of older adults (n=740),174 participants 
who did not meet the recommended daily intake (RDI) for protein, of 64 – 81 g/day for 
men and 46 – 57 g/day for women depending on the age group, had lower levels of 
appendicular lean mass at baseline after adjusting for confounding factors (mean 
difference -0.81, [95% CI -1.54 - -0.08] kg; p=0.03). In the Health, Aging and Body 
Composition study175 where older adults aged between 70 and 79 years (n=2732) were 
followed for three years, total protein intake was inversely associated with change in total 
lean mass and appendicular skeletal muscle mass after adjusting for confounding factors. 
Specifically, higher protein intake was associated with less muscle loss. Additionally, 
participants with the highest protein intake of 1.2 g/kg/day lost 43% less total lean mass 
and 39% less appendicular lean mass than those with the lowest protein intake of 0.8 
g/kg/day (p<0.01). This indicates that adequate protein intake is protective against muscle 
loss and that the level of adequate protein intake is higher in older adults compared to 
young adults.  As with physical activity, there is a lack of information on the relationship 
between dietary intake and changes in skeletal muscle in patients with cancer, which is 
critical for the development of supportive care interventions. 
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2.11.3 Prevalence and factors contributing to low muscle mass in cancer 
populations 
The overall prevalence of low muscle mass in patients with cancer is reported to be 
40%.176 In a review paper, Ryan et al177 summarised the prevalence of low muscle mass 
according to cancer diagnosis, and reported the median prevalence of low muscle mass 
ranged between 38 – 70%, although there was a large prevalence range within each 
diagnosis. There is little information on the prevalence of low muscle mass in patients 
with MPD, however a systematic review and meta-analysis has reported the overall 
prevalence of low muscle mass in patients with lung cancer was 45%.178 Five of the studies 
included in this publication were specifically in advanced lung cancer (Table 2.5).179-183 
Other studies have also reported on the prevalence of low muscle mass in advanced lung 
cancer.184, 185 The studies ranged in size from 33 – 441 participants and the majority of 
studies used CT180-185 to measure muscle mass with only one study using DXA.179 There 
was a large range in the prevalence of low muscle mass of between 38 – 71% of 
participants. This large range in prevalence of low muscle mass could be related to the 
different cut-points used to assess muscle mass between studies. Regardless, these results 
indicate high rates of low muscle mass among patients with advanced lung cancer. This 
suggests that low muscle mass may also be common among patients with MPD, however 
currently there is a lack of body composition data specific to patients with MPD to 
investigate this hypothesis. 
There is limited data available on characteristics associated with low muscle mass in 
patients with cancer, however the prevalence of low muscle mass in men, at 25%, is almost 
double that of women, at 13%.176 While chemotherapy is thought to contribute to muscle 
loss in patients with cancer, due to its proteolytic effect on muscle,186 existing research 
indicates that muscle loss can occur regardless of cancer treatment.183, 187 In a study of 
patients with advanced lung cancer (n=222) who received a placebo in phase III trials, and 
were therefore not receiving active treatment, 53% of participants lost skeletal muscle over 
the trial period.187 In another study of patients with lung cancer (n=35) who were receiving 
cancer treatment,183 54% of participants lost skeletal muscle over the treatment period, and 
46% of participants maintained skeletal muscle.183 These findings indicate that muscle loss 
may be related to factors beyond cancer treatment. 
Progressive or advanced disease is a factor associated with muscle loss over time. 
Conceptually, this make sense as the tumour is assumed to be responsible for the 
catabolism associated with cancer cachexia.93 In a large study of patients with advanced 
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cancer (n=368),188 skeletal muscle loss was greater and occurred more rapidly within 1 
month of death compared with skeletal muscle loss that occurred more than 9 months from 
death (cross-sectional muscle area -20.4 ± 13.4 cm2 vs. -13.6 ± 5.5 cm2; p<0.003),188 and 
the chance of skeletal muscle loss within 90 days of death was increased (OR 2.67 [95% 
CI 1.45 – 4.94]; p=0.002).188 These results could indicate that an increased rate and amount 
muscle loss are indicative of the end of life. Prospective evaluation of body composition 
in patients with MPM is needed to provide knowledge of the body composition changes 
that occur over time and the factors associated with these changes. This could lead to the 
development of targeted interventions to prevent or manage losses.  
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Table 2.5 Prevalence of low muscle mass in advanced cancer populations 




(age, % men) 
Timing of 
observation Assessment criteria 
Prevalence low 
muscle mass 
Antoun, 2019142 Metastatic colorectal 
cancer 




CT SMI at L3 <43 
cm2/m2 for men if BMI 
<25 kg/m2 and <53 
cm2/m2 if BMI >25 
kg/m2, and <41 cm2/m2 
for women 
53% 
Baracos, 2010184 Advanced non-small cell 
lung cancer 
Prospective, n=441 Mean age 67 years 
for men and 65 






CT SMI at L3 <55.4 
cm2/m2 for men and 
<38.9 cm2/m2 for 
women 
47% 
Chambard, 2018179 Non-small cell lung 
cancer with bone 
metastasis 
Prospective, n=64 Mean age 52 years, 
75% men 
Time of first bone 
metastasis 
DXA ASM <7.26 kg/m2 
for men and >5.45 
kg/m2 for women 
47% 
Daly, 2018189 Foregut cancer (61% 
gastro-oesophageal, 
39% hepato pancreato-
biliary); 51% with 
stage IV disease 




CT SMI at L3 <43 
cm2/m2 for men if BMI 
<25 kg/m2 and <53 
cm2/m2 if BMI ≥25 
kg/m2, and <41 
cm2/m2 in women 
40% 
Kakinuma, 2018185 Advanced non-small cell 
lung cancer 






CT SMI at L3 <49 
cm2/m2 for men and 
31cm2/m2 for women 
40% 
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(age, % men) 
Timing of 
observation  Assessment criteria  
Prevalence low 
muscle mass 
Kim, 2015190 Small cell lung cancer; 
68% extensive disease  
Retrospective, n=149 Mean age 69 years, 
85% men 
Newly diagnosed CT SMI at L3 <49 
cm2/m2 for men and 
31cm2/m2 for women 
53% 
Kim, 2018191 Lung cancer; 72% with 
advanced disease 
Retrospective, n=778 Mean age 68 years, 
73% men 
Newly diagnosed CT SMI at L3 of <55 
cm2/m2 for men and 
<39 cm2/m2 for women 
48%  
Kimura, 2015180 Advanced non-small cell 
lung cancer 
Retrospective, n=134 Median age 66 
years, 60% men 
Newly diagnosed CT SMI at L3 of <41 
cm2/m2 for men and 
<38 cm2/m2 for women 
38% 
Kiss, 2018192 Non-small cell lung 









<43cm2 for men if BMI 
<24.9 kg/m2 and <53 
cm2 in men if BMI >25 
kg/m2, and <41cm2 for 
women,   
61% 
Nipp, 2018193 Incurable lung or non-
colorectal 
gastrointestinal cancer 
(57% lung cancer) 
Prospective, n=237 Mean age 64 years, 
54% men 
Within 8 weeks of 
diagnosis; no 
prior therapy for 
metastatic 
disease 
CT SMI at L3 of <55 
cm2/m2 for men and 
<39 cm2/m2 for women 
55% 
Onishi, 2019194 Unresectable advanced 
oesophageal cancer 
Prospective, n=176 Mean age 65 years; 
85% men 
Prior to treatment CT SMI at L3 of <52.4 
cm2/m2 for men and 
<38.5 cm2/m2 for 
women 
57% 
Prado, 2008163 Respiratory and 
colorectal cancer (43% 
lung cancer); 34% 
stage IV disease 




CT SMI at L3 of <52.4 
cm2/m2 for men and 
<38.5 cm2/m2 for 
women 
15%  
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(age, % men) 
Timing of 
observation Assessment criteria 
Prevalence low 
muscle mass 
Prado, 2013195 Advanced non-small cell 





Mean age 65 years, 
68% men 
No particular time 
point described. 
DXA ASMI <7.26 kg/m2 
for men and <5.45 
kg/m2 for women 
36% 
Rier, 2018196 All cancer groups 
(haematological and 
solid cancers); 45% 
stage IV disease 
Prospective cohort, 
n=131 
Median age 72 
years, 56% men 
Prior to, during 
and after 
chemotherapy 
CT SMI at L3 <43 
cm2/m2 for men if BMI 
<25 kg/m2 and <53 
cm2/m2 if BMI ≥25 
kg/m2, and <41 cm2/m2 
for women  
48% 
Rossi, 2018181 Advanced non-small cell 
lung cancer 
Retrospective, n=33 Mean age 66 years, 
18% men 
Prior to treatment 
with Gefinitib 
CT SMI at L3 <55 
cm2/m2 for men and 
<39 cm2/m2 for women 
61% 
Sheean, 2019197 Metastatic breast cancer 
(oestrogen receptor 
positive) 
Prospective, n=41 Median age 62 




CT SMI at L3 <41 
cm2/m2 
34% 
Srdic, 2016182 Advanced non-small cell 
lung cancer 
Prospective, n=55 Median age 64 
years, 67% men 
Prior to 
chemotherapy 
CT SMI at L3 <55 
cm2/m2 for men and 
<39 cm2/m2 for women 
47% 
Stene, 2015183 Advanced non-small cell 
lung cancer 




CT SMI at L3 of <52.4 
cm2/m2 for men and 
<38.5 cm2/m2 for 
women 
71% 
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2.12 Relationship between low muscle mass and patient-related 
health outcomes 
2.12.1 Quality of life 
A small number of studies have reported on the relationship between low muscle mass 
and quality of life in cancer populations.193, 198 In a large study in chemotherapy naïve 
patients with advanced lung cancer (n=734)198 the authors reported an association between 
skeletal muscle mass and global quality of life among men, where men with lower skeletal 
muscle mass had significantly poorer scores on the EORTC QLQ-C30. Notably, the 
researchers identified a cut-point for both men and women below which quality of life 
scores began to deteriorate, while above the cut-point quality of life scores were stable.198 
In a retrospective, study of patients with newly diagnosed advanced cancer (n=237), low 
skeletal muscle mass, was associated with lower scores on the Functional Assessment of 
Cancer Therapy – General (FACT-G) quality of life assessment after adjusting for age, sex, 
marital status, education and cancer type (p=0.048).193 These data indicates that low 
skeletal muscle mass could be associated with poorer quality of life in patients with 
advanced cancer, however it is not known if this relationship exists in MPM. 
2.12.2 Physical activity, physical functioning and muscle strength 
There is a lack of information on the relationship between low muscle mass and 
physical activity in patients with cancer, however a small number of studies have reported 
on the relationship between low muscle mass, physical functioning and strength. In a study 
of older adults with cancer (n=131), including 45% with stage IV disease, participants 
underwent evaluation of muscle mass via CT and completed five functional tests; the five 
times sit to stand test (FTSTS); handgrip strength; steep ramp test; walking speed and Timed 
Up and Go.199 There was a significant association between muscle mass and FTSTS, 
handgrip strength and the steep ramp test, but not walking speed or Timed Up and Go;199 
and participants with low muscle mass in combination with slow walking speed or low 
handgrip strength (n=10) had greater limitations in their activities of daily living following 
chemotherapy.199 In a study of overweight patients with advanced cancer (n=28),195 
participants completed handgrip strength testing and a two-minute walk test. Compared to 
those with normal muscle mass, mean handgrip strength was lower among participants with 
low skeletal muscle mass;195 no differences were observed in two-minute walk test results 
between groups. Similar findings were reported in a prospective study of older adults with 
advanced lung cancer (n=30) undergoing chemotherapy.200 Participants in this study 
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underwent handgrip strength measurements and completed an incremental shuttle walking 
test at study enrolment, 6 and 12 weeks;200 a significant linear association was found between 
changes in skeletal muscle index and changes in handgrip strength, however no differences 
were observed with regard to the walk test.200 These preliminary data indicate a relationship 
between muscle mass and handgrip strength, however handgrip strength may not reflect 
overall strength or function.201 Physical activity data and physical performance tests, 
especially muscle strength-dependent tests such as the chair rise and Timed Up and Go,43 
are therefore needed to evaluate the relationship between low muscle mass and physical 
functioning in patients with MPM. 
2.13 Effects of exercise on physical function and body composition 
Exercise is distinct from physical activity in that it is planned, structured and 
repetitive; and undertaken with the purpose of maintaining or improving physical fitness.47 
The two principal modes of exercise are resistance and aerobic exercise training. The 
American College of Sports Medicine has defined resistance exercise training as exercise 
in which muscles work against a force 60% or higher of maximum,38, 202 while aerobic 
exercise training has been defined as exercise in which the large muscles of the body move 
in a rhythmic manner over a period of time.38 
Considerable research has examined the impact of exercise interventions on patients 
with cancer203 and more recently the impact of exercise has been examined in patients with 
advanced cancer. When the first systematic review article of exercise interventions in 
patients with advanced cancer was published in 2009204 only three were randomised 
controlled trials were identified. Several review articles of exercise interventions in 
patients with advanced cancer have since been published205-208 and 15 randomised 
controlled trials have now been identified.206  
2.13.1 Physical functioning 
Physical functioning is commonly reported as an outcome measure in exercise 
intervention studies in patients with advanced cancer.208 Outcome measures include a 
combination of self-report questionnaires, physical performance tests and muscle strength 
tests.208 The physical performance tests included were the Six Minute Walk Test, 400 m 
walk, 6 m walk, chair stand, timed up and go and Self Physical Performance Battery.208 
Results showed that 87% of the studies that assessed physical function reported a 
significant improvement in at least one physical functioning measure following the 
exercise intervention.208 
Chapter Two.  Literature Review 
52 
A Cochrane review has recently investigated the effects of exercise training 
specifically in patients with advanced lung cancer.209 Regarding the outcome measures, 
three randomised trials included six-minute walk test (n=59) and three randomised trials 
included self-reported physical functioning (n=73).209 The findings were that exercise 
participants had a significantly greater improvement in six-minute walk distance when 
compared with the control participants.209 However, there was no difference between 
groups for self-reported physical functioning.209  
In another randomised trial in advanced lung cancer (n=218),210 patients participated 
in a 12 week supervised aerobic and resistance exercise intervention or received usual care 
and completed measurements of muscle strength and a six-minute walk test. Participants in 
the intervention group had significantly greater strength at the end of the intervention, when 
compared with the control group.210 However, there was no difference between groups for 
six-minute walk distance.210  
In a randomised trial of women with metastatic breast cancer (n=14), women 
participated in a supervised resistance exercise and unsupervised walking intervention or 
received usual care.211 Participants completed a measurement of leg strength and a six-
minute walk test. While adherence to the supervised resistance exercise was high, there 
were no differences between the intervention and control group for leg strength or six-
minute walk distance.211 Overall, exercise interventions appear to have a positive effect on 
physical functioning outcomes in advanced cancer populations.  
2.13.2 Body composition 
There has been substantial research on the effects of exercise interventions on body 
composition outcomes in patients with prostate and breast cancer. A meta-analysis which 
included seven prostate cancer studies,212 concluded that whole body lean mass increased 
significantly following resistance exercise interventions.  The estimated improvement in 
whole body lean mass was 1 kg (95% CI [0.15 – 1.84]; p=0.028). Two randomised 
controlled trials in prostate cancer have been published since this meta-analysis. The first 
was a study of the effect of aerobic and resistance exercise training in men treated with 
androgen deprivation therapy.213 The findings were that, compared with the control group 
the intervention group gained significantly more lean mass (mean difference 0.8 kg; 
p=0.015).213 The second study, was an investigation of the effects of aerobic, resistance 
and flexibility training in men with advanced prostate cancer and bone metastases.214 In 
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contrast, there were no differences between the control and intervention group with regard 
to the change in lean mass (mean difference 0.3 kg; p=0.584). 
Randomised controlled trials conducted in patients with breast cancer also indicate 
that resistance exercise interventions have a positive impact on lean mass.215, 216, 217, 218 In 
a study of patients with breast cancer undergoing chemotherapy, resistance exercise 
training was compared with aerobic exercise and usual care.215 Compared with the usual 
care group the resistance exercise group gained significantly more lean mass (mean 
difference 0.32 kg/m2; p=0.017), however there were no differences between the aerobic 
and resistance exercise intervention groups (mean difference 0.18 kg/m2; p=0.35).215 This 
indicates that there is evidence that exercise training improves lean mass in patients with 
prostate and breast cancer. 
There is currently limited data on the effects of exercise training on body composition 
outcomes in advanced cancer populations. Of the review articles on exercise interventions 
in patients with advanced cancer, only one reported on body composition outcomes.208 In 
this review, nine randomised controlled trials were identified that assessed body 
composition.208 Of these, only four used non-anthropometric measures for body 
composition assessment; three used DXA and one used plethysmography. The four studies 
were conducted in patients with prostate cancer, lymphoma and myeloma. All exercise 
interventions were of 3-months duration, but differed in the level of supervision and type 
of exercise. The findings were that exercise training significantly improved lean mass in 
all four studies. Notably, none of these studies included patients with MPD or other 
thoracic cancers. As patients with thoracic cancers have a particularly high disease burden, 
it may be more difficult to achieve improvements in lean mass with exercise training in 
these cancer populations. 
2.14 Effects of dietary intake on exercise efficacy 
One concern around exercise training in advanced cancer populations is the potential 
impact of inadequate dietary intake on exercise outcomes. Approximately one-quarter of 
patients with advanced cancer have inadequate energy intake.97, 98 During periods of 
inadequate energy intake amino acids from the diet or skeletal muscle may be used as an 
energy source rather than for muscle protein synthesis,219 which may result in a reduced 
physical functioning and body composition response to exercise. However, there is a lack 
of published research on the relationship between dietary intake and response to exercise 
interventions in cancer populations. 
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Although there is a lack of information on the relationship between dietary intake and 
exercise outcomes in cancer populations, there are a small number of studies in healthy 
older adult populations. A recent systematic review and meta-analysis reported on 
randomised controlled trials that compared the effects of dietary protein on body 
composition outcomes in healthy older adults.220 Only three of the studies had compared 
dietary protein intakes and body composition outcomes following resistance exercise 
training.221-223 Overall, findings indicated that participants with protein intakes greater than 
the Recommended Daily Allowance (RDA) of 0.8 g/kg/day had significant improvements 
in lean mass while participants who had protein intakes consistent with the RDA had no 
change in lean mass.220 These findings indicate that higher than usual protein intakes may 
be required to produce improvements in lean mass in older adults participating in 
resistance exercise training. 
Contrasting results were reported in a randomised controlled trial of postmenopausal 
women (n=23) who participated in a 10-week resistance exercise intervention.224 All 
participants in the study were given individualised dietary plans with the same calories as 
their usual diet, however the intervention group consumed 1.2 g/kg/day of protein and the 
control group consumed 0.8 g/kg/day of protein.224 Both the intervention and control 
groups had a significant improvement in lean mass.224 Therefore, higher protein intake in 
excess of the RDA did not result in greater improvements in lean mass. 
One study has explored the effects of protein intake on body composition and physical 
functioning outcomes in older women living in retirement villages.225 The women, aged 60 
– 90 years, participated in a 4-month progressive resistance exercise intervention.225  The
intervention group had two 80 g servings of cooked lean red meat per day, while the control 
group had cooked rice or pasta as the alternative.225  There were no significant differences 
between the intervention and control groups with regard to energy intake but protein intake 
was significantly higher in the intervention group.225  Compared with the control group, the 
intervention group had a greater improvement in lean mass and muscle strength. However, 
both groups had similar improvements in the physical performance tests.225 This indicates 
that while adequate protein intake may be important for optimising muscle mass, 
improvements in physical performance could be independent of dietary intake. 
There is limited information on the relationship between energy intake and outcomes 
of exercise training. However, one study in adults aged 56 – 80 years (n=12) has reported 
on the relationship between energy intake and body composition outcomes following a 
12-week resistance exercise intervention.223 Energy expenditure increased as a result of
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increased resting metabolic rate and exercise, and the mean energy intake required for 
weight maintenance increased by approximately 15%.223 These results indicate that during 
exercise training participants may need greater amounts of energy to achieve muscle gains 
and maintain a stable weight. This finding is particularly relevant for development of 
exercise interventions for patients with advanced cancer, as participants may have 
difficulty increasing their energy intake to meet the metabolic demands of exercise. As 
weight maintenance is an important clinical goal it is imperative that this outcome is not 
disrupted with exercise training. Research is needed to clarify the relationship between 
dietary intake and exercise outcomes in advanced cancer populations, which will help to 
inform the design of future exercise interventions. 
Chapter Two.  Literature Review 
56 
References 
1. Wang NS. Anatomy of the pleura. Clin Chest Med. 1998;19(2):229-40.
doi:10.1016/s0272-5231(05)70074-5
2. Light RW. Pleural diseases. Dis Mon. 1992;38(5):266-331. doi:10.1016/0011-
5029(92)90007-c
3. Thomas R, Cheah HM, Creaney J, Turlach BA, Lee YC. Longitudinal Measurement
of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions. Chest.
2016;149(6):1494-500. doi:10.1016/j.chest.2016.01.001
4. Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96
patients. Am J Med. 1977;63(5):695-702. doi:10.1016/0002-9343(77)90154-1
5. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a
malignant pleural effusion: British Thoracic Society Pleural Disease Guideline
2010. Thorax. 2010;65 Suppl 2:ii32-40. doi:10.1136/thx.2010.136994
6. Baas P, Burgers S. Malignant pleural effusions: will PROMISE make its name true?
Lancet Oncol. 2018;19(7):853-855. doi:10.1016/s1470-2045(18)30361-9
7. Azzopardi M, Thomas R, Muruganandan S, Lam DC, Garske LA, Kwan BC, et al.
Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a
multicentre randomised study of aggressive versus symptom-guided drainage via
indwelling pleural catheters. BMJ Open. 2016;6(7):e011480.
doi:10.1136/bmjopen-2016-011480
8. Bonomo L, Feragalli B, Sacco R, Merlino B, Storto ML. Malignant pleural disease.
Eur J Radiol. 2000;34(2):98-118.
9. Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al.
Predicting survival in malignant pleural effusion: development and validation of the
LENT prognostic score. Thorax. 2014;69(12):1098-104. doi:10.1136/thoraxjnl-
2014-205285
10. Simmons CP, Koinis F, Fallon MT, Fearon KC, Bowden J, Solheim TS, et al.
Prognosis in advanced lung cancer--A prospective study examining key
clinicopathological factors. Lung Cancer. 2015;88(3):304-9.
doi:10.1016/j.lungcan.2015.03.020
11. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, et al. High
blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant
mesothelioma patients undergoing systemic therapy. Clin Cancer Res.
2010;16(23):5805-13. doi:10.1158/1078-0432.ccr-10-2245
12. Thomas R, Francis R, Davies HE, Lee YC. Interventional therapies for malignant
pleural effusions: the present and the future. Respirology. 2014;19(6):809-22.
doi:10.1111/resp.12328
Chapter Two.  Literature Review 
57 
13. Muruganandan S, Azzopardi M, Fitzgerald DB, Shrestha R, Kwan BCH, Lam DCL,
et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via
indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet
Respir Med. 2018  doi:10.1016/s2213-2600(18)30288-1
14. Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, et al.
Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for
relieving dyspnea in patients with malignant pleural effusion: the TIME2
randomized controlled trial. Jama. 2012;307(22):2383-9.
doi:10.1001/jama.2012.5535
15. Thomas R, Fysh ETH, Smith NA, Lee P, Kwan BCH, Yap E, et al. Effect of an
Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients
With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial. Jama.
2017;318(19):1903-1912. doi:10.1001/jama.2017.17426
16. Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, et al.
British Thoracic Society Guideline for the investigation and management of
malignant pleural mesothelioma. Thorax. 2018;73(Suppl 1):i1-i30.
doi:10.1136/thoraxjnl-2017-211321
17. Kao SCH, Rei G, Lee K, Vardy J, Clarke S, van Zandwijk N. Malignant
mesothelioma. Intern Med J. 2010;40:742-750.
18. Muruganandan S, Alfonso H, Franklin P, Shilkin K, Segal A, Olsen N, et al.
Comparison of outcomes following a cytological or histological diagnosis of
malignant mesothelioma. Br J Cancer. 2017;116(6):703-708.
doi:10.1038/bjc.2017.20
19. Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet.
2005;366:397-408.
20. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos
exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260-71.
doi:10.1136/oem.17.4.260
21. Bourdes V, Boffetta P, Pisani P. Environmental exposure to asbestos and risk of
pleural mesothelioma: review and meta-analysis. Eur J Epidemiol. 2000;16(5):411-7.
22. Olsen NJ, Franklin PJ, Reid A, de Klerk NH, Threlfall TJ, Shilkin K, et al.
Increasing incidence of malignant mesothelioma after exposure to asbestos during
home maintenance and renovation. MJA. 2011;195(5):271-274.
23. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma
mortality in Britain. Lancet. 1995;345(8949):535-9. doi:10.1016/s0140-
6736(95)90462-x
Chapter Two.  Literature Review 
58 
24. Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east
England: clinicopathological experience of 272 cases. Thorax. 1997;52(6):507-12.
doi:10.1136/thx.52.6.507
25. Hyland RA, Ware S, Johnson AR, Yates DH. Incidence trends and gender
differences in malignant mesothelioma in New South Wales, Australia. Scand J
Work Environ Health. 2007;33(4):286-292.
26. Tanrikulu AC, Abakay A, Kaplan MA, Kucukoner M, Palanci Y, Evliyaoglu O, et
al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363
patients with malignant pleural mesothelioma. Respiration. 2010;80(6):480-7.
doi:10.1159/000321370
27. Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, et al. Malignant
pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur
Respir Rev. 2016;25(142):472-486. doi:10.1183/16000617.0063-2016
28. Borasio P, Berruti A, Bille A, Lausi P, Levra MG, Giardino R, et al. Malignant
pleural mesothelioma: clinicopathologic and survival characteristics in a
consecutive series of 394 patients. Eur J Cardiothorac Surg. 2008;33(2):307-13.
doi:10.1016/j.ejcts.2007.09.044
29. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ.
Prognostic factors for malignant mesothelioma in 142 patients: validation of
CALGB and EORTC prognostic scoring systems. Thorax. 2000;55(9):731-5.
Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1745842/pdf/v055p00731.pdf
30. Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship
with asbestos. Ind Health. 2007;45(3):379-87. Available from:
https://www.jstage.jst.go.jp/article/indhealth/45/3/45_3_379/_pdf
31. Finn RS, Brims FJ, Gandhi A, Olsen N, Musk AW, Maskell NA, et al. Postmortem
findings of malignant pleural mesothelioma: a two-center study of 318 patients.
Chest. 2012;142(5):1267-73. doi:DOI 10.1378/chest.11-3204
32. Brims FJ, Meniawy TM, Duffus I, de Fonseka D, Segal A, Creaney J, et al. A Novel
Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using
Decision Tree Analysis. J Thorac Oncol. 2016;11(4):573-82.
doi:10.1016/j.jtho.2015.12.108
33. Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake MD.
Demographics, management and survival of patients with malignant pleural
mesothelioma in the National Lung Cancer Audit in England and Wales. Lung
Cancer. 2015;88(3):344-8. doi:10.1016/j.lungcan.2015.03.005
Chapter Two.  Literature Review 
59 
34. Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. 
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural 
mesothelioma. Eur Respir J. 2020  doi:10.1183/13993003.00953-2019 
35. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. 
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in 
patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-44. 
doi:10.1200/jco.2003.11.136 
36. Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-
pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with 
malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and 
Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 
2011;12(8):763-72. doi:10.1016/s1470-2045(11)70149-8 
37. de Gooijer CJ, Borm FJ, Scherpereel A, Baas P. Immunotherapy in Malignant 
Pleural Mesothelioma. Front Oncol. 2020;10:187. doi:10.3389/fonc.2020.00187 
38. Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, Minson CT, Nigg CR, Salem 
GJ, et al. American College of Sports Medicine position stand. Exercise and 
physical activity for older adults. Med Sci Sports Exerc. 2009;41(7):1510-30. 
doi:10.1249/MSS.0b013e3181a0c95c 
39. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. 
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J 
Clin Oncol. 1982;5(6):649-55. 
40. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: 
reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187-93. Available from: 
http://jco.ascopubs.org/content/2/3/187.full.pdf 
41. Popovic G, Harhara T, Pope A, Al-Awamer A, Banerjee S, Bryson J, et al. Patient-
Reported Functional Status in Outpatients With Advanced Cancer: Correlation With 
Physician-Reported Scores and Survival. J Pain Symptom Manage. 
2018;55(6):1500-1508. doi:10.1016/j.jpainsymman.2018.02.015 
42. Kelly CM, Shahrokni A. Moving beyond Karnofsky and ECOG Performance Status 
Assessments with New Technologies. J Oncol. 2016;2016:6186543. 
doi:10.1155/2016/6186543 
43. Beaudart C, Rolland Y, Cruz-Jentoft AJ, Bauer JM, Sieber C, Cooper C, et al. 
Assessment of Muscle Function and Physical Performance in Daily Clinical Practice 
: A position paper endorsed by the European Society for Clinical and Economic 
Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). 
Calcif Tissue Int. 2019;105(1):1-14. doi:10.1007/s00223-019-00545-w 
Chapter Two.  Literature Review 
60 
44. Owusu C, Margevicius S, Schluchter M, Koroukian SM, Berger NA. Short Physical 
Performance Battery, usual gait speed, grip strength and Vulnerable Elders Survey 
each predict functional decline among older women with breast cancer. J Geriatr 
Oncol. 2017;8(5):356-362. doi:10.1016/j.jgo.2017.07.004 
45. Verweij NM, Schiphorst AH, Pronk A, van den Bos F, Hamaker ME. Physical 
performance measures for predicting outcome in cancer patients: a systematic 
review. Acta Oncol. 2016;55(12):1386-1391. doi:10.1080/0284186x.2016.1219047 
46. Collins JT, Noble S, Chester J, Davies HE, Evans WD, Farewell D, et al. The value 
of physical performance measurements alongside assessment of sarcopenia in 
predicting receipt and completion of planned treatment in non-small cell lung 
cancer: an observational exploratory study. Support Care Cancer. 2018;26(1):119-
127. doi:10.1007/s00520-017-3821-6 
47. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical 
fitness: definitions and distinctions for health-related research. Public Health Rep. 
1985;100(2):126-31. Available from: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1424733/pdf/pubhealthrep00100-0016.pdf 
48. Amireault S, Godin G, Lacombe J, Sabiston CM. The use of the Godin-Shephard 
Leisure-Time Physical Activity Questionnaire in oncology research: a systematic 
review. BMC Med Res Methodol. 2015;15:60. doi:10.1186/s12874-015-0045-7 
49. Godin G, Shephard RJ. A simple method to assess exercise behavior in the 
community. Can J Appl Sport Sci. 1985;10(3):141-6. 
50. Ruiz-Casado A, Alejo LB, Santos-Lozano A, Soria A, Ortega MJ, Pagola I, et al. 
Validity of the Physical Activity Questionnaires IPAQ-SF and GPAQ for Cancer 
Survivors: Insights from a Spanish Cohort. Int J Sports Med. 2016;37(12):979-985. 
doi:10.1055/s-0042-103967 
51. Amireault S, Godin G, Lacombe J, Sabiston CM. Validation of the Godin-Shephard 
Leisure-Time Physical Activity Questionnaire classification coding system using 
accelerometer assessment among breast cancer survivors. J Cancer Surviv. 
2015;9(3):532-40. doi:10.1007/s11764-015-0430-6 
52. Dyrstad SM, Hansen BH, Holme IM, Anderssen SA. Comparison of self-reported 
versus accelerometer-measured physical activity. Med Sci Sports Exerc. 
2014;46(1):99-106. doi:10.1249/MSS.0b013e3182a0595f 
53. Boyle T, Lynch BM, Courneya KS, Vallance JK. Agreement between 
accelerometer-assessed and self-reported physical activity and sedentary time in 
colon cancer survivors. Support Care Cancer. 2015;23(4):1121-6. 
doi:10.1007/s00520-014-2453-3 
Chapter Two.  Literature Review 
61 
54. Cleland CL, Hunter RF, Kee F, Cupples ME, Sallis JF, Tully MA. Validity of the 
global physical activity questionnaire (GPAQ) in assessing levels and change in 
moderate-vigorous physical activity and sedentary behaviour. BMC Public Health. 
2014;14:1255. doi:10.1186/1471-2458-14-1255 
55. Van Remoortel H, Giavedoni S, Raste Y, Burtin C, Louvaris Z, Gimeno-Santos E, 
et al. Validity of activity monitors in health and chronic disease: a systematic 
review. Int J Behav Nutr Phys Act. 2012;9:84. doi:DOI 10.1186/1479-5868-9-84 
56. Peddle-McIntyre CJ, Cavalheri V, Boyle T, McVeigh JA, Jeffery E, Lynch BM, et 
al. A Review of Accelerometer-based Activity Monitoring in Cancer Survivorship 
Research. Med Sci Sports Exerc. 2018;50(9):1790-1801. 
doi:10.1249/mss.0000000000001644 
57. Plasqui G, Bonomi AG, Westerterp KR. Daily physical activity assessment with 
accelerometers: new insights and validation studies. Obes Rev. 2013;14(6):451-62. 
doi:10.1111/obr.12021 
58. Cavalheri V, Jenkins S, Cecins N, Phillips M, Sanders LH, Hill K. Patterns of 
sedentary behaviour and physical activity in people following curative intent 
treatment for non-small cell lung cancer. Chron Respir Dis. 2016;13(1):82-5. 
doi:10.1177/1479972315616931 
59. Granger CL, McDonald CF, Irving L, Clark RA, Gough K, Murnane A, et al. Low 
physical activity levels and functional decline in individuals with lung cancer. Lung 
Cancer. 2014;83(2):292-9. doi:10.1016/j.lungcan.2013.11.014 
60. Maddocks M, Wilcock A. Exploring physical activity level in patients with thoracic 
cancer: implications for use as an outcome measure. Support Care Cancer. 
2012;20(5):1113-6. doi:10.1007/s00520-012-1393-z 
61. D'Silva A, Bebb G, Boyle T, Johnson ST, Vallance JK. Demographic and clinical 
correlates of accelerometer assessed physical activity and sedentary time in lung 
cancer survivors. Psychooncology. 2018;27(3):1042-1049. doi:10.1002/pon.4608 
62. Lowe SS, Danielson B, Beaumont C, Watanabe SM, Baracos VE, Courneya KS. 
Associations between objectively measured physical activity and quality of life in 
cancer patients with brain metastases. J Pain Symptom Manag. 2014;48(3):322-32. 
doi:DOI 10.1016/j.jpainsymman.2013.10.012 
63. Australian Bureau of Statistics. Australian Health Survey: Physical Activity, 2011-12 
[Internet]. 2013 [cited 09/06/2020]. Available from: 
https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4364.0.55.004Chapter5002011-12 
64. Hummler S, Thomas M, Hoffmann B, Gartner P, Zoz M, Huber G, et al. Physical 
performance and psychosocial status in lung cancer patients: results from a pilot 
study. Oncol Res Treat. 2014;37(1-2):36-41. doi:10.1159/000358157 
Chapter Two.  Literature Review 
62 
65. Winters-Stone KM, Medysky ME, Savin MA. Patient-reported and objectively 
measured physical function in older breast cancer survivors and cancer-free 
controls. J Geriatr Oncol. 2019;10(2):311-316. doi:10.1016/j.jgo.2018.10.006 
66. Loh KP, Pandya C, Zittel J, Kadambi S, Flannery M, Reizine N, et al. Associations 
of sleep disturbance with physical function and cognition in older adults with cancer. 
Support Care Cancer. 2017;25(10):3161-3169. doi:10.1007/s00520-017-3724-6 
67. Pandya C, Magnuson A, Flannery M, Zittel J, Duberstein P, Loh KP, et al. 
Association Between Symptom Burden and Physical Function in Older Patients 
with Cancer. J Am Geriatr Soc. 2019;67(5):998-1004. doi:10.1111/jgs.15864 
68. Prado CM, Gonzalez MC, Heymsfield SB. Body composition phenotypes and 
obesity paradox. Curr Opin Clin Nutr Metab Care. 2015;18(6):535-51. 
doi:10.1097/mco.0000000000000216 
69. Wang ZM, Pierson RN, Jr., Heymsfield SB. The five-level model: a new approach 
to organizing body-composition research. Am J Clin Nutr. 1992;56(1):19-28. 
doi:10.1093/ajcn/56.1.19 
70. Prado CM, Heymsfield SB. Lean tissue imaging: a new era for nutritional 
assessment and intervention. JPEN J Parenter Enteral Nutr. 2014;38(8):940-53. 
doi:10.1177/0148607114550189 
71. Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, et al. Pitfalls in 
the measurement of muscle mass: a need for a reference standard. J Cachexia 
Sarcopenia Muscle. 2018;9(2):269-278. doi:10.1002/jcsm.12268 
72. Heymsfield SB, Wang Z, Baumgartner RN, Ross R. Human body composition: 
advances in models and methods. Annu Rev Nutr. 1997;17:527-58. 
doi:10.1146/annurev.nutr.17.1.527 
73. Morsbach F, Zhang YH, Martin L, Lindqvist C, Brismar T. Body composition 
evaluation with computed tomography: Contrast media and slice thickness cause 
methodological errors. Nutrition. 2018;59:50-55. doi:10.1016/j.nut.2018.08.001 
74. Fuchs G, Chretien YR, Mario J, Do S, Eikermann M, Liu B, et al. Quantifying the 
effect of slice thickness, intravenous contrast and tube current on muscle 
segmentation: Implications for body composition analysis. Eur Radiol. 
2018;28(6):2455-2463. doi:10.1007/s00330-017-5191-3 
75. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized 
tomography in assessing cancer cachexia. Curr Opin Support Palliat Care. 
2009;3(4):269-75. doi:10.1097/SPC.0b013e328331124a 
76. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A 
practical and precise approach to quantification of body composition in cancer 
patients using computed tomography images acquired during routine care. Appl 
Physiol Nutr Metab. 2008;33(5):997-1006. doi:10.1139/h08-075 
Chapter Two.  Literature Review 
63 
77. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total 
body skeletal muscle and adipose tissue volumes: estimation from a single 
abdominal cross-sectional image. J Appl Physiol (1985). 2004;97(6):2333-8. 
doi:10.1152/japplphysiol.00744.2004 
78. Kilgour RD, Cardiff K, Rosenthall L, Lucar E, Trutschnigg B, Vigano A. Use of 
prediction equations to determine the accuracy of whole-body fat and fat-free mass 
and appendicular skeletal muscle mass measurements from a single abdominal 
image using computed tomography in advanced cancer patients. Appl Physiol Nutr 
Metab. 2016;41(1):70-5. doi:10.1139/apnm-2015-0068 
79. Pietrobelli A, Formica C, Wang Z, Heymsfield SB. Dual-energy X-ray 
absorptiometry body composition model: review of physical concepts. Am J 
Physiol. 1996;271(6 Pt 1):E941-51. doi:10.1152/ajpendo.1996.271.6.E941 
80. Hangartner TN, Warner S, Braillon P, Jankowski L, Shepherd J. The Official 
Positions of the International Society for Clinical Densitometry: acquisition of dual-
energy X-ray absorptiometry body composition and considerations regarding 
analysis and repeatability of measures. J Clin Densitom. 2013;16(4):520-36. 
doi:10.1016/j.jocd.2013.08.007 
81. Prado CM, Baracos VE, Xiao J, Birdsell L, Stuyckens K, Park YC, et al. The 
association between body composition and toxicities from the combination of Doxil 
and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol 
Nutr Metab. 2014;39(6):693-8. doi:10.1139/apnm-2013-0403 
82. Chen Z, Wang Z, Lohman T, Heymsfield SB, Outwater E, Nicholas JS, et al. Dual-
energy X-ray absorptiometry is a valid tool for assessing skeletal muscle mass in 
older women. J Nutr. 2007;137(12):2775-80. doi:10.1093/jn/137.12.2775 
83. Kim J, Wang Z, Heymsfield SB, Baumgartner RN, Gallagher D. Total-body skeletal 
muscle mass: estimation by a new dual-energy X-ray absorptiometry method. Am J 
Clin Nutr. 2002;76(2):378-83. doi:10.1093/ajcn/76.2.378 
84. Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. 
ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 
2017;36(1):49-64. doi:10.1016/j.clnu.2016.09.004 
85. Argiles JM, Campos N, Lopez-Pedrosa JM, Rueda R, Rodriguez-Manas L. Skeletal 
Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and 
Disease. J Am Med Dir Assoc. 2016;17(9):789-96. 
doi:10.1016/j.jamda.2016.04.019 
86. Wolfe RR. The underappreciated role of muscle in health and disease. Am J Clin 
Nutr. 2006;84(3):475-82. doi:10.1093/ajcn/84.3.475 
Chapter Two.  Literature Review 
64 
87. Cederholm T, Bosaeus I, Barazzoni R, Bauer J, Van Gossum A, Klek S, et al. 
Diagnostic criteria for malnutrition - An ESPEN Consensus Statement. Clin Nutr. 
2015;34(3):335-40. doi:10.1016/j.clnu.2015.03.001 
88. Cederholm T, Jensen GL, Correia M, Gonzalez MC, Fukushima R, Higashiguchi T, 
et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the 
global clinical nutrition community. Clin Nutr. 2018  
doi:10.1016/j.clnu.2018.08.002 
89. White JV, Guenter P, Jensen G, Malone A, Schofield M. Consensus statement: 
Academy of Nutrition and Dietetics and American Society for Parenteral and 
Enteral Nutrition: characteristics recommended for the identification and 
documentation of adult malnutrition (undernutrition). JPEN J Parenter Enteral Nutr. 
2012;36(3):275-83. doi:10.1177/0148607112440285 
90. Jensen GL, Mirtallo J, Compher C, Dhaliwal R, Forbes A, Grijalba RF, et al. Adult 
starvation and disease-related malnutrition: a proposal for etiology-based diagnosis 
in the clinical practice setting from the International Consensus Guideline 
Committee. JPEN J Parenter Enteral Nutr. 2010;34(2):156-9. 
doi:10.1177/0148607110361910 
91. Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective 
Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. 
Eur J Clin Nutr. 2002;56(8):779-85. doi:DOI 10.1038/sj.ejcn.1601412 
92.  Ottery FD. Definition of standardized nutritional assessment and interventional 
pathways in oncology. Nutrition. 1996;12(1 Suppl):S15-9. 
93. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment 
options in cancer cachexia. Nature Reviews Clinical Oncology. 2013;10:90-99. 
doi:doi:10.1038/nrclinonc.2012.209 
94. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. 
Definition and classification of cancer cachexia: an international consensus. Lancet 
Oncol. 2011;12(5):489-95. doi:DOI 10.1016/s1470-2045(10)70218-7 
95. Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A. Cancer cachexia--
pathophysiology and management. J Gastroenterol. 2013;48(5):574-94. doi:DOI 
10.1007/s00535-013-0787-0 
96. Brook MS, Wilkinson DJ, Phillips BE, Perez-Schindler J, Philp A, Smith K, et al. 
Skeletal muscle homeostasis and plasticity in youth and ageing: impact of nutrition 
and exercise. Acta Physiol (Oxf). 2016;216(1):15-41. doi:10.1111/apha.12532 
97. Prado CM, Lieffers JR, Bergsten G, Mourtzakis M, Baracos VE, Reiman T, et al. 
Dietary patterns of patients with advanced lung or colorectal cancer. Can J Diet 
Pract Res. 2012;73(4):e298-303. 
Chapter Two.  Literature Review 
65 
98. Vidra N, Kontogianni MD, Schina E, Gioulbasanis I. Detailed Dietary Assessment 
in Patients with Inoperable Tumors: Potential Deficits for Nutrition Care Plans. Nutr 
Cancer. 2016;68(7):1131-9. doi:10.1080/01635581.2016.1213867 
99. de Vries YC, van den Berg M, de Vries JHM, Boesveldt S, de Kruif J, Buist N, et 
al. Differences in dietary intake during chemotherapy in breast cancer patients 
compared to women without cancer. Support Care Cancer. 2017;25(8):2581-2591. 
doi:10.1007/s00520-017-3668-x 
100. Bovio G, Fonte ML, Baiardi P. Prevalence of upper gastrointestinal symptoms and 
their influence on nutritional state and performance status in patients with different 
primary tumors receiving palliative care. Am J Hosp Palliat Care. 2014;31(1):20-6. 
doi:10.1177/1049909112474713 
101. Bye A, Jordhoy MS, Skjegstad G, Ledsaak O, Iversen PO, Hjermstad MJ. 
Symptoms in advanced pancreatic cancer are of importance for energy intake. 
Support Care Cancer. 2013;21(1):219-27. doi:DOI 10.1007/s00520-012-1514-8 
102. Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake and resting energy 
expenditure in relation to weight loss in unselected cancer patients. Int J Cancer. 
2001;93(3):380-3. Available from: 
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.1332 
103. Bye A, Wesseltoft-Rao N, Iversen PO, Skjegstad G, Holven KB, Ulven S, et al. 
Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a 
prospective study in patients with inoperable pancreatic cancer. Med Oncol. 
2016;33(6):54. doi:10.1007/s12032-016-0768-2 
104. Purcell SA, Baracos VE, Chu QSC, Sawyer MB, Severin D, Mourtzakis M, et al. 
Profiling Determinants of Resting Energy Expenditure in Colorectal Cancer. Nutr 
Cancer. 2020;72(3):431-438. doi:10.1080/01635581.2019.1635172 
105. Gould DW, Lahart I, Carmichael AR, Koutedakis Y, Metsios G. Cancer cachexia 
prevention via physical exercise: molecular mechanisms. J Cachexia Sarcopenia 
Muscle. 2013;4:111-124. doi:DOI 10.1007/s13539-012-0096-0 
106. Dulger H, Alici S, Sekeroglu MR, Erkog R, Ozbek H, Noyan T, et al. Serum levels 
of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int 





107. Gioulbasanis I, Georgoulias P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi 
Z, et al. Mini Nutritional Assessment (MNA) and biochemical markers of cachexia 
in metastatic lung cancer patients: interrelations and associations with prognosis. 
Lung Cancer. 2011;74(3):516-20. doi:10.1016/j.lungcan.2011.05.009 
Chapter Two.  Literature Review 
66 
108. Gulen ST, Karadag F, Karul AB, Kilicarslan N, Ceylan E, Kuman NK, et al. 
Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung. 
2012;190(3):327-32. doi:10.1007/s00408-011-9364-6 
109. Batista ML, Jr., Olivan M, Alcantara PS, Sandoval R, Peres SB, Neves RX, et al. 
Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients. 
Cytokine. 2013;61(2):532-9. doi:10.1016/j.cyto.2012.10.023 
110. Op den Kamp CM, Langen RC, Snepvangers FJ, de Theije CC, Schellekens JM, 
Laugs F, et al. Nuclear transcription factor kappa B activation and protein turnover 
adaptations in skeletal muscle of patients with progressive stages of lung cancer 
cachexia. Am J Clin Nutr. 2013;98(3):738-48. doi:10.3945/ajcn.113.058388 
111. Smiechowska J, Utech A, Taffet G, Hayes T, Marcelli M, Garcia JM. Adipokines in 
patients with cancer anorexia and cachexia. J Investig Med. 2010;58(3):554-9. 
doi:10.231/JIM.0b013e3181cf91ca 
112. Paillaud E, Bories PN, Aita SL, Scherman E, Jeanfaivre V, Lejonc JL, et al. 
Prognostic value of dietary intake and inflammation on survival in patients with 
advanced cancer: relationship with performance status, pain, and digestive 
disorders. Nutr Cancer. 2003;45(1):30-5. 
113. Wallengren O BI, Lundholm K. Dietary energy density, inflammation and energy 
balance in palliative care cancer patients. Clin Nutr. 2013;32(1):88-92. doi:doi: 
10.1016/j.clnu.2012.05.023 
114. Richards CH, Roxburgh CS, MacMillan MT, Isswiasi S, Robertson EG, Guthrie 
GK, et al. The relationships between body composition and the systemic 
inflammatory response in patients with primary operable colorectal cancer. PLoS 
One. 2012;7(8):e41883. doi:DOI 10.1371/journal.pone.0041883 
115. da Silva JB, Mauricio SF, Bering T, Correia MI. The relationship between 
nutritional status and the Glasgow prognostic score in patients with cancer of the 
esophagus and stomach. Nutr Cancer. 2013;65(1):25-33. doi:DOI 
10.1080/01635581.2013.741755 
116. Mauricio SF, da Silva JB, Bering T, Correia MI. Relationship between nutritional 
status and the Glasgow Prognostic Score in patients with colorectal cancer. 
Nutrition. 2013;29(4):625-9. doi:DOI 10.1016/j.nut.2012.09.016 
117. Burney BO, Garcia JM. Hypogonadism in male cancer patients. J Cachexia 
Sarcopenia Muscle. 2012;3(3):149-55. doi:10.1007/s13539-012-0065-7 
118. Skipworth RJ, Moses AG, Sangster K, Sturgeon CM, Voss AC, Fallon MT, et al. 
Interaction of gonadal status with systemic inflammation and opioid use in 
determining nutritional status and prognosis in advanced pancreatic cancer. Support 
Care Cancer. 2011;19(3):391-401. doi:10.1007/s00520-010-0832-y 
Chapter Two.  Literature Review 
67 
119. Dev R, Hui D, Del Fabbro E, Delgado-Guay MO, Sobti N, Dalal S, et al. 
Association between hypogonadism, symptom burden, and survival in male patients 
with advanced cancer. Cancer. 2014;120(10):1586-93. doi:10.1002/cncr.28619 
120. Purcell SA, Elliott SA, Baracos VE, Chu QS, Prado CM. Key determinants of 
energy expenditure in cancer and implications for clinical practice. Eur J Clin Nutr. 
2016;70(11):1230-1238. doi:10.1038/ejcn.2016.96 
121. Ulmann G, Jouinot A, Tlemsani C, Curis E, Kousignian I, Neveux N, et al. Lean 
Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy 
Expenditure in Patients with Non-Small Cell Lung Cancer. Ann Nutr Metab. 
2019;75(4):223-230. doi:10.1159/000504874 
122. Cao DX, Wu GH, Zhang B, Quan YJ, Wei J, Jin H, et al. Resting energy 
expenditure and body composition in patients with newly detected cancer. Clin 
Nutr. 2010;29(1):72-7. doi:10.1016/j.clnu.2009.07.001 
123. Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, et al. 
Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol. 
2020:Jco2000611. doi:10.1200/jco.20.00611 
124. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. 
ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11-48. 
doi:10.1016/j.clnu.2016.07.015 
125. Brook MS, Wilkinson DJ, Smith K, Atherton PJ. The metabolic and temporal basis 
of muscle hypertrophy in response to resistance exercise. Eur J Sport Sci. 
2016;16(6):633-44. doi:10.1080/17461391.2015.1073362 
126. Molfino A, Amabile MI, Giorgi A, Monti M, D'Andrea V, Muscaritoli M. 
Investigational drugs for the treatment of cancer cachexia: a focus on phase I and 
phase II clinical trials. Expert Opin Investig Drugs. 2019;28(8):733-740. 
doi:10.1080/13543784.2019.1646727 
127. Marshall KM, Loeliger J, Nolte L, Kelaart A, Kiss NK. Prevalence of malnutrition 
and impact on clinical outcomes in cancer services: A comparison of two time 
points. Clin Nutr. 2019;38(2):644-651. doi:10.1016/j.clnu.2018.04.007 
128. Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman AR, et al. Symptoms 
and weight loss in patients with gastrointestinal and lung cancer at presentation. 
Support Care Cancer. 2007;15(1):39-46. doi:DOI 10.1007/s00520-006-0091-0 
129. Arrieta O, Michel Ortega RM, Villanueva-Rodriguez G, Serna-Thome MG, Flores-
Estrada D, Diaz-Romero C, et al. Association of nutritional status and serum 
albumin levels with development of toxicity in patients with advanced non-small 
cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. 
BMC Cancer. 2010;10:50. doi:10.1186/1471-2407-10-50 
Chapter Two.  Literature Review 
68 
130. Barata AT, Santos C, Cravo M, Vinhas MD, Morais C, Carolino E, et al. Handgrip 
Dynamometry and Patient-Generated Subjective Global Assessment in Patients with 
Nonresectable Lung Cancer. Nutr Cancer. 2017;69(1):154-158. 
doi:10.1080/01635581.2017.1250923 
131. Cehreli R, Yavuzsen T, Ates H, Akman T, Ellidokuz H, Oztop I. Can Inflammatory 
and Nutritional Serum Markers Predict Chemotherapy Outcomes and Survival in 
Advanced Stage Nonsmall Cell Lung Cancer Patients? Biomed Res Int. 
2019;2019:1648072. doi:10.1155/2019/1648072 
132. Dong J, Zeng Y, Zhang P, Li C, Chen Y, Li Y, et al. Serum IGFBP2 Level Is a New 
Candidate Biomarker of Severe Malnutrition in Advanced Lung Cancer. Nutr 
Cancer. 2020;72(5):858-863. doi:10.1080/01635581.2019.1656755 
133. Ge T, Lin T, Yang J, Wang M. Nutritional status and related factors of patients with 
advanced lung cancer in northern China: a retrospective study. Cancer Manag Res. 
2019;11:2225-2231. doi:10.2147/cmar.S193567 
134. Lin T, Yang J, Hong X, Yang Z, Ge T, Wang M. Nutritional status in patients with 
advanced lung cancer undergoing chemotherapy: a prospective observational study. 
Nutr Cancer. 2019:1-6. doi:10.1080/01635581.2019.1675720 
135. Mohan A, Poulose R, Kulshreshtha I, Chautani AM, Madan K, Hadda V, et al. High 
prevalence of malnutrition and deranged relationship between energy demands and 
food intake in advanced non-small cell lung cancer. Eur J Cancer Care (Engl). 
2017;26(4) doi:10.1111/ecc.12503 
136. Sanchez-Lara K, Turcott JG, Juarez E, Guevara P, Nunez-Valencia C, Onate-Ocana 
LF, et al. Association of nutrition parameters including bioelectrical impedance and 
systemic inflammatory response with quality of life and prognosis in patients with 
advanced non-small-cell lung cancer: a prospective study. Nutr Cancer. 
2012;64(4):526-34. doi:10.1080/01635581.2012.668744 
137. Yin L, Lin X, Li N, Zhang M, He X, Liu J, et al. Evaluation of the Global 
Leadership Initiative on Malnutrition Criteria Using Different Muscle Mass Indices 
for Diagnosing Malnutrition and Predicting Survival in Lung Cancer Patients. JPEN 
J Parenter Enteral Nutr. 2020  doi:10.1002/jpen.1873 
138. Sanchez-Lara K, Turcott JG, Juarez-Hernandez E, Nunez-Valencia C, Villanueva G, 
Guevara P, et al. Effects of an oral nutritional supplement containing 
eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced 
non-small cell lung cancer: randomised trial. Clin Nutr. 2014;33(6):1017-23. 
doi:10.1016/j.clnu.2014.03.006 
139. Wigmore SJ, Plester CE, Richardson RA, Fearon KC. Changes in nutritional status 
associated with unresectable pancreatic cancer. Br J Cancer. 1997;75(1):106-9. 
Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222706/pdf/brjcancer00178-0111.pdf 
Chapter Two.  Literature Review 
69 
140. Vagnildhaug OM, Blum D, Wilcock A, Fayers P, Strasser F, Baracos VE, et al. The
applicability of a weight loss grading system in cancer cachexia: a longitudinal
analysis. J Cachexia Sarcopenia Muscle. 2017;8(5):789-797.
doi:10.1002/jcsm.12220
141. Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, et al. Quality of
life and survival survey of cancer cachexia in advanced non-small cell lung cancer
patients-Japan nutrition and QOL survey in patients with advanced non-small cell
lung cancer study. Support Care Cancer. 2016  doi:10.1007/s00520-016-3156-8
142. Antoun S, Bayar MA, Dyevre V, Lanoy E, Smolenschi C, Ducreux M. No evidence
for changes in skeletal muscle mass or weight during first-line chemotherapy for
metastatic colorectal cancer. BMC Cancer. 2019;19(1):847. doi:10.1186/s12885-
019-6086-2
143. Araujo dos Santos C, de Oliveira Barbosa Rosa C, Queiroz Ribeiro A, Lanes
Ribeiro Rde C. Patient-generated subjective global assessment and classic
anthropometry: comparison between the methods in detection of malnutrition
among elderly with cancer. Nutr Hosp. 2015;31(1):384-92.
doi:10.3305/nh.2015.31.1.7543
144. Bozzetti F. Screening the nutritional status in oncology: a preliminary report on 1,000
outpatients. Support Care Cancer. 2009;17(3):279-84. doi:10.1007/s00520-008-0476-3
145. Chabowski M, Polanski J, Jankowska-Polanska B, Janczak D, Rosinczuk J. Is
nutritional status associated with the level of anxiety, depression and pain in patients
with lung cancer? J Thorac Dis. 2018;10(4):2303-2310.
doi:10.21037/jtd.2018.03.108
146. Kiss N, Isenring E, Gough K, Krishnasamy M. The prevalence of weight loss during
(chemo)radiotherapy treatment for lung cancer and associated patient- and
treatment-related factors. Clin Nutr. 2014;33(6):1074-80.
doi:10.1016/j.clnu.2013.11.013
147. Koom WS, Ahn SD, Song SY, Lee CG, Moon SH, Chie EK, et al. Nutritional status
of patients treated with radiotherapy as determined by subjective global assessment.
Radiat Oncol J. 2012;30(3):132-9. doi:10.3857/roj.2012.30.3.132
148. Li Z, Chen W, Li H, Zhao B. Nutrition support in hospitalized cancer patients with
malnutrition in China. Asia Pac J Clin Nutr. 2018;27(6):1216-1224.
doi:10.6133/apjcn.201811_27(6).0007
149. Montoya JE, Domingo F, Jr., Luna CA, Berroya RM, Catli CA, Ginete JK, et al.
Nutritional status of cancer patients admitted for chemotherapy at the National
Kidney and Transplant Institute. Singapore Med J. 2010;51(11):860-4.
Chapter Two.  Literature Review 
70 
150. Muscaritoli M, Lucia S, Farcomeni A, Lorusso V, Saracino V, Barone C, et al.
Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO
study. Oncotarget. 2017;8(45):79884-79896. doi:10.18632/oncotarget.20168
151. Percival C, Hussain A, Zadora-Chrzastowska S, White G, Maddocks M, Wilcock A.
Providing nutritional support to patients with thoracic cancer: findings of a
dedicated rehabilitation service. Respir Med. 2013;107(5):753-61.
doi:10.1016/j.rmed.2013.01.012
152. Platek ME, Popp JV, Possinger CS, Denysschen CA, Horvath P, Brown JK.
Comparison of the prevalence of malnutrition diagnosis in head and neck,
gastrointestinal, and lung cancer patients by 3 classification methods. Cancer Nurs.
2011;34(5):410-6. doi:10.1097/NCC.0b013e318206b013
153. Segura A, Pardo J, Jara C, Zugazabeitia L, Carulla J, de Las Penas R, et al. An
epidemiological evaluation of the prevalence of malnutrition in Spanish patients
with locally advanced or metastatic cancer. Clin Nutr. 2005;24(5):801-14.
doi:10.1016/j.clnu.2005.05.001
154. Wie GA, Cho YA, Kim SY, Kim SM, Bae JM, Joung H. Prevalence and risk factors
of malnutrition among cancer patients according to tumor location and stage in the
National Cancer Center in Korea. Nutrition. 2010;26(3):263-8.
doi:10.1016/j.nut.2009.04.013
155. Wheelwright S, Darlington AS, Hopkinson JB, Fitzsimmons D, White A, Johnson
CD. A systematic review of health-related quality of life instruments in patients
with cancer cachexia. Support Care Cancer. 2013;21(9):2625-36. 
doi:10.1007/s00520-013-1881-9 
156. Polanski J, Jankowska-Polanska B, Uchmanowicz I, Chabowski M, Janczak D,
Mazur G, et al. Malnutrition and Quality of Life in Patients with Non-Small-Cell
Lung Cancer. Adv Exp Med Biol. 2017;1021:15-26. doi:10.1007/5584_2017_23
157. Antoun S, Morel H, Souquet PJ, Surmont V, Planchard D, Bonnetain F, et al.
Staging of nutrition disorders in non-small-cell lung cancer patients: utility of
skeletal muscle mass assessment. J Cachexia Sarcopenia Muscle. 2019;10(4):782-
793. doi:10.1002/jcsm.12418
158. Burden ST, Hill J, Shaffer JL, Todd C. Nutritional status of preoperative colorectal
cancer patients. J Hum Nutr Diet. 2010;23(4):402-7. doi:10.1111/j.1365-
277X.2010.01070.x
159. Reijnierse EM, Trappenburg MC, Leter MJ, Blauw GJ, de van der Schueren MA,
Meskers CG, et al. The Association between Parameters of Malnutrition and
Diagnostic Measures of Sarcopenia in Geriatric Outpatients. PLoS One.
2015;10(8):e0135933. doi:10.1371/journal.pone.0135933
Chapter Two.  Literature Review 
71 
160. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 
Suppl):990s-991s. doi:10.1093/jn/127.5.990S 
161. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. 
Sarcopenia: European consensus on definition and diagnosis: Report of the 
European Working Group on Sarcopenia in Older People. Age Ageing. 
2010;39(4):412-23. doi:10.1093/ageing/afq034 
162. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. 
Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 
2019;48(1):16-31. doi:10.1093/ageing/afy169 
163. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. 
Prevalence and clinical implications of sarcopenic obesity in patients with solid 
tumours of the respiratory and gastrointestinal tracts: a population-based study. 
Lancet Oncol. 2008;9:629-635. doi:DOI 10.1016/S1470- 2045(08)70153-0 
164. Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin T, McCargar L, et al. 
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful 
Prognostic Factor, Independent of Body Mass Index. J Clin Oncol. 
2013;31(12):1539-1547. doi:DOI 10.1200/JCO.2012.45.2722 
165. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, 
et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J 
Epidemiol. 1998;147(8):755-63. Available from: 
http://aje.oxfordjournals.org/content/147/8/755.full.pdf 
166. Gould H, Brennan SL, Kotowicz MA, Nicholson GC, Pasco JA. Total and 
appendicular lean mass reference ranges for Australian men and women: the 
Geelong osteoporosis study. Calcif Tissue Int. 2014;94(4):363-72. 
doi:10.1007/s00223-013-9830-7 
167. Newman AB, Kupelian V, Visser M, Simonsick E, Goodpaster B, Nevitt M, et al. 
Sarcopenia: alternative definitions and associations with lower extremity function. J 
Am Geriatr Soc. 2003;51(11):1602-9. doi:10.1046/j.1532-5415.2003.51534.x 
168. Delmonico MJ, Harris TB, Lee JS, Visser M, Nevitt M, Kritchevsky SB, et al. 
Alternative definitions of sarcopenia, lower extremity performance, and functional 
impairment with aging in older men and women. J Am Geriatr Soc. 2007;55(5):769-
74. doi:10.1111/j.1532-5415.2007.01140.x 
169. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) 
in older persons is associated with functional impairment and physical disability. J 
Am Geriatr Soc. 2002;50(5):889-96. doi:10.1046/j.1532-5415.2002.50216.x 
170. Janssen I, Heymsfield SB, Wang ZM, Ross R. Skeletal muscle mass and distribution 
in 468 men and women aged 18-88 yr. J Appl Physiol (1985). 2000;89(1):81-8. 
doi:10.1152/jappl.2000.89.1.81 
Chapter Two.  Literature Review 
72 
171. Mitchell WK, Williams J, Atherton P, Larvin M, Lund J, Narici M. Sarcopenia, 
dynapenia, and the impact of advancing age on human skeletal muscle size and 
strength; a quantitative review. Front Physiol. 2012;3:260. 
doi:10.3389/fphys.2012.00260 
172. Wilkinson DJ, Piasecki M, Atherton PJ. The age-related loss of skeletal muscle 
mass and function: Measurement and physiology of muscle fibre atrophy and 
muscle fibre loss in humans. Ageing Res Rev. 2018;47:123-132. 
doi:10.1016/j.arr.2018.07.005 
173. Steffl M, Bohannon RW, Sontakova L, Tufano JJ, Shiells K, Holmerova I. 
Relationship between sarcopenia and physical activity in older people: a systematic 
review and meta-analysis. Clin Interv Aging. 2017;12:835-845. 
doi:10.2147/cia.S132940 
174. Scott D, Blizzard L, Fell J, Giles G, Jones G. Associations between dietary nutrient 
intake and muscle mass and strength in community-dwelling older adults: the 
Tasmanian Older Adult Cohort Study. J Am Geriatr Soc. 2010;58(11):2129-34. 
doi:10.1111/j.1532-5415.2010.03147.x 
175. Houston DK, Nicklas BJ, Ding J, Harris TB, Tylavsky FA, Newman AB, et al. 
Dietary protein intake is associated with lean mass change in older, community-
dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study. 
Am J Clin Nutr. 2008;87(1):150-5. doi:10.1093/ajcn/87.1.150 
176. Pamoukdjian F, Bouillet T, Levy V, Soussan M, Zelek L, Paillaud E. Prevalence 
and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic 
review. Clin Nutr. 2018;37(4):1101-1113. doi:10.1016/j.clnu.2017.07.010 
177. Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE. Effects of weight loss and 
sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition. 
2019;67-68:110539. doi:10.1016/j.nut.2019.06.020 
178. Yang M, Shen Y, Tan L, Li W. Prognostic Value of Sarcopenia in Lung Cancer: A 
Systematic Review and Meta-analysis. Chest. 2019;156(1):101-111. 
doi:10.1016/j.chest.2019.04.115 
179. Chambard L, Girard N, Ollier E, Rousseau JC, Duboeuf F, Carlier MC, et al. Bone, 
muscle, and metabolic parameters predict survival in patients with synchronous 
bone metastases from lung cancers. Bone. 2018;108:202-209. 
doi:10.1016/j.bone.2018.01.004 
180. Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, Oyakawa T, et al. Prognostic 
impact of cancer cachexia in patients with advanced non-small cell lung cancer. 
Support Care Cancer. 2015;23(6):1699-708. doi:10.1007/s00520-014-2534-3 
Chapter Two.  Literature Review 
73 
181. Rossi S, Di Noia V, Tonetti L, Strippoli A, Basso M, Schinzari G, et al. Does 
sarcopenia affect outcome in patients with non-small-cell lung cancer harboring 
EGFR mutations? Future Oncol. 2018;14(10):919-926. doi:10.2217/fon-2017-0499 
182. Srdic D, Plestina S, Sverko-Peternac A, Nikolac N, Simundic AM, Samarzija M. 
Cancer cachexia, sarcopenia and biochemical markers in patients with advanced 
non-small cell lung cancer-chemotherapy toxicity and prognostic value. Support 
Care Cancer. 2016;24(11):4495-502. doi:10.1007/s00520-016-3287-y 
183. Stene GB, Helbostad JL, Amundsen T, Sorhaug S, Hjelde H, Kaasa S, et al. 
Changes in skeletal muscle mass during palliative chemotherapy in patients with 
advanced lung cancer. Acta Oncol. 2015;54(3):340-8. 
doi:10.3109/0284186x.2014.953259 
184. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body 
composition in patients with non–small cell lung cancer: a contemporary view of 
cancer cachexia with the use of computed tomography image analysis. Am J Clin 
Nutr. 2010;91 ((suppl)):1133S-7S. 
185. Kakinuma K, Tsuruoka H, Morikawa K, Furuya N, Inoue T, Miyazawa T, et al. 
Differences in skeletal muscle loss caused by cytotoxic chemotherapy and 
molecular targeted therapy in patients with advanced non-small cell lung cancer. 
Thorac Cancer. 2018;9(1):99-104. doi:10.1111/1759-7714.12545 
186. Schiessel DL, Baracos VE. Barriers to cancer nutrition therapy: excess catabolism 
of muscle and adipose tissues induced by tumour products and chemotherapy. Proc 
Nutr Soc. 2018;77(4):394-402. doi:10.1017/s0029665118000186 
187. Kinsey E, Ajazi E, Wang X, Johnston MAM, Crawford J. Predictors of Physical and 
Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum 
Chemotherapy. J Thorac Oncol. 2018;13(9):1294-1301. 
doi:10.1016/j.jtho.2018.05.029 
188. Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, Antoun S, et al. Central 
tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable 
anabolic potential? Am J Clin Nutr. 2013;98(4):1012-9. doi:DOI 
10.3945/ajcn.113.060228 
189. Daly LE, Ni Bhuachalla EB, Power DG, Cushen SJ, James K, Ryan AM. Loss of 
skeletal muscle during systemic chemotherapy is prognostic of poor survival in 
patients with foregut cancer. J Cachexia Sarcopenia Muscle. 2018;9(2):315-325. 
doi:10.1002/jcsm.12267 
190. Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM. Prognostic Significance of 
CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer. J Thorac 
Oncol. 2015;10(12):1795-9. doi:10.1097/jto.0000000000000690 
Chapter Two.  Literature Review 
74 
191. Kim CR, Kim EY, Kim YS, Ahn HK, Kim KW, Jeong YM, et al. Histologic 
subtypes are not associated with the presence of sarcopenia in lung cancer. PLoS 
One. 2018;13(3):e0194626. doi:10.1371/journal.pone.0194626 
192. Kiss N, Beraldo J, Everitt S. Early Skeletal Muscle Loss in Non-Small Cell Lung 
Cancer Patients Receiving Chemoradiation and Relationship to Survival. Support 
Care Cancer. 2019;27(7):2657-2664. doi:10.1007/s00520-018-4563-9 
193. Nipp RD, Fuchs G, El-Jawahri A, Mario J, Troschel FM, Greer JA, et al. Sarcopenia 
Is Associated with Quality of Life and Depression in Patients with Advanced 
Cancer. Oncologist. 2018;23(1):97-104. doi:10.1634/theoncologist.2017-0255 
194. Onishi S, Tajika M, Tanaka T, Hirayama Y, Hara K, Mizuno N, et al. Prognostic 
Significance of Sarcopenia in Patients with Unresectable Advanced Esophageal 
Cancer. J Clin Med. 2019;8(10) doi:10.3390/jcm8101647 
195. Prado CM, Lieffers JR, Bowthorpe L, Baracos VE, Mourtzakis M, McCargar LJ. 
Sarcopenia and physical function in overweight patients with advanced cancer. Can 
J Diet Pract Res. 2013;74(2):69-74. 
196. Rier HN, Jager A, Meinardi MC, van Rosmalen J, Kock M, Westerweel PE, et al. 
Severe sarcopenia might be associated with a decline of physical independence in 
older patients undergoing chemotherapeutic treatment. Support Care Cancer. 2017  
doi:10.1007/s00520-017-4018-8 
197. Sheean P, Gomez-Perez S, Joyce C, Vasilopoulos V, Bartolotta MB, Robinson P, et 
al. Body Composition, Serum Biomarkers of Inflammation and Quality of Life in 
Clinically Stable Women with Estrogen Receptor Positive Metastatic Breast Cancer. 
Nutr Cancer. 2019;71(6):981-991. doi:10.1080/01635581.2019.1595053 
198. Bye A, Sjoblom B, Wentzel-Larsen T, Gronberg BH, Baracos VE, Hjermstad MJ, et 
al. Muscle mass and association to quality of life in non-small cell lung cancer 
patients. J Cachexia Sarcopenia Muscle. 2017;8(5):759-767. 
doi:10.1002/jcsm.12206 
199. Rier HN, Jager A, Meinardi MC, van Rosmalen J, Kock M, Westerweel PE, et al. 
Severe sarcopenia might be associated with a decline of physical independence in 
older patients undergoing chemotherapeutic treatment. Support Care Cancer. 
2018;26(6):1781-1789. doi:10.1007/s00520-017-4018-8 
200. Naito T, Okayama T, Aoyama T, Ohashi T, Masuda Y, Kimura M, et al. Skeletal 
muscle depletion during chemotherapy has a large impact on physical function in 
elderly Japanese patients with advanced non-small-cell lung cancer. BMC Cancer. 
2017;17(1):571. doi:10.1186/s12885-017-3562-4 
Chapter Two.  Literature Review 
75 
201. Tieland M, Verdijk LB, de Groot LC, van Loon LJ. Handgrip strength does not 
represent an appropriate measure to evaluate changes in muscle strength during an 
exercise intervention program in frail older people. Int J Sport Nutr Exerc Metab. 
2015;25(1):27-36. doi:10.1123/ijsnem.2013-0123 
202. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. 
American College of Sports Medicine position stand. Quantity and quality of 
exercise for developing and maintaining cardiorespiratory, musculoskeletal, and 
neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. 
Med Sci Sports Exerc. 2011;43(7):1334-59. doi:10.1249/MSS.0b013e318213fefb 
203. Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J. A Systematic Review 
of Exercise Systematic Reviews in the Cancer Literature (2005-2017). Pm r. 
2017;9(9s2):S347-s384. doi:10.1016/j.pmrj.2017.07.074 
204. Beaton R, Pagdin-Friesen W, Robertson C, Vigar C, Watson H, Harris SR. Effects 
of exercise intervention on persons with metastatic cancer: a systematic review. 
Physiother Can. 2009;61(3):141-53. doi:10.3138/physio.61.3.141 
205. Nadler MB, Desnoyers A, Langelier DM, Amir E. The Effect of Exercise on 
Quality of Life, Fatigue, Physical Function, and Safety in Advanced Solid Tumor 
Cancers: A Meta-analysis of Randomized Control Trials. J Pain Symptom Manage. 
2019;58(5):899-908.e7. doi:10.1016/j.jpainsymman.2019.07.005 
206. Chen YJ, Li XX, Ma HK, Zhang X, Wang BW, Guo TT, et al. Exercise Training for 
Improving Patient-Reported Outcomes in Patients With Advanced-Stage Cancer: A 
Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2019  
doi:10.1016/j.jpainsymman.2019.09.010 
207. Dittus KL, Gramling RE, Ades PA. Exercise interventions for individuals with 
advanced cancer: A systematic review. Prev Med. 2017;104:124-132. 
doi:10.1016/j.ypmed.2017.07.015 
208. Heywood R, McCarthy AL, Skinner TL. Efficacy of Exercise Interventions in 
Patients With Advanced Cancer: A Systematic Review. Arch Phys Med Rehabil. 
2018  doi:10.1016/j.apmr.2018.04.008 
209. Peddle-McIntyre CJ, Singh F, Thomas R, Newton RU, Galvao DA, Cavalheri V. 
Exercise training for advanced lung cancer. Cochrane Database Syst Rev. 
2019;2:Cd012685. doi:10.1002/14651858.CD012685.pub2 
210. Quist M, Langer SW, Lillelund C, Winther L, Laursen JH, Christensen KB, et al. 
Effects of an exercise intervention for patients with advanced inoperable lung 
cancer undergoing chemotherapy: A randomized clinical trial. Lung Cancer. 
2020;145:76-82. doi:10.1016/j.lungcan.2020.05.003 
Chapter Two.  Literature Review 
76 
211. Yee J, Davis GM, Hackett D, Beith JM, Wilcken N, Currow D, et al. Physical 
Activity for Symptom Management in Women With Metastatic Breast Cancer: A 
Randomized Feasibility Trial on Physical Activity and Breast Metastases. J Pain 
Symptom Manage. 2019;58(6):929-939. doi:10.1016/j.jpainsymman.2019.07.022 
212. Keilani M, Hasenoehrl T, Baumann L, Ristl R, Schwarz M, Marhold M, et al. 
Effects of resistance exercise in prostate cancer patients: a meta-analysis. Support 
Care Cancer. 2017;25(9):2953-2968. doi:10.1007/s00520-017-3771-z 
213. Wall BA, DA GA, Fatehee N, Taaffe DR, Spry N, Joseph D, et al. Exercise 
Improves V O2max and Body Composition in Androgen Deprivation Therapy-
treated Prostate Cancer Patients. Med Sci Sports Exerc. 2017;49(8):1503-1510. 
doi:10.1249/mss.0000000000001277 
214. Galvao DA, Taaffe DR, Spry N, Cormie P, Joseph D, Chambers SK, et al. Exercise 
Preserves Physical Function in Prostate Cancer Patients with Bone Metastases. Med 
Sci Sports Exerc. 2018;50(3):393-399. doi:10.1249/mss.0000000000001454 
215. Adams SC, Segal RJ, McKenzie DC, Vallerand JR, Morielli AR, Mackey JR, et al. 
Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast 
cancer patients receiving adjuvant chemotherapy: a multicenter randomized 
controlled trial. Breast Cancer Res Treat. 2016;158(3):497-507. 
doi:10.1007/s10549-016-3900-2 
216. Dieli-Conwright CM, Parmentier JH, Sami N, Lee K, Spicer D, Mack WJ, et al. 
Adipose tissue inflammation in breast cancer survivors: effects of a 16-week 
combined aerobic and resistance exercise training intervention. Breast Cancer Res 
Treat. 2018;168(1):147-157. doi:10.1007/s10549-017-4576-y 
217. Thomas GA, Cartmel B, Harrigan M, Fiellin M, Capozza S, Zhou Y, et al. The 
effect of exercise on body composition and bone mineral density in breast cancer 
survivors taking aromatase inhibitors. Obesity (Silver Spring). 2017;25(2):346-351. 
doi:10.1002/oby.21729 
218. Casla S, Lopez-Tarruella S, Jerez Y, Marquez-Rodas I, Galvao DA, Newton RU, et 
al. Supervised physical exercise improves VO2max, quality of life, and health in 
early stage breast cancer patients: a randomized controlled trial. Breast Cancer Res 
Treat. 2015;153(2):371-82. doi:10.1007/s10549-015-3541-x 
219. Finn PF, Dice JF. Proteolytic and lipolytic responses to starvation. Nutrition. 
2006;22(7-8):830-44. doi:10.1016/j.nut.2006.04.008 
220. Hudson JL, Wang Y, Bergia Iii RE, Campbell WW. Protein Intake Greater than the 
RDA Differentially Influences Whole-Body Lean Mass Responses to Purposeful 
Catabolic and Anabolic Stressors: A Systematic Review and Meta-analysis. Adv 
Nutr. 2019  doi:10.1093/advances/nmz106 
Chapter Two.  Literature Review 
77 
221. Josse AR, Atkinson SA, Tarnopolsky MA, Phillips SM. Increased consumption of
dairy foods and protein during diet- and exercise-induced weight loss promotes fat
mass loss and lean mass gain in overweight and obese premenopausal women. J
Nutr. 2011;141(9):1626-34. doi:10.3945/jn.111.141028
222. Verreijen AM, Verlaan S, Engberink MF, Swinkels S, de Vogel-van den Bosch J,
Weijs PJ. A high whey protein-, leucine-, and vitamin D-enriched supplement
preserves muscle mass during intentional weight loss in obese older adults: a
double-blind randomized controlled trial. Am J Clin Nutr. 2015;101(2):279-86.
doi:10.3945/ajcn.114.090290
223. Campbell WW, Crim MC, Young VR, Evans WJ. Increased energy requirements
and changes in body composition with resistance training in older adults. Am J Clin
Nutr. 1994;60(2):167-75. doi:10.1093/ajcn/60.2.167
224. Rossato LT, Nahas PC, de Branco FMS, Martins FM, Souza AP, Carneiro MAS, et
al. Higher Protein Intake Does Not Improve Lean Mass Gain When Compared with
RDA Recommendation in Postmenopausal Women Following Resistance Exercise
Protocol: A Randomized Clinical Trial. Nutrients. 2017;9(9)
doi:10.3390/nu9091007
225. Daly RM, O'Connell SL, Mundell NL, Grimes CA, Dunstan DW, Nowson CA.
Protein-enriched diet, with the use of lean red meat, combined with progressive
resistance training enhances lean tissue mass and muscle strength and reduces
circulating IL-6 concentrations in elderly women: a cluster randomized controlled




Feasibility of Objectively Measured Physical 
Activity and Sedentary Behaviour in Patients 
with Malignant Pleural Effusion 
Abstract................................................................................................................. 80 
3.1 Introduction ............................................................................................... 81 
3.2 Methods ..................................................................................................... 82 
3.3 Results ....................................................................................................... 84 
3.4 Discussion ................................................................................................. 93 
References ............................................................................................................ 97 
Chapter Three 
Chapter Three.  Feasibility of Objectively Measured Physical Activity and Sedentary Behaviour 
80 
Abstract 
Purpose: Malignant pleural effusion (MPE) affects 1 million people worldwide annually 
and can significantly impair physical activity.  Accelerometry is a validated method of 
objectively assessing physical activity. The purpose of this study was to determine the 
compliance in patients with MPE to accelerometry and describe their activity. 
Methods: Patients with MPE wore an Actigraph GT3X accelerometer over a 7-day 
continuous wear protocol. Compliance was measured as the percent of patients who had 
≥4 valid days (i.e., 8-hour/day of waking wear-time). Eastern Cooperative Oncology 
Group performance status was documented the day of actigraphy initialization. 
Results: Forty-six patients with MPE received accelerometers; 44 (95.7%) returned their 
device. No complications were reported on their use.  Forty subjects (90.9%) had ≥4 valid 
days of wear-time. Patients spent most of their waking hours sedentary [mean 11.0 (SD 1.95) 
hours], with limited participation in moderate and vigorous physical activity [mean 9.5 (SD 
14.16) minutes]. Compared to patients with better performance status (n=32), patients with 
poorer performance status (n=11) spent significantly more hours/day sedentary [mean 
difference 2.1 (CI 0.86-3.32); p=0.001], as did those who survived <3 months (n=5) 
compared to >12 months (n=27) [mean difference 2.6 (CI 0.49-4.77); p=0.013). 
Conclusion: Accelerometry was applied successfully in patients with MPE with high 
compliance and no adverse events. This is the first reported objectively measured physical 
activity in patients with MPE and revealed high sedentary behavior and low physical 
activity. The data reflected patient performance status and discriminated between survival 
groups. Accelerometry can provide a useful measure for future interventional studies in 
patients with MPE.  
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3.1 Introduction 
Malignant pleural effusions (MPE) are estimated to develop in 200,000 people in the 
United States each year.1 The development of an MPE can be a consequence of metastatic 
spread of any cancer, but more commonly lung, breast and gynecological cancers or from 
primary pleural neoplasms (e.g., mesothelioma).2 The presence of MPE represents 
incurable disease and median survival ranges from 3 to 12 months from first presentation.2 
Breathlessness is a common and debilitating symptom reported by this patient group and 
interventions are aimed at managing symptoms for optimal quality of life.3 
Breathlessness and other symptoms that result from MPE are likely to limit a person’s 
ability to be physically active. In patients with lung cancer, breathlessness and fatigue 
appear to be associated with lower physical activity levels.4, 5 Preliminary research 
suggests that patients with advanced cancer spend the majority of their time sedentary, 
with Lowe et al6 reporting that patients with brain metastases spend an average of 20.2 
hours per day supine or sitting, and none met physical activity guidelines of 150 minutes 
per week of moderate to vigorous physical activity (MVPA). In patients with breast, 
colorectal, lung and ovarian cancer, those that are more physically active report better 
quality of life.7-12  However, activity levels in patients with MPE remain unknown. 
Considering this clinical population has a poor prognosis, high symptom burden, and often 
undergoes invasive medical treatments (e.g., indwelling pleural catheter, chemotherapy).3 
data regarding physical activity and sedentary behavior in patients with MPE is needed. 
Performance status rating is routinely used in cancer populations to assess patient 
suitability for interventions13 and is a reliable predictor of survival in patients with MPE.2 
The Eastern Cooperative Oncology Group (ECOG) and Karnofsky performance status 
scales are the most commonly used measures of performance status in this population.14, 
15 These ratings are largely based on the ability of patients to engage in their usual activities 
of daily living, including physical activity.14, 15 However, as performance status ratings are 
subjective and broad, they may fail to detect small but meaningful changes in physical 
activity levels. Accelerometers, which objectively measure physical activity and sedentary 
behavior, may be more sensitive to these modest changes and could be more reliable. 
However, it remains to be seen if accelerometry derived objective measures of physical 
activity and sedentary time can differentiate between patients by performance status 
category or categorized survival groups. 
Chapter Three.  Feasibility of Objectively Measured Physical Activity and Sedentary Behaviour 
82 
The primary aim of this study was to determine if patients with malignant pleural 
effusion (MPE) were compliant with accelerometry designed to measure physical activity 
and sedentary behavior. Second, we aimed to describe the physical activity and sedentary 
behavior of patients with MPE. We also aimed investigate the relationship between 
physician ratings of physical performance status, survival and accelerometer measured 
physical activity and sedentary behavior. 
3.2 Methods 
3.2.1 Participants 
This study was approved by the Sir Charles Gairdner Group Human Research Ethics 
Committee (Quality Improvement No: 11149). From December 2014, patients with MPE 
at this center were asked by their physician to wear an accelerometer as part of clinical 
care. Patients were included in this study if they had a confirmed diagnosis of MPE and 
had worn an accelerometer between December 2014 and April 2016. 
3.2.2 Measures 
Demographic and medical variables 
Patient’s medical records were reviewed for baseline demographic data, cancer 
diagnosis, performance status, pleural effusion characteristics and comorbidities. iSOFT 
Clinical Manager was used to access date of death. Survival was calculated as the time 
between accelerometer initialization and date of death. Patients were then categorized into 
groups <3 months, 3-12 months or >12 months based on their survival. Chest radiographs 
completed within one week of accelerometer wear were characterized and graded on a 
scale of 0 to 5 according to established criteria.16 Specifically, a grade 1 effusion 
represented blunting of the costophrenic angle, grade 2 is more than blunting of the 
costophrenic angle but less than 25% of the hemithorax occupied by pleural fluid, grade 3 
occupying 25-50% of the hemithorax, grade 4 occupying 50-75% of the hemithorax and 
grade 5 occupying >75% of the hemithorax.16 
Accelerometer compliance 
Compliance with actigraphy protocol was assessed by the number and percentage of 
patients who wore the actigraph for 4 or more valid wear days.17 
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Physical activity and sedentary behavior 
Patients were instructed to wear the accelerometer (Actigraph GT3X+; Actigraph, 
Pensacola, FL, USA) on their hip continuously (24hr/day) for 7 days and record any non-
wear time in a diary provided for the 7-day period. 
Accelerometers were programmed to record raw data at a frequency of 30Hz. Data 
were later reduced to vertical axis movement counts per 60-second epoch. Accelerometer 
data were downloaded and processed in SAS (version 9.3, SAS Institute, Cary, NC, USA). 
Waking wear time was determined by visual inspection of the ActiGraph file by a trained 
rater and an automated algorithm.18 A valid day was defined as 8-hours (hr) of waking 
wear time.19 Accelerometers with at least one valid day of data were analyzed. 
Common cut off points were used to classify sedentary time as <100 counts/minute 
(cpm), light activity as 100-1952 cpm and MVPA as >1952 cpm.20, 21 Bouts of sedentary 
time and physical activity were classified as <5 min, 5 to <10 min, 10 to <20 min, 20 to 
<30 min, 30 to <60 min and ≥ 60 min. Prolonged sedentary time was defined as time spent 
in sedentary bouts of ≥20 and ≥30 minutes. Step counts were processed as uncensored 
(Low Frequency Extension turned on) and censored (36% adjustment for 
overestimation).22 We used commonly reported targets of ≥150 minutes moderate 
intensity activity/week and ≥7,000 accelerometer measured steps/day to assess adherence 
to physical activity recommendations.23 All variables were calculated per day and then 
averaged across all valid days for each patient. Data from returned Actigraph GT3X 
devices were analyzed and the results filed in the patient’s medical record. For the current 
study, the information on physical activity and sedentary behavior was accessed from 
medical records retrospectively. 
Performance status 
Physicians’ recorded physical performance status was assigned according to the 
ECOG rating classification.14 An ECOG rating of 0 is assigned to a person who is fully 
active and able to carry on all pre-disease performance without restriction, a rating of 1 is 
given when a person is restricted in physically strenuous activity but ambulatory and able 
to carry out work of a light or sedentary nature, a rating of 2 is assigned to a person who 
is ambulatory and capable of all self-care but unable to carry out any work activities and 
are up and about more than 50% of waking hours, a rating of 3 is assigned to a person 
capable of only limited self-care and confined to bed or chair more than 50% of waking 
hours, a rating of 4 is given when a person is completely disabled and cannot carry out any 
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self-care and is totally confined to bed or chair.14 Physician rated performance status was 
recorded on the same day that accelerometers were initialized and accessed from medical 
records retrospectively. Patients were grouped as either good performance status (I.e., 
ECOG 0-1) or poor performance status (I.e., ECOG ≥2), as these are common cut-points 
used in decision making for treatment and clinical trials. 
3.2.3 Statistical analyses 
Patients with at least one valid day of data were included in the analysis. Statistical 
analyses were conducted using SPSS (version 23, IBM Corporation, Somers, NY, USA). 
Data were expressed as mean (SD) unless otherwise stated. Demographic and medical data 
were analyzed using descriptive statistics. Patients were grouped according to ECOG 
status (i.e., 0-1 and ≥2) and physical activity and sedentary behavior were analyzed using 
descriptive statistics. Two-tailed independent t tests were used to test for differences 
between the mean physical activity and sedentary time for ECOG groups 0-1 and ≥2. One-
way ANOVA was used to test for differences between the mean physical activity and 
sedentary time for survival groups <3 months, 3-12 months and >12 months. Where the 
data were not normally distributed, the Mann-Whitney and Kruskal Wallis tests were 
applied and the median and inter-quartile range (IQR) is reported. An alpha of 0.05 was 
used to determine statistical significance. Figures were created using GraphPad Prism 
(version 7, GraphPad Software, La Jolla, California, USA). 
3.3 Results 
3.3.1 Participant characteristics 
Actigraph GT3X accelerometers were given to 46 patients with MPE [72% male; mean 
age 69 (SD 8.2)]. Thirty-three patients (71.7%) had an ECOG performance status rating of 
0 to 1, seven patients (15.2%) had an ECOG rating of 2 and six patients (13.0%) were given 
an ECOG rating of 3. Twenty-nine patients (63.0%) survived more than 12 months from the 
date of accelerometer initialization, eleven patients (23.9%) survived 3-12 months, six 
(13.0%) survived less than three months. Demographic and medical characteristics of 
patients are reported in Table 3.1. Approximately two-thirds (65.2%) of patients had a 
diagnosis of mesothelioma. Most (70%) of the patients had a mild to moderate sized effusion 
occupying up to 50% of the hemithorax (i.e., grade 2 or 3 on chest radiograph). 
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3.3.2 Accelerometer compliance 
Forty-four accelerometers (95.7%) were returned and one accelerometer did not meet 
the minimum requirements for analysis. Of the two accelerometers that were not returned, 
one patient died shortly after the 7-day wear time was completed and the patient’s family 
did not return the accelerometer, the second patient reported they lost the device. Of the 
forty-three accelerometers analysed, forty (93.0%) were returned with four or more valid 
days. The number of valid days and average wear time obtained from returned 
accelerometers is presented in Table 3.2. 
3.3.3 Physical Activity and sedentary behavior 
Patients in this study averaged 15.3 (SD 1.69) hours of waking wear time per day. 
On average patients spent 11.0 (SD 1.95) hours sedentary and participated in 4.2 (SD 
1.65) hours of light activity and 9.5 (SD 14.16) minutes of MVPA per day, which was 
equivalent to 71.6%, 27.4% and 1.0% of their waking hours, respectively. Five (10.9%) 
patients completed ≥150 minutes of MVPA over the seven-day period. More than a third 
(37.1%) of all sedentary time was spent in bouts of 30 minutes or more, equivalent to 4.1 
(SD 2.10) hours per day. On average patients took 8817 (SD 4838) uncensored or 5643 
(SD 3096) censored steps per day. Fifteen (34.9%) patients achieved the target of ≥7000 
censored steps per day. 
3.3.4 Physical activity and sedentary behavior according to performance 
status and survival groups 
Patient physical activity level according to performance status is reported in Table 
3.3. The two performance status groups had equivalent wear time however, patients with 
good performance status spent significantly less time as sedentary compared to those with 
poor performance status [10.4 (SD 1.67) hr/day vs. 12.5 (SD 1.94) hr/day; p=0.001]. Light 
activity in patients with good performance status was on average 1.5 hours higher than for 
the poor performance status group [4.6 (SD 1.65) hr/day vs. 3.1 (SD 1.04) hr/day; p=0.06]. 
Patients with good performance status took more than double the median number of steps 
compared with patients of poor performance status [6721 (IQR 4150 - 9193) vs. 3126 
(IQR 1035 - 3845); p<0.001; Figure 3.1]. 
Wear time and patient physical activity according to survival groups is reported in 
Table 3.4. Patients with a survival of >12 months and 3-12 months spent significantly less 
time sedentary compared to those who survived <3 months [10.8 (SD 2.09) hr/day and 
10.6 (SD 1.51) hr/day vs. 13.3 (SD 2.62) hr/day; p=0.013 and p=0.044 respectively; 
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Figure 3.2]. Those patients who survived >12 months participated in almost 2 hours more 
light activity per day than those who survived <3 months [4.5 (SD 1.48) vs. 2.6 (SD 1.45) 
hr/day; p=0.044; Figure 3.2]. The median number of steps taken by patients with a survival 
of >12 months was 1.5 times the steps recorded by those with 3-12 months survival and more 
than double the steps taken by those with <3 months survival. However, this result was not 
statistically significant [6340 (IQR 3728-9224) vs. 4114 (IQR 1753-6632) vs. 3216 (IQR 
1831-5830); p=0.106; Figure 3.1]. 
Patients with good performance status had two fewer bouts of prolonged sedentary time 
of ≥20 minutes compared with patients of poor performance status [7.5 (SD 2.26) vs. 9.4 
(SD 2.14); p=0.019]. Performance status groups did not differ significantly in the number of 
prolonged bouts of sedentary time ≥30 minutes [4.2 (SD 1.81) vs. 5.0 (SD 1.78; p=0.177]. 
Patients with good and poor performance status participated in a similar number of 
bouts of light activity for short periods of <5 minutes [71.7 (SD 14.06) vs. 72.4; (SD 
10.81); p=0.871]. These short bouts of light activity were the most common form of light 
activity in both performance status groups.  Patients with good performance status spent 
50.9% (SD 14.23) of total light activity in short bouts compared to 69.0% (SD 16.48) for 
those with poor performance status (p=0.001). Patients with good performance status 
completed almost five additional bouts of light activity of between 5 and 10 minutes [11.7 
(SD 4.41) vs. 6.9 (SD 4.52); p=0.004]. Light activity according to performance status 
accumulated in bouts of 5 minutes or more is presented in Figure 3.3. 
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Table 3.1 Demographic and medical characteristics of patients 
Total (n=46) 
n (%) 
















Body mass index 
(kg/m2) (n=43) 
26.7 (SD=4.82) 27.2 (SD=3.73) 25.3 (SD=7.19) 













Pleural effusion (%) (n=37) 






























































COPD: Chronic Obstructive Pulmonary Disease; IHD: Ischemic Heart Disease, OA: Osteoarthritis 
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Table 3.2 Number and mean valid days of accelerometry data. 
Total (n=46) 
n (%) 







































Mean valid days 5.9 (SD=1.18) 6.12 (SD=0.94) 5.36 (SD=1.63) 
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Table 3.3 Comparison of physical activity levels and sedentary time according to Eastern Cooperative Oncology Group performance status group 
Eastern Cooperative Oncology Group 
performance status group 
Mean difference (95% CI) 
Test 
statistic P value Good (n=32) Poor (n=11) 
Waking wear time (hr/day) 15.3 (SD 1.13) 15.6 (SD 1.99) -0.40 (-1.38, -0.59) t = -0.81 0.421 
Sedentary time (% waking wear time) 68.6 (SD 10.20) 80.1 (SD 6.32) -11.46 (18.09; -4.82) t = -3.49 0.010 
Light activity (% waking wear time) 30.1 (SD 10.08) 19.7 (SD 6.24) 10.34 (3.78; 16.90) t = 3.18 0.003 
MVPA (% waking wear time), median 0.9 (IQR 0.32 – 1.43) 0.1 (IQR 0.05 – 0.25) z = -3.67 <0.001 
Prolonged sedentary time 
 ≥30 min bouts (hr/day), median 
3.4 (IQR 2.09 – 4.78) 4.5 (IQR 2.97 – 6.97) z = -1.56 0.119 
Meeting MVPA guidelines 
≥150 mins/wk, n (%) 
5 (15.63) 0 (0.00) 
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Table 3.4 Comparison of physical activity levels and sedentary time according to survival group. 
Survival group 
Test 
statistic P value <3 months (n=5) 3-12 months (n=11) >12 months (n=27)
Waking wear time (hr/day) 15.9 (SD 1.26) 15.0 (SD 1.90) 15.4 (SD 1.16) F = 0.77 0.470 
Sedentary time (% waking wear time) 82.6 (SD 11.27) 72.4 (SD 11.61) 69.2 (SD 8.93) F = 3.92 0.028 
Light activity (% waking wear time) 17.1 (SD 10.76) 27.2 (SD 11.32) 29.4 (SD 8.84) F = 3.39 0.044 
MVPA (% waking wear time), median 0.04 (IQR 0.01-0.72) 0.26 (IQR 0.18-0.57) 0.93 (IQR 0.32-1.69) Chi square 
= 8.25 
0.016 
Prolonged sedentary time 
 ≥30 min bouts (hr/day), median 
7.0 (IQR 4.65-9.70) 3.6 (IQR 2.97-4.51) 




Meeting MVPA guidelines 
≥150 mins/wk, n (%) 
0 (0.00) 0 (0.00) 5 (18.52) 
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Figure 3.1 Median censored steps taken per day by patients of A) ECOG performance 
status 0-1 and ≥2 and B) survival group >12 months, 3-12 months and <3 
months. (*) p<0.001 
 
 
Figure 3.2 Time spent as sedentary and in light activity according to survival group 
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Figure 3.3 Time spent in light activity according to duration of activity and 
performance status (ECOG) group. Data are presented as median and IQR. 
a) 5 to <10 min; p=0.004, b) 10 to <20 min; p=0.004, c) 20 to <30 min;
p=0.009, d) 30 to < 60 min; p=0.018, e) ≥60 min; p=0.298. (*) p<0.05
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3.4 Discussion 
Our study is the first to report the use of accelerometry in patients with MPE and 
provides objective measurements of their physical activity and sedentary behavior using a 
24-hr wear protocol. Overall, patients with MPE were compliant with accelerometer wear.
These patients with MPE were predominantly sedentary and only a small portion met 
current physical activity recommendations. This research indicates that physical activity 
in patients with MPE was associated with performance status. Compared to those with a 
good performance status, patients with poorer performance status were more sedentary 
and participated in fewer and shorter bouts of physical activity. Patients who survived less 
than three months were also more sedentary and participated in less physical activity than 
patients who survived more than twelve months. 
Over 90% of patients with MPE provided ≥4 valid days of data from the 7-day 
recording period. The mean valid accelerometer wear was 5.9 days. These results are 
consistent with those from a study of 500 women with breast cancer where compliance 
with a hip-worn accelerometer was 90%17 and also with those from the National Health 
and Nutritional Examination Survey study of healthy older adults,24 where mean valid hip-
worn accelerometer wear was 5.8 days. Two studies of cancer survivor populations 
reported slightly higher mean valid accelerometer wear of 6.6 – 6.8 days.7, 25 However, 
these studies used different accelerometer devices, the first used a hip-worn accelerometer7 
and the second used an accelerometer positioned on the anterior mid thigh.25 Other 
accelerometry studies in people with cancer have not reported on patient compliance with 
the accelerometer protocol.7, 26-28 The high compliance rate in the current study 
demonstrates that accelerometry is a feasible tool for measuring physical activity and 
sedentary behavior in patients with MPE. 
During the 7-day recording period only one in ten patients in our study met physical 
activity recommendations and mean MVPA was only 9.5 min/day. Within a cohort with 
colorectal cancer, patients participated in an average of 28.5 min/day of MVPA as 
measured by accelerometry, which is almost three times our result.7 In contrast, in a study 
of patients with brain metastases, none of the participants registered any activity on their 
accelerometer that could be considered of moderate or vigorous intensity.6 The very low 
activity level of these patients with brain metastases8 was also reflected in the average step 
count of 2784 steps/day, which is half of the average steps taken by patients in our study. 
Two studies of patients with lung cancer reported higher average step counts of 604727 
and 8863.26 These large differences in physical activity are likely related to differences in 
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symptom burden, disease stage and prognosis between cancer groups. Variance in 
accelerometer wear protocols in relation to the wear time (24 hr vs. waking hours), 
placement of accelerometer (hip vs. thigh vs. wrist) and the device used amongst studies 
and processing of step counts as uncensored or censored may also contribute to differences 
in physical activity results. 
Sedentary behavior comprised the bulk of the waking wear time in our study, with 
patients on average spending 72% percent or 11 hours of their day sedentary. These results 
were comparable with a sample of twenty patients with lung cancer26 were sedentary 68% 
of the time but higher than a cohort of patients with colorectal cancer who spent 61% of 
their day sedentary.7 In a prospective study of patients with colorectal cancer who 
completed a self-reported recreational physical activity questionnaire, the risk of cancer-
specific mortality was higher for those who spent ≥6 hr/day sedentary compared to patients 
who were sedentary for <3 hr/day.29 However, in healthy adults who were predominantly 
sedentary, the risk of mortality was reduced through replacing 1hr/day of sedentary time 
with physical activity of any intensity.30 Therefore it is reasonable to consider that 
replacing modest amounts of sedentary behavior with light activity may also be an 
important consideration in optimizing the health of cancer patients, particularly those with 
very low levels of physical activity like our current study population. 
Our results were that the physical activity of patients with MPE was associated with 
their performance status and survival group. In this setting, performance status is a strong 
predictor of survival, and is often used to differentiate between patients well enough to 
receive treatment and those not.13 The ability of accelerometry to function in a similar way 
to performance status suggests the information provided by objective measurement of 
physical activity may benefit physicians or researchers who need to determine patient 
suitability for and response to treatment. 
In the current study, those patients with good performance status engaged in longer 
periods of light activity compared to patients with poor performance status. Only one other 
study to-date has reported on the duration of bouts of light activity.  Previous research into 
patients with lung cancer revealed median percentage of waking wear time in bouts of 10 
or more minutes of light activity was 13% compared to 19% in healthy controls 
(p=0.025).26 As MVPA is very low in these clinical populations, the ability to engage in 
light activity for longer periods is likely the most suitable indicator of better or improving 
health. Accelerometry can accurately and reliably determine the duration of bouts of light 
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activity and this information may be of benefit in interventional studies where increasing 
physical activity level is the goal. 
There are limitations in the current study that should be considered when interpreting 
the results. A retrospective audit design was used in this study because accelerometers 
were part of clinical care.  However, as a result we have no data on patient factors that 
may have influenced physical activity and sedentary behavior such as quality of life or 
symptom burden. Regarding the measurement protocol, as only one 7-day monitoring 
period was completed for each patient, intra-person reliability of the protocol has not been 
established in this clinical sample. Further, the sample may have selection bias as patients 
with MPE were not consecutively asked to wear an accelerometer, rather it was at the 
discretion of the physician to ask patients to wear an accelerometer and physicians may 
have avoided asking a patient if they were unwell or in need of another procedure at the 
time. As not all patients with MPE wore the accelerometers it is plausible that the 
compliance, physical activity and sedentary behavior of patients in our study could differ 
to those who did not wear an accelerometer. Additionally, there was a large proportion of 
patients with mesothelioma in our sample, which is not representative of the worldwide 
population with MPE. A diagnosis of mesothelioma has a favourable prognosis compared 
to other primary cancers with MPE2 and it is probable that this may also impact on physical 
activity and sedentary behavior. 
Despite these limitations, the current study is the first time accelerometer use has been 
investigated in a population with MPE and it provides a good starting point for further 
research in this area. A strength of our study is that a 24-hr, 7-day protocol was used to 
objectively assess physical activity and sedentary behavior in this population. A 24-hr 
accelerometer protocol has not been used in any previous research in cancer patients 
rather, all studies have asked participants to wear the accelerometer during waking hours 
only.7, 26 However, a 24-hr protocol is thought to maximize waking wear time.31 
Furthermore, the 7-day protocol used in this study is the current best practice for objective 
measurement of physical activity as it accurately reflects habitual sedentary behaviour.32 
To better understand the mechanisms contributing to low physical activity levels in 
the MPE population, future studies should be prospective in nature and include 
measurements of breathlessness and fatigue amongst others, as these appear to correlate 
to physical activity levels in other populations.4, 5 Considering the very low levels of 
participation in MVPA paired with the high levels of sedentary behavior, the target of 
interventions to increase physical activity in this population should consider focusing on 
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increasing light activity and reducing sedentary bouts rather than on the traditional goal of 
increasing MVPA which may be unachievable for patients with poor performance status. 
In addition, targeted exercise in particular involving strength training should be considered 
to slow or reverse deconditioning and functional decline likely to be underlying factors in 
the low physical activity levels in this population.33, 34 As this study has demonstrated 
patients with MPE are compliant with accelerometer wear, future studies can now examine 
the usefulness of accelerometry in determining suitability for treatment and assessing 
response to treatment as a patient-centred outcome measure in clinical interventions. 
Accelerometry, on a 7-day continuous wear protocol, can be applied successfully in 
patients with MPE with high compliance and no adverse events. The data obtained 
reflected patient performance status as assessed with ECOG ratings.  The accelerometry 
results provided, for the first time, quantitative data of the physical activity of patients with 
MPE and revealed low physical activity and high sedentary behavior in this population. 
Accelerometry can provide a useful measure for future interventional studies to improve 
physical activity levels in patients with MPE. 
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Abstract 
Body composition analysis techniques commonly used to classify low muscle mass 
in cancer populations are used interchangeably, yet there has been little comparison of 
these methods reported. This study in patients with malignant pleural mesothelioma 
(MPM) aimed to assess the relationship between muscle measured with computed 
tomography (CT) and dual-energy x-ray absorptiometry (DXA) and the agreement 
between cut-points for the classification of low muscle mass. This was a retrospective 
study of patients with available CT and DXA data collected ≤28 days apart. Skeletal 
muscle index (SMI; cm2/m2) was measured with CT at the third lumbar vertebrae using 
sliceOmatic software v.5.0. Appendicular skeletal muscle index (ASMI; kg/m2) was 
segmented from whole-body DXA. Commonly cited CT and DXA cut-points for low 
muscle mass were used to assess the agreement between methods.  Thirty-seven 
participants with MPM were included (81% male; median age 67.0 [IQR 62.0-73.0] 
years). There was a positive correlation between SMI and ASMI (r=0.679; p<0.001). 
Percent agreement between CT and DXA cut-points ranged between 54-73%. There was 
moderate agreement between the CT cut-points from Prado et al and the DXA cut-points 
from Baumgartner et al (ĸ=0.424; p=0.006). There was no significant agreement between 
the other cut-points evaluated (p>0.05).  
Novelty 
 For the first time in patients with MPM, we reported that SMI and ASMI were 
positively correlated. 
 Classification of low muscle mass differs according to the method and cut-point used, 
and are not universally interchangeable. 
 Choice of method needs to be made carefully with consideration of the patient 
outcome of interest. 
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4.1 Introduction 
In many cancer populations, low muscle mass is associated with poorer outcomes, 
including decreased survival and greater treatment toxicity.1 Patients with malignant 
pleural mesothelioma (MPM) commonly experience weight loss,2 which is an adverse 
prognostic indicator.3 However, few studies have investigated body composition in 
patients with MPM. As MPM is an incurable cancer, an understanding of the relationship 
between muscle mass and patient outcomes has the potential to improve clinical practice. 
We previously reported difficulty completing dual-energy x-ray absorptiometry 
(DXA) scans in unwell patients with MPM,2 which was likely due to the additional burden 
this placed on them.  In contrast, thoracic computed tomography (CT) scans obtained from 
medical records are performed routinely as part of standard patient care, are more easily 
accessible to researchers, and do not add to participant burden. Therefore, when available, 
CT may be a more practical alternative to DXA in patients with MPM. Existing guidelines 
state that either CT or DXA can be used to identify low muscle mass in patients with 
cancer,4 however inherent differences between these methods suggest that they would not 
produce comparable results, which would hinder our ability to draw conclusions when 
comparing studies. 
CT and DXA are both imaging techniques, one measures skeletal muscle mass, the 
other lean soft tissue, (i.e., lean mass), which is fundamentally different. Skeletal muscle 
quantification by CT is possible due to the different radiodensity thresholds (Hounsfield 
units) of different tissues. The third lumbar vertebrae (L3) is the best correlate of whole 
body muscle mass, hence used as a single abdominal cross-sectional CT image to provide 
body composition information.5 DXA does not measure skeletal muscle. It uses dual-
photons to determine lean mass, which is comprised of skeletal muscle, organs and other 
soft tissue.6 As skeletal muscle cannot be distinguished from whole body lean mass, 
appendicular lean mass, which is known to be predominantly skeletal muscle, is 
segmented from whole body lean mass, and termed appendicular skeletal muscle mass; 
we will hereby refer to this compartment as “muscle” or appendicular skeletal muscle for 
consistency in terminology but acknowledge it is actually lean mass, therefore including 
muscle, water, fibrotic and connective tissue.6   
To determine whether an individual has low muscle mass, muscle measured with CT 
and DXA is compared to cut-points, derived from each of these methods. Most commonly 
used CT cut-points were developed in cancer populations using values associated with 
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shorter survival,7, 8 while others were derived from DXA and converted to CT units using 
a regression equation.9, 10 Commonly used DXA cut-points were determined in older adults 
using values that were 2 standard deviations below the mean of a young adult reference 
population.11 These cut-points were associated with functional impairment.12 Therefore, 
cut-points associated with these body composition assessment methods were derived from 
different populations, with differing outcomes of interest.  
Our previous research suggests that low muscle mass determined with DXA has the 
potential to predict important clinical outcomes in patients with MPM,2 however DXA 
may not be feasible for a sub-group of the population. Information on the comparability 
of CT and DXA will allow us to understand if these methods categorise patients in the 
same way, which is important for interpretation and comparability of our research within 
the literature. Therefore, the aim of this study was to assess the relationship between 
muscle measured with CT and DXA and compare the agreement between CT and DXA 
cut-points for the classification of low muscle mass in patients with MPM.  
4.2 Materials and methods 
4.2.1 Study design and setting 
The study was a retrospective, cross-sectional analysis which included a subset of 
MPM participants from a longitudinal observational study and an exercise intervention 
study.9 The studies were approved by the Sir Charles Gairdner Group and Edith Cowan 
University Human Research Ethics Committees (ID: 2014-124 and 13255). 
4.2.2 Participants 
Patients were recruited from a tertiary specialist pleural disease and medical oncology 
clinic in Western Australia between August 2015 and May 2017. Patient and physician 
consent was obtained prior to study participation. Participants in the observational and 
intervention studies with a diagnosis of MPM were screened for eligibility for the current 
study. Inclusion criteria were completion of a CT and DXA scan within 28 days of each 
other. Participants were only included in the analysis once, using the first valid set of scans 
for participants in the observational study or the baseline scans for participants in the 
intervention study. Those with no CT image available at L3 or of inadequate image quality 
were excluded. 
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4.2.3 Measures 
Demographic and medical characteristics 
Participant’s medical records were reviewed for baseline demographic and medical 
data. Eastern Cooperative Oncology Group performance status was assigned by the 
physician on the date of assessment.10 
Anthropometric measures 
Weight and height, measured with participants dressed in light clothing with shoes 
removed, were used to calculate the body mass index (BMI). Participants were classified 
as underweight, normal weight, overweight or obese based on World Health Organization 
BMI criteria.11 
Computed tomography 
CT scans performed as part of routine medical care were retrieved from the tertiary 
specialist imaging system and downloaded in Digital Imaging and Communications in 
Medicine (DICOM) format. A trained person (EJ) identified a single cross-sectional image 
at L3 and measured skeletal muscle cross-sectional area (cm2) using sliceOmatic software 
v.5.0 (Tomovision, Montreal, QC, Canada). To ensure the reliability of our data, a second 
independent person (CS) measured skeletal muscle cross-sectional area on all included CT 
scans.  The radiodensity of skeletal muscle was defined as -29 to +150 Hounsfield units12 and 
pixels were manually corrected at tissue boundaries. The skeletal muscle index was 
calculated by dividing the cross-sectional muscle area (cm2) by the participant’s height in m2. 
The following cut-points were used to define low muscle mass from CT: 1) Prado et al7: 
<52.4 cm2/m2 for men and <38.5 cm2/m2 for women, and 2) Martin et al8: <43 cm2/m2 for 
men with a BMI ≤24.9 kg/m2, <53 cm2/m2 for men with BMI >24.9 cm2/m2 and <41 
cm2/m2 for all women.  
Dual energy x-ray absorptiometry 
Whole-body lean mass was measured using whole-body DXA scans (Hologic Discovery 
A, Hologic Inc., Marlborough, MA, USA). A trained person (EJ) segmented appendicular 
skeletal muscle from whole-body lean mass at the acromio-humeral and pelvic-femoral 
joints.5 Appendicular skeletal muscle mass was then adjusted for height (kg/m2). To define 
low muscle mass based on this variable, we used appendicular skeletal muscle index cut-
points from 1) Baumgartner et al17: ≤7.26 kg/m2 for men and ≤5.45 kg/m2 for women, and 
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2) Cruz-Jentoft et al11: ≤7.00 kg/m2 for men and ≤5.50 kg/m2 for women, which for ease
of use, were rounded from cut-points reported by Gould et al18 of ≤6.94 kg/m2 for men 
and ≤5.30 kg/m2 for women. 
4.2.4 Statistical analysis 
Statistical analyses were conducted using Statistical Package for the Social Sciences 
(v. 25, IBM Corporation, Somers, NY, USA). Data were expressed as mean ± SD or 
median [IQR] where the data were not normally distributed. An Intraclass Correlation 
Coefficient (ICC) was obtained to assess the inter-rater reliability for skeletal muscle index 
measured at L3. Pearson’s correlations were performed to assess the relationship between 
skeletal muscle index measured at L3 and appendicular skeletal muscle index measured 
by DXA. Kappa (ĸ) coefficients were used to assess the agreement between commonly 
used low muscle mass cut-points on CT and DXA. Receiver Operating Characteristics 
analysis were used to evaluate the ability of skeletal muscle index to predict low muscle 
mass on DXA by comparing the sensitivity versus the specificity. 
4.3 Results 
4.3.1 Participants 
Participant characteristics are described in Table 4.1. The participants were 
predominantly male (81%), with the epithelioid subtype of MPM (73%) and all had an 
ECOG performance status rating of 0 – 1. Participants had a median age of 67.0 [IQR 62.0 
– 73.0] years and a mean BMI of 25.9 ± 2.9 kg/m2.
4.3.2 CT and DXA scans 
Of the 40 eligible CT scans, 37 (93%) scans were included in the analysis (Figure 
4.1). Two scans (5%) were excluded as there was no image available at L3, while one scan 
(2%) was excluded as the scan was of inadequate quality to apply the analysis technique. 
Mean time elapsed between CT and DXA scan was 10.8 ± 8.5 days. Twenty-five scans 
(68%) were completed within 0 – 14 days of DXA, while 12 scans (32%) were completed 
within 15 – 28 days from DXA. 
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4.3.3 Relationship between body composition techniques for 
measurement of skeletal muscle 
A high degree of reliability was found between raters for skeletal muscle index when 
assessed using the ICC (r=0.992 [95% CI 0.984 – 0.996]; p<0.001). The median skeletal 
muscle index and appendicular skeletal muscle index of included scans are presented in 
Table 4.2. There was a moderate positive correlation between skeletal muscle index and 
appendicular skeletal muscle index (r=0.679, p<0.001; Figure 4.2). 
4.3.4 Agreement between CT and DXA for the classification of low muscle 
mass using existing cut-points 
For each cut-point comparison, the proportion of scans with agreement and 
disagreement is presented in Figure 4.3. Moderate agreement was observed between CT 
cut-points from Prado et al7 and DXA cut-points from Baumgartner et al17 (ĸ=0.424; 
p=0.006). There was no significant agreement between the CT cut-points from Martin et al8 
and DXA cut-points from Baumgartner et al17 (ĸ=0.132; p=0.419). There was no significant 
agreement between the CT cut-points from Martin et al8 and DXA cut-points from 
Baumgartner et al17(ĸ=0.173; p=0.173). There was no significant agreement between the 
CT cut-points from Prado et al7 and Martin et al8 and DXA cut-points supported by Cruz-
Jentoft et al11 (ĸ=0.173; p=0.173; and ĸ=0.087; p=0.582, respectively). 
4.3.5 Skeletal muscle index for predicting low muscle mass using Dual-
Energy X-Ray Absorptiometry as the reference standard 
Skeletal muscle index was a fair predictor of low muscle mass in males (n=30) when 
the DXA cut-point from Baumgartner et al17 was used as the reference standard 
(AUC=0.787, 95% CI 0.613 – 0.961; p=0.009). A skeletal muscle index cut-point of 52.9 
cm2/m2 had a sensitivity of 0.947 and specificity of 0.462 for predicting low muscle mass. 
Skeletal muscle index was not a significant predictor of low muscle mass in males when 
the DXA cut-point supported by Cruz-Jentoft et al11 was used as the reference standard 
(AUC=0.715, 95% CI 0.529 – 0.901; p=0.059). Skeletal muscle index was not a significant 
predictor of low muscle mass in females (n=7) when the DXA cut-points from 
Baumgartner et al17 and supported by Cruz-Jentoft et al11 were used as the reference 
standards (AUC=0.667, 95% CI 0.229 – 1.000; p=0.480 and AUC=0.417, 95% CI 0.000 – 
0.886; p=0.724, respectively). 
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Table 4.1 Participant characteristics, n=37 
n % 
Age, years^ 67 62.0 – 73.0 
Sex, male 30 81.0 
BMI, kg/m2# 25.9 2.9 

































Cancer treatment prior to assessment, yes 14 37.8 
Type of cancer treatment 
Chemotherapy 
Radiotherapy 
Chemotherapy and radiotherapy 









^mean, standard deviation; #median, interquartile range; ECOG – Eastern Cooperative Oncology Group 








Mean SD Mean SD Median IQR 
SMI, cm2/m2 46.9 6.5 48.6 5.5 37.9 35.9–43.2 
ASMI, kg/m2 6.8 0.9 7.1 0.7 5.5 5.4–5.9 
SMI – skeletal muscle index, ASM – appendicular skeletal muscle index 
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Figure 4.1 Participants included in the retrospective, cross-sectional study 
Figure 4.2 Correlation between appendicular skeletal muscle index (ASMI) and 
skeletal muscle index (SMI) at L3, n=37 
r=0.679, p<0.001 
I Participants screened for eligibility I 
(n=56) 
Excluded (n= I 6) . No CT scan available <27 days from DXA 
I 
Potentially eligible participants 
I (n=40) 
Excluded (n=3) . Image of inadequate quality (n=l) . L3 not visible (n=2) 
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Figure 4.3 Agreement between CT and DXA cut-points for low muscle mass, n=37 
2 
19 
a) Prado and Baumgartner b) Martin and Baumgartner 
2 
Agreement normal muscle mass 
[Agreement low muscle mass 
■ No agreement: low muscle mass on CT only 




Prado: <52.4 cm/m- for men and <38.5 em/m for 
women 
Martin°: <43 em/m for men with a BMI <24.9 kg/m, 
<53 em/m for men with BMI 24.9 em/m and <41 
em/m for all women 
DXA cut-points: 
Baumgartner": <7.26 kg/m for men and <5.45 kg/m 
for women 
Cruz Jentoft!: <7.00 kg/m for men and <5.50 kg/m for 
women 
8 
e) Prado and Cruz-Jentoft d) Martin and Cruz-Jentoft 
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4.4 Discussion 
Methods commonly used to assess body composition in cancer populations are 
inherently different, yet current guidelines do not indicate whether these methods differ in 
their classification of low muscle mass.4 There has been little comparison of techniques 
reported, which make it difficult to come to informed conclusions when comparing studies. 
In our study we compared muscle measured with CT and DXA and the agreement between 
cut-points for the classification of low muscle mass in a cohort of patients with MPM. We 
reported that skeletal muscle index and appendicular skeletal muscle index were positively 
correlated, but as expected, there was no significant agreement between CT and DXA for 
the classification of low muscle mass for the majority of cut-points compared.  
We found a moderate correlation between skeletal muscle index and appendicular 
skeletal muscle mass index (r=0.679). In studies of patients with advanced lung and 
gastrointestinal cancer, the correlation between skeletal muscle index and appendicular 
skeletal muscle is reported as moderate to strong (ρ=0.704 and r=0.89, respectively).10, 19 
One possible reason for this variability could be the inherent differences between methods. 
Appendicular skeletal muscle is lean soft tissue and includes muscle, water, fibrotic and 
connective tissue, therefore individual variability in the proportion of fibrotic and 
connective tissue in the arms and legs could affect the strength of the relationship between 
CT and DXA. The proportion of fibrotic and connective tissue present in the lean soft 
tissue of the arms and legs is greater in older age20 and with increasing adiposity.21 Our 
participants with MPM were heterogeneous with regard to their age (range 42 – 81 years) 
and BMI category (54% overweight or obese), which may explain the lack of a strong 
correlation between CT and DXA in our study. Although DXA does not directly measure 
skeletal muscle, it is an important body composition assessment technique. If research 
intends to investigate the relationship between body composition and functional outcomes 
then DXA may preferred over CT as it can estimate the muscle in the arms and legs which 
are typically responsible for movement. We previously reported that DXA cut-points from 
Baumgartner et al17 were associated with poorer physical activity levels and self-reported 
physical functioning in patients with MPM.2 It is not known if this relationship exists with 
skeletal muscle index. 
An alternate hypothesis for our finding of a moderate correlation between methods is 
possible differences in trunk and appendicular loss of skeletal muscle in MPM. Multiple 
factors could affect the distribution of muscle in patients with MPM. Age is known to 
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affect skeletal muscle distribution.22 In a study of healthy older adults, lower body skeletal 
muscle was lost more rapidly than upper body skeletal muscle.22 Therefore, it is possible 
that participants in our study, with a median age of 67 years, could be affected by a similar 
wasting pattern. One third (n=12) of our participants had received chemotherapy 
treatment. To our knowledge, no study has reported on regional changes in muscle 
following chemotherapy, however in a study of patients with prostate cancer receiving 
androgen deprivation therapy, participants lost a greater percentage of lean mass in the 
upper limbs compared with the lower limbs.23 Additionally, MPM is a very localised 
disease where the bulk of the tumour burden resides in the pleural space and rarely 
metastasises.24 This difference, compared to other advanced cancers where tumour burden 
tends to be more widespread could also impact on wasting patterns. Thus, skeletal muscle 
distribution could vary between different populations. Further research is needed to 
determine if there are differences in skeletal muscle distribution between cancer 
populations, and to understand the implications for body composition research.  
There was moderate agreement between CT and DXA cut-points for low muscle mass 
(ĸ=0.438) using the CT cut-points from Prado et al7 and DXA cut-points from 
Baumgartner et al17, however there was no significant agreement between CT and DXA 
for the other cut-points compared. When we used receiver operating characteristics using 
the Baumgartner cut-point to determine the skeletal muscle index value that had the 
optimal sensitivity and specificity for detecting low muscle mass in men, it was 
comparable to the Prado cut-point (52.9 cm2/m2 vs. 52.4 cm2/m2). These results indicate 
that in patients with MPM, greater agreement between methods may not be achieved by 
creating new cut-points. This outcome is not surprising given our finding of a moderate 
correlation between methods. Researchers should be cognisant that criteria for the 
classification of low muscle mass are not interchangeable. As there is currently no 
consensus on diagnostic criteria for the classification of low muscle mass, researchers 
could consider using continuous variables to evaluate the relationship between muscle and 
patient outcomes, which would enable comparison between studies.25  
This study has several limitations. The sample size is small and consists only of patients 
with MPM and therefore, may not be representative of other cancer populations. There is 
heterogeneity in our sample with regard to disease status and cancer treatments. 
Additionally, MPM is substantially more common in men than in women, hence women 
were underrepresented in this study. This was a retrospective study of CT scans performed 
as part of routine clinical care and therefore the make and model of CT scanner, slice 
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thickness and use of contrast enhancement, were not standardised.26, 27 Changes in muscle 
could have occurred between the time of CT and DXA scan, although the mean time elapsed 
between scans was 10.8 days and two thirds of scans were performed on participants >12 
months prior to death, a time where reported changes in muscle over time are small.28 
Furthermore, the strong correlation between raters for CT-measured cross-sectional skeletal 
muscle area indicates that the data is reliable. As this was a retrospective study that utilised 
CT scans completed as part of routine clinical care, the high inclusion rate of participants 
(71%) from our longitudinal observational study and exercise intervention study indicates 
that CT evaluation of body composition is feasible in patients with MPM.  
The present study supports the hypothesis that there is a lack of agreement between 
CT and DXA for the classification of low muscle mass in patients with MPM. Although 
CT and DXA cannot be used interchangeably, both are relevant body composition 
assessment methods in cancer research. The decision to use CT or DXA may be dependent 
on the patient outcome of interest, such as survival or physical functioning, as well as 
practical considerations. Thoracic CT scans are performed routinely in patients with 
MPM, and researchers can access scans for retrospective analysis, which can be valuable 
as prospective research could take many years to complete given the low prevalence of 
disease and challenges of performing DXA scans in unwell patients with MPM.2 
Considering cut-points for the classification of low muscle mass are subjective, future 
research in MPM should use continuous data to evaluate the relationship between muscle 
and patient outcomes. 
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Abstract 
Background/Objectives: Malignant pleural mesothelioma (MPM) is an incurable cancer 
and optimizing daily physical activity and quality-of-life are key goals of patient 
management. Little is known about the prevalence of pre-sarcopenia and malnutrition in 
MPM or their associations with patient outcomes. This study aimed to determine the 
prevalence of pre-sarcopenia and malnutrition in MPM and investigate if activity levels 
and quality-of-life differed according to body composition and nutritional status. 
Subjects/Methods: Patients with a diagnosis of MPM were recruited. Pre-sarcopenia was 
defined as low appendicular skeletal muscle mass (≤7.26 kg/m2 for men and ≤5.45 kg/m2 
for women), measured by Dual Energy X-Ray Absorptiometry. Malnutrition was defined 
as a rating of B or C on the Patient-Generated Subjective Global Assessment. Outcome 
measures included objective activity levels (Actigraph GT3X) and health-related quality-
of-life (HRQoL; Functional Assessment of Cancer Therapy General). 
Results: Sixty-one people participated (79% male, median age 69 [IQR 62-74] years and 
median BMI 25.8 [IQR 24.3-28.4] kg/m2). Fifty-four percent were pre-sarcopenic and 
38% were malnourished. Percent of time spent in light activity/day was lower in 
participants with pre-sarcopenia compared with non-sarcopenic participants (median 25.4 
[IQR 19.8–32.1]% vs. 32.3 [27.1–35.6]%; p=0.008). Participants with malnutrition had 
poorer HRQoL than well-nourished participants (mean 69.0(16.3) vs. 84.4(13.3); 
p<0.001). 
Conclusion: Participants with MPM had high rates of pre-sarcopenia and malnutrition. 
Pre-sarcopenia was associated with poorer activity levels, whilst malnutrition was 
associated with poorer quality-of-life. Interventions that aim to address reduced muscle 
mass and weight loss, should be tested in MPM to assess their impact on patient outcomes. 
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5.1 Introduction 
Malignant pleural mesothelioma (MPM) is an incurable cancer that develops 
primarily as a result of exposure to asbestos.1 MPM is distinctly different from advanced 
lung cancer given the longer median survival of 9 – 12 months,2 localized nature of the 
disease 3 and lack of clarity surrounding cause of death.3 Standard treatment for MPM is 
chemotherapy, which offers a modest survival benefit.4, 5 Given the palliative nature of 
management of MPM, optimizing and maintaining daily physical activity and quality-of-
life are primary goals of treatment. As weight loss has been identified as an independent 
predictor of poor survival in people with MPM,2 body composition and nutritional status 
could be integral to optimal supportive care for those with MPM. 
While weight loss is commonly noted in MPM, the prevalence of malnutrition has 
not been reported and no body composition analyses are available. Low muscle mass and 
malnutrition can exist in people who are not underweight,6-8 making it challenging for 
clinicians to identify. If undetected, patients with low muscle mass and malnutrition are 
unlikely to receive timely treatment to address these conditions. 
The implications of low muscle mass and malnutrition on patient-centred outcomes 
have not been studied in MPM. In patients with advanced cancers, low muscle mass9, 10 
and weight loss, or malnutrition,11-16 have been associated with poorer quality-of-life. 
However, none have examined the associations between body composition and nutritional 
status and daily physical activity. Given that management of MPM is of palliative intent, 
understanding how modifiable factors, such as muscle mass and nutritional status, 
influence health-related quality-of-life and patients’ ability to take part in daily activities 
is critical for planning interventions to improve supportive care in MPM. 
In cancer populations, reduced muscle mass and malnutrition are conditions with a 
complicated etiology that could be impacted by dietary intake as well as systemic 
inflammation.17 Weight loss can occur in those with adequate energy intakes, suggesting 
that factors beyond dietary intake influence weight loss.18 Inflammatory cytokines and 
many other molecules have been associated with the pathobiology of low muscle mass 
and malnutrition in cancer patients.19-24 Knowledge regarding dietary intake and 
inflammatory profile is therefore essential for guiding the development of interventions to 
address low muscle mass and malnutrition in MPM. 
The primary aim of this study was to determine the prevalence of low muscle mass 
and malnutrition in patients with MPM. Secondly, we aimed to investigate if there were 
differences in activity levels, health-related quality-of-life, dietary intake and serum 
biomarkers according to body composition and nutritional status. 
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5.2 Materials and methods 
5.2.1 Participants 
Recruitment took place between August 2015 and May 2017 from a tertiary specialist 
pleural disease and medical oncology clinic in Western Australia (WA), which has one of 
the highest incidences of MPM per capita in the world.25 Patients were eligible if they had 
cytological or histological confirmation of MPM. Patients were excluded if they were aged 
<18 years, pregnant or lactating, unable to read and understand English, unable to obtain 
physician consent, or unable to give informed consent or comply with the protocol. 
5.2.2 Study design and setting 
The study was a cross-sectional analysis of the baseline data collected from two 
prospective studies. The studies were 1) a longitudinal observational study of nutritional 
status and body composition and participants were followed until death or for up to 18 
months and 2) a 6-week progressive resistance exercise intervention. Both were pilot 
studies, designed to provide data for proof of concept and no sample size calculation was 
performed. The studies were approved by the Sir Charles Gairdner Group and Edith 
Cowan University Human Research Ethics Committees (ID: 2014-124 and 13255). 
5.2.3 Measures 
Demographic and medical variables 
Participants’ medical records were reviewed for baseline demographic and medical 
data. Physician-rated Eastern Cooperative Oncology Group (ECOG) performance status26 
was recorded on the date of assessment. 
Anthropometric measures 
Weight and height, measured with participants dressed in light clothing with shoes 
removed, were used to calculate the body mass index (BMI).  Participants were classified 
as underweight, normal weight, overweight or obese based on World Health Organization 
(WHO) BMI criteria.27 
Body composition 
Body composition was assessed using whole body dual-energy x-ray absorptiometry 
(DXA) scans (Hologic Discovery A, Hologic Inc., Marlborough, MA, USA). Low skeletal 
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muscle mass was defined as an appendicular skeletal muscle mass/height2 of ≤7.26 kg/m2 
for males and ≤5.45 kg/m2 for females.28 The cut-points for appendicular skeletal muscle 
mass were set as two standard deviations below the mean of a reference sample of young 
Caucasian adults, and are associated with physical disability in older adults.28 Participants 
with low skeletal muscle mass were categorized as pre-sarcopenic, consistent with the 
European Working Group on Sarcopenia in Older People diagnosis criteria.29 Gait speed 
was not measured in the study and as it is an essential criteria for the classification of 
sarcopenia and severe sarcopenia, we could not further categorize participants as 
sarcopenic or severely sarcopenic.29 
Nutritional status 
Nutritional status was assessed using the Patient-Generated Subjective Global 
Assessment (PG-SGA).30 Participants were categorized with a global rating of A – well 
nourished, B – suspected malnutrition/malnutrition or C – severe malnutrition. 
Malnutrition was defined as a rating of B or C on the PG-SGA. As the PG-SGA categories 
of B and C both represent participants with malnutrition, the two categories were 
amalgamated for statistical analysis. 
Accelerometer-measured activity levels 
Physical activity and sedentary behavior were objectively assessed using the 
ActiGraph GT3X+ accelerometer (Actigraph, Pensacola, FL, USA). Participants were 
instructed to wear the accelerometer on their hip continuously (24hr/day) for 3 days, to 
only remove for bathing or swimming and to record any non-wear time in a logbook. 
Common cut off points were used to classify sedentary time, light activity and moderate 
and vigorous physical activity (MVPA).31, 32 Variables were calculated per day and then 
averaged across all valid days for each participant. Additional accelerometer data 
collection and analysis methodology is presented in Supplementary Table 5.3. 
Patient-rated outcomes 
Participants completed validated questionnaires to assess cancer specific health-
related quality-of-life (HRQoL, Functional Assessment of Cancer Therapy – General; 
FACT-G),33 general health-related quality-of-life (Short Form – 36 (SF-36)),34 appetite 
(Anorexia Cachexia Scale; ACS)35 and fatigue (Functional Assessment of Chronic Illness 
Therapy – Fatigue; FACIT-Fatigue).36 A score of ≤37 on the ACS indicates poor appetite 
and a score of ≤34 on the FACIT-fatigue indicates clinically meaningful fatigue.37, 38 
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Dietary intake 
Dietary intake was measured prospectively, using an estimated food record over three 
consecutive days. Written and verbal instructions were provided to participants, 
explaining how to complete the food record and accurately estimate portion sizes using 
household measures (e.g. measuring cups and spoons). Returned food records were 
visually inspected by the researchers and incomplete details were clarified with 
participants. The food records were then analyzed using Foodworks 8 software (Xyris 
Software Pty Ltd, Australia). Intake variables were calculated per day and averaged across 
three days for each participant. Energy and protein intake were expressed as kJ or g per 
kg of body weight per day. Participants consuming ≥105 kJ/kg/day (1 kcal = 4.186 kJ) or 
≥1.0 g/kg/day were classified as meeting energy or protein requirements, respectively.39 
Participant self-reported changes in dietary intake over the previous month were extracted 
from the PG-SGA. 
Serum biomarkers 
A blood sample was taken for biomarker analysis. Enzyme linked immunosorbent 
assay (ELISA) kits was used to measure serum levels of interleukin-6 (IL-6, pg/mL), 
insulin-like growth factor-1 (IGF-1, ng/mL), ghrelin (ng/mL), leptin (ng/mL), myostatin 
(ng/mL), adiponectin (mg/L), vascular endothelial growth factors-A (VEGF-A, pg/mL) 
and C (VEGF-C, ng/mL), tumor necrosis factor-alpha (TNF-α, pg/mL) and interferon-
gamma (IFN-γ, pg/mL). ELISA kit manufacturer information is presented in 
(Supplementary Table 5.4). Serum samples of each patient were assayed in duplicates in 
the same assay. Concentrations of serum CRP (mg/L) and albumin (g/L) measured as part 
of standard clinical care were obtained from the hospital records. 
5.2.4 Statistical analyses 
Statistical analyses were conducted using Statistical Package for the Social Sciences 
(v. 23, IBM Corporation, Somers, NY, USA). Data were expressed as mean (SD) or 
median [IQR] where the data were not normally distributed. Two-tailed independent t-
tests, or the Mann-Whitney test where the data were not normally distributed, were used 
to test for differences in activity levels, quality-of-life, appetite, fatigue, dietary intake and 
serum biomarkers between body composition and nutritional status groups. The Chi-
Squared test was used to test for associations between body composition and nutritional 
status and meeting dietary recommendations and self-reported changes in dietary intake. 
A p-level of <0.05 was considered statistically significant. 




Sixty-one participants enrolled in the study (Figure 5.1). Participants were 
predominantly male (79%), with a median age of 69 years, and were enrolled a median 2 
months from diagnosis. Forty-three (71%) participants had the epithelioid subtype of 
MPM and 56 (92%) participants had an ECOG performance status of 0-1. On average 
patients were overweight (median BMI was 25.8 kg/m2): no participants were 
underweight, 41% were in the normal weight range, 44% were overweight and 15% were 
obese. Demographic and medical characteristics are presented in Table 5.1. 
5.3.2 Prevalence of pre-sarcopenia and malnutrition 
Fifty-three participants completed a DXA scan. Of those, 28 (54%) had pre-
sarcopenia. All participants completed the PGSGA, of those 23 (38%) participants were 
classified as malnourished. Half (54%) of participants with pre-sarcopenia were 
malnourished. The pre-sarcopenic and malnourished participants are presented according 
to their BMI category and nutritional status or body composition group in Figure 5.2. 
Differences in characteristics between body composition and nutritional status groups and 
participants with and without DXA scans are presented in Supplementary Table 5.5 and 
Supplementary Table 5.6, respectively. 
5.3.3 Differences in activity levels, HRQoL, dietary intake and serum 
biomarkers according to body composition 
Activity levels 
Participants with pre-sarcopenia spent a lower proportion of their awake time per day 
in light activity (median 25.4 [IQR 19.8 – 32.1]% vs. 32.3 [27.1 – 35.6]%; p=0.008) and 
a higher proportion as sedentary (mean 72.8 (9.3)% vs. 63.5 (9.0)%; p=0.001), compared 
to non-sarcopenic participants. There was also a significant difference in MVPA time 
between the two groups (median 0.7 [IQR 0.2 – 2.1]%; vs. 2.9 [0.8 – 4.0]%; p=0.005). 
Participants with pre-sarcopenia also completed fewer bouts of light activity of 20 to <30 
minutes duration (median 0.0 [IQR 0.0 – 0.3] vs. 0.3 [0.0 – 1.0]; p=0.010), 10 to <20 
minutes duration (median 1.0 [IQR 0.7 – 2.8] vs. 3.7 [2.3 – 5.7]; p=0.004) and of 5 to <10 
minutes duration (median 9.0 [IQR 5.9 – 11.8] vs. 12.7 [11.0 – 15.0]; p=0.002), compared 
Chapter Five.  Body Composition and Nutritional Status in Malignant Pleural Mesothelioma 
124 
to non-sarcopenic participants (Figure 5.3). The majority of participants (67%) recorded 
no light activity in bouts ≥30 minutes therefore, statistical analysis was not performed. 
HRQoL, fatigue and appetite 
Between pre-sarcopenic and non-sarcopenic participants, there were no statistically 
significant differences in cancer specific HRQoL (mean 78.5 (15.8) vs. 82.2 (14.0); 
p=0.414), fatigue (median 35.0 [IQR 28.0 – 47.0] vs. 41.0 [IQR 33.5 – 46.5]; p=0.290), 
or any of the domains for general HRQoL (p≥0.073, Figure 5.4). Appetite scores were 
significantly poorer in pre-sarcopenic participants compared with non-sarcopenic 
participants (median 37.0 [IQR 29.0 – 42.0] vs. 42.5 [38.8 – 44.3]; p=0.014). 
Dietary intake 
Pre-sarcopenic and non-sarcopenic participants did not differ significantly in their 
energy or protein intake (median 125 [IQR 93.2 – 138.2] kJ/kg/day vs. 128 [87.2 – 141.0] 
kJ/kg/day; p=0.975 and mean 1.4 (0.4) g/kg/day vs. 1.3 (0.5) g/kg/day; p=0.504]). There 
was no difference between body composition groups with regard to the proportion of 
participants meeting energy (p=0.606) or protein requirements (p=0.404). The proportion 
of participants who reported a decrease from their usual intake in the past month did not 
differ significantly between pre-sarcopenic and non-sarcopenic participants (57.1% vs. 
33.3%; p=0.086). Of the twelve participants taking high protein supplements, seven had a 
DXA scan, of whom 86% (n=6) were pre-sarcopenic. 
Serum biomarkers 
Differences in serum biomarkers according to body composition group are presented 
in Table 5.2. Among the cytokines analyzed, only IL-6 levels were higher in pre-
sarcopenic compared with non-sarcopenic participants (p=0.006). Between pre-sarcopenic 
and non-sarcopenic participants, there were no differences in levels of myostatin 
(p=0.085), albumin concentration (p=0.143) or any other measured serum biomarkers. 
5.3.4 Differences in activity levels, HRQoL, dietary intake and serum 
biomarkers according to nutritional status 
Activity levels 
Malnourished and well-nourished participants did not differ in the proportion of time 
per day spent in light activity (median 26.6 [IQR 21.2 – 34.8]% vs. 29.7 [24.0 – 34.6]%; 
p=0.380) or as sedentary (median 72.5 [IQR 65.0 – 78.7]% vs. 68.4 [62.8 – 73.0]%; 
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p=0.208). There was a significant difference in MVPA between malnourished and well-
nourished participants (median 0.6 [IQR 0.2 – 1.3]% vs. 1.6 [0.6 – 3.5]%; p=0.013). There 
were no significant differences between the two groups for light activity of 20 to <30 
minutes, 10 to <20 minutes or 5 to <10 minutes [median 0.0 [IQR 0.0 – 0.7] vs. 0.3 [0.0 – 
0.7]; p=0.267, median 1.0 [IQR 0.7 – 3.7] vs. 2.7 [1.3 – 4.3]; p=0.075, median 10.0 [IQR 
5.5 – 13.0] vs. 11.3 [8.3 – 13.7]; p=0.189, respectively] (Figure 5.3). The majority of 
participants (72%) recorded no light activity in bouts ≥30 minutes therefore, statistical 
analysis was not performed. 
HRQoL, fatigue and appetite 
Compared with well-nourished participants, malnourished participants scored lower 
for cancer specific HRQoL (mean 69.0 (16.3) vs. 84.4 (13.3); p<0.001) and fatigue (mean 
27.4 (12.0) vs. 40.2 (8.9); p<0.001), as well as on all general HRQoL domains (p≤0.041), 
with the exception of role emotional and mental health (p=0.075 and p=0.124, 
respectively; Figure 5.4). Appetite scores were significantly poorer in malnourished 
participants compared with well-nourished participants (median 29.0 [IQR 19.0 – 36.0] 
vs. 41.0 [36.8 – 44.3]; p<0.001). 
Dietary intake 
There was no difference in energy or protein intake between malnourished and well-
nourished participants (median 110 [IQR 86.7 – 132.0] kJ/kg/day vs. 128 [93.4 – 140.4] 
kJ/kg/day; p=0.182 and mean 1.3 (0.4) g/kg/day vs. 1.4 (0.5) g/kg/day; p=0.521) or in the 
proportion of participants meeting energy (p=0.388) or protein requirements (p=0.814). 
The proportion of participants who reported a decrease from their usual intake in the past 
month was significantly higher in malnourished compared with well-nourished 
participants (91.3% vs. 26.3%; p<0.001). Ninety percent (n=11) of those consuming high 
energy, high protein nutrition supplements were malnourished. 
Serum biomarkers 
Differences in serum biomarkers according nutritional status are presented in Table 
5.2. Among the cytokines, IL-6 and was higher and myostatin was lower for 
malnourished compared with well-nourished participants (p=0.002 and p=0.032, 
respectively). Compared with well-nourished participants, malnourished participants had 
a lower albumin concentration (p=0.004). There were no differences in any other 
measured serum biomarkers. 
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Table 5.1 Demographic and medical characteristics of participants, n=61 
n % 
Age, years 69.0^ 62.0-74.0^ 
Gender, male 48 78.7 
BMI, kg/m2 25.8^ 24.3-28.4^ 
BMI category 
Underweight 











Time since diagnosis, months 2.0^ 1.0-9.0^ 



























Received cancer treatment prior to study, yes 21 34.4 




Surgery and radiotherapy 
Chemotherapy & radiotherapy 
















Undergoing cancer treatment at the time of study, yes 9 14.8 
Type of ongoing treatment 
Cisplatin and Pemetrexed 
Carboplatin and Pemetrexed 
Vinorelbine 
Clinical trial – AZD4547 
Clinical trial – Cisplatin, Pemetrexed and Nintedanib 
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n % 



















Side of pleural effusion, right 41 67.2 




























Ischemic heart disease 
Atrial fibrillation 
Type 2 diabetes 
COPD 
Osteoarthritis 






















18.0 – 23.0^ 
6.2 – 7.5^ 







Self-reported weight loss in 6 months, % 2.6 0.0 – 7.0 










Nutritional status, PG-SGA 
A – well nourished 
B – suspected malnutrition/moderately malnourished 
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n % 






91 – 140^ 







Energy and protein requirements (n=56) 
Energy requirement met 
Protein requirements met 







Consumed nutritional supplements (n=56) 12 21.4 
Poor appetite□ (n=53) 23 43.4 
Fatigued■ (n=52) 21 40.4 
^Median, interquartile range; Last treatment prior to date of assessment; □Score ≤37 on Anorexia 
Cachexia Scale, ■Score ≤34 on Functional Assessment of Chronic Illness Therapy – Fatigue Scale; BMI – 
Body mass index; IPC – indwelling pleural catheter; ICC – intercostal catheter; VATS – video-assisted 
thoracoscopic surgery; ECOG – Eastern Cooperative Oncology Group; COPD – chronic obstructive 
pulmonary disease; DXA – Dual Energy X-ray Absorptiometry; PG-SGA – Patient-Generated Subjective 
Global Assessment 
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Table 5.2 Inflammatory markers and cytokines according to body composition and nutritional status 
All participants 
(n=57) 








(n=22) P value 
IL-6, pg/mL 5.3 (2.0-13.5) 2.5 (2.0-7.9) 6.5 (3.1-18.3) 0.006* 2.6 (2.0-7.9) 11.0 (4.7-18.8) 0.002* 
IGF-1, ng/mL 9.1 (3.4-15.0) 7.1 (1.6-10.8) 9.9 (5.3-15.0) 0.179 7.1 (2.0-14.0) 11.3 (6.4-17.4) 0.090 
Ghrelin, ng/mL 0.38 (0.15-0.75) 0.28 (0.09-0.59) 0.34 (0.14-0.94) 0.255 0.38 (0.09-0.63) 0.39 (0.23-0.88) 0.294 
Leptin, ng/mL 5.1 (4.0-7.4) 5.7 (3.9-7.8) 5.2 (4.0-7.2) 0.869 5.1 (4.1-7.0) 5.2 (3.9-8.4) 0.896 
Myostatin, ng/mL 1.3 (0.9-1.8) 1.7 (1.0-1.9) 1.2 (0.8-1.8) 0.085 1.6 (1.1-1.9) 1.1 (0.7-1.8) 0.032* 
Adiponectin, mg/L 3.5 (1.9-6.3) 3.2 (0.9-4.6) 4.0 (2.3-6.5) 0.127 3.3 (2.5-5.7) 3.8 (0.0-6.6) 0.935 
VEGF-A, pg/mL 0.29 (0.13-0.57) 0.27 (0.13-0.46) 0.30 (0.13-0.64) 0.704 0.33 (0.13-0.59) 0.21 (0.13-0.53) 0.768 
VEGF-C, ng/mL 22.7 (16.0-26.7) 23.1 (20.4-31.6) 22.7 (15.4-23.9) 0.216 23.1 (17.0-28.0) 18.5 (13.2-23.9) 0.127 
Albumin, g/L (n=55) 40.0 (37.0 – 42.0) 40.0 (38.0-43.0) 39.5 (36.0-41.0) 0.167 40.0 (38.5-42.0) 37.0 (34.8-41.0) 0.005* 
CRP, mg/L (n=46) 19.5 (6.5-70.3) 13.0 (2.1-49.0) 27.0 (7.1-98.0) 0.122 19.0 (3.2-60.5) 35.0 (6.7-84.0) 0.516 
Data is presented as median (interquartile range); *p<0.05; IL-6 – Interleukin-6; IGF-1 – Insulin-like Growth Factor-1; VEGF – Vascular Endothelial Growth Factor 
TNF-α and IFN-γ levels were undetectable in 89.7% (n=52) and 74.1% (n=43) of samples, respectively, and statistical analyses were not performed. 
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• Not eligible (n=7) 
• Too unwell (Physician) (n=4) 
• Cognitive impairment (n=1) 
• Unable to comply with study protocol (n=2) 
• Declined (n=51) 
• Too unwell (n=l6) 
• Not interested (n= 13) 
• Too much time commitment (n=6) 
• Overwhelmed (n=6) 
• Lives too far away (n=4) 
• Unable to contact (n=2) 
• Other reasons (n=4) 
Recruited (n=6 l) 
• PG-SGA (n=61) 
• Blood samples (n=57) 
• Not completed (n=4) 
• Questionnaire (n=54) 
• Not returned (n=4) 
• Not completed (n=3) 
• Accelerometer (n=54) 
• Declined (n=l) 
• Not returned (n=2) 
• Not worn or worn incorrectly (n=4) 
• DXA (n=52) 
• Machine error (n=2) 
• Declined, time constraints (n=2), too unwell (n=5) 
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Figure 5.2 Pre-sarcopenic and malnourished participants. a) Pre-sarcopenic and malnourished participants according to BMI category (n=23 and 
n=28, respectively), b) pre-sarcopenic participants according to nutritional status (n=28), and c) malnourished participants according to 
body composition group (n=17) 
a) b) c) 
100% 100% 100% 
90% 90% 90% 
80% 80% 80% 
70% 9 70% 70% 
60% 9 60% 60% Obese Pre-sarcopenic 
50% a Overweight 50% 50% Malnourished 
Normal weight 15 Normal muscle Well-nourished 40% 40% mass 40% 
30% 16 30% 30% 
10 20% 20% 13 20% 
10% 10% 10% 
0% 0% 0% 
Pre-sarcopenic Malnourished Malnourished Pre.sarcopenic 
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Figure 5.3 Differences in the number of bouts of light activity according to a) body composition (n=48) and b) nutritional status (n=54),*p<0.05 
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Figure 5.4 Median scores for the general health-related quality of life domains according to a) body composition (n=46) and 
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5.4 Discussion 
Our study found high rates of pre-sarcopenia (54%) and malnutrition (38%). 
Compared to data from healthy older adults, we report a much higher prevalence of these 
conditions in MPM.40, 41 This result is particularly striking because none of the participants 
were underweight, the large majority had a good performance status and were early in 
their diagnosis. Consistent with population trends, a high proportion of cancer patients are 
overweight or obese.42 In our study, two thirds of participants were overweight or obese 
and had similar rates of pre-sarcopenia and malnutrition compared with those in the 
normal weight category. Studies in other cancer populations have reported reduced muscle 
mass6 and malnutrition7, 8 across all weight categories and in those with good performance 
status.43 These results highlight that pre-sarcopenia and malnutrition are common in MPM 
patients where clinicians might not expect, for example, newly diagnosed, overweight and 
obese patients of a good performance status. 
Pre-sarcopenic participants spent significantly less time per day in light activity, and 
did fewer bouts of longer periods of light activity (>5 min), compared with non-sarcopenic 
patients. Self-reported fatigue and physical functioning were not lower in participants with 
pre-sarcopenia which raises the possibility that habitually low levels of physical activity 
may have contributed to reduced muscle mass. However, people with reduced muscle 
mass need to work closer to their maximum capacity to generate the necessary strength 
and power to complete activities of daily living. Therefore, reduced muscle mass could 
result in increased fatigue and compensatory reductions in activity levels. Further research 
is required to determine if interventions which enhance muscle mass, could improve 
participation in daily physical activity for patients with MPM. 
We observed a significant inverse association between malnutrition and quality-of-
life, in particular poorer self-rated physical functioning, which supports work in other 
cancer survivor populations.11, 14, 15 However, the relationship between malnutrition and 
quality-of-life is complex, particularly as malnourished participants had higher IL-6 
concentrations and fatigue levels which could be indicative of greater disease burden.44 
While patients with MPM can maintain quality of life with chemotherapy,45 there are 
limited effective treatments available.5 For patients who do not respond to treatment, 
supportive care strategies could offer some benefit. An important next step will be to test 
interventions to address malnutrition in MPM to determine their impact on quality-of-life. 
Notably, nutritional interventions consisting of dietary counseling and oral nutrition 
supplements alone, provided to patients with cancer receiving chemotherapy or 
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radiotherapy, have had no impact on quality-of-life.46 This suggests that interventions may 
need to do more than increase dietary intake or weight to impact on quality-of-life. 
Interventions which also address the psychosocial aspects of eating may be an integral part 
of optimizing quality-of-life in patients with MPM.47 
Overall energy and protein intake did not differ between nutritional status or body 
composition groups. High rates of reported nutrition supplement consumption amongst 
malnourished participants suggest that participants may have already made changes to 
their diet to address malnutrition. These results indicate malnourished patients with MPM 
can meet their recommended energy and protein intake with nutrition support. Although, 
given the higher IL-6 concentrations amongst participants with malnutrition and pre-
sarcopenia, these conditions may not be resolved without addressing the underlying 
inflammation.17 Anti-inflammatory agents (e.g., eicosapentanoic acid or non-steroidal 
anti-inflammatory drugs) have the potential to offer some benefit but are yet to be tested 
in MPM and may be contraindicated for patients receiving active cancer treatment.17 
There are several limitations to the current study. The study is cross-sectional and 
therefore cannot draw causative conclusions. The study has a small sample size and was 
underpowered to detect differences in quality-of-life scores, as demonstrated by the 
clinically meaningful differences between body composition groups that were not 
statistically significant (e.g., a 6-point median difference in the vitality domain of quality-
of-life; Figure 4a). However, a larger, retrospective study of patients with advanced lung 
cancer (n=734) has reported a significant association between skeletal muscle and 
quality-of-life.10 
There is also heterogeneity in the sample with regard to time from diagnosis and 
treatments received. One of the most common reasons for non-inclusion in the study was 
being too unwell. Therefore, this study possibly included patients who were in better 
health, as indicated by longer the median survival of our sample, and may not be 
representative of the larger MPM population. Additionally, we were unable to obtain body 
composition data for 15% of participants and being too unwell was the most common 
reason for not completing a DXA (Figure 5.1). Compared with participants who 
completed a DXA, participants without a DXA were significantly older, and had a poorer 
appetite. This data suggests that in cancer patients who are older with significant 
symptoms, body composition analysis techniques that do not add to participant burden e.g. 
computed tomography scan analysis, could be more feasible. 
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Our study is the first to investigate body composition and nutritional status 
specifically in patients with MPM and provides valuable information on the extent of pre-
sarcopenia and malnutrition in this population. Gold standard assessments were employed 
to comprehensively assess body composition, nutritional status, patient-rated outcomes 
and objective physical activity. We have included a relatively homogenous sample of 
patients with MPM. As MPM is a unique disease with a different disease process, 
prognosis and treatment options to advanced lung cancer, it is important that MPM is 
studied independently. 
5.5 Conclusion 
Despite good performance status and a normal or high BMI, participants with MPM 
had high rates of pre-sarcopenia and malnutrition. Both pre-sarcopenia and malnutrition 
were associated with negative outcomes for participants. For the first time in MPM, we 
report that pre-sarcopenia was associated with lower activity levels whilst malnutrition 
was associated with poorer quality-of-life. Interventions that aim to address reduced 
muscle mass and weight loss, should be tested in MPM to assess their impact on activity 
levels and quality-of-life. 
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Supplementary Tables 
Supplementary Table 5.3 Accelerometer data collection and analysis methods 
Paradata Method 
Raw data collection Accelerometers were programmed to record raw data at a 
frequency of 30 Hz. 
Epoch length Data were reduced to vertical axis movement counts per 60-second 
epoch. 
Software used Accelerometer data were downloaded and processed in Statistical 
Analysis Software (version 9.3, SAS Institute, Cary, NC, USA). 
Non-wear time Waking wear time was determined by visual inspection by a 
trained rater and an automated algorithm.1 
Minimum wear time  A valid day was classified as ≥10-hours of waking wear time. 
Minimum valid days Participants with at least one valid day of data were analyzed. 
Reference in table 
1. McVeigh JA, Winkler EA, Healy GN, Slater J, Eastwood PR, Straker LM. Validity of an automated
algorithm to identify waking and in-bed wear time in hip-worn accelerometer data collected with a 24 h
wear protocol in young adults. Physiol Meas. 2016;37(10):1636-1652. doi:10.1088/0967-3334/37/10/1636
Supplementary Table 5.4  Manufacturer information for ELISA kits used in serum 
biomarker analysis 
Biomarker ELISA kit manufacturer 
Interleukin-6 Thermo Fisher Scientific, Waltham, MA, USA 
Insulin-like growth factor elisakit.com, Melbourne, Australia 
Ghrelin Thermo Fisher Scientific, Waltham, MA, USA 
Leptin eBioscience Inc., San Diego, CA, USA 
Myostatin R&D Systems Inc., Minneapolis, MN, USA 
Adiponectin R&D Systems Inc., Minneapolis, MN, USA 
Vascular endothelial growth factor-A R&D Systems Inc., Minneapolis, MN, USA 
Vascular endothelial growth factor-C R&D Systems Inc., Minneapolis, MN, USA 
Tumor necrosis factor-alpha Thermo Fisher Scientific, Waltham, MA, USA 
Interferon-gamma Thermo Fisher Scientific, Waltham, MA, USA 
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Supplementary Table 5.5 Differences in demographic and medical characteristics according to body composition and nutritional status 
Body composition Nutritional status 
Non-sarcopenic (n=24) Pre-sarcopenic (n=28) 
p value 
Well-nourished (n=38) Malnourished (n=23) 
p value n % n % n % n % 
Age, years 65.0 59.0–70.0^ 69.0 62.5–74.0^ 0.042* 67.0 61.5–74.0^ 70.0 67.0–74.0^ 0.171 
Gender, male 19 79.2 22 78.6 0.958 31 81.6 17 73.9 0.479 
BMI, kg/m2 26.4 25.0– 29.7^ 24.6 23.5–27.2^ 0.012* 25.8 24.6–28.2^ 25.4 23.7–28.7^ 0.592 
BMI category 
Underweight 
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 Body composition Nutritional status 
 Non-sarcopenic (n=24) Pre-sarcopenic (n=28) 
p value 
Well-nourished (n=38) Malnourished (n=23) 
p value  n % n % n % n % 































Received treatment prior  
to study, yes 
8 33.3 9 32.1 0.927 13 34.2 8 34.8 0.964 











































































Grade of pleural effusion (n=52)* 
0 – 2 





























Side of pleural effusion, right 
(n=52) 
15  62.5 21  75.0 0.446 25  65.8 16  69.6 0.872 
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Body composition Nutritional status 
Non-sarcopenic (n=24) Pre-sarcopenic (n=28) 
p value 
Well-nourished (n=38) Malnourished (n=23) 
p value n % n % n % n % 












































































Ischemic heart disease 
Atrial fibrillation 
Type 2 diabetes 
COPD 
Osteoarthritis 
Hip or knee replacement 









































































^Median, interquartile range; Last treatment prior to date of assessment; BMI – Body mass index; IPC – indwelling pleural catheter; ICC – intercostal catheter; VATS – video-assisted 
thoracoscopic surgery; ECOG – Eastern Cooperative Oncology Group; COPD – chronic obstructive pulmonary disease; *statistical comparisons not carried out 
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Supplementary Table 5.6 Differences in demographic and medical characteristics 
between participants with and without DXA scans, n=61 
DXA available (n=52) DXA missing (n=9) 
p value n % n % 
Age, years 68.0^ 62.0-74.0^ 73.0^ 69.5-78.0^ 0.026* 
Gender, male 41 78.8 7 77.8 0.942 
BMI, kg/m2 25.8^ 24.1-28.5^ 25.4^ 24.8-28.9^ 0.745 
Time since diagnosis, months 2.0^ 1.0-9.8^ 2.0^ 1.0-5.0^ 0.483 












Received treatment prior to 
study, yes 
17 32.7 4 44.4 0.493 
Side of effusion, right (n=60) 36 70.6 5 55.6 0.371 





















































PG-SGA global rating 
A – well-nourished 
B – suspected malnutrition or 
malnourished 
































Poor appetite (n=53) 15 33.3 8 100.0 <0.001* 
FACT-G (n=53) 80.3# 14.9# 70.9 21.3 0.132 
^Median, interquartile range; #mean ± SD, *p<0.05; Last treatment prior to date of assessment; IPC – 
indwelling pleural catheter; PG-SGA – Patient-Generated Subjective Global Assessment, FACT-G – 
Functional Assessment of Cancer Therapy - General 
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Abstract 
Context: There is little information on the functional and nutritional characteristics of 
patients with malignant pleural mesothelioma (MPM). 
Objectives: To report the prevalence of functional and nutritional impairment across the 
2-years following diagnosis of MPM and to describe functional and nutritional status over
time. 
Methods: This was a prospective observational study and participants were followed for 
up to 18-months. Functional data were collected using the: Short-Form Health Survey (SF-
36) – physical functioning domain and Timed Up and Go (TUG). Nutritional data were
collected using the: Anorexia Cachexia Scale (ACS) and Patient-Generated Subjective 
Global Assessment (PG-SGA). Two analyses were performed: the prevalence of 
impairment at six time intervals within 2-years of diagnosis and status over time in 
participants with ≥2 assessments. 
Results: Thirty-six patients with MPM were enrolled (mean age 69.7±7.3 years, 81% 
male, median survival 17.5 [IQR 10.3–29.3] months). Across all time intervals within 2-
years of diagnosis, 57-75% of participants had poor SF-36 physical functioning, 50-88% 
had a poor TUG result, 56-71% had a poor appetite and 18-38% had a high need for 
nutrition support. Of the participants studied longitudinally (n=25), 52% had poor SF-36 
physical functioning, 69% had a poor TUG result, 69% had a poor appetite and 36% had 
a high need for nutrition support at ≥2 assessments. 
Conclusion: In patients with MPM, functional and nutritional impairment was common. 
For many participants, impairments persisted or reoccurred during follow-up. Screening 
for functional and nutritional impairment is recommended from diagnosis to identify those 
that could benefit from supportive care interventions. 
Key message statement: This article describes a prospective observational study that 
provides new information about the functional and nutritional characteristics of patients 
with MPM, and indicates that functional and nutritional impairments are prevalent across 
the 2-years from diagnosis and commonly persist or reoccur over time. 
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6.1 Introduction 
Malignant pleural mesothelioma (MPM) is a universally fatal cancer attributed to 
asbestos exposure.1 Given the incurable nature of the disease and short median survival of 
12 months,2 the care of patients with MPM is primarily aimed at optimising quality-of-life. 
The ability to perform usual daily life activities is a core component of quality-of-
life.3 Additionally, malnutrition is associated with poorer quality-of-life in patients with 
thoracic cancer.4-6 However, currently there is no comprehensive description of the 
functional and nutritional characteristics of this patient population. 
Existing research on physical functioning of patients with MPM is limited to those 
who have undergone pleurectomy or decortication,7 which represents a small select 
proportion of patients with MPM. Information on nutritional status in MPM is limited to 
a cross-sectional analysis of patients assessed close to the time of diagnosis.8 Research in 
patients with lung cancer indicates physical functioning and nutritional status decline 
following diagnosis,9-11 suggesting supportive care needs are greater over time.9-11 
However, a greater understanding of the functional and nutritional characteristics of 
patients with MPM is needed as it is a predominantly localised disease,12 with a longer 
median survival,2 which could impact on physical functioning and nutritional outcomes. 
Therefore, the aim of our study was to report the prevalence of functional and nutritional 
impairment across the 2 years following diagnosis of MPM and to describe functional and 
nutritional status over time. 
6.2 Methods 
6.2.1 Participants 
Recruitment took place between August 2015 and March 2017 from a tertiary 
specialist pleural disease clinic in Western Australia (WA). Inclusion criteria for 
participation in the study were cytological or histological confirmation of MPM. Patients 
could enrol any time following MPM diagnosis. Patients were excluded from the study if 
they were aged <18 years, pregnant or lactating or unable to read and understand English, 
to give informed consent, or to comply with the protocol or participating in a concurrent 
exercise intervention study. Patient consent and physician approval were required for 
participation in the study. 
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6.2.2 Study design and setting 
In this prospective observational study, participants completed study assessments 
during routine hospital visits approximately every 3 months and were followed until death 
or for a maximum of 18 months. The study was approved by the Sir Charles Gairdner 
Group and Edith Cowan University Human Research Ethics Committees (ID: 2014-124 
and 13255). 
6.2.3 Measures 
Demographic and medical variables 
Participants’ medical records were reviewed for demographic and medical data. 
Self-reported physical functioning 
Self-reported physical functioning was assessed with the physical functioning domain 
of the Short-Form Health Survey (SF-36).3 Participants were classified as having a poor 
self-reported physical functioning if they had a norm-based score <45.3 
Objective physical functioning 
Objective physical functioning was assessed with the Timed Up and Go test.13 
Participants were instructed using a standard procedure to get out of a chair, walk 2.44 
meters, turn around a marker and return to sitting as quickly as possible. Participants 
completed three trials with a one minute rest between each test. All tests were timed using 
a stopwatch, with the best time used in the analysis. We applied the age and sex specific 
criterion-reference standards that are associated with maintaining physical independence in 
older adults, which range from 4.8 – 8.0 seconds for men and 5.0 – 8.0 seconds for 
women.14 Participants were classified as having poor objective physical functioning if they 
had a result that exceeded the criterion-reference standard range, i.e. greater than 8 seconds. 
Appetite 
Appetite status was assessed using the validated Anorexia Cachexia Scale (ACS).15 
Participants were classified as having a poor appetite if they had an ACS score ≤37.16 
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Nutritional status 
Nutritional status was assessed using the scored Patient-Generated Subjective Global 
Assessment (PG-SGA).17 Participants were classified as having a high need for symptom 
control and nutrition support if they had a PG-SGA score ≥9.17 
6.2.4 Statistical analysis 
Statistical analyses were conducted using the Statistical Package for the Social 
Sciences (v. 26, IBM Corporation, Somers, NY, USA). Data were expressed as mean ± 
SD or median [IQR] where the data were not normally distributed. To report on the 
prevalence of nutritional and functional impairment, data were allocated into six time 
intervals across the 2 years following diagnosis of MPM (Analysis 1). Participants with 
no assessments within 2 years of diagnosis were excluded from this analysis. The number 
of months between diagnosis and each participant assessment was calculated and 
participant data were then categorised into the corresponding time interval. Participants 
were included in multiple time intervals if they completed more than one assessment, 
however no participant was included in the same time interval twice. To provide a 
description of functional and nutritional status over time (Analysis 2), we examined 
outcomes longitudinally at five time intervals within the 18 months of study enrolment. 
Participants who did not complete ≥2 assessments were excluded from this analysis. The 
number of months between study enrolment and each participant assessment was 
calculated and participant data were then categorised into the corresponding time interval. 
Due to small numbers in each time interval, statistical tests were not used to compare 
differences in outcomes between time intervals. 
6.3 Results 
6.3.1 Participant characteristics 
Thirty-six participants with MPM enrolled in the study with 34 (94%) included in 
Analysis 1 and 25 (69%) in Analysis 2 (Figure 6.1). Participants were predominantly 
male (81%) with the epithelioid subtype of MPM (69%). The mean age of participants 
was 69.7 ± 7.3 years and median survival was 17.5 [IQR 10.3 – 29.3] months. 
Demographic and medical characteristics are presented in Table 6.1. 
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6.3.2 Analysis 1: Prevalence of functional and nutritional impairment 
between diagnosis and 2-years post-diagnosis 
Self-reported physical functioning 
At all time intervals, there was a consistently high proportion of participants with a poor 
physical functioning score on the SF-36. At diagnosis, 74% of participants had below 
average self-reported physical functioning and of these participants, 14% were receiving 
cancer treatment. At each of the remaining time intervals, 57 – 75% of participants reported 
the poor physical functioning and of these participants, 42 – 75% were receiving cancer 
treatment (Figure 6.2). 
Objective physical functioning 
At all time intervals, there was a consistently high proportion of participants with a 
poor result from the Timed Up and Go test. At diagnosis, 91% of participants had a poor 
Timed Up and Go result and of these participants, 10% were receiving cancer treatment. 
At each of the remaining time intervals, 50 – 88% of participants had a poor Timed Up and 
Go result and of these participants, 25 – 50% were receiving cancer treatment (Figure 6.2). 
Appetite 
At all time intervals, there was a consistently high proportion of participants with a 
low appetite score on the ACS. At diagnosis, 68% of participants had a poor appetite and 
of these participants, 31% were receiving cancer treatment. At each of the remaining time 
intervals, 56 –71% of participants had a poor appetite and of these participants, 25 – 80% 
were receiving cancer treatment (Figure 6.2). 
Nutritional status 
Diagnosis was the time interval where the greatest proportion of participants had a 
high PG-SGA score indicating a high need for symptom control and nutrition support. At 
diagnosis, 57% of participants had a high need for symptom control and nutrition support 
and of these participants, 23% were receiving cancer treatment. At each of the remaining 
time intervals, 18 – 38% of participants had a high need for symptom control and nutrition 
support and of these participants, 33 – 67% were receiving cancer treatment (Figure 6.2). 
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6.3.3 Analysis 2: Longitudinal description of functional and nutritional 
status between enrolment and 18 months 
Self-reported physical functioning 
Seventeen percent of participants had normal SF-36 physical functioning scores for 
the duration of follow-up. The remaining participants had poor SF-36 physical functioning 
scores at one (32%), two (16%) or three or more (36%) assessments (Figure 6.3). 
Objective physical functioning 
Seventeen percent of participants had normal Timed Up and Go results for the 
duration of follow-up. The remaining participants had poor Timed Up and Go results at 
one (13%), two (26%) or three or more (43%) assessments (Figure 6.3). 
Appetite 
Twenty-two percent of participants had a normal appetite score for the duration of 
follow-up. The remaining participants had a poor appetite at one (9%), two (30%) or three 
or more (39%) assessments (Figure 6.3). 
Nutritional status 
Thirty-two percent of participants did not have a high need for symptom control and 
nutrition support for the duration of follow-up. The remaining participants had a high need 
for symptom control and nutrition support at one (32%), two (32%) or three or more (4%) 
assessments (Figure 6.3). 
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Table 6.1 Participant characteristics 
All participants (n=36) 
n (%) 












Time since diagnosis 




















Ischemic heart disease 
Atrial fibrillation 
Type 2 diabetes 
COPD 
Osteoarthritis 
Hip or knee replacement 










Cancer treatment prior to study, yes 9 (25.7) 
Type of cancer treatment 
Chemotherapy 
Radiotherapy 
Chemotherapy and radiotherapy 






Cancer treatment during study, yes 22 (62.9) 
Type of cancer treatment 
Chemotherapy 
Radiotherapy 
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Figure 6.1 Participants included in the prospective observational study. 
Thirty-six participants were enrolled at baseline: 2 were excluded and the remaining participants included in Analysis 1 (n=34); 10 were lost to follow up and the remaining 24 were included 
in Analysis 2 plus 1 extra participant who was excluded from Analysis 1 but eligible for Analysis 2. 
Screened in Pleural Outpatient Clinic 
(=84) 
Excluded (48) 
Not eligible (r=18) 
Too unwell (Physician) (n=9) 
Enrolled in alternate study (rel) 
Cognitive impairment (ne) 
Unable to comply with the study protocol (n=2) 
Declined (n=30) 
Not interested (ne10) 
Too unwell (9) 
Overwhelmed (n=6) 
Too much time commitment (nee3) 
Unable to contact (=I) 
Other reasons (n=I) 
E rolled and completed baseline 
assessment (=36) 
Excluded (=2) 
Completed < study assessment within 2 
years of diagnosis 
ANALYSIS I(=34) 
Completed 2l study assessment within l 
years of diagnosis 
Lost to follow up (=10) ]Lost to follow p (=D) 
Deceased (n=7) l· hdrawn (nee1) 
No longer attending hospital (nee2) 
Wehdrawn (seep 
ANALYSIS 2 (=25) 
Completed 2l study assessments at any 
point in the disease course 
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A) Subjective physical functioning B) Objective physical functioning
C) Appetite D) Need for nutrition support
Figure 6.2 Prevalence of poor subjective and objective physical functioning, poor appetite 
and high need for nutrition support across the 2 years from MPM diagnosis 
A) SF-36 physical functioning B) Timed Up and Go
C) Anorexia Cachexia Scale D) Patient-Generated Subjective Global Assessment
Figure 6.3 Line graphs of individual participants depicting changes in SF-36 physical 
functioning, Timed Up and Go, Anorexia Cachexia Scale and Patient-
Generated Subjective Global Assessment from baseline, n=25 
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6.4 Discussion 
This study provides new information about the functional and nutritional 
characteristics of patients with MPM. We report that functional and nutritional impairment 
was common in the 2 years following MPM diagnosis and occurred in the presence and 
absence of cancer treatment. For many participants in our longitudinal analysis, functional 
and nutritional impairment persisted across multiple assessments. 
Functional impairment was prevalent across the 2 years from MPM diagnosis. 
Between 50 and 91% of participants at each time interval had poor subjective and objective 
physical functioning. Previous studies have shown that patients with lung cancer have 
poorer physical functioning than healthy adults, and that function deteriorates over time,10 
however there is a lack of information on the prevalence of functional impairment. In a 
study of older adults with cancer, 76% of participants reported limitations in physical 
functioning and 70% of participants had suboptimal objective physical functioning.18 Our 
results are consistent with these findings and comparable as many patients with MPM are 
older adults at diagnosis due to the long latency period between asbestos exposure and 
diagnosis.19 Together, the results suggest that functional impairment is common among 
older patients with cancer. 
Poor appetite was prevalent across the 2 years from MPM diagnosis. Poor appetite 
was reported by 56 – 71% of participants across all time intervals in our study, which is 
higher than the 40% reported by patients with advanced lung cancer.5 The participants 
with advanced lung cancer were assessed prior to cancer treatment,5 and as chemotherapy 
can adversely affect appetite, this could have contributed to the higher prevalence of poor 
appetite reported in our study. Notably, the majority of participants with a poor appetite at 
diagnosis were not receiving cancer treatment, which indicates poor appetite can occur 
irrespective of treatment status. This indicates that an evaluation of appetite should be 
included in management of patients with MPM regardless of whether they are receiving 
cancer treatment. 
As MPM is an incurable cancer and median survival is 12 months,1 it is encouraging 
that a proportion of participants had normal function and nutritional status throughout 
follow-up. However, it is concerning that more than half of participants had persistent or 
recurrent functional and nutritional impairment, as the extended duration of impairment 
could have a more profound impact on patient quality-of-life. 
Patients with MPM who have functional and nutritional impairment could benefit 
from supportive care interventions, however these impairments could go undetected in 
clinical practice. Existing guidelines recommend routine assessment of physical 
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functioning to identify functional impairment20 and the use of screening tools to identify 
nutritional impairment.21 Our findings suggest that screening or assessment tools which 
identify functional and nutritional impairment should be recommended for all patients 
with MPM from the point of diagnosis. Functional impairment can be identified with self-
report questionnaires such as the SARC-F22 or objective tests such as the Short 
Performance Physical Battery23 while nutritional impairments can be identified with the 
use of a validated nutrition screening tool such as the Malnutrition Screening Tool.21 
Resistance exercise training could be used to improve physical functioning in patients with 
MPM23 although to date, interventions to address nutritional impairments via nutritional 
support have not been tested in MPM. 
There are several limitations to this study. Our study may not be representative of all 
patients with MPM. The enrolment rate was 43% and poor health was the most common 
reason for non-participation; therefore the actual prevalence of functional and nutritional 
impairment in this clinical group may be higher than we have reported. Additionally, 
participants identified as malnourished during the study were referred to a dietitian. 
Dietitian intervention, including nutritional counselling and nutrition supplements, may 
have contributed to improved nutritional status at subsequent assessments. We did not 
track which participants received nutritional intervention. Functional and nutritional 
impairments are associated with multiple factors including cancer stage25 and treatment,26, 
27 baseline co-morbidities,28 and physical activity level.29 As the sample size of our study 
was relatively small, we could not adjust for these confounding factors. Further research 
with a larger sample size is needed to gain an understanding of the factors that contribute 
to changes in functional and nutritional outcomes in patients with MPM. 
This study is the first to provide a description of the functional and nutritional 
characteristics in an unselected group of patients with MPM. The majority of participants 
in our study received non-surgical cancer treatment or no cancer treatment, which is 
representative of standard care pathways for patients with MPM. A strength of our study 
is the prospective collection of functional and nutritional data from participants for up to 
18 months from enrolment. Additionally, we used validated measures to evaluate self-
reported as well as objective physical functioning, appetite and nutritional status. 
In patients with MPM, functional and nutritional impairment was common and not 
exclusive to participants receiving cancer treatment. For many participants, functional and 
nutritional impairments were persistent or reoccurred during follow-up. Screening for 
functional and nutritional impairment is recommended for all patients with MPM from the 
time of diagnosis to identify those who could benefit from supportive care interventions. 
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Abstract 
Background: Cachexia is common in advanced cancer and is associated with negative 
patient outcomes. In malignant pleural mesothelioma (MPM), no study has reported body 
composition changes or factors associated with these changes. This study aimed to 
describe changes in body composition over time and its relationship with activity levels 
and dietary intake. 
Methods: The study was a secondary analysis of data collected from a longitudinal 
observational study of patients with MPM. Participants completed 3-monthly assessments 
for up to 18 months. Participants with two dual-energy x-ray absorptiometry (DXA) scans 
were included. Change in appendicular skeletal muscle mass (ASM) and total fat mass 
(FM) were used to categorise participants into phenotypes. Activity levels were measured 
with an Actigraph GT3X+ accelerometer and energy and protein intake were measured 
with a 3-day food record and 24-hour recall. 
Results: Eighteen participants were included (89% male, mean age 68.9±7.1 years). 
Median time between DXA was 91 [IQR 84–118] days. Compared to participants with 
ASM maintenance (n=8), fewer participants with ASM loss (n=10) survived ≥12 months 
from follow-up (p=0.04). Participants with ASM loss increased sedentary time (p=0.028), 
and decreased light activity (p=0.028) and step count (p=0.008). Activity levels did not 
change in participants who maintained ASM (p>0.05). Energy and protein intake did not 
change in either group (p>0.05). 
Conclusion: Multiple patterns of change in body composition were identified in patients with 
MPM. Muscle loss was associated with poorer survival and decreased activity levels. 
Interventions that improve physical activity or muscle mass could benefit patients with MPM. 
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7.1 Introduction 
Malignant pleural mesothelioma (MPM) is an incurable cancer that results from 
asbestos exposure.1 Patients with MPM have limited treatment options and a short median 
survival of 12 months.1 It has been hypothesised that cancer cachexia could contribute to 
the cause of death in MPM.2 
Cancer cachexia is a form of malnutrition characterised by the loss of skeletal muscle 
mass in the presence or absence of loss of fat mass, and is often accompanied by anorexia 
and systemic inflammation.3 Cancer cachexia can lead to the development of low skeletal 
muscle mass, which is associated with a range of negative outcomes in some advanced 
cancer populations including poorer quality of life,4 lower activity levels,5 increased 
treatment toxicity6 and poorer survival.6 Further, people with both low skeletal muscle 
mass and excess fat mass (i.e. sarcopenic obese) have had an even greater risk of negative 
outcomes.7 
In our previous research we reported that 50% of patients with MPM had low skeletal 
muscle mass close to the time of diagnosis, and of these 11% were obese.8 Although 
clinicians report patients with MPM become emaciated over the disease course, and often 
die with a low BMI,2 there are no studies in patients with MPM on changes in body 
composition over time. Information on the patterns of change in body composition could 
improve our understanding of the need for interventions which can prevent and treat 
cancer cachexia in MPM. 
Physical activity and dietary intake are modifiable factors which could be central to 
the development of cancer cachexia. Physical activity and dietary protein intake stimulate 
muscle protein synthesis9 and in sufficient quantities could protect against the 
development of low skeletal muscle mass.10, 11 Additionally, lower levels of physical 
activity and high dietary energy intake can create a positive energy balance resulting in 
weight gain that is largely an increase in fat mass.12 There is little research into the 
relationship between physical activity, dietary intake and changes in body composition in 
cancer populations. Understanding these complex relationships is critical for the design of 
interventions to prevent and treat cancer cachexia. 
The aims of this study in patients with MPM were to describe the changes in body 
composition over time and the relationship between body composition changes and 
activity levels and dietary intake. 
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7.2 Methods 
7.2.1 Study design and participants 
The study was a secondary analysis of data collected from a longitudinal 
observational study which aimed to describe the functional and nutritional status of 
patients with MPM. Patients were recruited from a tertiary specialist pleural disease clinic 
in Perth, Western Australia and were eligible if they had cytological or histological 
confirmation of MPM. Exclusion criteria were: aged <18 years, pregnant or lactating, 
unable to read and understand English, unable to comply with the protocol or were 
participating in an intervention study likely to influence body composition. Participant 
consent and physician approval were required before commencing the study. Participants 
completed assessments of body composition, activity levels and dietary intake during 
routine hospital visits, approximately every 3 months and were followed until death or for 
a maximum of 18 months. Participants that did not complete body composition scans at 
two consecutive assessments were excluded from this analysis. The study was approved 
by the Sir Charles Gairdner Group and Edith Cowan University Human Research Ethics 
Committees (ID: 2014-124 and 13255). 
7.2.2 Measurements 
Demographic and medical variables 
Demographic and medical data were obtained from participant medical records. 
Disease progression at the time of follow up was determined by clinician examination of the 
Computed Tomography scan completed closest to the time of the second body composition 
scan. The  Eastern Cooperative Oncology Group (ECOG) performance status was recorded 
on the date of assessment.13 
Anthropometric measures 
Weight and height, measured with participants dressed in light clothing with shoes 
removed, were used to calculate the BMI. Participants were classified as underweight, normal 
weight, overweight or obese based on World Health Organisation (WHO) BMI criteria.14 
Body composition 
Body composition was assessed using whole body dual-energy x-ray absorptiometry 
(DXA) scans (Hologic Discovery A, Hologic Inc., Marlborough, MA, USA). Appendicular 
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skeletal muscle and fat mass was segmented from trunk lean and fat mass at the acromio-
humeral and pelvic-femoral joints.15 Low skeletal muscle mass was defined as an 
appendicular skeletal muscle mass/height2 of ≤7.26 kg/m2 for males and ≤5.45 kg/m2 for 
females. Participants with low skeletal muscle mass were categorised as pre-sarcopenic, 
consistent with diagnostic criteria from the European Working Group on Sarcopenia in 
Older People.16 Participants with low skeletal muscle mass and a BMI ≥30.0 kg/m2 were 
categorised as sarcopenic obese.7 Change in body composition variables were calculated as 
the percent change between the second and first measurements. 
To characterise changes in body composition over time, participants were categorised 
into body composition phenotypes according to changes in skeletal muscle mass and fat 
mass. Total lean mass measured with DXA includes both skeletal muscle and residual 
mass (i.e., organs), however appendicular lean mass is predominantly skeletal muscle.17 
Therefore, to report on changes in skeletal muscle mass we considered it more accurate to 
use appendicular lean mass, also known as appendicular skeletal muscle mass, which 
represents, on average 75% of whole-body skeletal muscle.17 The four body composition 
phenotypes were: 1) loss of appendicular skeletal muscle mass and loss of total fat mass; 
2) loss of appendicular skeletal muscle mass and maintenance or gain of total fat mass; 3)
maintenance or gain of appendicular skeletal muscle mass and loss of total fat mass and 
4) maintenance or gain of appendicular skeletal muscle mass and maintenance or gain of
total fat mass. A loss was defined a change of <0.00 kg between the first and second 
measurements; maintenance or gain was defined as a change of ≥0.00 kg between the first 
and second measurements. 
Activity levels 
Sedentary behaviour and physical activity were objectively assessed following each 
body composition scan using the Actigraph GT3X+ accelerometer (Actigraph, Pensacola, 
FL, USA). Participants were instructed to wear the accelerometer on their hip continuously 
24 hr/day for 3 days, to only remove for bathing or swimming and to record any non-wear 
time in a logbook. Cut-points were applied to classify sedentary behaviour as <100 
counts/minute (cpm), light activity as 100-1952 cpm and moderate and vigorous physical 
activity (MVPA) as >1952 cpm.18, 19 Variables were calculated per day and then averaged 
across all valid days, defined as at least 10 hours of data per day. Additional accelerometer 
methodology for this study has been reported previously.5 
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Dietary intake 
Dietary intake was measured following each body composition scan using a 3-day 
estimated food record at the initial assessment and a 24-hour recall at subsequent assessments. 
To assist participants with completion of the food record, written and verbal instructions were 
provided explaining how to complete the food record and accurately estimate portion sizes 
using household measures. Returned food records were visually inspected by the researchers 
and incomplete details were clarified with participants. Participants completed the 24-hour 
recall in a face-to-face interview with a dietitian using the multiple pass method.20 The food 
records and 24-hour recalls were analysed using Foodworks 8 software (Xyris Software Pty 
Ltd, Queensland, Australia). Intake variables were calculated per day, and for the food 
records, intake was averaged across all three days. Energy (kJ) and protein intake (g) were 
expressed per kg of body weight per day respectively. 
7.2.3 Statistical analyses 
Statistical analyses were conducted using the Statistical Package for the Social 
Sciences (v. 23, IBM Corporation, Somers, NY, USA). Data were expressed as mean ± SD 
or median [IQR] where the data were not normally distributed. To examine the relationship 
between changes in body composition and participant characteristics, activity levels and 
dietary intake, participants were condensed into two groups: 1) muscle loss group; and 2) 
muscle maintenance group, with definitions provided above. Fisher’s exact test was used 
to test for differences in characteristics between participants with muscle loss and muscle 
maintenance where the data were categorical. As the data were not normally distributed, 
the Mann-Whitney test was used to test for differences in characteristics between 
participants with muscle loss and muscle maintenance where the data were continuous, and 
for differences in change in activity levels and dietary intake between muscle groups. The 
Wilcoxon signed-rank test was used to test for differences in body composition, activity 
levels and dietary intake between the first and second measurements. 
7.3 Results 
7.3.1 Participant characteristics 
Of the 36 patients recruited to the longitudinal observational study, 18 (50%) were 
included in the current study (Figure 7.1). 
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The median time between the first and second body composition scans was 91 (IQR 84 
– 118) days. Participant characteristics are presented in (Table 7.1). The majority of
participants were male (89%) and the mean age was 68.9 ± 7.1 years. Nine participants 
(50%) received cancer treatment during the follow up period. Ten participants (56%) met 
the criteria for muscle loss and eight participants (44%) met the criteria for muscle 
maintenance. Three participants (30%) with muscle loss survived more than 12 months from 
the second body composition scan, while all participants (100%) with muscle maintenance 
survived more than 12 months from the second scan (p=0.04). No other differences in 
participant characteristics were observed between muscle groups (p>0.05) (Table 7.1). 
7.3.2 Changes in sarcopenia status 
There was a 17% increase in the proportion of participants who were pre-sarcopenic 
between the first and second body composition scans. Eight participants (44%) were pre-
sarcopenic at the first measurement and eleven participants (61%) were pre-sarcopenic at 
the second scan. Three participants (30%) who were non-sarcopenic at the first 
measurement were pre-sarcopenic at the second scan. None of the participants who were 
pre-sarcopenic at the first measurement became non-sarcopenic. Of the participants who 
were pre-sarcopenic at the first scan, none (0%) were obese. Of the participants who were 
pre-sarcopenic at the second scan, one (9%) was obese. 
7.3.3 Changes in body composition 
When participants were condensed into the four body composition phenotypes, eight 
participants (44%) had a loss of appendicular skeletal muscle and fat mass, two participants 
(11%) had a loss of appendicular skeletal muscle and maintained fat mass, four participants 
(22%) maintained appendicular skeletal muscle and lost fat mass and, four participants 
(22%) maintained appendicular skeletal muscle and fat mass (Figure 7.2). 
There were no significant changes in total, lean or fat mass during the follow up period 
in the whole group (Table 7.2). Participants with muscle loss (n=10) experienced a 
significant decrease in total mass (p=0.005), trunk lean mass (p=0.009), appendicular 
skeletal muscle mass (p=0.005) and trunk fat mass (p=0.013) but not appendicular fat mass 
(p=0.721). Participants with muscle maintenance (n=8) experienced a significant increase 
in appendicular skeletal muscle mass (p=0.012) but not total mass (p=0.093) trunk lean 
mass (p=0.484), trunk fat mass (p=0.401) or appendicular fat mass (p=0.889). 
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7.3.4 Change in activity levels according to muscle change group 
There were no significant changes in activity levels during the follow up period in the 
whole group (Table 7.3). Participants with muscle loss had a significant decrease in 
median step count (p=0.008), an increase in the proportion of waking hours spent as 
sedentary (p=0.028) and a decrease in the proportion of waking hours spent in light activity 
(p=0.028) (Table 7.3). There was no significant change in the proportion of waking hours 
spent in moderate and vigorous physical activity (p=0.260). Participants with muscle 
maintenance maintained step count (p=0.176), and the proportion of waking hours spent 
as sedentary (p=0.499), in light activity (p=0.499) or in moderate and vigorous physical 
activity (p=0.176) (Table 7.3). 
There was a significant difference between participants with muscle loss and muscle 
maintenance for change in step count (-1020 [IQR -4667 – 56] vs. 1234 [IQR -204 – 2221] 
steps/day; p=0.008; Figure 7.3) and for the proportion of waking hours spent in light 
activity (-4.8 [IQR -9.2 – 0.2] vs. -0.7 [IQR -2.0 – 7.5]; p=0.023; Figure 7.3) but not for 
the proportion of waking hours spent as sedentary (4.9 [IQR -2.3 – 11.1] vs. 0.5 [IQR -8.6 
– 2.2]; p=0.142; Figure 7.3).
7.3.5 Change in dietary intake according to muscle change group 
There were no significant changes in energy and protein intake during the follow up 
period in the whole group (Table 7.3) or in participants with muscle loss and those with 
muscle maintenance (Table 7.3). 
There was a significant difference between participants with muscle loss and muscle 
maintenance for change in protein intake (-0.28 [IQR -0.48 – 0.15] vs. 0.74 [IQR -0.14 – 
0.82] g/kg/day; p=0.025; Figure 7.3) but not for energy intake (-7.9 [IQR -45.0 – -0.9] vs. 
28.9 [IQR -23.6 – 123.1] kJ/kg/day; p=0.193; Figure 7.3). 
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Age, years 68.9 ± 7.1 67.0 [61.5-74.3] 71.5 [62.5-75.0] 0.633 
Sex, male 16 (88.9%) 8 (80%) 8 (100%) 0.477 
BMI, kg/m2 25.2 [23.9-28.7] 25.9 [24.1-29.5] 24.3 [23.8-27.7] 0.237 
BMI category 
Underweight 
















Pre-sarcopenic, yes 8 (44.4%) 4 (40.0%) 4 (50.0%) 0.520 
Histological subtype, epithelioid 15 (83.3%) 8 (80%) 7 (87.5%) 1.000 
ECOG performance status at first scan*, 0-1 18 (100%) 10 (100%) 8 (100%) - 














Time from first to second scan, days 91.0 [84.0-118.0] 87.5 [82.5-92.5] 105.5 [87.5-143.5] 0.083 
Cancer treatment during follow up, yes 9 (50%) 5 (50%) 4 (50%) 1.000 










Type of cancer treatment 
Cisplatin and Pemetrexed 
Carboplatin and Pemetrexed 
Vinorelbine 















Disease progression at second scan* 
Progressed 
Stable 
Response to treatment 
























*First or second body composition scan
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Table 7.2 Participant changes in body composition, n=18 
All participants (n=18) Muscle loss (n=10) Muscle maintenance (n=8) 
Mass (kg) First scan Second scan 
P 
value First scan Second scan 
P 
value First scan Second scan 
P 
value 
Total 75.0 (70.3-87.4) 74.1 (67.3-88.7) 0.133 75.0 (70.4-91.6) 72.5 (66.9-88.7) 0.005* 74.1 (68.4-87.1) 75.7 (68.8-90.9) 0.093 
Lean mass 
Total 50.4 (47.3-53.9) 49.5 (46.9-53.9) 0.248 51.4 (46.9-56.4) 48.7 (43.9-54.6) 0.005* 49.6 (46.8-53.5) 50.8 (49.0-53.7) 0.012* 
Trunk 26.6 (24.8-29.1) 25.4 (24.5-28.3) 0.085 26.9 (25.2-29.9) 25.2 (23.8-29.0) 0.009* 25.2 (24.7-28.9) 26.5 (24.8-28.2) 0.484 
Appendicular 21.4 (18.9-22.2) 20.5 (19.7-22.2) 0.306 21.4 (18.6-23.0) 20.4 (17.3-21.8) 0.005* 21.2 (18.5-22.0) 21.8 (20.3-22.2) 0.012* 
Fat mass 
Total 24.3 (20.1-30.1) 24.2 (19.8-28.7) 0.215 25.9 (20.1-30.1) 24.3 (20.5-28.0) 0.037* 22.9 (16.8-30.1) 23.6 (16.2-31.1) 0.575 
Trunk 12.3 (9.8-15.1) 11.2 (9.4-15.1) 0.184 12.4 (10.1-15.3) 10.8 (9.4-14.0) 0.013* 11.9 (7.8-15.5) 11.8 (7.7-17.0) 0.401 
Appendicular 11.3 (8.3-13.8) 11.5 (8.4-13.9) 0.679 11.9 (8.3-15.2) 11.5 (8.7-14.2) 0.721 10.2 (8.2-13.0) 10.1 (7.5-14.0) 0.889 
Data is presented as median (interquartile range); *p<0.05 
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Table 7.3 Participant activity levels and dietary intake, n=17 
All participants (n=17) Muscle loss (n=10) Muscle maintenance (n=7) 
First scan Second scan 
P 
value First scan Second scan 
P 














































Energy intake, kJ/kg 



















Data is presented as median (interquartile range); MVPA – Moderate and Vigorous Physical Activity; *p<0.05 
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Figure 7.1 Participants included in the secondary analysis 
Figure 7.2 Proportion of participants within each body composition phenotype, n=18 
Enrolled in longitudinal 
observational study (n=36) 
Excluded (n=18) 
. Lost to follow ap (n=1) 
. Deceased (n=7) 
. Withdrawn (=2) 
. No longer attending hospital (n=2) . Participated but incomplete DA data (n=7) 
. To  unwell (n=4) 
. To  burdensome (n2) 
. Time constraints (participant) (n=1) 
Eligible for inclusion (n=18) 
. Accelerometer (n=16) 
Not wor at baseline (n=1) 
Declined at follow up (n=D) 
. Food record (=17) 




■ Loss of appendicular skeletal 
muscle and fat mass 
■ Loss of appendicular skeletal 
muscle and maintenance or gain 
of fat mass 
■ Maintenance or gain of 
appendicular skeletal muscle 
and loss of fat mass 
■ Maintenance or gain of 
appendicular skeletal muscle 
and fat mass 
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A) Steps B) Sedentary behaviour
C) Light activity D) Energy intake
E) Protein intake
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7.4 Discussion 
Our study is the first to prospectively assess changes in body composition in relation 
to activity levels and dietary intake in patients with MPM. We identified multiple 
patterns of body composition change among our participants. Notably, participants with 
muscle loss and muscle maintenance had distinct survival, physical activity and dietary 
intake characteristics. 
Our participants could be categorised across all four body composition phenotypes. 
The most common phenotype, which included 44% of participants, was the loss of 
appendicular skeletal muscle mass and fat mass, which is consistent with the cachexia 
phenotype.3 When we condensed the four body composition phenotypes into two groups: 
1) muscle loss and 2) muscle maintenance; 56% of participants had muscle loss and 44%
had muscle maintenance. This result is particularly notable as the low mean BMI reported 
in a previous post-mortem study indicated patients with MPM become emaciated over 
the disease course.2 While muscle loss was common, our results suggested that a 
proportion of participants with MPM had the ability to maintain muscle, at least for a 
fraction of the disease course. 
There were significant differences in survival between participants with muscle loss 
and muscle maintenance. A small proportion (30%) of participants with muscle loss 
survived at least 12 months from the second body composition scan while all (100%) 
participants with muscle maintenance survived at least 12 months from the second body 
composition scan. Therefore, muscle loss could be indicative of shorter survival in patients 
with MPM. Similar findings have been reported in a large retrospective study of patients 
with advanced cancer (n=368)21 where the authors stated that muscle loss became more 
common as death approached. Tumour burden is thought to mediate the metabolic changes 
that cause loss of muscle and fat mass22 highlighting the importance of efficacious cancer 
treatments for the management of cachexia.3 There are currently limited treatment options 
for those with MPM and in a previous clinical trial only 40% of patients responded to first-
line chemotherapy treatment.23 Therefore, addressing lifestyle factors that contribute to 
cancer cachexia could offer benefit. 
Participants with muscle loss had a significant decline in activity levels over the 
follow up period of 3 months, while participants with muscle maintenance sustained their 
activity levels. As physical activity is required for muscle protein synthesis,9 a decrease in 
physical activity may have contributed to muscle loss among our participants. 
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Additionally, as the majority of participants (70%) with muscle loss were categorised as 
pre-sarcopenic at follow up, participants may not have had the strength and endurance to 
participate in their usual physical activity. The lack of physical activity could result in an 
even greater reduction in muscle loss. Therefore, regardless of the causal pathway between 
muscle loss and activity levels, resistance exercise training may offer benefit to patients 
with MPM as it can improve skeletal muscle mass, strength and physical function.24 
There were no statistically significant changes in dietary intake over the follow up 
period for participants with muscle loss and muscle maintenance, however we made 
clinically meaningful observations. Participants with muscle loss had a median energy and 
protein intake that was within the recommended energy and protein intake range of 105 – 
126 kJ/kg and 1.0 – 1.5 g/day, respectively,25 while median energy and protein intake 
among participants with muscle maintenance exceeded these recommendations. In a larger 
study (n=52) of patients with incurable non-small cell lung cancer (NSCLC), higher 
energy and protein intakes (149 kJ/kg and 1.4 g/kg, respectively) were associated with 
maintenance of skeletal muscle mass during chemotherapy.26 Approximately 40-50% of 
patients with NSCLC are reported to have an elevated resting energy expenditure,27, 28 
which could lead to muscle and fat loss unless dietary intake is increased proportionally. 
As muscle loss developed in our participants meeting dietary intake recommendations, it 
is possible that an elevated resting energy expenditure could have been a contributing 
factor in these patients with MPM. Intakes of energy and protein that exceed 
recommendations may be needed to preserve skeletal muscle mass in patients with MPM. 
This study has several potential limitations worthy of consideration. Several factors 
are known to affect muscle and fat metabolism, including disease progression, 
inflammation, cancer treatment and older age.29 While these characteristics were 
compared between participants with and without muscle loss, the sample size was too 
small to allow further evaluation in relation to changes in body composition. Energy and 
protein intake at baseline and follow up were measured using different dietary assessment 
methods. Participant feedback indicated that a 3-day food record was too burdensome, 
therefore we used 24-hour recalls at follow up assessments. Compared with a 24-hour 
recall, a 3-day food record could be more representative of usual dietary intake as 
measurement is carried out over a greater number of days. However, a 24-hour food recall 
is not less accurate than a food record.20 Considering this population of advanced cancer 
patients, participant burden was a key consideration in our study that should also be taken 
into account in future investigations. 
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Our study provides an insight into changes in body composition experienced by 
patients with MPM. A strength of our study is the use of DXA for body composition 
analysis, which enabled us to complete reliable evaluation of appendicular skeletal muscle 
mass and whole-body and regional fat mass.17 This data cannot be obtained through 
computed tomography evaluation of body composition, which employs a single cross-
section analysis, and existing prediction equations used to convert cross-sectional data to 
appendicular skeletal muscle mass may be inaccurate.30 Additionally, we report device-
assessed sedentary behaviour and physical activity using an accelerometer, which has 
greater accuracy when compared with self-report questionnaires.31 
7.5 Conclusion 
For the first time, we report on body composition changes over time in patients with 
MPM. Our results indicate that multiple patterns of change in body composition exist in 
this patient population. Muscle loss was associated with poorer survival and decreased 
activity levels. Interventions that improve physical activity or muscle mass could benefit 
patients with MPM. 
Chapter Seven.  Changes in Body Composition 
180 
References 
1. Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet.
2005;366:397-408.
2. Finn RS, Brims FJ, Gandhi A, Olsen N, Musk AW, Maskell NA, et al. Postmortem
findings of malignant pleural mesothelioma: a two-center study of 318 patients.
Chest. 2012;142(5):1267-73. doi:DOI 10.1378/chest.11-3204
3. Fearon KA, J. Baracos, V. Understanding the mechanisms and treatment options in
cancer cachexia. Nature Reviews Clinical Oncology. 2013;10:90-99.
doi:doi:10.1038/nrclinonc.2012.209
4. Bye A, Sjoblom B, Wentzel-Larsen T, Gronberg BH, Baracos VE, Hjermstad MJ, et
al. Muscle mass and association to quality of life in non-small cell lung cancer
patients. J Cachexia Sarcopenia Muscle. 2017;8(5):759-767.
doi:10.1002/jcsm.12206
5. Jeffery E, Lee YCG, Newton RU, Lyons-Wall P, McVeigh J, Nowak AK, et al.
Body composition and nutritional status in malignant pleural mesothelioma:
implications for activity levels and quality of life. Eur J Clin Nutr. 2019
6. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia
in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer.
2016;57:58-67. doi:10.1016/j.ejca.2015.12.030
7. Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact
for survival and complications of cancer therapy. Ann Oncol. 2018;29(suppl_2):ii1-
ii9. doi:10.1093/annonc/mdx810
8. Jeffery E, Lee YCG, Newton RU, Lyons-Wall P, McVeigh J, Nowak AK, et al.
Body composition and nutritional status in malignant pleural mesothelioma:
implications for activity levels and quality of life. European Journal of Clinical
Nutrition. 2019  doi:10.1038/s41430-019-0418-9
9. Brook MS, Wilkinson DJ, Smith K, Atherton PJ. The metabolic and temporal basis
of muscle hypertrophy in response to resistance exercise. Eur J Sport Sci.
2016;16(6):633-44. doi:10.1080/17461391.2015.1073362
10. Steffl M, Bohannon RW, Sontakova L, Tufano JJ, Shiells K, Holmerova I.
Relationship between sarcopenia and physical activity in older people: a systematic
review and meta-analysis. Clin Interv Aging. 2017;12:835-845.
doi:10.2147/cia.S132940
11. Houston DK, Nicklas BJ, Ding J, Harris TB, Tylavsky FA, Newman AB, et al.
Dietary protein intake is associated with lean mass change in older, community-
dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study.
Am J Clin Nutr. 2008;87(1):150-5. doi:10.1093/ajcn/87.1.150
Chapter Seven.  Changes in Body Composition 
181 
12. Jequier E, Tappy L. Regulation of body weight in humans. Physiol Rev.
1999;79(2):451-80. doi:10.1152/physrev.1999.79.2.451
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J
Clin Oncol. 1982;5(6):649-55.
14. World Health Organisation. Waist circumference and waist-hip ratio: Reports of a
WHO expert consultation, Geneva, 8-11 December 2008: World Health
Organisation; 2011.
15. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A
practical and precise approach to quantification of body composition in cancer
patients using computed tomography images acquired during routine care. Appl
Physiol Nutr Metab. 2008;33(5):997-1006. doi:10.1139/h08-075
16. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al.
Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing.
2019;48(1):16-31. doi:10.1093/ageing/afy169
17. Prado CM, Heymsfield SB. Lean tissue imaging: a new era for nutritional
assessment and intervention. JPEN J Parenter Enteral Nutr. 2014;38(8):940-53.
doi:10.1177/0148607114550189
18. Freedson PS, Melanson E, Sirard J. Calibration of the Computer Science and
Applications, Inc. accelerometer. Med Sci Sports Exerc. 1998;30(5):777-81.
19. Matthews CE, Chen KY, Freedson PS, Buchowski MS, Beech BM, Pate RR, et al.
Amount of time spent in sedentary behaviors in the United States, 2003-2004. Am J
Epidemiol. 2008;167(7):875-81. doi:10.1093/aje/kwm390
20. Conway JM, Ingwersen LA, Moshfegh AJ. Accuracy of dietary recall using the
USDA five-step multiple-pass method in men: an observational validation study. J
Am Diet Assoc. 2004;104(4):595-603. doi:10.1016/j.jada.2004.01.007
21. Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, Antoun S, et al. Central
tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable
anabolic potential? Am J Clin Nutr. 2013;98(4):1012-9. doi:DOI
10.3945/ajcn.113.060228
22. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia:
understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754-62.
doi:10.1038/nrc3829
23. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al.
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in
patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-44.
doi:10.1200/jco.2003.11.136
Chapter Seven.  Changes in Body Composition 
182 
24. Peddle-McIntyre C, Jeffery E, Lee YCG, Nowak A, McVeigh J, Nguyen B, et al.
Resistance exercise training improves physical functioning and sarcopenia status in
patients with malignant pleural disease. in preparation
25. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al.
ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11-48.
doi:10.1016/j.clnu.2016.07.015
26. Tobberup R, Rasmussen HH, Holst M, Jensen NA, Falkmer UG, Bogsted M, et al.
Exploring the dietary protein intake and skeletal muscle during first-line anti-
neoplastic treatment in patients with non-small cell lung cancer. Clin Nutr ESPEN.
2019;34:94-100. doi:10.1016/j.clnesp.2019.08.006
27. Ulmann G, Jouinot A, Tlemsani C, Curis E, Kousignian I, Neveux N, et al. Lean
Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy
Expenditure in Patients with Non-Small Cell Lung Cancer. Ann Nutr Metab.
2019;75(4):223-230. doi:10.1159/000504874
28. Cao DX, Wu GH, Zhang B, Quan YJ, Wei J, Jin H, et al. Resting energy
expenditure and body composition in patients with newly detected cancer. Clin
Nutr. 2010;29(1):72-7. doi:10.1016/j.clnu.2009.07.001
29. Engelen MP, van der Meij BS, Deutz NE. Protein anabolic resistance in cancer:
does it really exist? Curr Opin Clin Nutr Metab Care. 2016;19(1):39-47.
doi:10.1097/mco.0000000000000236
30. Kilgour RD, Cardiff K, Rosenthall L, Lucar E, Trutschnigg B, Vigano A. Use of
prediction equations to determine the accuracy of whole-body fat and fat-free mass
and appendicular skeletal muscle mass measurements from a single abdominal
image using computed tomography in advanced cancer patients. Appl Physiol Nutr
Metab. 2016;41(1):70-5. doi:10.1139/apnm-2015-0068
31. Cleland C, Ferguson S, Ellis G, Hunter RF. Validity of the International Physical
Activity Questionnaire (IPAQ) for assessing moderate-to-vigorous physical activity




Nutritional Status, Dietary Intake and 
Resistance Exercise Adherence and Outcomes 
in Patients with Malignant Pleural Disease 
Abstract............................................................................................................... 184 
8.1 Introduction ............................................................................................. 185 
8.2 Methods ................................................................................................... 186 
8.3 Results ..................................................................................................... 189 
8.4 Discussion ............................................................................................... 198 
References .......................................................................................................... 201 
Chapter Eight 
Chapter Eight.  Nutritional Status, Dietary Intake and Resistance Exercise 
184 
Abstract 
Purpose: Little is known about the effects of nutritional status and dietary intake on 
response to exercise interventions in advanced cancer. This study aimed to determine if 
completion rates and response to an exercise intervention differ according to nutritional 
status and dietary intake in patients with malignant pleural disease (MPD). 
Methods: Patients with MPD participated in a 6-week resistance exercise intervention. 
Outcome measures were assessed before and after the intervention. Nutritional status was 
assessed with the Patient-Generated Subjective Global Assessment (malnutrition defined as 
a rating of B or C). Dietary intake was assessed with 3-day food records (adequate intake 
defined as energy ≥25 kcal/kg/day and protein ≥1.0 g/kg/day). Appendicular skeletal muscle 
mass (ASM, kg) was segmented from whole-body dual-energy x-ray absorptiometry and 
adjusted for height (kg/m2). Physical functioning was assessed with repeated chair rise, 
Timed Up and Go, one-repetition maximum leg press and Six-Minute Walk Test. 
Results: Thirty-three participants were recruited (median age 68 [IQR 62-73] years, 68% 
men). Study completion rates were not significantly different between well-nourished and 
malnourished participants (84% vs. 75%; p=0.616). Gain in ASM was significantly greater 
in participants with adequate compared to inadequate intake (mean difference 0.40 [95% 
CI 0.14-0.67] kg/m2; p=0.005). There were no differences between those with adequate and 
inadequate intake for change in repeated chair rise (p=0.504) Timed Up and Go (p=0.734), 
relative one-repetition maximum leg press (p=0.643) and Six-Minute Walk Test (p=0.600). 
Conclusion: There were acceptable study completion rates for participants with 
malnutrition. Dietary intake may not affect the physical functioning response to resistance 
exercise, however adequate intake could optimize muscle gains. This could have 
implications for the development of exercise and multimodal interventions in advanced 
cancer populations. 
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8.1 Introduction 
Malignant pleural disease (MPD) indicates the presence of advanced cancer, and 
occurs as a result of malignant pleural mesothelioma (MPM) or the metastatic spread of 
cancer to the pleura.1 Malnutrition is common in patients with advanced cancer, including 
those with MPM.2 Malnutrition is characterized by changes in weight and body 
composition that result from inadequate dietary intake or the impaired absorption or 
utilization of nutrients.3 
A high proportion of malnourished patients with advanced cancer have low skeletal 
muscle mass2 which has been associated with poorer quality of life,4 greater treatment 
toxicity5 and shorter overall survival.6 Therefore, interventions which increase skeletal 
muscle mass have the potential to improve quality of life, treatment tolerance and survival. 
Resistance exercise training can increase skeletal muscle mass and improve physical 
functioning in patients with cancer.7 While malnourished patients are represented in 
exercise interventions targeting patients with advanced cancer,8 little is known about the 
feasibility of exercise interventions in cancer patients with malnutrition, as nutritional 
status is rarely assessed.8, 9 Due to higher fatigue levels,2 combined with the negative 
impact of low skeletal muscle mass on physical functioning,10 malnourished patients 
could have poorer adherence to exercise interventions than well-nourished patients. This 
could indicate the need for additional support during exercise interventions for patients 
that are malnourished. 
There is a lack of data on the relationship between dietary intake and the response to 
resistance exercise training in advanced or poorer prognosis cancer populations. Dietary 
intake plays a central role in skeletal muscle homeostasis, yet intake is inadequate in a 
high proportion of patients with advanced cancer.2 When dietary intake is inadequate, 
amino acids from the diet may be used as an energy source, reducing availability for 
skeletal muscle synthesis,11 and skeletal muscle may be broken down to provide the body 
with amino acids for energy.11 Therefore, skeletal muscle growth and functional responses 
to exercise could be impeded in cancer patients with inadequate dietary intake.7 
The aim of this study in patients with MPD was to determine whether: 1) completion 
rates, adherence and tolerance to a resistance exercise intervention differed according to 
nutritional status and dietary intake; and 2) the body composition and physical functioning 
response to resistance exercise training differed according to dietary intake. 




Participants were recruited from tertiary specialist pleural disease and medical 
oncology clinics in Perth, Western Australia (WA). Participants were eligible if they had 
cytological or histological confirmation of MPD. Exclusion criteria were aged <18 years, 
pregnant or lactating, unable to read and understand English, unstable bone metastases or 
metastases of the long bones, acute illness or disorder precluding exercise, physician 
recommendation against participation and patient unable to give informed consent or 
comply with the protocol. The study was approved by the Sir Charles Gairdner Group and 
Edith Cowan University Human Research Ethics Committees (ID: 2014-124 and 13255). 
8.2.2 Measures 
Assessment schedule 
Participants completed a baseline assessment fewer than 7 days prior to commencing 
the exercise intervention and a post-intervention assessment fewer than 7 days after 
completing their final exercise training session. 
Demographic and medical data 
Participant medical records were reviewed for demographic and medical data. At 
baseline and post-intervention, participants were assigned an Eastern Cooperative 
Oncology Group (ECOG) performance status rating of 0 to 4.12 
Anthropometric data 
Height (m) was measured at baseline and weight (kg) was measured baseline and 
post-intervention. Participants were dressed in light clothing with shoes removed. Weight 
and height data were used to calculate the body mass index (BMI) (kg/m2). 
Nutritional status, appetite and dietary intake 
Nutritional status was assessed at baseline and post-intervention using the Patient-
Generated Subjective Global Assessment (PG-SGA).13 Participants were categorized with 
a global rating of A – well nourished, B – suspected malnutrition/malnutrition or C – 
severe malnutrition. Participants with malnutrition (global rating of B and C) were 
combined for data analysis. Participants who were well-nourished at baseline and post-
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intervention were considered well-nourished and participants who were malnourished at 
either or both time-points were considered malnourished. 
Participants completed a validated questionnaire at baseline and post-intervention to 
assess appetite (Anorexia Cachexia Scale; ACS).14 A poor appetite was defined as a score 
of ≤37 on the ACS, consistent with previously reported cut-points.15 
Dietary intake was collected following the baseline and post-intervention assessments 
with a 3-day food record. Written and verbal instructions were provided to participants, 
explaining how to complete the food record and estimate portion sizes using household 
measures (including measuring cups and spoons). Food records were analysed by an 
Accredited Practising Dietitian (EJ) using FoodWorks 8 Professional (Xyris Software Pty 
Ltd, Australia). Intake variables were calculated per day and averaged across three days 
for each participant. Energy (kcal) and protein intake (g) were expressed per kilogram (kg) 
of body weight per day. 
The recommendations of the European Society of Parenteral and Enteral Nutrition 
(ESPEN) expert group were used to classify energy and protein intake as adequate or 
inadequate.16 These guidelines recommend patients with cancer achieve a minimum 
energy intake of 25 kcal/kg/day and protein intake 1.0 g/kg/day.16 Participants with an 
intake that met the ESPEN expert group recommendations at baseline and post-
intervention were considered to have adequate dietary intake. Participants with an intake 
below the ESPEN expert group recommendations at either or both time-points were 
considered to have inadequate dietary intake. 
Body composition 
Body composition was measured at baseline and post-intervention using whole body 
dual-energy x-ray absorptiometry (DXA) (Hologic Discovery A, Hologic Inc., 
Marlborough, MA, USA). Appendicular skeletal muscle mass was segmented from trunk 
lean mass at the acromio-humeral and pelvic-femoral joints and adjusted for height 
(kg/m2).17 Low appendicular skeletal muscle mass was defined as ≤7.26 kg/m2 for males 
and ≤5.45 kg/m2 for females.18 Change in appendicular skeletal muscle mass (kg/m2) and 
body fat (%) were determined by the absolute difference between the baseline and post-
intervention measurements. 
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Physical functioning 
Participants completed a series of standardized tests at baseline and post-intervention 
to assess physical functioning. Lower body function was assessed with the repeated chair 
rise (sec), where participants were asked to rise from a seated position and return to sitting, 
five consecutive times.19 Functional mobility was assessed with the Timed Up and Go 
(sec), where participants were asked to rise from a seated position, walk 8-feet forward, 
turn around, walk back to the chair and sit down.20 Lower body strength was assessed with 
the one-repetition maximum (1RM) leg press, or the maximum weight (kg) that can be 
lifted one time.21 Relative 1RM was calculated as 1RM leg press divided by current 
weight. Functional capacity was assessed with the Six-Minute Walk Test (m), where 
participants were asked to walk as far as possible on a flat 50 m course in six minutes.22 
Exercise intervention 
Supervised resistance exercise training was undertaken by participants in small groups, 
three times per week for six weeks with a total of 18 sessions. Participants had an additional 
two-week period where they could make up for any missed sessions. Exercise training was 
supervised by an Accredited Exercise Physiologist. The training involved resistance 
exercises that were designed to target the major muscles of the upper and lower body, with 
1 – 3 sets of each exercise performed at an intensity of 8 – 12 repetition maximum, defined 
as the maximum weight that could be lifted 8 – 12 times. Exercise prescription was 
progressive and modified by the Accredited Exercise Physiologist according to the 
individual’s response. 
Adherence and tolerance to the exercise intervention 
Completion of the study was defined as attendance at both the baseline and post-
intervention assessments. Adherence to the exercise intervention was recorded as the total 
number of exercise sessions attended out of a possible 18. Following each exercise session, 
participants were asked to rate their perceived exertion during exercise and their tolerance 
of the session. Perceived exertion was assessed with the Borg scale, where a score of 6 
represents no exertion and a score of 20 represents maximal exertion.23 Tolerance was 
assessed using a 7-point Likert scale, where a score of 1 indicated the exercise session was 
extremely intolerable and a score of 7 indicated an extremely tolerable session. Average 
perceived exertion and average tolerance of the exercise intervention were calculated for 
each participant and determined by the sum of each participant’s data divided by the 
number of exercise sessions attended. 
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8.2.3 Statistical analysis 
Statistical analyses were conducted using Statistical Package for the Social Sciences 
(v. 25, IBM Corporation, Somers, NY, USA). Data are expressed as mean ± SD or median 
[IQR] where the data were not normally distributed. Fisher’s Exact Test was used to assess 
differences in study completion rates between well-nourished and malnourished 
participants. Two-tailed independent t-tests, or the Mann-Whitney test where the data were 
not normally distributed, were used to test for differences in participant characteristics and 
change scores of variables according to nutritional status or dietary intake. Paired t-tests, 
or the Wilcoxon signed rank test where the data were not normally distributed, were used 
to assess if body composition and physical functioning variables changed significantly 
from baseline to post-intervention. 
8.3 Results 
8.3.1 Participant characteristics 
Participant flow through the study and baseline participant characteristics have been 
reported previously (Appendix B).24 Briefly, thirty-three patients enrolled in the study with 
a median age of 68 [IQR 62 – 73] years and a mean BMI of 25.7 ± 3.4 kg/m2. Participants 
were predominantly male (68%), with a diagnosis of MPM (85%) and an ECOG 
performance status rating of 0-1 (97%). All participants completed the PG-SGA and eight 
(24%) were classified as malnourished. Thirty participants (91%) completed the appetite 
questionnaire and food record, and of these, nine (30%) had a poor appetite and eleven 
(37%) did not meet energy and protein requirements. 
8.3.2 Nutritional status and dietary intake among participants who 
completed the intervention 
Of the 27 participants who completed the intervention, 26 (96%) had complete 
nutritional status data available and 25 (93%) had complete dietary intake data. Regarding 
the incomplete data, one participant did not complete the 3-day food record at baseline and 
one participant declined to complete the PG-SGA and weight measurement post-
intervention; therefore energy (kcal/kg/day) and protein (g/kg/day) intake could not be 
calculated for these participants. No differences were observed in demographic or disease 
characteristics between participants according to nutritional status or dietary intake group 
(Table 8.1 and Table 8.2). The majority of participants (73%) who completed the 
intervention were well-nourished at baseline and post-intervention (Figure 8.1). Only 40% 
had adequate energy and protein intake at both baseline and post-intervention (Figure 8.1). 
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8.3.3 Differences in completion rates, exercise adherence and tolerance 
according to nutritional status and dietary intake 
Study completion rates were not significantly different between participants who 
were well-nourished or malnourished at baseline (84% vs. 75%; p=0.616). Among 
participants who completed the intervention, there were no significant differences between 
participants well-nourished and malnourished with regard to the number of exercise 
sessions attended (median 18.0 [IQR 18.0 – 18.0] vs. median 18.0 [IQR 13.0 – 18.0]; 
p=0.427), the average tolerance of exercise sessions (median 6.1 [IQR 5.8 – 6.5] vs. 
median 5.7 [IQR 5.2 – 5.9]; p=0.073) or the average rating of perceived exertion of 
exercise sessions (median 12.7 [IQR 12.1 – 13.8] vs. median 12.3 [IQR 12.3 – 12.8]; 
p=0.611; Table 8.3). 
Study completion rates were not significantly different between those with adequate 
and inadequate dietary intake at baseline (89% vs. 82%; p=0.611), although three 
participants did not complete the baseline food record. Among participants who completed 
the intervention, there were no significant differences between participants with adequate 
and inadequate intake with regard to the number of exercise sessions attended (median 
18.0 [IQR 14.5 – 18.0] vs. 18.0 [IQR 18.0 – 18.0]; p=0.567), the average tolerance of 
exercise sessions (median 6.0 [IQR 5.9 – 6.3] vs. median 5.8 [5.3 – 6.5]; p=0.495) or the 
average rating of perceived exertion of exercise sessions (median 12.6 [IQR 12.3 – 13.7] 
vs. median 12.3 [IQR 12.0 – 12.9]; p=0.338; Table 8.3). 
8.3.4 Changes in body composition following the exercise intervention, 
according to dietary intake 
Change in appendicular skeletal muscle mass differed significantly between the 
adequate and inadequate dietary intake groups (mean difference 0.40 [95% CI 0.14 – 0.67] 
kg/m2; p=0.005; Figure 8.2). Following exercise training, appendicular skeletal muscle 
mass significantly increased in participants who had adequate dietary intake (mean change 
+0.43 [95% CI 0.18 – 0.67] kg/m2; p=0.004); there was no significant change in participants
with inadequate dietary intake (mean change +0.03 [95% CI -0.13 – 0.19] kg/m2; p=0.737). 
Change in body fat (%) did not differ significantly between the adequate and 
inadequate dietary intake groups (median difference -0.15 %; p=0.765; Figure 8.2). 
Following exercise training, body fat (%) did not change significantly in participants with 
adequate dietary intake (median change -0.45 [IQR -2.7 – 0.4] %; p=0.314) or inadequate 
dietary intake (median change -0.3 [IQR -1.2 – 0.5] %; p=0.414). 
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8.3.5 Changes in physical functioning following the exercise intervention, 
according to dietary intake 
There were no differences between those with adequate and inadequate dietary intake 
for change in the repeated chair rise (mean difference 0.43 [95% CI -0.90 – 1.76] sec; 
p=0.504), Timed Up and Go (median difference -0.09 sec; p=0.734), relative one-
repetition maximum leg press (median difference 0.02; p=0.643) or Six Minute Walk Test 
(median difference -4.7 m; p=0.600; Figure 8.3). 
Following exercise training, the chair rise improved significantly in participants with 
both adequate dietary intake (median change -0.93 [IQR -2.25 – -0.37] sec; p=0.021) and 
inadequate dietary intake (median change -1.23 [IQR -2.75 – -0.24] sec; p=0.004). Timed 
up and go improved significantly in participants with adequate dietary intake (median 
change -0.30 [IQR -1.55 – 0.39]; p=0.012) but not in those with inadequate dietary intake 
(median change -0.39 [IQR -0.65 – 0.17] sec; p=0.221). Relative 1RM leg press improved 
significantly in participants with both adequate dietary intake (median change 0.23 [IQR 
0.06 – 0.38]; p=0.008) and inadequate dietary intake (median change 0.21 [IQR 0.05 – 
0.32]; p=0.001). Six Minute Walk Test improved significantly in participants with adequate 
dietary intake (median change 46.8 [IQR 27.7 – 100.0] m; p=0.011) but not in those with 
inadequate dietary intake (median change 42.1 [IQR -11.3 – 120.0] m; p=0.075). 
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Table 8.1 Demographic, disease and nutritional characteristics of participants who were well-nourished and malnourished, n=26 
All participants (n=26) Well-nourished (n=19) Malnourished (n=7) 
n % n % n % P value 


















































Cancer treatment prior to intervention, 
yes 
9 34.6 5 26.3 4 57.1 0.188 
Cancer treatment during intervention, 
yes 
7 26.9 4 21.0 3 42.9 0.340 

















Normal appendicular lean mass over 
study period 
11 42.3 9 47.4 2 28.6 0.658 
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All participants (n=26) Well-nourished (n=19) Malnourished (n=7) 
n % n % n % P value 
















Adequate intake over study period 10 38.5 8 44.4 2 28.6 0.659 
















Normal appetite over study period* 17 65.4 16 88.9 1 14.3 0.001 
ECOG – Eastern Cooperative Oncology Group; DXA – Dual-Energy X-Ray Absorptiometry; #assessed at baseline, ^median, IQR, □DXA measured appendicular lean mass ≤7.26 kg/m2 
for men and ≤5.45 kg/m2 for women; ■Score ≤37 on Anorexia Cachexia Scale; *Well-nourished, n=18 and malnourished, n=7 
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Table 8.2 Demographic, disease and nutritional characteristics of participants with adequate and inadequate intake, n=25 
All participants (n=25) Adequate intake (n=10) Inadequate intake (n=15) 
n % n % n % P value 


















































Cancer treatment prior to intervention, 
yes 
9 36.0 4 40.0 5 33.3 0.734 
Cancer treatment during intervention, 
yes 
7 28.0 3 30.0 4 26.7 0.856 

















Normal appendicular lean mass over 
study period 
10 40.0 3 30.0 7 43.8 0.405 
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All participants (n=25) Adequate intake (n=10) Inadequate intake (n=15) 
n % n % n % P value 
Nutritional status at baseline (PG-SGA) 
Well-nourished 






















Well-nourished over study period 18 72 8 80.0 10 66.7 0.467 
















Normal appetite over study period* 16 64.0 6 66.7 10 66.7 1.000 
ECOG – Eastern Cooperative Oncology Group; DXA – Dual-Energy X-Ray Absorptiometry, PG-SGA – Patient-Generated Subjective Global Assessment; #assessed at baseline, ^median, IQR, 
□DXA measured appendicular lean mass ≤7.26 kg/m2 for men and ≤5.45 kg/m2 for women; ■Score ≤37 on Anorexia Cachexia Scale *inadequate intake, n=15 and adequate intake, n=9
Table 8.3 Differences in adherence and tolerance to exercise between nutritional status and dietary intake groups 
Well-nourished (n=19) Malnourished (n=7) Adequate intake (n=10) Inadequate intake (n=15) 
Median IQR Median IQR P value Median IQR Median IQR P value 
Sessions attended, # 18.0 18.0 – 18.0 18.0 13.0 – 18.0 0.427 18.0 14.5 – 18.0 18.0 18.0 – 18.0 0.567 
Average tolerance 6.1 5.8 – 6.5 5.7 5.2 – 5.9 0.073 6.0 5.9 – 6.3 5.8 5.3 – 6.5 0.495 
Average RPE 12.7 12.1 – 13.8 12.3 12.3 – 12.8 0.611 12.6 12.3 – 13.7 12.3 12.0 – 12.9 0.338 
RPE – Rating of Perceived Exertion 
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Figure 8.1 Nutritional status and dietary intake at baseline and post-intervention
Figure 8.2 Differences in the change in body composition. a) appendicular skeletal 













Malnourished or inadequate intake: 
post-intervention only 
Malnourished or inadequate intake: 
baseline only 
Malnourished or inadequate intake: 
baseline and post intervention 
■ \Veil-nourished or adequate intake: 
baseline and post-intervention 
Nutritional status Dietary intake 
a) b) 
£ p<0.05 a 1.5 8 e � 
;J • 6 £ 1.0 
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" -0.5 0 E :a z • r r • .. G -4 • • -1.0 z 
5 -6 .. 
tr -1.5 n C -8 " • Adequate intake Inadequate intake Adequate intake Inadequate intake u 
Adequate intake: a:25 kcal/kg/day and 21.0 g/kg/day protein and baseline and post-intervention 
0 Inadequate intake: <25 kcal/kg/day and/or <1.0 g/kg/day protein at baseline and/or post-intervention 
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a) Chair rise b) Timed Up and Go
c) Relative one-repetition maximum d) Six-Minute Walk Test
Figure 8.3 Differences in change in physical functioning outcomes according to 
dietary intake group, n=23 
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8.4 Discussion 
We examined if nutritional outcomes impacted completion or efficacy of a 6-week 
resistance exercise intervention.  The majority of participants (73%) were well nourished 
over the course of the intervention, however only 40% of participants maintained adequate 
intake at pre and post intervention. There were no differences in completion rates, 
adherence to, or tolerance of the exercise sessions according to nutritional status or dietary 
intake group. Participants with adequate intake had a significant increase in appendicular 
skeletal muscle mass, while those with inadequate intake had no change in appendicular 
skeletal muscle mass. Notably, there were no significant differences in the physical 
functioning response to exercise according to the dietary intake group. 
We previously reported excellent adherence and tolerance to the exercise intervention 
overall, and in this study we report that there were acceptable study completion rates among 
both well-nourished and malnourished participants (84% and 75%, respectively) and both 
nutritional status groups reported the exercise sessions were tolerable. Our results indicated 
that malnourished patients with MPD are capable of completing a short resistance exercise 
training program. To our knowledge, no other study in advanced cancer has directly 
compared exercise intervention completion rates according to nutritional status. However, 
in a previous 3-month combined nutrition and exercise intervention, where one-third of the 
participants with advanced cancer were at nutritional risk, the majority of participants 
(97%) completed the intervention.25 The individualized prescription of exercise was a 
central component of our study and the previous intervention. Having flexibility in the 
exercise prescription for participants with malnutrition, who have poorer baseline physical 
functioning and greater fatigue, may be integral to their successful completion of exercise 
interventions. 
Participants with MPD who consumed adequate intake had a significant increase in 
appendicular skeletal muscle mass following the exercise intervention. There was no 
change in appendicular skeletal muscle mass among participants with inadequate intake. 
To our knowledge, this is the first study in patients with an advanced cancer to evaluate 
the relationship between dietary intake and body composition outcomes from resistance 
exercise training. Our results raise the possibility that addressing inadequate intake or 
maintaining adequate intake could optimize the skeletal muscle response to exercise. This 
is a particularly important finding as low muscle mass is associated with a range of 
negative outcomes for patients, including poorer quality of life,4 increased risk of 
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treatment toxicities6 and poorer survival.6 Nutrition screening, using a tool such as the 
Malnutrition Screening Tool (MST)26 could be a fast and effective way to identify patients 
eating less than usual and requiring nutritional counselling and oral nutrition supplements 
to meet dietary intake recommendations.26 As patients with MPD are at high risk of 
inadequate intake,2 routine screening and access to nutrition support should be considered 
alongside exercise interventions. 
Optimizing physical functioning is also important for patients with advanced cancer. 
We found no significant differences in physical functioning outcomes between 
participants with inadequate and adequate energy and protein intake. Following the 
exercise intervention, we observed positive changes among both dietary intake groups for 
the chair rise and 1RM leg press. This suggests that resistance exercise training is 
beneficial even for cancer patients who are unable to meet dietary intake 
recommendations. This is particularly relevant for advanced cancer patients, as dietary 
intake can remain suboptimal even following nutritional intervention.27 
A limitation of the current study is the small sample size, therefore we were unable 
to incorporate other confounding health issues such as cancer progression and treatment 
into our statistical analysis and cannot draw conclusions about causality. The majority of 
participants with malnutrition also had a good performance status and therefore may not 
be representative of the broader population of malnourished patients with advanced 
cancer, particularly those with poorer performance status. More unwell patients could be 
less likely to commence, complete, adhere to and tolerate the exercise intervention. 
Exertion and tolerance of the exercise intervention were measured using the Borg scale 
and a 7-point Likert scale, respectively. Both measures are participant-rated and therefore 
subjective and may not represent the level of objective physiological exertion or tolerance 
experienced by participants. Additionally, as dietary intake was only assessed at two time 
points, before and after the intervention, we are unable to determine the duration and 
stability of any inadequate energy and protein intake. More frequent monitoring of dietary 
intake for example weekly or fortnightly could capture the duration of inadequate intake. 
Repeated 24-hour dietary recalls28 could be one way to increase the frequency of dietary 
intake monitoring, without substantially increasing participant burden. 
As resistance exercise interventions can increase skeletal muscle mass and improve 
physical functioning, they have the potential to improve quality of life, treatment tolerance 
and survival in patients with advanced cancer. However, the response to resistance 
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exercise could be impeded by poor tolerance to exercise prescription and inadequate 
intake. Compared to patients with early stage cancer, patients with advanced cancer, as in 
the current study, are more likely to experience malnutrition and a poor appetite,29 which 
may negatively affect their ability to participate in exercise and eat adequately during an 
exercise intervention.  
As exercise oncology research begins to include more patients with advanced cancer,30 
the impact of the unique nutritional issues that characterize this patient group needs to be 
evaluated to determine how to best optimize patient outcomes. This study offers insight into 
how nutrition and exercise outcomes interact in patients with MPD and the potential to 
improve response to exercise with combined interventions. 
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9.1 Overview 
This research aimed to provide information on the physical activity, nutritional status 
and body composition of patients with MPD and their relationship with patient outcomes, 
as well as examine the effects of nutritional status and dietary intake on outcomes of an 
exercise intervention. This chapter is a summary of the findings from a literature review 
and three experimental studies that were conducted in patients with MPD, and 
acknowledges the strengths, limitations and implications of the work. 
Chapter Two is a critical review of the literature. There is a lack of information in the 
literature regarding the prevalence of inactivity, functional impairment, malnutrition and 
low muscle mass in patients with MPD, and their associations with patient outcomes, 
confirming the value of further investigation. There is also a limited understanding on the 
effect of different body composition assessment methods on the classification of low 
muscle mass and the subsequent conclusions that are drawn. Furthermore, there is little 
information on the nutritional status and dietary intake of participants included in exercise 
interventions, and the impact that these nutritional factors have on exercise outcomes. 
In Chapter Three, the aim was to use accelerometry to characterise physical activity 
levels and their relationship with patient outcomes. The majority of participants did not 
meet physical activity guidelines; and compared to participants with good performance 
status, participants with a poor performance status spent a greater proportion of their day 
as sedentary and a lower proportion of their day participating in light activity. These results 
indicated that patients with MPD were inactive, and performance status and survival were 
associated with activity levels. Accelerometry was well tolerated as a tool for assessing 
physical activity levels in this population. 
In Chapter Four, the aim was to compare body composition assessment methods, 
namely CT and DXA, which are commonly used in the classification of low muscle mass 
in research. There was a moderate positive correlation between skeletal muscle index and 
appendicular skeletal muscle index and a moderate agreement between the CT cut-points 
from Prado et al1 and the DXA cut-points from Baumgartner et al2, but no significant 
agreement between the other cut-points evaluated. These findings highlighted that 
although the body composition assessment methods of CT and DXA were correlated, there 
were differences between methods when they were used to classify low muscle mass. 
In Chapter Five, the aim was to determine the prevalence of low muscle mass and 
malnutrition and investigate their relationship with physical activity levels and quality of 
life in patients with MPM. There were high rates of low muscle mass and malnutrition. 
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Compared to participants with normal muscle mass, participants with low muscle mass 
were more sedentary and participated in less light activity; and compared to participants 
who were well-nourished, those with malnutrition had poorer quality of life. These results 
indicated that low muscle mass and malnutrition were common among patients with MPM 
and were associated with negative outcomes. 
In Chapter Six, the aim was to determine the prevalence of poor physical functioning 
and nutritional outcomes in the two years from MPM diagnosis and provide a description 
of functional and nutritional status over time. Functional and nutritional impairment were 
common throughout the 2 years post diagnosis and for many participants, impairments 
persisted or reoccurred during the follow-up. These results indicate a need for screening 
in clinical practice to identify patients with functional and nutritional impairment who 
could benefit from supportive care interventions. 
In Chapter Seven, the aim was to describe changes in body composition over time and 
their relationship with activity levels and dietary intake. Multiple patterns of change in body 
composition were found. Ultimately, compared to participants with muscle maintenance, 
those with muscle loss had poorer survival and decreased activity levels over time. 
Interventions that target muscle loss or physical activity may benefit patients with MPM. 
In Chapter Eight, the aim was to determine if completion rates and response to an 
exercise intervention differed according to nutritional status and dietary intake. There were 
acceptable study completion rates for participants with malnutrition. Compared to 
participants with inadequate dietary intake, participants with adequate intake had a greater 
increase in muscle mass, however there were no differences in the physical functioning 
response to exercise. This result suggests that adequate intake could optimise muscle 
gains. Importantly, those with malnutrition or inadequate intake can still complete and 
gain benefit from an exercise intervention. This could have implications for the 
development of exercise and combined interventions in advanced cancer populations. 
9.2 Limitations and strengths 
The research has a small sample size relative to studies completed in other cancer 
populations, such as those with advanced lung cancer.3, 4 This was expected given MPM 
is a rare cancer with fewer than 800 new cases diagnosed across Australia each year.5 
Despite the anticipated small sample size, research in MPM was needed given the lack of 
existing data on physical activity, nutritional status and body composition. Research in 
this field was particularly important as supportive care interventions could offer benefit to 
a patient population with incurable disease and limited treatment options. Therefore, the 
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overarching purpose of this research was to provide a platform from which intervention 
studies could be developed. 
The research includes a heterogeneous population of patients with MPM. Patients 
with MPM could enrol in the studies at any time from the point of diagnosis and regardless 
of their past, present or future cancer treatment plans. As a result, there are multiple 
confounding factors that were not adjusted for in the statistical analysis due to the 
relatively small sample size, which limit the conclusions that can be drawn from the 
research. The alternative would have been to control for these confounding factors and 
include patients at specified time points within the disease course or treatment journey. 
However, this would have had a negative impact on the sample size for two reasons. 
Firstly, the time of diagnosis was a particularly challenging time to recruit participants. 
Twenty percent of the participants who declined to participate reported feeling too 
overwhelmed with their recent diagnosis. Second, there is no standard treatment pathway 
for patients with MPM and while approximately half of participants had treatment during 
the course of their disease, the other half of participants did not. Therefore, the research 
would not have been feasible if the eligibility criteria were restricted to patients who were 
newly diagnosed or due to commence chemotherapy. 
A lack of benefit to patients is a commonly reported barrier to participation in clinical 
trials.6 Two of the experimental studies conducted, the cross-sectional and longitudinal 
observational studies offered no direct benefit to participants. The recruitment rate for the 
longitudinal observational study was 43%. Of the patients excluded, approximately one-
third were ineligible, however the remaining two-thirds declined to participate. None of the 
patients who declined participation reported a lack of benefit to themselves as a reason for 
non-participation, however this may have been due to social desirability bias. Therefore, 
the lack of benefit to patients may have had a negative effect on the participation rate. 
The health of the patients with MPM may also have had an impact on the participation 
rate. Almost one-third of patients who declined to participate reported being too unwell. 
Assessments for this research were completed over one hour, which could be inconvenient 
for unwell patients. Consequently, this research most likely included the more well 
patients with MPM and the results may not be generalisable to the larger MPM population. 
Considering ways that patients can participate with minimal time and effort could improve 
future participation rates of unwell patients with MPM. 
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Previous research has reported that the inconvenience and cost of travel for patients 
with cancer are also important considerations for participation in clinical trials.7 Similarly 
during the recruitment process in this research, patients indicated that one of the main 
considerations for study participation was whether they would need to make additional 
visits to the hospital. A high proportion of the participants were from regional or remote 
Western Australia, and additional travel would have been a significant burden. 
Consequently, the timing of study assessments in the longitudinal observational study was 
flexible. This meant that on occasion there was a longer than expected time between study 
assessments. The differences in the timing of follow up between participants created some 
challenges during data analysis. However, the alternative would substantially limit 
participation. The burden associated with attending assessments should be carefully 
considered when planning future research in patients with MPD. 
As the study was conducted in an advanced cancer population, participant burden was 
a key consideration when planning the research. For example, informal feedback from 
participants during the longitudinal observational study indicated that completing a 3-day 
food record was burdensome. Therefore, an amendment was made to the study protocol 
and participants were asked to complete a 3-day food record at the baseline assessment 
only; and the shorter 24-hour recall was completed at subsequent assessments. Participants 
appeared to be more engaged in the 24-hour recall process. While results of a 24-hour 
recall may not represent habitual dietary intake, the method was more acceptable to 
patients. Compared with a 3-day food record, the 24-hour recall could be more feasible in 
patients with advanced cancer when dietary intake needs to be assessed at multiple time 
points. This also indicates the need to be pragmatic in these types of studies. 
The completion of body composition assessments was a significant challenge in this 
study population. The DXA machine used for this study was a 10-minute walk from the 
Respiratory and Medical Oncology clinics, which was difficult for most participants. This 
was managed by using wheelchairs and the hospital buggy service to transport participants 
to the DXA machine. Some participants were not able to lie flat on the DXA bed or 
independently get on and off the DXA bed. This was managed by providing pillows and 
physical assistance to participants. Although these challenges understandably led to some 
participants declining to complete a DXA scan, there were no serious adverse events 
related to body composition assessment or any other measurements, indicating that the 
assessments were safe. However, this experience highlighted that DXA may not be the 
most practical way to assess muscle mass in patients with advanced cancer; particularly in 
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prospective research where participants have disease progression and become more unwell 
over time. For future research it may be more feasible to measure muscle mass using CT. 
9.3 Implications for practice and future research 
This research provides preliminary data on functional and nutritional impairment in 
MPM and indicates that these issues are prevalent in this patient population. While this 
research did not investigate the proportion of participants who had received a referral to 
an exercise physiologist, physiotherapist or dietitian for supportive care, current figures 
suggests that functional and nutritional impairment in patients with cancer goes undetected 
in a high proportion of cases,8, 9 which could have a negative impact on patient-centred 
outcomes. Several factors could contribute to this finding, including a lack of awareness 
of the benefits of interventions to address functional impairment,10 and insufficient 
clinician skills to identify nutritional issues.11 Exercise physiologists, physiotherapists and 
dietitians have an important role to play in providing education to clinicians to increase 
awareness of functional and nutritional impairment in MPM, and to improve clinician 
skills in identifying these problems. Existing guidelines recommend the integration of 
functional assessment10 and nutrition screening12 into routine clinical care for patients with 
cancer to facilitate timely access to supportive care interventions. The high rates of 
functional and nutritional impairment reported in this research indicate there is a need for 
health services to implement functional assessment and nutrition screening into routine 
care of patients with MPM. At present, routine assessment of function and nutrition is not 
conducted in the pleural outpatient clinic in Western Australia. Consequently, future 
research will focus on implementing functional assessment and nutritional screening 
practices into routine clinical care using an implementation science approach that 
considers the barriers and enablers of change. 
As MPM has no cure, improving survival and the ability to tolerate cancer treatments 
is of high importance. A growing body of research suggests that low muscle mass and 
poor muscle quality is associated with reduced time to disease progression and overall 
survival13 and could increase the likelihood and severity of toxicity from chemotherapy.14 
A study investigating muscle mass, muscle quality, survival and treatment toxicity in 
MPM presents several methodological challenges. First, the study would require a much 
greater sample size than the one recruited in this research. Based on the research in this 
thesis, using DXA prospectively is unlikely to be feasible due to low incidence of disease5 
and the additional burden associated with DXA in unwell patients with advanced cancer. 
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Additionally, DXA does not measure muscle quality.15 CT could be a more practical way 
to undertake this research as scans are performed as part of routine clinical care, accessible 
for retrospective analysis. CT also has the capacity to measure both muscle mass and 
quality.15 Although CT is more practical, the findings of this work indicate existing cut-
points may have limited utility. Therefore, the relationship between muscle mass, muscle 
quality, survival and treatment toxicity will be evaluated with data as continuous variables 
as recommended by the American Society of Parenteral and Enteral Nutrition.16  
Research presented in this thesis indicates that inadequate dietary intake and 
malnutrition are common in patients with MPD and associated with poor outcomes such 
as reduced quality of life.  Additionally, adequate dietary intake may be required to 
increase muscle mass during exercise training. Therefore, the next phase of this research 
will be to determine if a multi-modal program of nutritional support with exercise training 
could optimise the therapeutic effect of exercise. Considering aerobic exercise may 
interfere with muscle maintenance or gain in patients with cancer,17 resistance training 
will be the primary mode of exercise. Existing research indicates that intervention with 
dietary counselling and oral nutrition supplements can improve energy and protein intake 
in patients with cancer.16, 17 These interventions will be the foundation of the nutritional 
support program. Additionally, preliminary research indicates amino acid 
supplementation with beta-hydroxy-beta-methylbutyrate (HMB), the active metabolite of 
leucine, slows the breakdown of protein in muscle tissue and enhances muscle protein 
synthesis, resulting in improvements in muscle mass.18 Given the substantial challenges 
to maintaining and improving muscle mass in advanced cancer patients, HMB 
supplementation could be a novel way to improve the effects of traditional nutrition 
support in combination with resistance exercise training. 
9.4 Conclusion 
This research investigated physical activity, functional and nutritional status and 
body composition in patients with MPD and its relationship with patient outcomes. In an 
effort to better understand supportive care outcomes, this research also evaluated the 
effects of nutritional status and dietary intake on outcomes of an exercise intervention. 
There were high rates of inactivity, poor physical function, malnutrition and low muscle 
mass among patients with MPD. Low muscle mass and malnutrition were associated with 
negative outcomes. Muscle loss over time was associated with a decline in physical 
activity, therefore interventions that target muscle mass or physical activity could offer 
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benefit to these patients. The results of the exercise intervention indicated that 
malnutrition should not preclude participation, however dietary intake could influence 
body composition outcomes. Therefore, combined nutrition and exercise interventions 
could be most impactful. Research is needed to investigate the relationship between low 
muscle mass and survival, as well as the feasibility and efficacy of combined 
interventions in patients with MPD. 
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outcomes including a lower risk of cancer recurrence, im- 
proved mortality, and beneficial effects on a range of patient- 
reported outcomes (1,2). More recent research has indicated 
that sedentary behavior may also impact the health of cancer 
survivors (3). While physical activity and sedentary behav- 
ior are important targets for cancer survivorship research, 
accurate and reliable measurement of these constructs re- 
mains a challenge. 
Most research to date on physical activity and sedentary 
behavior in cancer survivors has been characterised by the 
use of self-reported assessments, most often using measures 
that rely on a person's recall of their physical activity and/or 
sedentary behavior. The reliability and validity of self-report 
physical activity questionnaires are dependent on participants 
activity levels (i.e., active adults have more measurement error 
than less active adults) (4-6). Additionally, high-volume and 
less discrete behaviors, such as sedentary time and light 
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intensity activity that occur throughout the day are difficult 
to capture by self-report. Self-reported measures of seden- 
tary time and physical activity have been shown to have 
only poor to fair agreement with objective measures of these 
behaviors using accelerometry (7), although it could be 
argued that these two methods are not measuring the same 
constructs (6). 
Using accelerometers to measure activity and sedentary 
behavior is becoming increasingly common in the cancer 
survivorship context. As accelerometry provides an objective 
measure of important patient-centered outcomes, it is appeal- 
ing to both researchers and clinicians. Accelerometry also 
enables precise and reliable measurement across the move- 
ment continuum (ie., sleep, sedentary, and physical activity 
behaviors) that occur at different intensities and patterns 
throughout the 24-h day. Accurate quantification of physical 
activity and sedentary behavior via accelerometry facilitates a 
better understanding of these exposures and how they relate to 
health outcomes in cancer survivors. Accelerometer data also 
allow for the complex characterisation of physical activity 
accumulation patters, including the identification of times of 
day and days of the week in which individuals are more or less 
active or sedentary. This information is valuable for develop- 
ing interventions aimed at changing these behaviors (8). 
Given the potential clinical applications of accelerometers 
for cancer populations, differences in population character- 
istics (compared to the general population), and the increas- 
ing research focus on cancer survivorship, understanding 
how accelerometers have been applied in cancer research is 
of particular importance. 
Although accelerometers have the capacity to provide 
richer and more accurate data about physical activity and 
sedentary behaviors compared with self-report measures, the 
quality of the data produced is dependent on an array of 
decisions made during data collection and processing. These 
critical decisions include device type and placement, wear- 
time protocols, epoch length, filter application, criteria for 
non-wear time, criteria for a valid day of wear time, and 
how to process data to obtain summary measures of seden- 
tary time, light-intensity activity and moderate and vigorous 
physical activity (MVPA) (9,10). These decisions can affect 
the summary measures derived (e.g., minutes of MVPA per 
day) and also the observed associations between these sum- 
mary measures and health outcomes. It is therefore vital that 
accelerometer data collection and processing decisions are 
clearly reported in journal articles summarizing accelerometer- 
based studies. Failure to report this information means that 
studies are not replicable and also makes it difficult to deter- 
mine if discrepant results across studies are "real" differences 
or simply due to measurement and data processing de- 
cisions (l). In this narrative review we aimed to: (a) 
summarize the quality of reporting on accelerometer data 
collection, data processing, and outcome measures of pub- 
lished research that has used accelerometers in cancer survivor 
populations; (b) identify gaps in reporting accelerometer data 
collecting, data processing, and outcome measures; and (c) 
OBJECTIVE ACTIVITY MONITORING 
provide recommendations to improve the quality of future 
accelerometer-based research. 
METHODS 
A comprehensive Pub.Med search of articles published 
in English was conducted. The initial search was run in 
January 20 I 7, and a subsequent final search was conducted 
in May 2017. The natural language and MeSH terms in- 
cluded were as follows: "physical activity," "sedentary," 
"sitting," "neoplasms," "cancer," "malignancy," "tumor," 
"tumor," "accelerometry," "actigraphy," "acceleromet," 
" monitor," "device," "tracker," "global positioning." Refer- 
ence lists of relevant review articles were also screened. Two 
review authors (V.C. and J.V.) independently examined the 
studies identified for inclusion in the review. Reviews, ab- 
stracts, editorials, study protocols, and studies that only used 
pedometers/step counters or physical activity trackers to 
measure physical activity were excluded. Data from the in- 
cluded studies were independently extracted and tabulated by 
four review authors (C.P.-M., E.J, T.B., and J.M.), with data 
from each study reviewed by at least two of these authors. The 
parameter was recorded as not applicable (NA) when it did not 
apply to the given study because of the device used(e.g., non- 
wear time protocol does not apply for studies that used the 
Sense Wear Armband device because it only records when 
being wom), or when the outcome measures were not relevant 
(e.g., sedentary time was not reported in the article, therefore 
no sedentary cut point was reported). In all cases, disagree- 
ments or discrepancies were resolved by consensus. 
Outcome Measures 
Study characteristics. Data were extracted regarding 
population characteristics (e.g., cancer population, average 
age), study design, timing of observations, and the acceler- 
ometer used. 
Accelerometer data collection and analysis. Information 
was extracted regarding how the device was delivered (i.e., in 
person or via mail), device used (e.g., activPALIM), device 
placement (e.g, hip), wear time protocols (i.e., instructions to 
participants on daily time of wear and the total nwnber of days 
of wear), software used for processing, the vector used in 
processing, any filters applied during processing, epoch length 
(in data collection and during processing), how non-wear time 
was identified, how a valid day of wear time was defined, 
minimum number of valid days of wear time required for 
inclusion in analysis, which cut points were used to create 
summary measures of sedentary time, light intensity activity 
and/or MVP A, and any additional information on how total 
physical activity was calculated. Where one of the included 
articles referred to a previously published article rather than 
describing any of the above items in their own methods 
section, the relevant information was extracted from the 
cited study. 
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Accelerometer data reporting. Data were collected 
regarding time spent in: D) sedentary time or sitting/lying, 2) 
light intensity activity or standing activity, and 3) MVPA or 
stepping. The proportion of participants meeting physical 
activity guidelines (ie., 2150 min MVPA or 75 min of 
vigorous activity) was also extracted, as well as any addi- 
tional information on how physical activity guideline cut 
points were applied (e.g., 10-min bouts, physical activity 
over 5 d of the week). Compliance with accelerometer wear 
(i.e., number of participants that wore the device and were 
included in the analysis) was recorded along with the aver- 
age valid days of data, average wear time, and whether the 
analysis was adjusted for waking wear time. 
RESULTS 
The initial search in January 2017 yielded a total of 271 
records. The final search in May 2017 detected 43 addi- 
tional records and four additional articles were detected 
through other sources, making a total number of 314 re- 
cords identified in the search. After screening of titles, ab- 
stracts, and full text, 46 articles were deemed eligible for 
inclusion in the review (see Figure, Supplemental Digital 
Content I, study flow diagram, http://links.lww.com/MSS/ 
B279). Where there was more than one article reporting on 
the same data set, only the primary article reporting 
accelerometry outcomes were included. Secondary articles 
were excluded. In randomized controlled trials (RCTs) or 
cohort studies, only the baseline data were included, and in 
the case where the intervention and control group data were 
presented separately, only intervention group data were 
included. 
Study characteristics. Study characteristics are reported 
in Table I. The majority of studies (72%) targeted a single 
cancer group, namely breast (n = 17) (12,14,16,20,22,29,36,40- 
46,48,52,57), lung ( = 6) (17,18,21,27,38,39), colorec- 
tal (n = 5) (31,32,49,53,58), prostate cancer (n = 4) 
(19,25,37,54), and non--Hodgkin lymphoma (n = 1) (13) 
Other study populations were based on clinical characteristics, 
such as advanced cancer (34), cachexia (24), or sites of disease, 
such as brain metastasis (35) or malignant pleural effusion 
(28). Most study designs were cross-sectional ( = 28), with a 
further 10 prospective studies (16,20,22-24,26,27,48,49,52), 
six RCTs (19,39,43-46), one nonrandomized clinical trial (33), 
and one case series (34). The majority of cross-sectional and 
RCT studies (n = 35) were either following completion of 
active treatment (34%) (12,17,21,25,30,32,38,43,45,47,51,53) 
or "postdiagnosis" (17%) (13,14,40,50,54,55), with 
fewer studies focusing on before (11%) (15,33,39,41) or 
during treatment (9%) (44,46,56), whereas a portion of 
studies did not specify (26%) (18,19,28,29,31,36,37,42,57). 
For the prospective studies and case series (n = II), as- 
sessments often began during treatment (27%) (20,23,52), 
or following completion of primary treatment (30%) 
(16,22,26,48,49), with only one beginning at diagnosis (27) 
and two unspecified (24,34) 
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Over half (54%) of the studies used an ActiGraph® accel- 
erometer. Sense Wear Armband (11%) and activPAL (11%) 
devices were the next most common accelerometer models 
used. Most studies measured physical activity and/or seden- 
tary behavior with one accelerometer (98%), with only a sin- 
gle study using more than one research-grade accelerometer 
simultaneously (2%) (20). The majority of studies (63%) used 
a waist placement. Most studies used protocols of 7 d of wear 
time (76%) and waking hours only wear time (65%). 
How have studies reported physical activity and 
sedentary behavior data? Table I and the Supplemen- 
tary Table I (Supplemental Digital Content 2, description of 
accelerometry data analysis methods, http://links. lww.com/ 
MSS/8280) report study characteristics, data reporting, and data 
analysis methods of the reviewed studies. Of the 46 studies 
included, 45 reported physical activity or sedentary behavior 
data. One study only reported methods (20). Of these studies, 
outcomes were most often reported as hours or minutes per 
day (52%), with other studies reporting data as hours per 
minute per week (20%) (12,19,26,29,32,44,45,50,56), steps 
per day (15%) (17,23,27,34,35), total physical activ- 
ity counts (n = 5) (18,24,30,46,5 1), or kilocalories per week 
(= D) (43) 
Sedentary time was reported in 50% of studies. Of 
those, three studies did not report the cut point used to 
define sedentary behavior (15,16,22). Among those reporting 
cut points, the most commonly used sedentary cut points were 
Matthews et al. (59) (i.e., <101 counts per minute, 61%) 
(7,13,14,21,25,28,29,32,36,37,40,42,47,48,53), or using METs 
(60) [i.e., <1.5 MET; 22% (17,39,41,52,55)]. Sedentary time 
ranged in the studies from 189 min per waking day (52) to 
713 min per waking day (41). Bouts of sedentary time were 
reported in six studies (14,17,21,28,31,53). Prolonged sed- 
entary bouts were described as 20- min (13,14,28,31) or 
30- min (17,21,28,53). Time in 20-min sedentary bouts 
ranged from 185 min per waking day (14) to 339 min per 
waking day (31). Time in 30-min sedentary bouts ranged from 
153 min per waking day (53) to 185 min per waking day (21). 
Light intensity activity was reported in 43% studies. 
Cut points to categorize light intensity activity were not 
reported in one study (22) and were most often listed as a 
combination of Freedson and Matthews cut points (59,61) 
(i.e., 100-1951 counts per minute; 55%) (13,14,19,21,28,36,37, 
40,47,49,53). Light intensity activity ranged from 125 mind ' 
(54) to 551 mind' (40). 
Moderate and vigorous physical activity was reported in 
78% of studies. Cut point references were provided for all 
but three studies (22,43,50). Five studies cited cut points and 
analysis methods from a primary article (15,16,19,44,46). 
The most commonly used MVPA eut points were Freedson 
(6D[ie, 1,952; 50% (12-14,19,21,25,28,32,36,37,40,44- 
49,53)], or a MET cut point (62) (most commonly 2 3 METs, 
20%) (17,29,39,41,52,56,57). Time in MVPA ranged from 
3.7 mind'(36) to 150 mind'(22). MVPA in 10-min bouts 
was reported in eight studies (13,14,17,21,31,32,41,53), and 
ranged from 5.7 mind '(2I) to 5l mind '(31). 
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In our review, we identified accelerometer studies in 
cancer survivor populations differed in how they defined and 
reported on sedentary behavior and physical activity. With 
DISCUSSION 
The current physical activity guidelines for cancer survivors 
[i.e., > 150 min of MVPA per week (63)] were applied in 38% 
of studies. Seven studies specified that MVPA must occur in 
10-min bouts (13,14,16,21,47,53,56), and two specified that 
activity must occur on at least S d out of 7 d of the week 
(16,29). In studies that applied the guidelines, the percentage 
of participants meeting current physical activity guidelines for 
cancer survivors ranged from 4% (16) to 94% (47). 
Quality of reporting on data collection and pro- 
cessing. Quality of accelerometer reporting for data col- 
lection and processing-related items is outlined in Figure L 
Additional information regarding data collection and processing- 
related items is available in Supplemental Table I (Supplemental 
Digita1 Content 2, description of accelerometry data analysis 
methods, http://links.lww.com/MSS/B280) and Supplemental 
Table 2 (Supplemental Digital Content 3, summary of methods 
used in accelerometer-based studies, http://links.lww.com/ 
MSSB281). Accelerometer data collection-related items were 
generally well reponed and included accelerometer brand and 
model (100%), monitor placement (91%), and wear protocol 
(98% for number of days; 91% for hours per day). Deliv- 
ery method was the exception, with only 54% of studies 
reporting this infonnation. 
In contrast, accelerometer data processing-related items 
were generally poorly reported, particularly the definition of 
non--wear time (reported by 51% of studies), filters applied 
during processing (reported by 8% where applicable), valid 
day definition and minimum number of valid days (reported 
by 62% and 57% of studies, respectively), software and epoch 
length for processing the accelerometer data (53% and 61% 
respectively), and vectors used during processing (reported by 
60% where applicable). The most reported data processing- 
related items were cm points used to define sedentary time 
(87%) and MVP A (91%). Device-specific software was most 
commonly used to process accelerometer data (40% of all 
studies), and just over half of the studies (54%) reported pro- 
cessing the accelerometer data using 60-s epochs. 
Compliance was not reported in sufficient detail in 17 
studies; three were not applicable as participants and were 
only included in the study if they had provided valid accel- 
erometer data (36,37,48). Compliance with accelerometer 
wear ranged from 74% (24,27) 10 99% (40). The average (or 
median) number of valid days of data was reported in 13 
studies. A minimum wear-time criterion of 600 min was the 
most common (40%). A variety ofcriteria were used to define 
non-wear time and minimum number of valid days. When 
reported, this ranged from 3.6 (56)10 7.0 4(12,48). Wear time 
was reported in I0 studies and ranged from 14.I hd'(21) to 
23.7h4'(56). Nine studies did not report wear time, but did 
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[URE I-Percentage of accelerometer par adata items reported (n = 46). Green cells, reported; red, not reported; white,NA. 
regard to the quality of reporting on data collection and pro- 
cessing methods, data collection-related items were reported 
in the majority of studies, whereas data processing-related 
items were described in a smaller proportion of studies. 
Accelerometry has potential to generate detailed knowl- 
edge of the levels and patters of physical activity and sed- 
entary behavior in cancer survivors. It also provides 
opportunities for the investigation of associations between 
physical activity and sedentary behavior with health out- 
comes (including clinical outcomes such as fatigue, mortal- 
ity, and recurrence), and insight on how cancer treatments 
impact engagement in physical activity and sedentary be- 
havior. Accelerometry research can contribute to identifying 
minimal clinically important differences in physical activity 
and sedentary behavior, as well as the specific characteristics 
of what amounts of physical activity (or reductions in sed- 
entary behavior) are needed to facilitate improved cancer 
outcomes, Accelerometry output can also be translated into 
meaningful messages for cancer survivors (i.e., convert 
metrics into behavior targets for patients). The decreasing 
cost of accelerometers and increasing access to open-source 
data extraction and processing methodologies will make it 
easier to integrate objective activity monitoring into cancer 
survivor studies (64). However, to achieve beneficial health 
outcomes in oncology and public health, carefully consid- 
ered data processing and reporting decisions must be made. 
In comparison to a recent review by Montoye et al. of 
accelerometer-based intervention studies in the general 
population (10), a similar percentage of studies in our re- 
view failed to report on epoch length (36% [present study] 
vs 38%), days of data collected (9% vs 2%), minimum 
valid days (52% vs 44%), and brand of accelerometer (0% 
vs 2%). However, we found that the cancer survivorship 
literature reported fewer studies failing to report compli- 
ance (40% [present study] vs 64%), delivery method (46% 
vs 69%), non--wear time definition (49% vs 69%) and 
minimum wear time (38% vs 50%). One possible reason 
for this difference is that the earliest study included in our 
review was published in 2005, whereas the Montoye review 
included studies dating back to 1998, before standards 
checklists of accelerometry data collection and reporting had 
OBJECTIVE ACTIVITY MONITORING 
been published. Overall, the completeness of reporting on 
methods used to collect, process, and report accelerometry 
data in cancer survivor studies needs improvement. A formal 
consensus process for internationally agreed standards for 
accelerometer data collection, processing, and reporting has 
been suggested to help address such limitations (65). 
However, such guidelines have not yet been developed and 
published. Therefore, as in other recent reviews (9,10), we 
recommend that authors report all data collection and 
processing-related accelerometer paradata (in the main text 
and/or as supplementary material) to ensure that data can be 
accurately compared across studies and that others are able 
to replicate their methods. Examples of adequate reporting 
of accelerometer paradata and a template for reporting 
paradata are available in the recent review by Montoye et al. 
(I0). Guidance related to data collection and data process- 
ing decisions relating specifically to Actigraph devices, 
which were used in 54% of the studies included in the 
present review, are available in a recent review by Migueles 
ct al. (9). 
Three quarters of the studies included in this review used 
cut points to summarize accelerometer data into discrete 
variables (e.g., sedentary behavior, MVPA). The most com- 
monly used cut points across studies of cancer survivors were 
<10I counts per minute for sedentary behavior (59) and 
>1952 counts per minute for MVPA (61). Although the 
widespread adoption of these particular cut points allows 
comparison across studies (provided data collection and 
processing protocols are comparable), their use requires 
careful consideration in cancer survivor research. The same 
intensity" measured by an accelerometer will impart a 
different level of physiological stress on different people. 
The commonly used >1952 counts per minute cut point for 
MVPA was developed by Freedson et al, (61) based on in- 
direct calorimetry data collected during treadmill activities 
in a group of university students with a mean age 24 yr. 
In the current review, the mean age of participants ranged 
from 50 (52) t0 73 (19). Cancer survivors are often older, 
have comorbid conditions as well as ongoing cancer-related 
side effects, that impact functional capacity. Therefore, cut 
points developed from young healthy volunteers may not be 
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representative of physiologically "light" or "moderate" in- 
tensity activity in cancer survivor populations. Thus, con- 
sideration of accelerometer cut point algorithms validated for 
specific cancer survivor populations (and subpopulations) 
will be important (9). When appropriate, using the total 
volume of physical activity could also allow comparisons to 
be made across studies, while avoiding some of the issues of 
generic application of cut points which could be problematic 
in certain cancer groups (e.g., advanced cancer or those on 
treatment). When cut points are applied, we recommend 
authors acknowledge that there may indeed be limitations 
of this approach and should be mindful to justify their choice 
of cut points. 
Almost 40% of the studies reviewed here repon the per- 
centage of survivors that were meeting current physical activity 
guidelines (e.g., 150 mine-wk ' of MVPA). Recent studies have 
highlighted some concems with using accelerometer-measured 
MVPA to classify individuals as sufficiently active based on 
public health guidelines, and it has been argued that there 
may be situations where it is preferable to consider the total 
volume of physical activity rather than simply MVPA (66). 
These concerns could be particularly salient for cancer 
survivors who often face functional limitations and ongoing 
side effects of disease and treatments that could impact 
functional capacity. For example, an individual may have 
functional/mobility issues, or a particular tumour (e.g, lung), 
stage (e.g., stage IV), and/or treatment regime (e.g., lung 
resection resulting in reduced pulmonary capacity) that pre- 
cludes participation in what accelerometers categorize as 
MVP A Thus, the application of physical activity guidelines 
(developed in a young and healthy population) may not be 
appropriate. Development of cancer population-specific (or 
functional stale-specific) physical activity guidelines could 
help with this issue and would also add value to oncology 
care, by providing more specific guidelines for survivors 
and cancer care professionals. Additionally, the development 
of minimal clinically important differences for these populations 
could assist with interpreting a meaningful change in physi- 
cal activity and sedentary behavior levels beyond the appli- 
cation of physical activity guidelines. Funher research into 
this area will help determine the optimal strategies to deter- 
mine whether cancer survivors are achieving sufficient levels 
of MVPA to confer health benefits. We recommend that au- 
thors carefully consider the use of physical activity guidelines 
as an outcome measure, and when used, the rationale for in- 
cluding this outcome should be articulated and the limitations 
of this approach acknowledged. 
The most commonly used device in the studies included 
in our review was the Actigraph®, with the majority of 
these studies using a waist placement. Used in this manner, 
the Actigraph@ device is not able to differentiate between 
sitting and standing. Although some standing activities 
(standing quietly) require little to no movement (<101 counts 
per minute) and low-energy expenditure (<1.5 METs), 
they are not considered sedentary behaviors because the 
individual is not in a seated posture. For an individual standing 
1798 Official Journal of the American College of Sports Medicine 
still, the Actigraph@ will record the subject as engaging in 
sedentary time (i.e., <101 counts per minute or <1-5 METs), 
This issue is likely to be exacerbated in populations, which 
may have high amounts of sedentary time, such as people 
with advanced cancer. This has implications for assessing in- 
terventions designed to reduce sedentary behavior (i.e., sitting 
time). Only 10% of studies reviewed here used thigh-worn 
accelerometers, which have higher accuracy when measuring 
sitting and reclining than waist or wrist worn accelerometers. 
However, it is important to note that thigh-worm devices are 
less accurate in capturing activities involving primarily upper 
body motion (e.g., rowing, upper body resistance training). 
Although the choice of device and body placement is de- 
pendent on several issues such as the study aims, cost, and 
availability, future studies with a primary focus on sedentary 
behavior should consider the use of devices which arc 
able to better differentiate between sitting and standing 
(e.g., activPAL9), 
Although accelerometers offer many advantages over 
self-reported measures, they do have important limitations. 
For example, accelerometers do not capture cycling or 
water-based activities, and they do not detect the context 
within which physical activity or sedentary behaviors are 
occurring (e.g., transport, occupational, screen time). In 
contrast, self-report measures are important for providing 
the context in which activities are occurring; depending on 
the self-reported measures used, distinction can be made 
between transport-related sedentary time and leisure sed- 
entary time (e.g., screen-based), and planned/intentional 
activity and occupational activity. Thus, we recommend 
continued use of self-repon measures of physical activity 
and sedentary behavior to complement objective assess- 
ment. Current ongoing research initiatives are using both 
devices as well as self-repon measures for a complete as- 
sessment of the full activity spectrum (20). 
The majority of studies (65%) reported collecting acceler- 
ometer data during waking hours. Even in studies that col- 
lected 24-h data, often only waking hours are reported (28). 
Across a 24-h period, individuals engage in a combination of 
sleep, sedentary behaviors, and physically active behaviors 
(of light, moderate or vigorous intensity), and recent research 
has considered these behaviors together rather than in isola- 
tion. New statistical techniques, such as compositional anal- 
yses or isotemporal substitution modeling, may help generate 
a clearer understanding of the dynamic interplay between 
movement behaviors measured during waking hours or the 
entire day (67). For example, isotemporal substitution model- 
ing allows the researcher to explore associations of altemat- 
ing allocations of time in one behavior with another while 
holding total time constant (68,69). Studies in the cancer 
survivorship context have used this approach to examine the 
reallocation of time and the projected impact on outcomes 
such as health-related quality of life, fatigue, and waist cir- 
cumference (55,70,71). Continued use of new and innovative 
statistical approaches will help inform intervention research 
in cancer survivor populations. 
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CONCLUSIONS 
The use of accelerometer-based activity monitors has im- 
proved understanding of the spectrum of physical activity 
and sedentary behavior undertaken in clinical and free-living 
environments by cancer survivors. However, the specific 
frequency, intensity, and duration of physical activity (or 
sedentary behavior) required to improve cancer outcomes re- 
mains unknown. The continued expansion of accelerometry in 
cancer survivor research will help to address these gaps in 
knowledge and infonn more robust and detailed physical ac- 
tivity recommendations for cancer control. However, ade- 
quate reporting of accelerometer paradata is needed so that we 
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Abstract 
Purpose: To investigate the feasibility and efficacy of exercise to improve muscular 
strength, physical functioning, body composition, and patient-rated outcomes in patients 
with malignant pleural disease (MPD).   
Methods: Thirty-three patients with MPD were recruited to complete an exercise training 
intervention of progressive resistance exercise training three times/week for six-weeks.  
Outcomes assessed at baseline and post-intervention included muscular strength (1-
repetition maximum leg press), functional capacity (6-Minute Walk Test), physical 
functioning (Timed Up and Go; chair rise), body composition (Dual energy X-ray 
Absorptiometry), quality of life (Short-Form 36 Health Survey; SF-36), physical activity 
and sedentary behaviour (Actigraph accelerometer), ratings of intervention burden and 
acceptability (7-point Likert scale; 1, not at all, to 7, very much). Attendance was assessed 
as the number of exercise sessions attended out of a possible 18. Paired T-test or Wilcoxon 
Signed Rank Test was used to assess changes over time. 
Results: Mean participant age was 64 (SD=11) years. The majority had mesothelioma 
(93%), Eastern Cooperative Oncology Group Performance Status 0-1 (97%), and were male 
(70%), and had low appendicular skeletal muscle mass (56%). Twenty-six participants 
(79%) completed the intervention; 24 (73%) completed post-intervention assessments. Post 
intervention, significant improvements were found for mean six-minute walk distance (+59 
m; 95% CI 24-93; p<0.05), 1-repetition maximum leg press (+17 kg; 95% CI 11-23; 
p<0.001), Timed Up and Go (-0.51 sec; 95% CI -0.94 - -0.08; p<0.05), chair rise (-1.5 sec; 
95% CI -2.2 - -0.9; p<0.001), and appendicular lean mass/height squared (+0.19 kg/m2; 95% 
CI 0.04 – 0.34; p<0.05).  
For patient-rated outcomes, only the mental health subscale of SF-36 changed significantly 
(median change +2.6, IQR 0.0, 5.2; p<0.05). Overall, no post-interventions changes in 
activity behaviors were observed (all p’s >0.05). Preliminary analysis indicates that changes 
in body composition might mediate this response. Median attendance at supervised exercise 
was 100% (inter-quartile range 72%-100%).  
Conclusion: This pilot study indicates progressive resistance exercise training in patients 
was feasibly in MPD and resulted in improvements in muscular strength, physical 
functioning and body composition. 
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B.1 Introduction
Despite medical advances, malignant pleural disease (MPD) remains an incurable
cancer with limited treatment options. Pleural malignancy can result from primary cancer 
(i.e., mesothelioma), or from metastatic spread of cancer into the pleural space (common 
in breast, lung, and ovarian cancer).1 The pleural effusion causes distressing 
breathlessness, restricts daily activities, impairs quality of life (QoL), and can be 
recurrent.1 The main goals in the treatment of MPD are to alleviate symptom burden 
and allow patients to take part in their nomal physical activities of daily living for as 
long as possible. 
In MPD, poor performance status, or immobility, is often clinically attributed to 
symptoms such as breathlessness, pain, fatigue and muscle wasting. Evidence suggests 
that patients with MPD are very inactive, spending the large majority of their waking hours 
sedentary.2 Even amongst patients early in their diagnosis with good performance status, 
low appendicular skeletal muscle mass (ASM) is common and is associated with reduced 
participation in daily physical activity.3 Muscle loss is a hallmark feature of cancer 
cachexia that severely impacts quality of life, physical functioning, and treatment 
tolerance. In advanced cancer populations, low muscle mass has been associated with 
poorer quality of life,4 worse overall survival,5 and increased likelihood of dose-limiting 
toxicities from chemotherapy.6  
Appropriately prescribed exercise provides a significant opportunity to counteract 
this aetiology of poor outcomes for patients with MPD. In advanced lung cancer, exercise 
training has shown promise for increasing functional capacity and health-related quality 
of life.7 However, there is little evidence to date on the effects of exercise on body 
composition in this group.7 The purpose of this study was to assess the feasibility and 
efficacy of a 6-week resistance exercise training intervention for improving physical 
functioning, body composition, and physical activity profile in patients with MPD.   
B.2 Methods
B.2.1 Participants
People with cytological or histological confirmation of MPD or those with a recurrent 
large exudative pleural effusion with cytological or histological proven cancer outside the 
thorax with no alternative cause were eligible to participate in the intervention. Potential 
participants were excluded if they were aged <18 years, pregnant or lactating, unable to 
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read and understand English, unable to give informed consent or comply with the protocol, 
had unstable bone metastasis or metastasis of long bones, had acute illness or any 
musculoskeletal, cardiovascular, or neurological disorder that could inhibit or put 
participants at risk from participating in assessments or exercise intervention, were unable 
to obtain physician consent, or were participating in a conflicting study.  
B.2.2 Design and recruitment
The study was a single group pilot intervention study. Ethical approval was provided 
by Sir Charles Gairdner Group and Edith Cowan University Human Research Ethics 
Committees (ID: 2014-124 and 13255). Recruitment took place between September 2015 
and July 2017 in a tertiary specialist pleural disease and medical oncology clinic in 
Western Australia (WA).   
B.2.3 Exercise training intervention
Supervised exercise sessions were scheduled to be completed three times a week for 
6-weeks. An optional two-week make-up period was provided for participants who chose
to make up sessions with the goal of completing 18 exercise training sessions. Exercise 
sessions began with a 5-minute warm up comprising of low-level aerobic activity such as 
walking and stationary cycling. The resistance training involved eight resistance exercises 
that targeted the major upper and lower body muscle groups (e.g., chest press, seated row, 
leg press, leg extension). Resistance was increased by a 5-10% increment for the next 
set/training session if participants were able to perform more repetitions than specified 
during a set. Intensity was manipulated from 8-12-repetition maximum (RM) using 1-3 
sets per exercise, with 1-2 minute rest periods between sets.8 Due to the advanced nature 
of MPD, the potentially high symptom burden, and changes in participant status due to 
treatment the exercise intervention was designed to be flexible with adjustments made as 
required. To achieve this, at the start of every exercise training session, participants were 
asked to rate their current level of pain (Visual Analog Scale; VAS; no pain/very severe 
pain), describe any changes in shortness of breath, fatigue, or new symptoms since their 
previous training session. It was then discussed between the exercise physiologist and 
participant if the planned exercise program required any changes to the volume, intensity, 
or rest periods.    
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B.2.4 Outcome Measures 
Demographic and medical variables 
Self-report questionnaires were used to obtain demographic information (e.g., marital 
status, education level, employment status, smoking status). Medical records and chest x-
rays were reviewed to obtain data regarding cancer diagnosis, pleural effusion 
characteristics, cancer treatments, and comorbid conditions. Eastern Cooperative 
Oncology Group (ECOG) performance status was rated on the day of baseline 
assessment.9 Patients were categorised as either good performance status (i.e., ECOG 0-
1) or poor performance status (i.e., ECOG ≥2). 
Physical functioning 
All study endpoints were assessed at baseline and post-intervention. Participants 
completed a series of tests to assess different aspects of physical functioning. Muscular 
strength was assessed by 1 RM for lower body using a seated leg press.10 Lower body 
1RM was divided by current body weight to determine relative 1RM. Cardiorespiratory 
functional capacity was assessed by Six-Minute Walk Test (distance in metres).11 
Participants were asked to walk as far as possible on a flat 50 m course in six minutes.12 
Functional ability was assessed via repeated chair rise (time in seconds taken to rise from 
seated and return to sitting ten times)13 and Timed Up-and-Go (TUG; time in seconds 
required to rise from sitting, walk a distance of 2.44 metres, turn around and return to 
sitting).14 Chair rise and TUG were performed in triplicate with one minute rest-periods 
provided between trials, with the best outcome (i.e., the shortest time) used in analysis. 
Participants were grouped according to change in leg strength from baseline to post-
intervention as gained (change ≥10%), and lost (change <10%). Participants were also 
grouped for Six-Minute Walk Distance (6MWD) using a cut point of a 9.5% change post 
intervention as this is considered a clinically meaningful difference.15 
Anthropometric measures and body composition 
Participant weight and height were measured at baseline. Participants were wearing 
light clothing and footwear was removed. Body mass index (BMI; kg/m2) was 
calculated, and participants were categorised according to World Health Organization 
(WHO) BMI criteria.16 
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Body composition (i.e., regional and whole-body lean and fat mass) was derived 
from whole-body dual-energy x-ray absorptiometry scans (DXA; Hologic Discovery A, 
Waltham, MA, USA). Appendicular skeletal muscle (ASM), whole body and regional fat 
mass were assessed using standard procedures.3 Low ASM, was defined as an 
appendicular skeletal muscle mass/height2 of ≤7.26 kg/m2 for males and ≤5.45 kg/m2 for 
females.17 Participants with low ASM were categorised as pre-sarcopenic.18 All 
participants were grouped according to change in ASM from baseline to post-intervention 
as gained (change >0.05 kg), and lost (change ≤ 0.05). 
Physical activity and sedentary behavior 
Objective activity behaviour was assessed via accelerometer (Actigraph GT3X+; 
Actigraph, Pensacola, FL, USA) the three-days prior to and following the intervention at 
baseline and post-intervention respectively. Participants were asked to wear the 
accelerometer on their hip continuously (24hr/day) for three-days and record any non-
wear time over that period. Accelerometers were programmed to record raw data at a 
frequency of 30 Hz, which were later reduced to vertical axis movement counts per 60-
second epoch. Accelerometer data were downloaded and processed in SAS (version 9.3, 
SAS Institute, Cary, NC, USA). Waking wear time was determined by an automated 
algorithm and visual inspection by a trained rater.19 A valid day was defined as 8hr of 
waking wear time.20 Commonly used cut off points were used to classify activity as 
sedentary time (i.e., <100 counts/minute; cpm), light activity (i.e., 100-1952 cpm) or 
moderate to vigorous physical activity (MVPA; >1952 cpm).21,22 All variables were 
calculated per day and then averaged across all valid days. 
Patient-reported Outcome Measures 
Patient-reported outcome measures were assessed using a battery of validated 
questionnaires.  Cancer-specific health-related QoL (HRQoL) and symptoms were 
assessed by the Functional Assessment of Chronic Illness Therapy (FACIT) General,23 
and Fatigue 24 scales. A score of ≤34 on the FACIT-Fatigue was categorised as clinically 
meaningful fatigue.25 General HRQoL was assessed by The Medical Outcomes Study 
Short-Form 36 (SF-36).26  Dyspnea was assessed using the Cancer Dyspnea Scale (CDS)27 
and 100 mm visual analogue scale (VAS) anchored with “no breathlessness” at 0mm and 
“maximum possible breathlessness” at 100mm.28  
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Safety, tolerance, and attendance 
Safety was measured by tracking the incidence and severity of adverse events related 
to the intervention. Additionally, an adverse events log was provided to participants to 
document any adverse events experienced throughout the exercise program. An additional 
home diary was used to self-report any adverse events that took place at home (e.g., muscle 
soreness). Following each exercise session participants were asked to rate their perceived 
exertion using  the Borg Scale (range 6-20)29 as well as session tolerance using a 7-point 
Likert scale (anchored with ‘1/extremely intolerable’ and ‘7/extremely tolerable’).30 
Ratings of intervention burden and acceptability were assessed post-intervention using 7-
point Likert scales (anchored with ‘1/not at all’, and ‘7/ very much’).31 The number of 
participants completing the intervention (i.e., attending baseline and post-intervention 
assessment), as well as the number of exercise sessions attended was recorded. Attendance 
was reported as the percent of sessions attended out of a possible 18. 
B.2.5 Statistical analyses
Statistical analyses were conducted using Statistical Package for the Social Sciences 
(v. 25, IBM Corporation, Somers, NY, USA). Data are reported using mean and standard 
deviation or median and interquartile range (IQR) when not normally distributed. 
Normality of the distribution for outcome measures was tested using the Kolmogorov–
Smirnov test. Changes in physical functioning, body composition, quality of life were 
assessed using paired t-tests. Independent t-tests were used to test for differences between 
groups in physical activity and sedentary time. The change in the proportion of 
participants categorised as pre-sarcopenic was assessed using the McNemar test. This 
was a pilot feasibility study.  Therefore, due to the nature of the intervention and variation 
in ability to complete tests, we used complete cases for the analyses. An alpha of 0.05 
was used to determine statistical significance. No adjustment was made for multiple 
comparisons.  Figures were created using GraphPad Prism (version 7, GraphPad 
Software, La Jolla, California, USA). 
B.3 Results
B.3.1 Participant characteristics
Participant flow through the trial is reported in Figure B.1.  Briefly, between September 
2015 and July 2017, 137 patients with MPD were identified, of whom, 118 (86%) were 
eligible and 33 (28%) of those enrolled. The main reason for ineligibility was choosing an 
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alternate conflicting study (n=15), and the main reason for non-enrolment was living too far 
away from the intervention site (n=27).  Twenty-six participants (79%) completed the 
intervention. Of those enrolled, seven were lost-to-follow up, the main reason cited by 
participants for dropout was fatigue (n=4). 
Participant medical and demographic characteristics are presented in Table B.1. The 
majority of participants were male (67%), with a diagnosis of mesothelioma (85%), and a 
good performance status (i.e., ECOG 0-1; 97%) and had received some treatment for pleural 
effusion (82%). On average, participants were 66 years old (SD 10.0), and half were 
overweight or obese (54%). Thirteen participants (39%) received anticancer treatment prior 
to entering the trial, while 11 (33%) received treatment during the intervention.  Median 
time from diagnosis of MPE was 6 months.  At baseline, 19 participants (58%) had low 
appendicular skeletal muscle mass, and 7 participants (23%) were clinically fatigued. 
B.3.2 Changes in physical functioning and QoL 
Those that completed the intervention demonstrated significant improvements across 
all measures of physical functioning (all <0.002; Table B.2, Figure B.2).  Only the mental 
component score of the SF-36 changed significantly following the intervention (p=0.022).  
All other outcomes showed no significant change following the intervention (Table B.2). 
B.3.3 Changes in body composition 
Changes in body composition following the intervention are reported in Table B.2. 
Following exercise training there was a significant increase in ASM, [mean change 0.66, 
(95% CI 0.20, 1.12) kg; p=0.007], and ASM relative to height [mean change 0.19, (95% 
CI 0.05, 0.34) kg/m2; p=0.011]. Among those that completed the intervention (n=26), 
there was a significant change in the proportion of participations that had pre-sarcopenia 
from baseline (54%) to post-intervention (27%; p=0.039). Following the intervention, 
52% remained not sarcopenic (n=11) with an average change of +0.16 (SD 0.30) kg in 
ASM; 31% (n=8) became not sarcopenic with average increase 0.30 kg ASM (SD 0.19). 
While, 23% (n=6) remained pre-sarcopenic with mean change of 0.10 kg ASM (SD 0.42), 
and 4% (n=1) became sarcopenic (change -0.35 kg). 
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B.3.4 Changes in physical activity behaviours and sedentary time
following exericse training 
There was no significant change from baseline to post-intervention in accelerometer 
waking wear time [mean difference 19.9, 95% CI (-25.12 – 64.98) min; p=0.369], or 
number of valid days of wear (z=-1.633, p=0.102). Overall, between baseline and post-
intervention there was no change in the proportion of waking wear time spent as sedentary 
[67.9 (SD 9.5)% to 67.4 (SD 9.6)%; mean difference -0.4, 95% CI (-3.4 – 2.5)%; p=0.765], 
in light activity [29.1 (SD 9.6)% to 30.2 (SD 8.8)%; mean difference 1.1, 95% CI (-1.8-
4.0)%; p=0.441) or MVPA [3.1(SD 2.5)% to 2.4(SD 2.4)%; mean difference -0.7, 95% 
95% CI(-1.5-0.2)%; p=0.122].   
B.3.5 Physical activity and sedentary behavior according to changes in
body composition, muscular strength, and functional capacity. 
Changes in physical activity were examined to determine if they differed based on 
response to the exercise intervention. Post-intervention, participants with a loss or no 
change in ASM (n=8) demonstrated an increase in the proportion of waking hours spent 
as sedentary [+5.1 (SD 6.5)%] compared with those that gained ASM [n=14; -3.4 (SD 
6.2)%] resulting a significant difference between groups [mean difference 8.5, 95% 
CI(3.3, 13.7)%; p=0.003]. Those that lost ASM demonstrated a reduction in light activity 
(-3.8% SD 6.2) compared to those that gained ASM [+3.8 (SD 5.8)%], resulting in a 
significant difference between groups [mean difference -7.6 95% CI(-13.0% - -2.1)%; 
p=0.009]. There was no statistically significant difference between groups for changes in 
MVPA [+1.9 (SD 3.2)% vs +5.5 (SD 8.1)%; mean difference -3.6, 95% CI(-9.9 – 3.7)%; 
p=0.244; Figure B.3].  
Within group changes indicate for the gain ASM group there was a significant 
decrease in the proportion of waking hours spent as sedentary [mean change -3.4; 95% 
CI(-0.5 - -2.5)%; p=0.026], an increase in light activity, [mean change 3.8; 95% CI(0.5 – 
7.1)%; p=0.028], but no change in MVPA [mean change 0.4; CI(-1.8 – 1.0)%; p=0.583]. 
Conversely the loss or no change of ASM group increased sedentary time [mean change 
5.1; 95% CI(-0.4 - -10.5)%; p=0.064], with no significant change in light activity [mean 
change -3.8; CI(-8.9 – 1.4)%; p=0.131], and reduced MVPA [mean change -1.3; 95% CI(-
2.1- -0.5)%; p=0.006]. 
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We examined differences in physical activity and sedentary behaviour outcomes by 
change in strength (leg press 1RM, >10% vs ≤ 10%) and a clinically meaningful change 
in functional capacity (6MWD, >9.5% vs ≤ 9.5% change). There were no significant 
differences between those with ≤ 10% increase from baseline 1RM (n=6) and those with 
>10% increase from baseline 1RM (n=14). Both 1RM groups had a similar change in the 
proportion of time spent sedentary [0.1 (SD 7.7)% vs -0.4 (SD 7.2)%; mean difference 0.6 
95% CI(-7.0, 8.1)%; p=0.874], in light activity [-0.1 (6.5)% vs. 1.1 (7.0)%; mean 
difference 1.2 (-8.2, 5.0)%; p=0.735], or MVPA [4.2 (5.8)% vs 5.3 (7.2)%, mean 
difference 1.1 (-8.1, 6.0)%; p=0.754]. There were no significant differences between those 
with >9.5% (n=8) and those with ≤ 9.5% increase from baseline 6MWD (n=12). Both 
6MWD groups had a similar change in the proportion of time spent sedentary time [1.1 
(SD 7.6)% vs 1.0 (SD 7.5)%; mean difference 2.0 CI(-9.0, 5.0)%; p=0.552)], light activity 
[1.2 (SD 6.4)% vs 0.0 (SD 7.5)%; mean difference 1.2 95% CI(-5.4, 7.7)%; p=0.714], and 
MVPA [5.5 (8.1)% vs 4.0 (4.1)%; mean difference 1.5 95% CI(-5.0, 8.1)%; p=0.632].  
B.3.6 Patient Rated Outcomes 
Following exercise training there was a significant improvement in the mental health 
composite score of the SF-36 (p=0.022). There were no significant changes in other patient 
reported outcomes following the intervention (Table B.2).    
B.3.7 Safety, Tolerance and Attendance 
There were no serious adverse events related to the intervention. There were two minor 
adverse events related to exercise reported. Both were resolved with no medical 
intervention required. One participant experienced a musculoskeletal injury during work 
(i.e., not related to the intervention). Two participants were admitted to hospital during the 
intervention for issues unrelated to the intervention (abdominal pain due to disease 
progression; and pleurodesis). Session rating of perceived exertion with the Borg scale (6-
20 scale; higher score is higher exertion) was median 11.6 (IQR 11.4-12.9), perceived 
tolerance (1-7 scale) was median 6.0 (IQR 5.7, 6.3). For all participants enrolled, the 
median attendance was 100% (IQR 7-100%; range 6%-100%). The reasons provided for 
missed sessions included fatigue, undergoing treatment/appointments, vacation, and family 
obligations.   The main reason given for dropping out of the study was fatigue (n=4). 
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Table B.1 Demographic and medical characteristics of patients, n=33 
n % 
Age, years, mean (SD) 65.7 (10.0) 
Gender, male 23 70 
Marital status 
Married/de-facto 31 94 
Divorced/widowed 2 6 
Education Level 
Primary 4 12 
Secondary (high school) 10 30 
Trade/certificate/diploma 11 33 
Bachelor degree or higher 8 24 
Employment Status 
Retired/unemployed 29 88 
Part-time/full time 4 12 
Smoking status 
Never 18 55 
Past smoker 9 27 
Current 7 21 
BMI, kg/m2, mean (SD) 26 (3) 
Underweight 
Healthy weight range 















Time since diagnosis of cancer, months 7 (2, 14)^ 
Time since diagnosis of MPD, months 6 (3, 13)^ 
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n % 










ECOG performance status 0/1 32 97 
Received treatment prior to study 13 39 
Chemotherapy alone 4 24 
Radiotherapy 5 15 
Surgery 3 9 
TKI inhibitor 1 3 
Chemotherapy + Immunotherapy 2 6 
Chemotherapy + TKI 2 6 
Received treatment during study 11 33 
Chemotherapy alone 3 9 
TKI  2  6 
Immunotherapy alone 1 3 
Chemotherapy + Immunotherapy 4  12 
Side of effusion, right 24  73 
Effusion treatment 
IPC 12 36 
ICC 3 9 
VATS 3 9 
Therapeutic aspirate 6 18 
Pleuroscopy 7 21 
None 4 12 
Unknown 2 6. 
No. of comorbid conditions, mean (SD) 2 (2) 
Arthritis 11 33 
Hypertension 9 27 
Hypercholesterolemia 7 21 
COPD  3 9 
Ischemic heart disease 2 6 
Clinically fatigued (n=30)** 7 23 
IPC – indwelling pleural catheter; ICC – intercostal catheter; VATS – video-assisted thoracoscopic surgery; 
ECOG – Eastern Cooperative Oncology Group;  
COPD – chronic obstructive pulmonary disease; ** score of ≤34 on the FACIT-fatigue; TKI Tyrosine Kinase Inhibitor 
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Mean change  
(95% CI) p-value 
Physical Functioning (n=24)     
Leg press 1RM, kg  88.2 (37.7)   105.1 (42.1) 16.9 (11.2, 22.6)  <0.001 
6MWD, m  524.2 (104.7) 582.7 (108.1)  58.5 (24.4, 92.5) 0.002 
Chair rise, sec  12.8 (3.4)  11.3 (3.4)  -1.5 (-2.2, -0.9) <0.001 
TUG, sec  6.4 (1.9) 5.9 (1.8)  -0.5 (-0.9, -0.1) 0.022 
Body Composition (n=26)     
Whole Body     
Total Mass, kg 77.78 (11.28) 78.17 (15.44) 0.39 (-0.64, 1.43) 0.443 
Lean Mass, kg 49.57 (10.86) 50.18 (11.28) 0.61 (-0.08, 1.31) 0.080 
Fat Mass, kg 25.82 (5.86) 25.57 (6.84) -0.25 (-1.20, 0.70) 0.597 
Fat Percentage, % 33.47 (5.63) 32.87 (6.68) -0.61 (-1.63, 0.42) 0.235 
Lean     
Trunk, kg 25.68 (5.64) 25.62 (5.53) -0.06 (-0.50, 0.38) 0.773 
ASM, kg 20.83 (5.04) 21.49 (5.63) 0.66 (0.20, 1.12) 0.007 
ASM kg/m2 6.83 (1.10) 7.03 (1.25) 0.19 (0.05, 0.34) 0.011 
Fat     
Body Fat Percentage, % 33.47 (5.63) 32.87 (6.68) -0.61 (-1.63, 0.42) 0.235 








Quality of life (n=26) 
FACT-General 83.4 (17.2)   82.6 (18.4) -0.8 0.703 
Fatigue Scale^ 39.5 (34.8, 48.3)^ 43.5 (27.8, 48.2)^ ---  0.736 
Physical Component Score (SF-36) 45.2 (11.8) 43.8 (9.8) -1.3 (-4.9, 2.3) 0.455 
Mental Component Score (SF-36)^ 52.6 (37.3, 58.8)^ 55.4 (47.8, 59.6)^ --- 0.022 
Dyspnea 
VAS (mm)^ 12.5 (1.1, 36.3)^ 5.0 (0, 22.5)^ --- 0.277 
CDS Total^ 3.5 (0, 10)^ 3.0 (0.5, 10.5)^ --- 0.897 
6MWD, Six Minute Walk Distance; m, metres; sec, seconds; kg, kilograms; ht, height; ^ Median, IQR; VAS, Visual Analogue Scale; CDS, Cancer Dyspnea Scale 
Appendix B.  Resistance exercise training improves physical functioning and body composition 
243 
 
Figure B.1 Participant flow through the trial 
137Malignant pleura disease patients identified 
Reasons for ineligibility (et9 
Chose alternate study (n15) 
Medical contraindications (n1) 
Doctor deemed too urwell (ne1) 
Did not speak English (nef) 
Long bone metastasis (ne1) 
118 (86%)Malignant pleural disease patients eligible 
Reasons for refusal (ma85) 
Live too far away (e27) 
Too urwell (e19) 
Not interested (n16) 
Too busy (n6) 
Travelling (ne3) 
Study was too much of time commitment (nee) 
Overwhelmed with appointments (n6) 
Not contactable (nee3) 
33(28%) malignant pleural disease patients enrolled in 
the exercise intervention 
• Patient rated outcomes (me30 ne3 not returned) 
• Aooeerometry (nee32; me1missed assessment) 
• DXA (ne33) 
• 64MT (nee31, me2 t00 unwell') 
• Physical functioning (nee32 ne1too urwell) 
Lost to follow-up (nae7, 21% 
Toe fatigued (n 4) 
Too unwell (ne1) 
Too many appointments (n1) 
Unable to contact par0ipant (n1) 
26(79%) malignant pleural disease patients completed post- 
intervention assessment 
• Patient rated outcomes (n 26) 
• DXA (ne26) 
• 6MT (n24 me2too unwell) 
• Physical functioning (nee24 me2too urwell') 
• Aooelerometry (nee23 n1missing. n2?faulty 
initialization) 
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Figure B.2 Changes in physical functioning following exercise training. 
* p<0.05
Figure B.3 Sarcopenia status following exercise intervention. 
Figure B.4 Changes in proportion of waking hours spent in activity behaviours 
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B.4 Discussion 
This study examined the feasibility and efficacy of a short resistance exercise training 
program for improving physical functioning and body composition in patients with MPD. 
There were several important findings: 1) the program was effective at improving 
muscular strength, physical functioning, and functional capacity; 2) there was an increase 
in ASM following the intervention and those that increased ASM had an improved 
physical activity profile; 3) there were no changes in quality of life or fatigue following 
the intervention, and 4) the program had good compliance and ratings of tolerability 
among these patients with high disease burden. 
Patients with MPD and mesothelioma have not been exclusively studied in the 
exercise oncology literature. Compared to other thoracic cancer patients, this is a unique 
subgroup, particularly those with mesothelioma due to the relatively long median survival 
(~12 months), lack of extrathoracic spread of disease, and low rates of a history of 
smoking. Improvements in muscular strength, functional capacity, and physical 
functioning paired with the positive feasibility and safety data presented indicate that 
exercise training could be a valuable supportive care intervention in this patient 
population. Average improvements in functional capacity reported here meet the cut-point 
for a clinical meaningful improvement,15 and are similar to research in other advanced 
lung cancer populations.7,32 Importantly, worse physical functioning has been associated 
with reduced survival in cancer popualtions.33 Functional capacity has been identified as 
a strong independent predictor of survival in those with advanced lung cancer.34,35 
Importantly, there were no serious adverse events and participants report the favourable 
measure of tolerability.  Therefore, a safe and tolerable intervention that improves 
functional capacity could be particularly important for those with MPD. 
Overall, there was an improvement in ASM following the intervention. A proportion 
of participants (31%) even progressed out of being categorised as pre-sarcopenic.  Recent 
literature in other advanced cancer populations has indicated the importance of adequate 
muscle mass due to associations with lower risk/rates of treatment toxicity,6 and improved 
survival. While this finding is preliminary and requires replication in larger randomised 
trials, these results suggest that even a short-term individualised resistance exercise 
training program could be effective for improving ASM, which could have important 
implications for clinical outcomes. Previous research in advanced cancer populations 
indicates some success in improving lean mass with exercise training (n=4 studies in 
prostate cancer, lymphoma, and myeloma).36 Further research is needed to examine ways 
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to optimise improvements in muscle mass in advanced cancer populations.  Multi-modal 
interventions that include exercise and nutrition support and pharmacological agents to 
optimise improvements in body composition have potential to be most effective.37 
While the exercise intervention showed no overall effect for improving physical 
activity behaviours, analysis indicated that participants that improved ASM also improved 
physical activity profile such that less time was spent sedentary and more time was spent 
in light activity. Previous research in MPD has indicated pre-sarcopenia is associated with 
a similar physical activity profile; specifically, greater sedentary time and lower light 
activity.3 This preliminary finding provides further evidence that ASM could be a key 
mediator of physical activity. This is particularly important considering the importance 
that clinicians and patients place on the ability to remain actively engaged in activities of 
daily living. Further research is needed to more fully elucidate the relationship between 
changes in ASM and physical activity and sedentary behaviour. 
This study has several important limitations to consider. This was a pilot feasibility 
study and therefore is subject to the inherent limitations of a small sample size, lack of 
control group, and inability to control for confounding factors that could affect results. 
One of the main confounders is treatment (including chemotherapy, fluid drainage of 
effusion, pain control etc.).  These treatments could improve some of the outcomes if 
patient responded, but are unlikely to affect others, particularly body composition and 
muscular strength. Additionally, while this group was a homogenous sample in terms of 
MPD diagnosis, participants were heterogeneous in terms of treatment status (on/off), 
types of treatment completed both during and following the diagnosis, and time since 
diagnosis. The vast majority of participants had good performance status and the results 
might not be generalisable to more unwell participants. However, this research does 
provide important information to inform future research aimed at improving physical 
functioning and body composition in this population of patients with advanced cancer. 
The study employed well validated measures of body composition, physical functioning 
and patient-rated outcomes.   
Overall, this work found that resistance exercise training that was provided in flexible 
and individualised prescription was feasible and beneficial for patients with MPD. 
Improvements in ASM and reductions in the proportion of patients with pre-sarcopenia 
indicate that resistance exercise could be an effective tool in addressing muscle loss in a 
select population of patients with advanced pleural cancers.  
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Supplementary Data 
Supplemental Table B.3 Differences in baseline physical function and body composition 






(95% CI) p 
Physical Functioning (n=25) 
Leg Press (kg)  89.9 (36.8)  64.0 (22.8) 25.9 (-4.1, 0.1) 0.089 
6MWD (m)  530.1 (106.7) 442.8 (81.7) 87.3 (-8.3, 182) 0.072 
Chair Rise (sec) 12.8 (3.9) 16.3 (4.4) -3.4 (-6.9, 0.1) 0.056 
TUG (sec) 6.3 (1.9) 7.1 (1.2) -0.7 (-2.2, 0.8) 0.346 
Body Composition (n=26) 
Appendicular lean 
mass (kg) 
20.8 (5.0) 18.5 (4.5) 2.3 (-2.0, 6.6) 0.283 
Appendicular lean 
mass/ht2 (kg/m2) 
6.8 (1.1) 6.3 (1.2) 0.5 (-0.5, 1.4) 0.339 
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What is the purpose of this study? 
Following a diagnosis of mesothelioma there can be declines in health and wellbeing. Many 
people experience weight loss, poor appetite, tiredness, shortness of breath, and pain. No 
research has examined how nutritional status (i.e., how well your diet is meeting your nutritional 
needs), physical functioning (e.g., ability to do tasks such as walking and lifting), and body 
composition (i.e., how much fat and muscle you have) changes over time for patients with 
mesothelioma. Therefore, one purpose of this research is to assess changes in nutritional 
status, body composition, and physical functioning over time. 
Research has demonstrated that exercise is a safe and effective intervention for the 
management of various adverse effects associated with cancer and cancer treatments. 
However, this information is based on research studies involving predominantly breast and 
prostate cancer patients. Currently, it is unknown if exercise can help lessen the negative 
symptoms associated with mesothelioma and its treatment. Therefore the second purpose of 
this research is to find out if a short, supervised exercise program could be useful for people 
with mesothelioma. 
What does participation in this study involve? 
As a participant in this study you will receive standard medical care. There are two groups in 
this study: 1. the nutrition group, 2. the exercise group. 
If you have mesothelioma you can choose to take part in the nutrition group. This involves 
nutrition and physical function assessments every 6 weeks. Assessments will alternate 
between brief assessments (takes about 30 minutes) and complete assessments (takes 
about an hour) as described below. 
If you have malignant pleural disease as a result of another primary cancer (e.g., lung 
cancer, breast cancer), or if you have mesothelioma then you may choose to take part in the 
exercise intervention. This is a 6-week supervised exercise program. You would have 
assessment before the exercise program, after the exercise program as described below. 
All participants will be asked to complete a series of tests or assessments. You will be 
thoroughly instructed on each of the assessments and supervised by qualified professionals at 
all times throughout these sessions. 
Assessments can be done at Sir Charles Gairdner Hospital (SCGH; in the Cancer Centre 
Gymnasium, outpatients department), the Harry Perkins Institute of Medical Research, or at the 
Edith Cowan University (ECU) Health & Wellness Institute in Joondalup. The brief assessments 
can be done at ECU in Mt Lawley. If you are unwell and unable to travel it could be possible to 
arrange for us to do the brief assessment at your home. 
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For the brief and complete questionnaires you will be asked to complete standardized 
questionnaires to assess quality of life and cancer-related symptoms. The brief questionnaire is 
expected to take you approximately 10 minutes to complete. The complete questionnaire will take 
approximately 15 minutes of your time. Before starting the exercise program you will be asked to 
complete a form with details such as your home address and contact phone number and also a 
health questionnaire that will provide information about your medical history, activity history, and 
other information that we will need to safely develop your tailored exercise program. Before and 
after the exercise program you will asked to completed standardized questionnaires to assess 
your quality of life, fatigue, shortness of breath, psychological distress, sleep quality, your physical 
activity level, your physical functioning and your motivation towards and thoughts about the 
exercise program. The questionnaires are anticipated to take you approximately forty minutes to 
complete at each of the assessment time points. 
• Body Composition Scan 
Dual Energy X-Ray Absorptiometry (known as DXA) will be used to assess your body 
composition (i.e., how much fat, muscle, and bone you have). This assessment involves lying 
still on a specifically designed platform for approximately 5 minutes and a scanning arm will move 
above your total body. A low-dosage x-ray will pass from underneath the platform to the scanning 
arm. The total radiation dose for all scans undertaken during the scan is very low, only a little 
more than normal background radiation from an airplane flight and much less than, for example, 
an international flight. A maximum of five scans will be completed in the nutrition study. 
• Nutritional status 
You will be asked to answer 4 questions about your weight and how much food you have 
been eating. Then you will undergo a brief physical exam to assess for any signs of muscle 
wasting and fat loss. The nutritional status assessment will take approximately 15 minutes 
to complete. 
• Physical Function 
A series of tests will be used to assess physical functional performance. Before physical 
function tests are performed, demonstrations, practice time, sufficient warm-up will be 
undertaken. You will be supervised during all tests and your safety will be observed at all 
times. Each of these tests will be performed three times. These tests involve: 
o Timed up and go: you will be seated in a chair, rise to stand, walk 8 feet, turn around 
and return to sitting. 
o Hand grip strength: You will be asked to squeeze a hand grip machine as hard as you 
can for each hand. 
o If you take part in the exercise study you will also complete a chair rise test: You will 
be seated in a chair and asked to rise and sit 5 consecutive times, without the use of 
your arms for support, as fast as possible. 
• Walking test 
For the Six-Minute Walk Test, you will be asked to walk 50 meters in a corridor, turn and 
return to the starting position for a total of six minutes. During this time you can take breaks 
if you need to. 
• Fooddiary 
You will be asked to record all of the food and drinks you consume over a 3-day period. It is 
recommended that you complete the diary at the time of eating or drinking. A food diary and 
instruction manual will be provided. 
• Food recall 
You will be asked to recall all of the food and drinks you consumed over the previous day. This 
will take approximately 15 minutes and can be completed in person or over the phone. 
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• Strength Test 
You will be asked to perform a one repetition maximum test, which is the most weight that can 
be lifted one time with your legs using correct technique. This will be performed on a leg press 
weight-training machine that you will be using during the exercise training sessions. You will 
be supervised and instructed by a qualified professional during this test. If you have disease 
that has spread to the bone you will not have to complete this test. 
• Monitor of Physical activity level 
You will be asked to wear a monitor to measure your activity for 3 days. The device is very 
small and lightweight and is worn around the waist 24 hours a day. 
• Blood Sample 
You will be asked to have blood taken for this research. Your blood will be analysed for 
substances that produce an inflammatory response in the body. Your blood samples would be 
stored in our secure research facilities at Sir Charles Gairdner Hospital for up to 5 years. Blood 
samples will collected by a member of the Pleural Medicine Clinical staff or at an accredited 
Australian National Association of Testing Authorities laboratory when you get other blood tests 
done (i.e., PathWest). You will not receive the results of these blood samples. 
Exercise program: 
If you are eligible and would like to, you can participate in a 6-week exercise program. If you 
indicate that you are interested in the exercise study, an exercise coordinator will follow-up with 
you. Your specialist doctor will be required to give consent for you to take part in this exercise 
study. Prior to beginning the exercise program, you will be asked to complete a demographics 
and health history questionnaire. This is to ensure that the exercise program can be 
individualized so that it is appropriate for you and specific to your current health status. 
The exercise program involves 3 supervised exercise sessions each week of resistance 
exercise (i.e. lifting weights). The sessions will be approximately 60 minutes long and 
conducted in small groups of up to 5 participants at the exercise clinic in the Cancer Centre at 
Sir Charles Gairdner Hospital, or at sites throughout Perth (i.e., Murdoch, Mt Lawley, 
Joondalup, and Crawley). You can choose the location that is most convenient for you. 
Accredited exercise physiologists experienced in working with people with cancer will be 
supervising your exercise program, which will be specifically tailored to you and your 
capabilities. The resistance exercise will involve 6-8 exercises that target the major upper and 
lower body muscle groups using weight training machines and other forms of resistance such 
as hand weights. The intensity will be moderate to vigorous (i.e. somewhat hard to hard) and 
will be manipulated by varying the amount of weight you are lifting, how many times in a row 
you lift it and how many sets of each exercise you perform. You might also complete aerobic 
exercise training at a moderate intensity. This could be walking on a treadmill, cycling on a 
stationary bike or rowing on a stationary ergometer or exercising or a cross trainer machine. 
Your program will be modified and progressed according to how you are feeling. 
At the end of the 6-weeks you will have a two-week period to make up any missed sessions, if 
you choose to do so. It is completely up to you if you would like to make up any missed 
sessions or not. 
What are the possible benefits of participating? 
The direct benefit for you is that all study activities, including the nutrition assessments, 
exercise program and assessments, are provided at no cost to you. Participating in an exercise 
program may maintain or improve your physical wellbeing. Additionally, it is hoped that this 
study will contribute important new information about the management of mesothelioma. 
What are the possible side effects and risks? 
Because there are no additional medical procedures involved in this study, there are few 
foreseeable major risks or side-effects associated with participation. However, as is the case 
with anyone who exercises, any exercise may result in mild discomfort and muscle soreness. 
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There is also the possibility of muscle pulls or strains associated the functional assessment, 
exercise assessment or the exercise program, common to any type of physical activity. In line 
with standard practice in exercise physiology, we will monitor and modify your program 
whenever necessary. In order to minimize these risks you will perform an adequate warm-up 
and cool-down before and after any exercise bout, be fully instructed on the correct lifting 
technique, familiarized with the movements involved in this investigation and supervised at all 
times by qualified professionals. Risk of falling may exist in the performance of some tasks, 
however, you will be closely supervised to minimize the risk of falling. During exercise it is 
possible to experience symptoms such as abnormal blood pressure, fainting, light-headedness, 
shortness of breath, muscle cramps or strain, nausea, and in very rare cases heart rhythm 
disturbances or heart attack. These potential risks are common to any form of physical activity. 
You will be asked to report any symptoms you experience during exercise and your safety will 
be of primary importance at all times. You will be given a log where you can write this 
information down. The Sir Charles Gairdner Hospital Cancer Centre gymnasium is associated 
with full medical facilities in the unlikely event that any medical assistance is needed. The other 
exercise sites have emergency action procedures in place in the unlikely event that medical 
assistance is needed. 
DXA scans are routine clinical tests but carry a small risk to you as they involve exposure to 
radiation. The level of radiation exposure is very small (10-30 micro Sieverts [µSv]) in comparison 
to the natural annual radiation dose in western communities (approximately 3000µSv). A person 
would receive radiation exposure of approximately 80 µSv on an airline flight of 8 hours or 30 to 
40 µSv during a typical chest x-ray. 
The discomforts associated with having blood taken are minimal. There is a risk that sometimes 
bruising and infection may occur and that the arm might become sore. Risk of bruising or 
infection will be minimised because all samples will be taken by a trained phlebotomist, medical 
doctor or nurse with extensive experience. The total amount of blood needed during each testing 
session will not be less than 10 ml (2 teaspoons). No syringes, needles or other devices capable 
of carrying infection from one person to another shall be reused. All of these items, which are 
disposable, will be destroyed after each use. All contaminated items will be disposed of promptly 
in special containers. 
If you experience discomfort during any of the tests, please let the study staff know immediately. 
You may experience some anxiety or discomfort in answering the questions about your quality of 
life, distress, and well-being. If you do experience this, you can choose to stop filling out the 
questionnaire at any time. Your responses will be kept strictly confidential. Some of the questions 
before and after the exercise program will ask about the level of distress you are experiencing. If 
our study identifies that you are experiencing significant distress, we will ask you if we can notify 
your GP or cancer specialist so that the appropriate referral for support services can be made. 
You may experience some distress when responding to questions about you weight and food 
intake during the nutritional status assessment. If you do experience any distress during 
assessment please tell the researcher. You can choose to stop any assessments at any time. If 
you are found to be malnourished, and are not currently under the care of a dietitian, your 
permission will be sought to contact your GP or cancer specialist who can make a referral to a 
dietitian. 
What will happen to the information collected as part of this research study? 
By signing the consent form you consent to the study doctor and relevant research staff 
collecting and using personal information about you for the research project. They may also need 
to get some of your health information from other health service providers e.g., another hospital, 
pathology laboratory, radiography (please note that your CT/MRI scans may be reviewed), GP or 
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other medical specialist. Any information obtained in connection with this research project that 
can identify you will be kept private and confidential. It will be stored securely and only authorised 
persons, who are aware that it must be kept confidential, will have access to it. Your study details 
will be given a unique number so your identity will not be revealed. As required for safety 
reasons, your emergency contact details (their name, phone number, and relationship to you) as 
well as any medical history relevant for exercise training will be given to the exercise physiologist 
who will be supervising your exercise training and kept in your exercise-training diary. This 
information will be kept in a secured locked location at the exercise-training site while not in use. 
Your exercise-training log will not have your full name on it, only your study id. The trial records 
will be kept in the Department of Respiratory Medicine during the study in a locked filing cabinet 
in a locked office and archived. A copy of the data without identifying information will be kept at 
ECU Joondalup. This data will be kept for at least 5 years from the time the study is closed. They 
may be destroyed at any time thereafter. Your exercise training log will contain only information 
required for exercise training and will be transferred to and from exercise sites with care and 
stored in a locked area at all possible times. Your health records and any information obtained 
during the research project are subject to inspection for the purpose of verifying the procedures 
and the data. This review may be done by the relevant authorities and authorised representatives 
of the institution relevant to this Participant Information Sheet, Sir Charles Gairdner Hospital or as 
required by law. By signing the Consent Form, you authorise release of, or access to, this 
confidential information to the relevant research personnel and regulatory authorities as noted 
above. It is anticipated that the results of this research project will be published and/or presented 
in a variety of forums. In any publication and/or presentation, information will be provided in such 
a way that you cannot be identified, except with your permission. By taking part in this study you 
agree not to restrict the use of any data even if you withdraw. Your rights under any applicable 
data protection laws are not affected. Information about your participation in this research project 
may be recorded in your health records. 
In accordance with relevant Australian privacy and other relevant laws, you have the right to 
request access to the information collected and stored by the research team about you. You also 
have the right to request that any information with which you disagree be corrected. Please 
contact the research team member named at the end of this document if you would like to 
access your information. Any information obtained for the purpose of this research project that 
can identify you will be treated as confidential and securely stored. It will be disclosed only with 
your permission, or as required by law. 
Are there any costs involved? 
There will be no direct costs incurred as a result of participation in this study. However, there 
will be expense associated with travelling to, and parking at, Sir Charles Gairdner Hospital or 
ECU Joondalup to complete the assessments or exercise training. About one hour of parking 
will be required If you attend exercise training or an assessment at Sir Charles Gairdner 
Hospital (approximately $3.00/hour) or ECU Joondalup (approximately $1.50/hour). You will 
not be paid for participation in this study. 
Voluntary participation and withdrawal 
Participation in this study is entirely voluntary. Whether you decide to participate in the study or 
not, your decision will not prejudice you in any way. No explanation or justification is needed if 
you choose not to participate. If you do decide to participate, you are free to withdraw your 
consent and discontinue your involvement at any time without reason or justification. If you 
decide to withdraw from this research project, please notify a member of the research team 
before you withdraw. A member of the research team will provide a form for Withdrawal of 
Participation for you to sign. 
If you do withdraw your consent during the research project, the study doctor and relevant 
study staff will not collect additional personal information from you, although personal 
information already collected will be retained to ensure that the results of the research project 
can be measured properly and to comply with law. You should be aware that data collected by 
the research team up to the time you withdraw will form part of the research project results. If 
you do not want them to do this, you must tell them before you join the research project. 
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Will I receive any feedback? 
A summary of study results will be made available to all interested participants upon 
completion of the trial. On request, we will provide you with a brief summary report of your 
individual results with relation to how your physical function test results changed following the 
exercise intervention. 
Who has reviewed the research project? 
All research in Australia involving humans is reviewed by an independent group of people called 
a Human Research Ethics Committee (HREC). The ethical aspects of this research project have 
been approved by the HREC of Sir Charles Gairdner Hospital. 
This project will be carried out according to the National Statement on Ethical Conduct in Human 
Research (2007). This statement has been developed to protect the interests of people who 
agree to participate in human research studies. 
Further information and who to contact? 
The person you may need to contact will depend on the nature of your query. 
If you want any further information concerning this project or if you have any medical problems 
which may be related to your involvement in the project (for example, any side effects), you can 
contact the principal study doctor, Professor Y C Gary Lee on phone 6457 4968, or any of the 
following people: 
Dr Carolyn McIntyre 
Ms Emily Jeffery 
Phone: (08) 6304 3987 
Phone: (08) 6304 2082 
Email: c.mcintyre@ecu.edu.au 
Email: ejeffery@our.ecu.edu.au 
Complaints contact person 
If you have any complaints about any aspect of the project, the way it is being conducted or any 
questions about being a research participant in general, then you may contact: 
Reviewing HREC approving this research and HREC Executive Officer details 
Reviewing HREC name 
HREC Executive Officer 
Telephone 
Email 
Sir Charles Gairdner Group 
Sean Howarth 
08 6457 2999 
sean.howarth@health.wa.gov.au 
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Consent Form - Adult providing own consent 
Title 
Protocol Number 
Investigating nutritional status, physical functioning, and the 
effects of an exercise intervention in malignant pleural 
mesothelioma 
version 1.2 




Declaration by Participant 
Dr Carolyn McIntyre, Ms Emily Jeffery 
Prof Rob Newton, Assoc/Prof Philippa Lyons-Wall 
Prof Jeanette Greaney, Prof Anna Nowak 
Sir Charles Gairdner Hospital, Perth, Western Australia 
Edith Cowan University Health and Wellness Institute 
1.I have read the Participant Information Sheet or someone has read it to me in a language that I 
understand. 
2.I understand the purposes, procedures and risks of the research described in the project. 
3. have been able to have a member of my family or a friend with me while I was told about the 
study if I so wish. I have had an opportunity to ask questions and I am satisfied with the answers I 
have received. 
4.I freely agree to participate in this research project as described and understand that I am free to 
withdraw at any time during the project without affecting my future health care. My participation in 
the study does not affect any right to compensation, which I may have under statute or common 
law. 
5.I understand that my personal details and the details of my emergency contact will be kept by the 
exercise physiologist for safety reasons. 
6.I understand that I will be given a signed copy of this document to keep. 
7. I understand that, if I decide to discontinue the research project treatment, I may be asked to 
attend follow-up visits to allow collection of information regarding my health status. Alternatively, a 
member of the research team may request my permission to obtain access to my medical records 
for collection of follow-up information for the purposes of research and analysis. 
If you are unclear about anything you have read in the Patient Information Sheet or this 
Consent Form, please speak to your doctor before signing this Consent Form. 
Name of Participant (please print) _ 
Signature Date 
Declaration by Study Doctor/Senior Researcher' 
I have given a verbal explanation of the research project, its procedures and risks and I believe 
that the participant has understood that explanation. 
Name of Study Doctor/ 
Senior Researcher' (lease pnnt) 
Signature Date 
t A senior member of the research team must provide the explanation of, and information concerning, the research project. 
Note: All parties signing the consent section must date their own signature. 
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Appendix G Participant Screening Form 
INTERMb - Nutrition Study 
SCREENING/ELIGIBILTY- CRF 1 
Patients Initials: I I Age: I I 
Date of Birth: (dd/mm/yy) h Sex: [MOFO [ 
Patient ID no: (First name/Nutr/no.) e.g f 
James/NU TR/OT 
DATE_ • Current ECOG _ 
• ELIGIBILITY/INELIGIBILITY CHECKLIST 
a. Eligible: 
Established diagnosis of malignant pleural mesothelioma: 
Histo-cytologically proven pleural mesothelioma 
b. Ineligible (any "Yes' answers means the patient is INELIGIBLE ): 
Yes O No O 
Age <18 years Yes @ No O 
Patients who are pregnant or lactating Yes @ No O 
• Inability to read and understand English Yes @ No O 
Inability to give informed consent or comply with the protocol Yes @ No O 
Unable to obtain physician consent Yes @ No O 
Participation in the exercise intervention Yes @ No O 
I confirm that the patient meets all the criteria for entry into the trial and is eligible 
for rticination Yes O No @ 
[ informed consent form signed by patient and a copy of the Patient Information Sheet has been given to 
the participant. 
[mis patient is in sufficient health to participate in the study 
Physician's Name (PRINT): Signature: Date: 
Please photocopy this form. File the original in the patient trial notes 
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The researcher will complete the rest of the form: 




Metabolic demand (See Worksheet 3) 
Physical (See Worksheet 4) 
Numerical score from Worksheet 3 




Disease and its relation to nutritional requirements (See Worksheet2) 
Al] relevant diagnoses (Specify) _
Primary disease stage (if known) -... 
Age_____ Numerical score from Worksheet 2 
Global Assessment (See Worksheet 5) 
D Well nourished or anabolic (SGA-A) □ Moderate or suspected malnutrition (SGA-B) □ Severely malnourished (SGA-C) 
Total PG-SGA Score 
(Total numerical score of A+B+C+D above) 
Worksheets for PG-SGA Scoring 
Boxes 1-4 of the PG-SGA are designed to be completed by the patient The PG-SGA numerical score is 
determined by 1) the parenthetical points noted in boxes 1-4 and 2) the worksheets below for items not marked 
with parenthetical points. Scores for boxes 1 and 3 are additive within each box and scores for boxes 2 and 4 are 
based on the highest scored item checked off by the patient 
Wt loss in 1 month 











Weight loss in 6 months 









Pulmonary or cardiac cachexia 1 
Presence of open wound, fistula 1 
Presence of trauma 1 
Age greater than 65 years 
Score for Worksheet 2 
Worksheet 1- Scoring Weight (Wt) Loss 
Score for Worksheet 1 
Worksheet 3-Scoring Metabolic Stress 
Score for metabolic stress is determined by a number of variables known to increase protein and calorie needs. The score is additive so that a 
patient who has a fever of> 102 degrees (3 points) and is on 10mg prednisolone chronically (2 points would have an additive score for this 






> 99 and <101 
=< 72 hours 
< 10 mg 
Moderate (2) 
2101 and <102 
72 hours 
2>10and < 30 mg 
High (3) 
> 102 
> 72 hours 
2 30 mg 
Fever duration no fever 
Steroids no steroids 
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Worksheet 4--Physical Examination 
Physical exam includes a subjective evaluation of 3 aspects of body composition; fat, muscle & fluid status. Definition of categories: 0 = no 
deficit, 1+ = mild deficit, 2+ moderate deficit, 3+ severe deficit 
Fat stores: 
Orbital fat pads 0 1+ 2+ 3+ 
Triceps skin fold 0 1+ 2+ 3+ 
Fat overlying lower ribs 0 1+ 2+ 3+ 
Global fat deficit rating 1+ 2+ 3+ 
Muscle status 
Temples (temporatis muscle) 0 1+ 2+ 3+ 
Clavicles (pectoralis & deltoids) 0 1+ 2+ 3+ 
Shoulders (deltoids) 0 1+ 2+ 3+ 
lnterosseous muscles 0 1+ 2+ 3+ 
Scapula (latis simus dorsi, trapezius, deltoids) 0 1+ 2+ 3+ 
Thigh (quadriceps) 0 1+ 2+ 3+ 
Calf (gastrocnemius) 0 1+ 2+ 3+ 
Global muscle deficit rating 1+ 2+ 3+ 
Fluid status 
Ankle oedema 0 1+ 2+ 3+ 
Ascites 0 1+ 2+ 3+ 
Global fluid status rating 1+ 2+ 3+ 
score = O points 
score = 1 point 
score = 2 points 
score = 3 points 
Moderate deficit 
Severe deficit 
Point score for the physical exam is determined by the overall subjective rating of 
total body deficit. 
No deficit 
Mild deficit 
Score for worksheet 4 D 








No wt loss OR Recent non- 
fluid wt gain 
No deficit OR Significant 
recent improvement 
None OR Significant recent 
improvement allowing 
adequate intake 
No deficit OR Significant 
recent improvement 
No deficit OR Chronic defict 
but with recent clinical 
improvement 
Moderately malnourished or 
suspected malnutrition 
~5% wt loss within 1 month 
(or 10% in 6 months) OR No 
wt stabilisation or wt gain 
(i.e. continued wt loss) 
Definite decrease in intake 
Presence of nutrition impact 
symptoms 
Moderate functional deficit 
OR recent deterioration 
Evidence of mild to 
moderate loss of SQ fat &/or 
muscle mass &/or muscle 
tone on palpation 
Severely malnourished 
> 5% wt loss in 1 month (or 
>10% in 6 months) OR No 
wt stabilisation or wt gain 
(i.e., continued wt loss) 
Severe deficit in intake 
Presence of nutrition impact 
symptoms 
Severe functional deficit OR 
recent significant 
deterioration 
Obvious signs of malnutrition 
(e.g., severe loss of SQ 
tissues, possible oedema) 
Global PG-SGA rating (A, B or C) 
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Appendix I Questionnaire – Baseline 
Sir Charles 
Gairdner Hospital 
Edith Cowan University 
Health and Wellness Institute 
UarIo wellness clinic 
8f 
Nutritional Status, Activity, and the Effects of Exercise in 
Mesothelioma 
Assessment: Complete 
Study ID: _ 
Date: ' __ / __ 
Instructions: 
• Please take your time completing these important questionnaires 
and answer all questions as honestly as you can. 
• Please note: there are questions on both sides of each page in this 
package. 
• Your responses provide extremely valuable information regarding 
the effects of exercise in cancer survivors and have the potential to 
influence the information and services provided to cancer survivors 
worldwide. 
• We really appreciate your time and value the contribution you are 
making to advancing the scientific knowledge surrounding exercise 
for cancer survivors. 
• If you have any questions whatsoever please don't hesitate to ask. 
THANK YOU! 
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These first questions ask for your views about your health. This information will help keep 
track of how you feel and how well you are able to do your usual activities. For each of the 
following questions, please circle the one number that best describes your answer. 











2. Compared to one year ago, how would you rate your health in general now? 
Much better Somewhat 
now than one better now than 
year ago one year ago 
1 2 
About the 
same as one 
year ago 
3 
Somewhat Much worse 
worse now than now than one 
one year ago year ago 
4 5 
3. The following questions are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so, how much? 
Yes, Yes, No, not 
limited limited limited 
a lot a little at all 
a) Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports. 1 2 3 
b) Moderate activities, such as moving a table, pushing 
a vacuum cleaner, bowling, or playing golf. 1 2 3 
c) Lifting or carrying groceries. 1 2 3 
d) Climbing several flights of stairs. 1 2 3 
e) Climbing one flight of stairs. 1 2 3 
f) Bending, kneeling, or stooping. 1 2 3 
g) Walking more than a mile. 1 2 3 
h) Walking several hundred yards. 1 2 3 
i) Walking one hundred yards. 1 2 3 
j) Bathing or dressing yourself 1 2 3 
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4. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of your physical 
health? 
All of Most Some A little None 
the of the of the of the of the 
time time time time time 
a) Cut down on the amount of time you 
spent on work or other activities. 1 2 3 4 5 
b) Accomplished less than you would like. 1 2 3 4 5 
c) Were limited in the kind of work or other 
activities. 1 2 3 4 5 
d) Had difficulty performing the work or 
other activities (for example, it took extra 1 2 3 4 5 
effort). 
5. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)? 
All of Most Some A little None 
the of the of the of the of the 
time time time time time 
a) Cut down on the amount of time you 
spent on work or other activities. 1 2 3 4 5 
b) Accomplished less than you would like. 1 2 3 4 5 
c) Did work or other activities less 
carefully than usual. 1 2 3 4 5 
6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors, or groups? 























8. During the past 4 weeks, how much did pain interfere with your normal work (including 
both work outside the home and housework)? 
Not at all 
1 
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9. These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question, please give the one answer that comes closest to the 
way you have been feeling. How much of the time during the past 4 weeks... 
All of Most Some A little None 
the of the of the of the of the 
time time time time time 
a) Did you feel full of life? 1 2 3 4 5 
b)Have you been very nervous? 1 2 3 4 5 
c) Have you felt so down in the dumps 
that nothing could cheer you up? 1 2 3 4 5 
d) Have you felt calm and peaceful? 1 2 3 4 5 
e) Did you have a lot of energy? 1 2 3 4 5 
f) Have you felt downhearted and 
depressed? 1 2 3 4 5 
g) Did you feel worn out? 1 2 3 4 5 
h) Have you been happy? 1 2 3 4 5 
i) Did you feel tired? 1 2 3 4 5 
10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives, etc.)? 
All of the time 
1 
Most of the 
time 
2 
Some of the 
time 
3 
A little of the 
time 
4 
None of the 
time 
5 
11. How TRUE or FALSE is each of the following statements for you? 
Definitely Mostly Don't Mostly Definitely 
true true know false false 
a) I seem to get sick a little easier 
than other people. 1 2 3 4 5 
b) I am as healthy as anybody I 
know. 1 2 3 4 5 
c) I expect my health to get worse. 1 2 3 4 5 
d) My health is excellent. 1 2 3 4 5 
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Below is a list of statements that other people with cancer have said are important to their 
quality of life. Please indicate the extent to which you have experienced each of the 
statements during the past 7 days by circling the appropriate number using the following 
scale. 
During the PAST 7 DAYS: not a little some- quite very 
at all bit what a bit much 
PHYSICAL WELL - BEING 
1. I have a lack of energy 0 1 2 3 4 
2. I have nausea 0 1 2 3 4 
3. Because of my physical condition, I have trouble 0 1 2 3 4 
meeting the needs of my family 
4. I have pain 0 1 2 3 4 
5.1 am bothered by side effects of treatment 0 1 2 3 4 
6. I feel sick 0 1 2 3 4 
7.1 am forced to spend time in bed 0 1 2 3 4 
SOCIAL/FAMILY WELL - BEING 
8. I feel close to my friends 0 1 2 3 4 
9. I get emotional support from my family 0 1 2 3 4 
10.I get support from my friends 0 1 2 3 4 
11. My family has accepted my illness 0 1 2 3 4 
12. I am satisfied with family communication about 0 1 2 3 4 
my illness 
13. feel close to my partner (or the person who is 0 1 2 3 4 
my main support) 
Regardless of your current level of sexual activity, please 
answer the following question. If you prefer not to answer 
it, please check this box [ and go to the next section 
14. am satisfied with my sex life 0 1 2 3 4 
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During the PAST 7 DAYS: not a little some- quite very 
at all bit what a bit much 
EMOTIONAL WELL - BEING 
15. I feel sad 0 1 2 3 4 
16.I am satisfied with how I am coping with my illness 0 1 2 3 4 
17. I am losing hope in the fight against my illness 0 1 2 3 4 
18. I feel nervous 0 1 2 3 4 
19. I worry about dying 0 1 2 3 4 
20. I worry that my condition will get worse 0 1 2 3 4 
FUNCTIONAL WELL - BEING 
21. I am able to work (include work at home) 0 1 2 3 4 
22.My work (include work at home) is fulfilling 0 1 2 3 4 
23. I am able to enjoy life 0 1 2 3 4 
24. I have accepted my illness 0 1 2 3 4 
25. I am sleeping well 0 1 2 3 4 
26.I am enjoying the things I usually do for fun 0 1 2 3 4 
27. I am content with the quality of my life right now 0 1 2 3 4 
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ADDITIONAL CONCERNS 
not a little some- quite very 
at all bit what a bit much 
1. I have a good appetite 0 1 2 3 4 
2. The amount I eat is sufficient to meet my needs 0 1 2 3 4 
3. I am worried about my weight 0 1 2 3 4 
4. Most food tastes unpleasant to me 0 1 2 3 4 
5. I am concerned about how thin I look 0 1 2 3 4 
6. My interest in food drops as soon as I try to eat 0 1 2 3 4 
7. I have difficulty eating rich or "heavy" foods 0 1 2 3 4 
8. My family or friends are pressuring me to eat 0 1 2 3 4 
9.I have been vomiting 0 1 2 3 4 
10. When I eat, I seem to get full quickly 0 1 2 3 4 
11. I have pain in my stomach area 0 1 2 3 4 
12. My general health is improving 0 1 2 3 4 
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FATIGUE SYMPTOMS 
not a little some- quite very 
at all bit what a bit much 
1. I feel fatigued 0 1 2 3 4 
2. I feel weak all over 0 1 2 3 4 
3. I feel listless ("washed out") 0 1 2 3 4 
4. I feel tired 0 1 2 3 4 
5. I have trouble starting things because I am tired 0 1 2 3 4 
6.I have trouble finishing things because I am tired 0 1 2 3 4 
7. I have energy 0 1 2 3 4 
8.I am able to do my usual activities 0 1 2 3 4 
9.I need to sleep during the day 0 1 2 3 4 
10. I am too tired to eat 0 1 2 3 4 
11. I need help doing my usual activities 0 1 2 3 4 
12. I am frustrated by being too tired to do 0 1 2 3 4 
the things I want to do 
13. I have to limit my social activity because I am tired 0 1 2 3 4 
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Please circle the number that best describes how you feel NOW: 
No Pain 0 1 2 3 4 5 6 7 8 9 10 Worst Possible 
Pain 
No Tiredness 0 1 2 3 4 5 6 7 8 9 10 Worst Possible 
(Tiredness = lack of energy) Tiredness 
No Drowsiness 0 1 2 3 4 5 6 7 8 9 10 Worst Possible 
(Drowsiness = feeling sleepy) Drowsiness 
No Nausea 0 1 2 3 4 5 6 7 8 9 10 Worst Possible 
Nausea 
No Lack of 0 1 2 3 4 5 6 7 8 9 10 Worst Possible 
Appetite Lack of Appetite 
No Shortness of 0 1 2 3 4 5 6 7 8 9 10 Worst Possible 
Breath Shortness of Breath 
No Depression 0 1 2 3 4 5 6 7 8 9 10 Worst Possible 
(Depression = feeling sad) Depression 
No Anxiety 0 1 2 3 4 5 6 7 8 9 10 Worst Possible 
(Anxiety = feeling nervous) Anxiety 
Best Wellbeing 0 1 2 3 4 5 6 7 8 9 10 Worst Possible 
Wellbeing 
No 0 1 2 3 4 5 6 7 8 9 10 Worst Possible 
Other Problem (for example constipation) 
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Appendix J Activity Monitor Instructions and Log 
ACTIVITY MONITOR INSTRUCTIONS 
The activity monitor measures the amount of physical activity you do in your 
everyday life. It is also used to measure the amount and quality of your sleep. 
1. Please start wearing the monitor from: 
2. Please take off the monitor: 
If you have any questions about the activity monitor please call and leave a 
message: 6304 2329 
If there is no answer, please leave a message. It will be checked and responded to 
as soon as possible between 8:00am and 4pm Monday to Friday. 
• Where do I wear the activity monitor? 
o The monitor needs to be worn at the hip area of your waist with the black 
button facing the top (Do not twist the button). 
o The monitor can be worn either above or beneath clothing, and it is not 
necessary for it to make contact with the skin. 
o The monitor must be held snugly against the body to work properly (i.e. must 
be secure and not bounce or slide when you're moving). 
• How long do I wear the activity monitor for? 
o We ask that you wear the monitor for a period of 3 days. 
o It is very important to wear the monitor 24 hours a day if possible. 
o This includes when you are asleep at night. 
o The monitor should be taken off to bath/shower. 
o You need to take off the activity monitor on the date and time listed 
above. 
• What happens if I get the activity monitor wet? 
o It's preferable if the monitor doesn't get wet but it is water resistant so will 
not be affected by getting slightly wet. 
o If you are a swimmer please take the device off before getting into the 
pool/ocean. 
o Note the device is water resistant and not water proof. 
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ACTIVITY MONITOR LOG 
Study ID: _ 
Date: ' __ / __ 
Please use this form to document any time that you didn't wear the monitor 
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Appendix K Food Record 
Sir Charles 
Gairdner Hospital 
Edith Cowan University 
Health and Wellness Institute 





Participant ID: _ 
Started diary on: (date) 
Finished diary on: (date) 
You are welcome to contact the researcher during business hours to 
discuss your questions or concerns about the food diary. 
Contact person: Emily Jeffery 
Contact details: (08) 6304 2082 
eieffery@our ecu edu. au 
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Food diary guidelines 
1. Record everything that you eat and drink for three (3) 
consecutive days 
• Start each day on a new page 
• You can use more than one page for each day 
• Record the date at the top of the page 
• We recommend you carry your food diary with you at all times throughout the 
three day recording period, so that nothing is forgotten 
• Write down the time that you eat and drink 
• Write down what you eat and drink as close as possible to the time that you 
consume it 
2. Describe your food and drink in as much detail as possible 
• Record the type and brand of each item e.g. Sunblest (brand) multigrain (type) 
bread 
• If eating meat, include the cut of meat (e.g. rump steak) and whether fat has been 
trimmed (e.g. chicken skin removed) 
• Describe your cooking method. For example, boiling, frying, BBQ, roasting or 
baking. If fat (e.g. oil) has been added, please state the brand and the amount 
• Where foods or drinks have been eaten outside the home (e.g. take-away) 
please describe what it is and where it has been bought 
• Record all accompaniments such as butter, gravy, sauce, salt and sugar 
3. Describe the amount of food and drink you consume 
• Use household measures (cups and spoons) to record the amount of food and 
drink you consume. For example, 1 cup of boiled, white rice or 1 tsp of Flora 
canola margarine. 
• You can weigh your food and drink if you like, but it is not required. 
• For mixed dishes (e.g. a salad or stir fry), estimate each ingredient separately. 
For example, garden salad: 1 lettuce leaf, 4 slices cucumber, 4 cherry tomatoes 
and 1 tsp Kraft 99% fat free French dressing. 
• You can also record your recipes in the 'notes' section at the end of each page. 
Then just tell us how much is your portion e.g. half or one-quarter. 
• Ensure you record all fluids (including water) and estimate the volume consumed 
in ml or by the type of cup e.g. pint glass, paper cup, coffee mug. 
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Food diary example 
Time Food and Drink Eaten 
Description Quantity 
eg. Weetbix eg. 3 biscuits/ 45g 
7.30am Cornflakes -- Kelloggs 45g 
Milk- Brownes Calcium Plus 1.5 cups 
Sugar- white 2 tsp 
Toast, white bread- He/gas 2 large thick slices 
Margarine -- Flora Light 3 teaspoons 
Tea -Lipton 1 cup 
Milk- Brownes Skim 30ml 
Sugar- white 3 tsp 
10.30am Granita - Arnotts 1 biscuit 
Black Coffee 1 cup 
Green Apple -- Granny Smith 1 medium 
1 pm Bought from deli: 
1 x cheese & salad sandwich 
White bread -- unknown 2 standard slices 
Butter- unknown Thickly spread 
Cheese grated, unknown ½ a cup 
Lettuce 2 small leaves 
Tomato 3 medium slices 
Beetroot, canned 3 slices 
Apple -- Red Delicious 1 large 
3.30pm Water- Mount Franklin 1 bottle 750ml 
Homemade chocolate slice from deli 1 medium slice 
7.30pm Spaghetti, white -- Maggi 320g 
Bolognaise Sauce - lean mince 1.5 cups (half the recipe) 
Parmesan Cheese -- Kraft 3 tsp 
Red wine, Shiraz 2 glasses 
Salad 
- carrots 3 slices 
- tomatoes 1 whole 
- lettuce 4 small leaves 
French dressing -- Kraft Fat Free 1 tbsp 
9.00pm Ice cream (vanilla) -Streets Blue 3 large scoops 
Ribbon 
Notes: 
Bolognaise Sauce: 500g lean mince, 1 x 420g can tinned whole tomatoes, 2 
tablespoons Leggo tomato paste, 1 tablespoon canola oil, ½ cup dry white wine, 
oregano, thyme, basil, salt and pepper 
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Appendix L Standard Operating Procedure – Dual 
Energy X-Ray Absorptiometry 
INTERMlx 
DXA standard procedures 
Prior to the scanning day 
• Advise participants: 
[l wear comfortable clothing with no metal (e.g. zips, metal buttons) 
D Not to undertake strenuous exercise on the morning of the scan 
D Eat breakfast but avoid a very large breakfast 
Equipment 
• Hologic DXA (Horizon A), Level 2, Harry Perkins Institute of Medical Research 
• Sample spine (calibration equipment) 
Set up 
1. Calibration 
• Turn on computer. 
• Turn on DXA by pressing the green button. 
• Double click on QDR account. 
• A pop-up will show asking to back up computer, click "no". 
• Make sure NHANES--BCA is enabled: 
• Click "Utilities". 
• Click "System Configuration". 
• Click "Analysis". 
• At the bottom of the screen, make sure the box is ticked. 
• Click and open up "Daily QC". 
• Collect sample spine from calibration equipment cupboard and remove the 
outer black cover. 
• Place the spine on DXA bed (largest vertebral body is closest to computer) 
and adjust position ensuring the red lasers crossover in the middle of the 
small air bubble and the middle number 1 at the opposite end of spine. 
• On computer click continue. 
• If the spine has been correctly positioned and scanned then the message 
'daily QC passed' should appear and click OK. 
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Testing Instructions 
1. Ask patient if there is any chance of pregnancy. DO NOT scan if pregnant. 
2. Ask the patient to remove any metallic items they have on/with them e.g. 
glasses, loose change, zips, metal buttons etc. Provide a towel/robe if necessary 
i.e. if they had to remove their jeans. 
3. Ask the patient if they have any internal objects that could interfere with the 
scan such as: 
a. Pacemaker leads 
b. Radioactive seeds 
c. Metal implants 
d. Surgical staples 
e. Radio-opaque catheters or tubes 
f. Wedding rings that cannot be removed 
i. Make a note on testing sheet if any of the above has been 
identified. 
4. Measure and record the patient's height and weight. 
5. Make sure 'NHANES-BCA' is enabled prior to scanning each client. 
6. Click on 'perform exam' and then 'new patient'. 
7. Enter the patient details including height, weight, gender, DOB, ID and press 'ok'. 
8. Instruct the client to lie supine with their feet closest to the computer. 
9. Position the individual so that they are central and within the scanning field as 
marked by the black lines with their head positioned 2cm from the end of the 
bed. 
10. Palms are faced down on the bed. If patient does not fit within scanning field, ask 
them to place their hands vertical. 
11. Feet are positioned wide and angled towards each other and held together by 
strapping tape. Explain to client that this position is used to scan both bones of 
the lower limbs. 
a. For hygienic reasons, new strapping tape is to be used for each patient. 
12. Explain to the patient what the scan is looking at, i.e. body composition and BMD 
and that the scanning process will last for 3-4 minutes. 
13. Instruct the patient to lie motionless on the table as movement can affect the 
scan quality. 
14. Select perform 'whole body' scan and click on 'scan now' when the patient is 
correctly aligned on the table. 
15. DEXA table must be cleaned with alcohol wipe after use. 
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Appendix M Standard Operating Procedure – 
Timed Up and Go Test 
INTERMIX 
'Timed up and go test' standard procedures 
Equipment required 
• Armed chair 
• Tape measure 
• Masking tape 
• Small marker or bean bag 
• Stop watch 
Set up 
1. Position armed chair up against a wall 
2. Measure 2.44 m (8 ft) from the front of the chair and mark the distance with 
masking tape 
3. Position a marker at the 2.44 m line 
Testing instructions 
1. Explain the purpose of the test 
a. This test is designed to mimic the activities of daily living 
2. Explain the process of the test 
a. In this test, you begin seated, stand up (unassisted if able), walk around 
cone and return to sitting as quickly as possible. You may use the arms on 
the chair when you return to sitting. 
3. Inform participant that they will be tested 3 times with a 1 minute rest in 
between 
4. Demonstrate the timed up and go 
5. Ask participant if they have any questions before they start 
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6. Instruct participant to sit in the chair with back firmly against the back of the 
chair and arms across chest. Feet are shoulder width apart on the floor with 
knees positioned at 90° 
7. Instruct participant to commence with "3, 2, 1, Go" 
8. Researcher to start stopwatch on "Go" and stop the stopwatch once the 
participant returns their upper back to the backrest 
9. Participant to have a 1-minute rest. If greater than a 1-minute rest is required, 
document this on the data collection form 
10. Complete two more trials to give three trials in total. If participants are unable to 
complete 3 trials, document this on the data collection form 
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Appendix N Data Collection Form 




Assessor Name: _ 
1. [ Baseline []Weeks 
2. D Informed Consent [l Physician Consent [l Demographic Info & Health History 
3. D Check medical history: (Is there any reason not to do the functional testing?) 
4. Performance Status: _ 
5. Height: cm (only at baseline) Weight: kg 
6. Grip Strength: {30 second rest between trials) 
D Seated, elbow flexed at 90°, forearm neutral, wrist 0-30° of dorsiflexion 
D Instructed to exhale when squeezing dynamometer 
D Hand dominance (R or L) __ 
D Hand dynamometer position used (1-5) 
RIGHT: Trial 1: _ 
LEFT: Trial 1: _ 
Trial 2: _ 
Trial 2: _ 
Trial 3: _ 
Trial 3: _ 
BEST: 
BEST: _ 
7. Timed up and go (1 min rest between trials) 
D Used arms to assist in standing 
Trial 1:sec Trial2:sec Trial 3:sec BEST:_sec 
8. D DXA full body scan: remove shoes, socks, ALL metal (jewellery, underwire bra) and any 
prosthetics 
9. [l PGsGA Completed 
10. D 3 Day diet record and ActiGraph explained (baseline) 
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11. Collect/Give out: 
Give out: 
D Questionnaire (complete) 
D 3 day food record 
[ ActiGraph 
How will the ActiGraph, questionnaire, and food diary 
be returned? 
Cl oroo off 
[l Mai (Return Tracking ID: 
Cl oate for next assessment confirmed 
Collect: 
D Check all data has been returned from 
previous assessment 
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Appendix O Sample Resistance Exercise 
Training Program 
EXERCISE TRAINING LOG 
Participant ID: EXER/_ 
First name / EXER/ number 
Emergency Contact Details: 
Name: _ 
Contact Details: ---------------------------- 
Relationship: _ 
Relevant Medical information: 
Medications: 
If there are any medical issues with participants, please contact our physician support: 
Dr Maree Azzopardi -- 0412 866 477 
In a last resort, contact the Pleural Medicine Hotline: 
0421 253 918 
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SESSION RATING OF PERCEIVED EXERTION (RPE) 
6 No exertion at all 
7 Extremely light 
8 




13 Somewhat hard 
14 
15 Hard (heavy) 
16 
17 Very hard 
18 
19 Extremely hard 
20 Maximal exertion 
TOLERANCE OF SESSION 
Please rate the number that best represents how you feel 
I have found the exercise session to be: 
1 2 3 4 5 6 7 
Extremely Quite Slightly 
Neutra 
Slightly Quite Extremel 
lntolerabl lntolerabl lntolerabl I Tolerabl Tolerabl y 
e e e e e Tolerable 
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Date Session 
Reason (if available) 
Missed 
Adherence Log: 
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Participant ID:_/EXER/_ Date: _ 
TRAINING PROGRAM LOG - WEEK 1 (session1) 
1. Please rate your current level of pain (if any): 
No pain t-----------------------1 Very severe pain 
2. Has pain affected your ability to undertake usual activities of daily living since your last exercise 
training session? 
• If yes, has the interference increased or decreased? 
• If yes, has it increased or decreased? 











3. Has shortness of breath changed since your last exercise training session? Yes 
4. Has how tired you feel changed since your last exercise training session? Yes 
5. Have you experienced any other pain, new symptoms/issues? _ 
6. Warm up: 5 mins cardio - Cycling or Walking 
7. Resistance Exercises: Target= 2 sets of 12 reps 
1. Leg Press reps X kg 
2. Chest Press reps X kg 
3. Seated Row reps X kg 
4. Leg Extension reps X kg 
5. Shoulder Press reps X kg 
6. Leg Curl reps X kg 
7. Lat Pull Down reps X kg 
reps X kg 
reps X kg 
reps X kg 
reps X kg 
reps X kg 
reps X kg 
reps X kg 
8. Cool down: Stretching 
• Hamstrings: x 15-30 sec • Quadriceps: x 15-30 sec • Calf: x 15-30 sec 
9. Session RPE: _ 
Notes: _ 
10. Tolerance of Session: _ 
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Appendix P Copyright Permission 
Permission regarding copyright has been obtained from the following publishers: 
Oxford University Press 
Thank you for your order with Rightslink / Oxford University Press 
no-reply@copyright.com <no-reply@copyright.com> 
Mon 20/01/2020 12:22 PM 
To: Emily JEFFERY 
Header 
Thank you for your order! 
Dear Miss. Emily Jeffery, 









Type of Use: 
Order Total: 
Miss. Emily Jeffery 
Jan 19, 2020 
4752840327308 
The American Journal of Clinical Nutrition 




View or print complete details of your order and the publisher's terms and conditions. 
Sincerely, 
Copyright Clearance Center 
Tel +1-855-239-3415/+1978-646-2777 
customercare@copyright. com 
bttos //myaccount copyright com 
Copyright Clearance Center Copyrighl Clearance Center 
This message (including attachments) is confidential, unless marked otherwise. It is 
intended for the addressee(s) only. If you are not an intended recipient. please delete it 
without further distribution and reply to the sender that you have received the message 
in error. 
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John Wiley and Sons 
Springer Nature 
Corvright 
wgoon Center RightsLink # 2 A Home Help Email Support Emily Jeffery v 
WILEY 
Lean Tissue Imaging 
Author: Steven B. Heymsfield, Carla M. M. Prado 
Publication: JOURNAL OF PARENTERAL AND ENTERAL NUTRITION 
Publisher: John Wiley and Sons 
Date: Sep 19, 2014 
Copyright 4 2014, John wWley and Sons 
Open Access Article 
This article is available under the terms of the Creative Commons Attribution Non-Commercial License CC BY-NC (which may be updated from time to time) and permits non 
commercial use, distribution and reproduction in any medium, provided the original work is properly cited. 
For an understanding of what is meant by the terms of the Creative Commons License, please refer to Wiley's Open Access Terms and Conditions. 
Permission is not required for noncommercial reuse. For commercial reuse, please hit the "back" button and select the most appropriate commercial requestor type before 
completing your order. 
IE 
02020Copyright All Rights Reserved ] Copyright Clearance Center, inc. ] Privacy statement ] Terms and Conditions 
Comments? We would like to hear from you. £-mail us at customercrecopyright.com 
RE: Request for permission to use article in thesis 
Journalpermissions <journalpermissions@springernature.com> 
Thu 16/01/2020 12:43 AM 
To: Emily JEFFERY 
Dear Emily, 
Thank you for your Springer Nature permissions query. Author retains the right to use his/her 
article for his/her further scientific career by including the final published journal article in other 
publications such as dissertations and postdoctoral qualifications provided acknowledgement is 
given to the original source of publication. 
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